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Amyotrophic Lateral Sclerosis (ALS) is a debilitating and life–limiting 
neurodegenerative disorder that causes progressive muscle atrophy and spasticity.           
A small proportion of ALS patients experience co–morbid Frontotemporal Dementia 
(FTD). Milder cognitive–behavioural changes have been noted in ALS patients without 
dementia. In these patients, deficits in executive functioning, language, memory and 
behaviour have been documented. Recently, changes to emotional processing and social 
cognition (EMOSOC) in ALS have also been reported, albeit with inconsistent findings.  
 
The primary aims of the current thesis were i) to delineate the nature and extent of 
changes in EMOSOC in ALS and ii) to determine the relationship between such 
changes and interindividual differences in mood, behaviour, personality, empathy and 
ALS–related executive dysfunction. The results of the study indicate a profile of 
predominant executive dysfunction, with relative sparing of EMOSOC in non–
demented ALS patients. However, the ALS patients did show impaired performance on 
a task requiring the attribution of thoughts and feelings to characters from cartoons and 
vignettes. ALS patients’ performance on EMOSOC tasks was predicted by their 
performance on tests of executive function, above and beyond mood, behaviour, 
personality and empathy variables.   
As a secondary aim, the impact of patients’ cognitive and behavioural changes on ALS 
caregivers’ outcomes (mood, perceived strain, burden and marital satisfaction) were 
examined. The data indicated patients’ behavioural dysfunction and functional 
impairment as key predictors of caregivers’ outcomes. Exploratory analyses revealed 
differences between patients’ and caregivers’ perceptions of patients’ personality, 
empathy and behaviour; these differences were associated with caregiver outcomes.  
In summary, the current thesis characterises the profile of EMOSOC changes in non–
demented ALS and highlights the role of ALS–related executive dysfunction in these 
changes. It also assesses the relative impact of patients’ disease, cognitive and 
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Motor Neuron Disease (MND) is a clinical hypernym which refers to a class of 
progressive neurodegenerative disorders, characterised by selective atrophy of upper 
and/or lower motor neurons in the central nervous system. Amyotrophic Lateral 
Sclerosis (ALS) is the most prevalent form of MND and is commonly used 
interchangeably with the ‘MND’ term in the literature. Throughout this thesis ‘ALS’ 
will refer exclusively to the most prevalent subtype while ‘MND’ will refer to all 
disease subtypes, including ALS.  
 
Frontotemporal Lobar Degeneration (FTLD) is an umbrella term which refers to a 
heterogeneous group of neurodegenerative disorders characterised by atrophy of the 
frontal and temporal lobes of the brain. FTLD corresponds to several overlapping 
dementia syndromes. As with the MND nomenclature, the terminology for FTLD varies 
in meaning throughout the literature. Here, ‘FTLD’ will be used to denote the 
histopathological or neuropathological correlates of its associated cognitive–
behavioural syndromes. Frontotemporal Dementia (FTD) will refer to the overarching 
FTLD–related syndrome that encompasses two sub–syndromes. These sub–syndromes 
will be referred to as behavioural variant frontotemporal dementia (bvFTD) and the 
language variants of primary progressive aphasia (PPA).  
 
1.2. Epidemiology  
ALS is perceived as a relatively rare disorder. The point prevalence in the 1990’s for 
Western countries ranges from 2.7 to 7.4 per 100,000 (Worms, 2001), while the United 
Kingdom (UK) prevalence ranges from 4.02 to 4.91 per 100,000 (Hoppitt et al., 2011). 
A recent incidence study noted the European incidence rate as 2.1 per 100,000 person 
years (Logroscino et al., 2010). The disease primarily affects adults in mid–to–late life, 
with a mean onset age varying between 55 to 65 years (Wijesekera & Leigh, 2009). 
Juvenile cases of sporadic ALS, where patients are below 25 years of age, are reported 
in approximately 5% of cases (Aggarwal & Shashiraj, 2006; Myllyla et al., 1979). 
There are two patterns of incidence. A disproportionate number of cases are sporadic, 
but a small proportion (~10% of cases) is familial, showing an autosomal dominant 
transmission (Byrne & Hardiman, 2010; Leigh et al., 1989). Recessive variants have 




Median survival from symptom onset to death is reported to vary from 20 to 48 months 
(Chio et al., 2009). The limbs are the most prevalent site of onset (~75% of cases); a 
minority of patients present with initial bulbar symptoms (~25% of cases), while 
respiratory onset is rare (Haverkamp et al., 1995). The disease is unrelenting, typically 
progressing from an initial location to encompass other regions and culminating in 
respiratory failure and eventual death.  
 
Incidence is 54% higher in men than women in the UK, with a male to female ratio of 
3:2. A lifetime risk of disease development is estimated at 1 in 472 for women and 1 in 
350 for men (Alonso et al., 2009). The reported gender–ratio varies extensively across 
studies. In general, higher ratios are reported in clinic–based studies while population 
data suggest it approaches equality (Abhinav et al., 2007; Logroscino et al., 2008). This 
disparity might be due to an over–representation of younger patients in clinic registers, 
as a relationship with age and the sex ratio has been demonstrated. In one study, gender 
ratios tended towards unity for age groups over 55 years in two European populations 
(Manjaly et al., 2010).This finding also highlights a possible increased female risk of 
developing ALS with the advancement of post–menopausal age. 
 
Despite an otherwise uniform world distribution, high risk geographical loci for MND 
have been detected in Western Pacific countries, such as Guam, the Kii Peninsula and 
West New Guinea. In the 1950s, incidence rates of MND in these countries were 
estimated at over 50 – 100 times higher than that of other global regions (Kurland & 
Mulder, 1954). The MND in these populations can be associated with a Parkinsonism–
dementia complex and referred to as ‘Guam syndrome’ (McGeer & Steele, 2011). Post–
mortem studies of Guamian patients have revealed neurofibrillary tangles (Rodgers-
Johnson et al., 1986), suggesting a degeneration common to Alzheimer’s Disease (AD) 
and Parkinson’s Disease (PD). The cause of these aggregations remains unknown but 
the clusters of incidence suggest an environmental trigger. For example, the cumulative 
consumption of a neurotoxin (B–methyl–amino–L–alanine) found in cycad flour in the 
Guam diet was posited as a putative predictor in this region (Whiting, 1964). This 
hypothesis was discounted, but has been recently revived (Borenstein et al., 2009; 
Steele & McGeer, 2008). Alternatively, a genetic predisposition may be a reasonable 
explanation for these region–specific incidence rates; yet, to date, only two genes have 
been identified as potential candidates for susceptibility to this version of the disease 
(Garruto & Yanagihara, 2009). Intriguingly, incidence rates in Guam appear to have 
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decreased rapidly since the 1950s (Plato et al., 2003). By contrast, age– and gender– 
adjusted incidence rates of ALS in the Kii peninsula have increased since the 1960s 
(Kihira et al., 2012). A change in water resource supply on a small island off the 
peninsula mainland coincided with a high incidence of 9.45 per 100,000 on the island 
during  2000 – 2009, supporting the argument for an environmental cause. However, 
due to the small population of this region, the precision of these estimates might be 
compromised (95% CI [7.39; 26.29]). Further study in these areas over time is 
warranted. 
    
1.3. Aetiology  
1.3.1 Environmental risk factors 
 
The identification of exogenous risk factors for ALS is challenged by a lack of 
replication studies and small sample sizes demonstrating insufficient power.  As such, 
no definitive causative environmental factor has been established. Numerous putative 
risk factors for the development of ALS have been proposed. These include: intense 
physical activity (Beghi et al., 2010; Chio & Mora, 2012) or rather premorbid lifetime 
athleticism (Huisman et al., 2013), smoking (Armon, 2009), previous head injury (Chen 
et al., 2007), military service (Coffman et al., 2005; Horner et al., 2003), low premorbid 
weight (Scarmeas et al., 2002) and exposure to electromagnetic fields (Bonvicini et al., 
2009; Li & Sung, 2003), metals and chemical toxins (Sutedja et al., 2009). Recent years 
have seen an increase in animal model studies which have isolated numerous putative 
neurotoxins for the study of neurodegenerative disease aetiology. Such studies have 
demonstrated that, in animal models at least, environmental neurotoxins can reproduce 
neurodegeneration, in the absence of genetic co–factors (see Shaw & Hoglinger, 2008). 
 
1.3.2. Genetic risk factors 
 
Alongside the search for exogenous risk factors, research in the genetic aetiology of 
ALS ensues. Gene hunting in ALS has been prolific in recent years. A description of 
each ALS gene is beyond the scope of this thesis, but the interested reader is directed to 
the following online resource for a complete list: ALS Online Genetics Database 
(ASLoD), http://alsod.iop.kcl.ac.uk (Abel et al., 2012; Wroe et al., 2008).  
 
Research has identified genetic factors underlying both inherited (familial) and, 
apparent, sporadic ALS (see Section 1.4. for clinical characteristics). Mutations in the 
superoxide dismutase–1 (SOD1) genes, the transactive response DNA Binding Protein 
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(TARDBP) genes and the fused in sarcoma/translated in lipsarcoma (FUS/TLS) genes 
have been documented in both populations (Andersen, 2006; Daoud et al., 2009). 
Recently, an expansion of the hexanucleotide repeat within gene C9orf72 on 
chromosome 9.p21.2 has also been implicated in both variants of the disorder (Renton 
et al., 2011; Shatunov et al., 2010). These findings imply that the boundaries between 
familial and sporadic forms of the disease may be artificial, if not merely convenient 
(Hanby et al., 2011). 
 
A similar argument can be applied to the boundaries of ALS and FTLD. Mutations in 
the TARDBP (Borroni et al., 2009), FUS/TLS (Van Langenhove et al., 2010), C9orf72 
(Simon-Sanchez et al., 2012) and other genes (see Van Langenhove et al., 2013) have 
also been associated with forms of FTLD, strongly propounding an aetiological link 
between the two diseases. In addition, epidemiological evidence indicates that first– and 
second–degree relatives of ALS patients bear a two–fold increased risk for the 
development of dementia (Fallis & Hardiman, 2009; Majoor-Krakauer et al., 1994), 




Evidence for phenotypic variability among patients with distinct genetic mutations 
exists. For example, SOD1 gene carriers typically show a different site of onset (in the 
lower limbs) than TARDBP mutation carriers (in the upper limbs) (Millecamps et al., 
2010a). ALS patients with C9orf72 expansions are more likely than those with other 
ALS–related mutations to present with bulbar signs (Chio et al., 2012; Millecamps et 
al., 2012) and cognitive impairment or FTD (Byrne et al., 2012). In ALS patients with 
co–morbid FTD, behavioural changes and psychotic features were associated with 
C9orf72 carriers rather than non–carriers (Snowden et al., 2013). In addition, patients 
with truncating mutations in the FUS/TLS gene show a more aggressive disease course 
and a younger age at onset, than those with missense mutations of the same gene 
(Waibel et al., 2013). The exploration of genotype–phenotype relationships is an 
exciting and potentially valuable enterprise for research and clinical practice. Some 
researchers propose the future practicality of stratifying patients in clinical trials or 
personalising therapeutics on the basis of genotypic information (Al-Chalabi et al., 
2012). Although, genetic mutations may not be the sole determinant of the clinical 
presentation, as phenotypic heterogeneity between and among families with inherited 
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ALS suggest that environmental or other genetic factors influence symptom 
predominance and the rate of disease evolution (Millecamps et al., 2010b).  
 
1.4. Clinical characteristics 
 
The hallmark of MND is progressive degeneration of the motor neurons of the motor 
system, leading to limb weakness and paralysis, speech and swallowing difficulties and 
respiratory failure. Two types of neurons are relevant: the upper motor neurons (UMNs) 
and lower motor neurons (LMNs). UMNs arise in the primary motor region and project 
down the corticospinal tract (CST) to the brainstem where they decussate to the 
contralateral side of the body and provide impulses to the LMNs. The LMNs originate 
in the spinal cord and brainstem from where they extend via the peripheral nerves to 
stimulate the muscles. Please see Figure 1.1. for a simplified illustration of the motor 
system.  
 
The spectrum of MND presentations encompasses disorders in which degeneration is 
restricted to the UMNs or the LMNs; or a combination of both, resulting in different 
MND subtypes. Degeneration of both UMNs and LMNs corresponds to the ALS 
variant, whilst predominant LMN and UMN degeneration results in Progressive 
Muscular Atrophy (PMA) and Primary Lateral Sclerosis (PLS), respectively. 
 
1.4.1. Amyotrophic Lateral Sclerosis (ALS) 
 
ALS is the most prevalent form of MND; accounting for approximately 85% of cases 
(Norris et al., 1993; Talbot, 2002). The term ALS was first conceived by Charcot and 
Joffroy in the 19
th
 century to describe a combination of UMN and LMN dysfunction. 
This MND subtype leads to a clinical picture of muscle fatigue, atrophy and spasticity. 
Muscle cramping and involuntary contractions may precede noticeable muscle 
weakness and atrophy but are seldomly the presenting symptoms (Wijesekera & Leigh, 
2009).    
 
The most common region of symptom onset is in the limbs, where distal or proximal 
weakness of the upper or lower limb muscles may appear. Patients might experience 
foot drop or notice focal muscle wasting. Limb onset is more common in men, 
particularly between the ages of 65 and 84 years. Bulbar onset occurs in approximately 
25% of cases and manifests in the form of sialorrhea (excessive drooling), dysphagia 
(swallowing difficulty), dysarthria (motor speech disorder) and tongue wasting. Bulbar 
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presentation is more common in older patients, with 43% of patients over the age of 70 
presenting with bulbar onset in comparison to 15% for those under 30 years of age 
(Haverkamp et al., 1995). Approximately 5% of patients present with respiratory onset, 
showing signs of diaphragmatic weakness in the absence of significant bulbar or limb 
symptoms (Chen et al., 1996; de Carvalho et al., 1996).  
 
Approximately 10% – 20% of ALS patients survive longer than 10 years (Chio et al., 
2009). Population–based research suggests that younger age, a prolonged interval from 
symptom onset to diagnosis (indicating less aggressive progression) and a 
predominance of UMN signs are associated with survival times beyond eight years 
(Zoccolella et al., 2008b). The region of onset is an important prognostic factor, as 
bulbar onset disease is associated with poorer prognosis compared to limb onset (del 
Aguila et al., 2003; Zoccolella et al., 2008a). Reduced forced vital capacity (FVC) at 
diagnosis is also associated with poorer survival (Czaplinski et al., 2006), but 
respiratory onset disease does not necessarily entail a rapidly progressive decline as 
comparable survival times between bulbar and respiratory onset patients using 
ventilation assistance have been found (Shoesmith et al., 2007). Other negative 
prognostic indicators include symptom progression rate, older age (Logroscino et al., 
2008), poor psychosocial status (Johnston et al., 1999; McDonald et al., 1994) and 
dementia comorbidity (Olney et al., 2005). More recently, a population–based study 
found that executive dysfunction was significantly associated with reduced survival in a 
























Reprinted with permission from "Amyotrophic lateral sclerosis 
(motor neuron disease): proposed mechanisms and pathways to 
treatment," by E.F. Goodall and K.E. Morrison, 2006, Expert 
Reviews in Molecular Medicine, 8 (11), pg. 2.  
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1.4.2. Familial Amyotrophic Lateral Sclerosis (fALS) 
 
ALS is generally accepted to be familial if the disease is reported in a first or second 
degree relative of the respective ALS patient. Epidemiological studies suggest that 
approximately 0.8% – 13.5% of patients report a family history; however, this 
prevalence increases to 17% – 23% in genealogical studies (Andersen & Al-Chalabi, 
2011). There are several patterns of inheritance including autosomal dominance with 
complete and incomplete penetrance (Orrell, 2000); as well as recessive transmission 
(Al-Chalabi et al., 1998; Gros-Louis et al., 2006). In response to the absence of clearly 
defined criteria for fALS, Byrne and his colleagues propose guidelines for diagnosis to 
aid epidemiological and genetic research (Byrne et al., 2011). These classify patients 
into categories of diagnostic certainty, such as ‘definite’, ‘probable’ and ‘possible’ 
fALS, on the basis of family history, genetics and neurodegeneration (or presence of 
family history of FTD). Approximately 20% of fALS cases are causally linked to SOD1 
mutations (Turner et al., 2013), while TARDBP and FUS/TLS mutations account for 
3.0% and 4.4%, respectively (Lagier-Tourenne & Cleveland, 2009; Millecamps et al., 
2010b). The C9orf72 expansion is responsible for approximately 40% of fALS 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). Clinically, fALS and sporadic 
ALS are indistinguishable, and, as discussed previously, share common genetic 
mutations and show similar pathological patterns. However, relative to the sporadic 
form, the fALS subgroup shows a younger age at onset and typically presents with limb 
symptomology. Gender distribution is equal between the two groups (Hand & Rouleau, 
2002; Li et al., 1988; Mulder et al., 1986).  
 
1.4.3. Primary Lateral Sclerosis (PLS) 
 
PLS is a variant of MND which is characterised by UMN degeneration and absent or 
minimal LMN symptoms, although electrophysiological evidence of LMN denervation 
may be present (Le Forestier et al., 2001). It is clinically differentiated from ALS on the 
basis of a lack of LMN symptoms, such as muscle wasting and fasciculations. Instead, 
patients typically present with increased muscle tone and spasticity of the limbs 
(Hudson et al., 1993). Bulbar symptoms at onset are uncommon in PLS (Tartaglia et al., 
2007). It is a rare subtype, occurring in approximately 5% – 10% of MND cases. The 
mean age of onset is between 45 to 54 years (Singer et al., 2007). The gender 
distribution shows a slight male predominance (Worms, 2001). Cognition was 
traditionally believed to be intact (Pringle et al., 1992), but recent evidence of cognitive 
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and behavioural dysfunction comparable to that seen in ALS has been reported (Grace 
et al., 2011).  
 
Over time the disease may progress and severity of an isolated region may worsen or 
LMN symptoms might develop (Floeter & Mills, 2009). Some PLS cases, may progress 
to meet criteria for ALS (Bruyn et al., 1995). Prognosis is typically better in PLS than 
ALS, with survival times reported at over 14 years. The disease progression is insidious 
and includes periods of accelerated decline and stability (Floeter & Mills, 2009; 
Tartaglia et al., 2007). The differentiation of MND patients with and without LMN 
signs appears to be an important indicator for prognosis. Patients with PLS who present 
or develop even subtle signs of LMN or electromyography (EMG) abnormalities show 
shorter survival compared to patients with exclusive UMN involvement (Gordon et al., 
2009). It is difficult to distinguish PLS from the ALS subtype early in the disease 
course, as classical ALS might initially present without noticeable LMN signs. For this 
reason, some authors recommend a period of 3 to 4 years without LMN signs for a 
definitive PLS diagnosis (Gordon et al., 2006; Pringle et al., 1992; Tartaglia et al., 
2007). 
 
Whether PLS and ALS are distinct disorders or different clinical presentations of the 
same disease remains controversial. Due to the relative rarity of PLS, few studies 
examining common pathological mechanisms with ALS are available. Nonetheless, 
case reports have noted occurrences of familial ALS and PLS phenotypes within the 
same families (Brugman et al., 2005; Praline et al., 2010), suggesting common genetic 
factors promoting motor degeneration. However, structural differences in white matter 
(WM) changes between the two disorders have been observed (Iwata et al., 2011), 
indicating distinct underlying pathology.  
 
1.4.4. Progressive Muscular Atrophy (PMA)  
 
The PMA subtype is characterised by the degeneration of the spinal motor neurons and 
exclusive lower motor neuron (LMN) involvement, such as muscle atrophy and 
weakness, almost always in the limbs. However, as the disease evolves, patients may 
develop typical ALS, which includes bulbar and upper motor neuron symptoms. 
Approximately 5% – 10% of MND patients are classified as suffering from PMA 
(Maragakis, 2010; Norris et al., 1993; Traynor et al., 2000b). In comparison to ALS, 
PMA is associated with a later age at diagnosis (Maragakis, 2010) and better prognosis, 
with survival times of approximately 200 months from symptom onset. The gender bias 
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is more marked in PMA, as a male to female ratio of 2:1 is consistently reported. A 
third of PMA cases survive beyond five years and 12% beyond 10 years according to a 
population–based study (Norris et al., 1993; Visser et al., 2007). Cognitive involvement 
is not strongly associated with the disease. An early neuropsychological study found 
that, unlike their ALS sample, PMA patients did not show cognitive impairment (Wicks 
et al., 2006); while, a larger study did find deteriorated performance on tasks of 
executive function and memory in their PMA sample (Raaphorst et al., 2011).  
 
The disease is considered a distinct nosological entity under current diagnostic criteria 
(Brooks et al., 2000), but recent evidence suggesting common clinical, genetic and 
pathological characteristics with ALS may endorse PMA as a clinical position within a 
broader ALS spectrum. A histological study of 18 PMA patients reported CST 
degeneration as a prevalent feature (50%) in their sample upon autopsy. In addition, 
ALS–associated ubiquitinated inclusions were also found in the spared motor neurons 
(Ince et al., 2003). Moreover, recent evidence has identified genetic mutations common 
to familial and sporadic ALS subtypes, such as SOD1, in patients presenting with 
isolated LMN signs (van Blitterswijk et al., 2012).  
 
1.4.5. ALS–Frontotemporal Lobar Degeneration (ALS–FTLD) 
 
The broad clinical heterogeneity of ALS is exemplified by its possible co–morbidity 
with another neurodegenerative condition, FTLD. This disease is characterised by focal 
atrophy of the frontal and anterior temporal lobes of the brain. It is associated with 
distinct syndromes of cognitive and behavioural dementias, defined here collectively as 
frontotemporal dementia (FTD). ALS–FTLD patients show the typical physical 
symptoms of ALS, with concomitant cognitive and/or behavioural changes common to 
FTD. These symptoms may follow, precede or present simultaneously with motor 
symptoms. FTD is divided into two variants: behavioural–variant–Frontotemporal 
Dementia (bvFTD) and Primary Progressive Aphasia (PPA). The two variants are 
associated with distinct behavioural and language–dominant symptoms respectively; an 
overlap of these symptoms has been reported in ALS–FTD (Bak & Hodges, 2004; Bak 
et al., 2001; Caselli et al., 1993; Mitsuyama & Takamiya, 1979). PPA, itself, is divided 
into two subtypes: progressive non–fluent aphasia (PNFA) and semantic dementia (SD). 
These FTLD–dementia subtypes are illustrated in Figure 1.2.  
 
FTD is the second most common dementia for adults under 65 years of age, showing an 
estimated prevalence of 10 – 20 per 100,000 and an incidence of 3.5 – 4.1 per 100,000  
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per year in this age group (Knopman et al., 2004; Mercy et al., 2008; Ratnavalli et al., 
2002). Prevalence rates for FTD in ALS vary from 5% – 18% (Goldstein & Leigh, 
1999; Lomen-Hoerth et al., 2003; Neary et al., 1990; Ringholz et al., 2005). 
Approximately 15% of FTD patients develop ALS symptoms following a diagnosis 
(Burrell et al., 2011; Lomen-Hoerth et al., 2002). Due to the variable nomenclature used 
in published studies, it is difficult to discern if these rates include all the FTD 
syndromes, or are weighted towards a particular variant. There is an impression of a 
predominant bvFTD profile in ALS–FTD (Lillo et al., 2010; Neary et al., 1990), but 



























2Figure 1.2.: Subtypes of Frontotemporal Lobar Degeneration (FTLD) associated     




Risk factors for the development of FTD in the course of ALS have not been 
determined, but some evidence suggest that bulbar–onset (Giordana et al., 2011; Neary 
et al., 2000) and presence of the C9orf72 gene mutation (Gijselinck et al., 2012; 
Whitwell et al., 2012) may increase patient susceptibility. The identification of co–
morbidity in ALS is of great clinical relevance. Relative to classical ALS patients, 
ALS–FTD patients show a more aggressive disease course and reduced median survival 
times (Gordon et al., 2010; Olney et al., 2005). Furthermore, the predominant FTLD 
phenotype occurring alongside ALS holds important implications for disease 
progression, as language–dominant ALS–PPA has been associated with bulbar 
symptomology and shorter survival than ALS–bvFTD (Coon et al., 2011). The clinical 
characteristics of each syndrome are described below. Diagnostic criteria for ALS–FTD 
are detailed in Section 1.5. An overview of the literature regarding the cognitive and 
behavioural profiles of ALS–FTD is provided in Chapter 2, Section 2.1.    
 
A. ALS–behavioural–variant–Frontotemporal Dementia (ALS–bvFTD) 
 
The co–existence of ALS symptoms and overt progressive behavioural change is 
recognised as ALS–bvFTD. In pure bvFTD, changes in personality, affect and social 
conduct are typical of the clinical picture, reflecting atrophy of the orbital and mesial 
frontal lobes (Neary et al., 2005).  Emotional blunting or apathy as well as disinhibited, 
perservative and sterotyped behaviour may present, either alone or alongside executive 
dysfunction. Patients may display reduced empathic response to others and lack insight 
into (anosognosia) or concern for (anosodiaphoria) their illness (Mendez & Shapira, 
2011; Neary et al., 1998). Psychotic symptoms may also be present, complicating the 
diagnosis (Floris et al., 2013; Snowden et al., 2013; Woolley et al., 2007b). Altered 
eating habits are common (Ikeda et al., 2002; Woolley et al., 2007a). Visuospatial and 
memory functions are typically preserved (Neary et al., 1998; Neary et al., 2005). A 
recent systematic review of nine studies (reporting 170 cases) described a similar profile 
of behavioural change in ALS–bvFTD to that of the pure bvFTD form, noting apathy, 
perseveration and disinhibition as the most commonly reported changes (Raaphorst et 
al., 2012). 
 
B. ALS– Primary Progressive Aphasia (ALS–PPA) 
 
ALS may also present concurrently with Primary Progressive Aphasia (PPA) in a 
phenotype referred to as ALS–PPA. Two subtypes of PPA have been associated with 
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ALS, namely progressive non–fluent aphasia (PNFA) and semantic dementia (SD). The 
former subtype is a disorder of expressive language, characterised by agrammatism 
(ungrammatical sentence construction), phonemic paraphasia (mispronunciation) and 
anomia (word retrieval failure). Word comprehension remains intact. In contrast, SD is 
a disorder of language meaning, in which patients display impaired naming and word 
comprehension; fluent speech but reduced content. Perceptual disorder, such as 
prosopagnosia (impaired face recognition) and associative agnosia (impaired object 
identification) may also be present (Neary et al., 1998; Neary et al., 2005). Each 
subtype is associated with distinct areas of cerebral atrophy: PNFA is associated with 
asymmetric atrophy of the left hemisphere, whilst SD is correlated with bilateral 
atrophy of the middle and inferior temporal neocortex (Neary et al., 2005). SD and 
bvFTD symptoms may overlap, with some SD patients displaying social disinhibition, a 
lack of insight and reduced empathy as the disease progresses (Grossman, 2010; Rosen 
et al., 2006). 
 
1.5. Diagnosis & diagnostic criteria 
1.5.1. Amyotrophic Lateral Sclerosis (ALS) 
 
As no accepted biomarkers for the disease currently exist, ALS diagnosis is established 
on the basis of characteristic features and the exclusion of possible mimic syndromes. 
Clinical, genetic, neuroimaging and electrophysiological data are used to aid and 
corroborate diagnosis. Symptoms indicative of combined upper and lower motor neuron 
impairment, which cannot be accounted for by co–morbid disease processes are 
suggestive of ALS. The El Escorial Revised criteria (Brooks et al., 2000) classifies 
patients into four categories: “Clinically Definite”; “Clinically probable”; “Clinically 
probable–laboratory supported”; and “Clinically possible” (see Table 1.1.). However, 
these criteria may fail to identify a large proportion of patients who, in the early stages 
of the disease, do not show clinical signs of UMN involvement, but may have ALS or a 
related variant. Furthermore, early detection of UMN signs with EMG is difficult 
(Rowland & Shneider, 2001). As a result, it has been suggested that these standards are 
more useful for research settings (Silani et al., 2011). Clinical practice might benefit 
from recently devised guidelines which combine the current criteria with expanded 
electrophysiological data. Known as the Awaji–Criteria (AC; de Carvalho et al., 2008), 
these standards suggest the inclusion of fasciculation potentials, characteristic of ALS, 
as evidence for developing denervation in the context of chronic neurogenic changes. 
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Earlier detection of ALS and greater diagnostic sensitivity for AC relative to the EL 
Escorial Revised Criteria has been demonstrated (Boekestein et al., 2010; Carvalho & 
Swash, 2009; Okita et al., 2011), yet the latter remains the current gold standard of ALS 
diagnosis for research purposes (Dengler, 2012). 
 
 
Table 1.1.: The El Escorial Revised Criteria for the diagnosis of ALS (adapted from 
Brooks et al 2000)  
 
 
1.5.2. ALS–Frontotemporal Dementia (ALS–FTD) 
 
The diagnosis of ALS–FTD is complex, due to the heterogeneous presentation of co–
morbid disease. ALS patients may experience mood and behavioural changes as a 
response to the emotional implications of a terminal diagnosis. Language or speech may 
appear compromised as a result of motor dysfunction. It is thus important that the 
perceived changes represent a marked departure from the patient’s premorbid state and 
that physical impairment is accounted for at diagnosis (Strong et al., 2009). Although 
not designed for use in ALS, criteria for FTD are commonly used to confirm co–
occurrence of the disease (Gregory et al., 1999; McKhann et al., 2001; Neary et al., 
1998). The 1998 International Consensus Criteria for FTLD proposed by Neary and 
colleagues (see Table 1.2.) are widely used in research and practice. Core clinical 
features for the distinct sub–syndromes of FTD are outlined (Neary et al., 1998). 
The diagnosis of ALS requires the presence of: 
A1: Evidence of LMN degeneration by clinical, electrophysiological or        
neuropathological examination 
A2: Evidence of UMN degeneration by clinical examination 
A3: Progressive spread of symptoms or signs within a region or to other regions 
  Together with the absence of: 
B1: Electrophysiological and pathological evidence of other disease processes that 
might explain the signs of LMN and/or UMN degeneration 
B2: Neuroimaging evidence of other disease processes that might explain the 
observed clinical and electrophysiological signs 
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Common to all sub–syndromes, an insidious onset and gradual progression of 
symptoms must be present. Beyond this criterion, each sub–syndrome is associated with 
distinct core features; the profiles of which are disproportionately behavioural or 
language–related for bvFTD and PPA, respectively. Supportive features, although not 
mandatory, are also listed to affirm the diagnosis. Motor neuron disease symptoms are 
categorised under an extension of the clinical diagnostic features. Formal 
neuropsychological testing, electroencephalography (EEG) and brain imaging are used 
to corroborate the clinical diagnosis, but are not a prerequisite.  
 
These criteria indicate good predictive value of ante mortem FTLD pathology 
(Knopman et al., 2005; Pijnenburg et al., 2008) and high sensitivity has been 
demonstrated (Knopman et al., 2005), although this is variable (Mendez & Perryman, 
2002; Piguet et al., 2009; Rascovsky et al., 2007). Some authors have questioned the 
sensitivity of these guidelines for their under–specification of some features, the number 
and nature of exclusion features, and their inflexible structure, which may lack 
sensitivity to early–stage bvFTD or variable symptom presentation (i.e. by requiring 
patients to meet all 5 core features) (Rascovsky et al., 2011). Consequently, revised 
guidelines for the diagnosis of bvFTD have been proposed by the International 
Behavioural Variant FTD Criteria Consortium (FTDC) (Rascovsky et al., 2011). These 
expand upon the earlier specifications and provide three levels of diagnostic certainty 
under a hierarchy of ‘definite’, ‘probable’ or ‘possible’ bvFTD (See Table 1.3.). The 
‘possible’ classification specifies that patients must show three out of six core features 
of bvFTD, eliminating the distinction between core and supportive features. ‘Probable’ 
bvFTD patients must meet criteria for the ‘possible’ diagnosis, but must also show 
functional decline and imaging results consistent with bvFTD. Together these 
classifications are deemed most useful to distinguish early bvFTD from other FTLD 
phenotypes and AD. ‘Definite’ bvFTD is reserved for patients who show core disease 
features and neuropathological or genetic evidence of FTLD. In keeping with the 
original consensus, the FTDC guidelines acknowledge motor neuron disease symptoms 
as possible overlapping features. A comparison of the original and revised criteria 
against retrospective neuropathological data, showed improved bvFTD sensitivity for 
the revised classification in a large cohort of patients (n=137; Rascovsky et al., 2011), 
while a later report showed that the revised criteria showed high sensitivity and 
specificity for early-onset bvFTD when applied to a larger (n=156) autopsy-confirmed 
cohort (Harris et al., 2013).   
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Table 1.2.: Core criteria for the diagnosis of FTLD subtypes (adapted from Neary et 















Behavioural–variant frontotemporal dementia 
1. Insidious onset and gradual progression 
2. Early decline in social interpersonal conduct 
3. Early impairment in regulation of personal conduct 
4. Early emotional blunting 
5. Early loss of insight 
 
Progressive non–fluent aphasia 
 
1. Insidious onset and gradual progression 
2. Non–fluent spontaneous speech with at least one of the following:  
Agrammatism, phonemic paraphasias, anomia.  
 
Semantic dementia 
1. Insidious onset and gradual progression  
2. Language disorder : fluent empty spontaneous speech, loss of word meaning, 
manifest by impaired naming and comprehension and semantic paraphasias  
and/or 
Perceptual disorder: prosopagnosia (impaired recognition of faces) and/or 
associative agnosia (impaired recognition of objects) 
3. Preserved perceptual matching 
4. Preserved single word repetition  






The following symptom must be present to meet criteria for bvFTD:  
 
1. shows progressive deterioration of behaviour and/or cognition by observation or    




Three of the following behavioural/cognitive symptoms must be present to meet 
criteria: 
 
1. Early behavioural disinhibition; one of the following symptoms must be present: 
                 1.1. Socially inappropriate behaviour 
                 1.2. Loss of manners or decorum 
                 1.3. Impulsive, rash or careless actions 
 
2. Early apathy or inertia; one of the following symptoms must be present: 
                 2.1. Apathy 
                 2.2. Inertia 
 
3. Early loss of sympathy or empathy; one of the following symptoms must be   
    present: 
                 3.1. Diminished response to other people’s needs and feelings 
                 3.2. Diminished social interest, interrelatedness or personal warmth 
 
4. Early perseverative, stereotyped or compulsive/ritualistic behaviour; one of the  
    following symptoms must be present: 
                 4.1. Simple repetitive movements 
                 4.2. Complex, compulsive or ritualistic behaviours 
                 4.3. Stereotypy of speech 
 
5. Hyperorality and dietary changes; one of the following symptoms must be present: 
                 5.1. Altered food preferences 
                 5.2. Binge eating, increased consumption of alcohol or cigarettes 
                 5.3. Oral exploration or consumption of inedible objects 
 
6. Neuropsychological profile: 
                 6.1. Deficits in executive tasks 
                 6.2. Relative sparing of episodic memory 




All of the following symptoms must be present to meet criteria: 
1. Meets criteria for possible bvFTD 
      2.   Exhibits significant functional decline  




Criterion 1. and either criterion 2. or 3. must be present to meet criteria: 
1.  Meets criteria for possible or probable bvFTD 
2.  Histopathological evidence of FTLD on biopsy or at post mortem 
3.  Presence of a known pathogenic mutation 
 
Table 1.3.: Revised international criteria for the diagnosis of bvFTD (adapted   




The following symptom must be present to meet criteria for bvFTD:  
 
1. shows progressive deterioration of behaviour and/or cognition by observation or    




Three of the following behavioural/cognitive symptoms must be present to meet 
criteria: 
 
1. Early behavioural disinhibition; one of the following symptoms must be present: 
                 1.1. Socially inappropriat  behaviour 
   1.2  Loss of manners or decorum 
                 1.3. Impulsive, rash or careless actions 
 
2. Early apathy or inertia; one of the following symptoms must be present: 
                2.1. Apathy 
                 2.2. Inerti  
 
3. Early loss of sympathy or empathy; one of the following symptoms must be   
    present: 
                 3.1. Diminished response to other people’s needs and feelings 
                 3.2. Diminished social interest, interrelatedness or personal warmth 
 
4. Early perseverative, stereotyped or compulsive/ritualistic behaviour; one of the  
    following symptoms must be present: 
                 4.1. Simple repetitive movements 
                4.2. Complex, compulsive or ritualistic behaviours 
                 4.3. Stereotypy of speech 
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1.5.3. Non–demented Amyotrophic Lateral Sclerosis with cognitive impairment 
(ALSci) and/or behavioural impairment (ALSbi) 
 
Strong and colleagues’ consensus criteria (2009) provide a unified framework which 
subtypes the range of cognitive impairment apparent in ALS patients. This framework 
provides clinicians and researchers with definite impairment cut–off criteria and advises 
the discernment of appropriate clinical control variables which might account for 
impairment (for example, mood, co–morbid disease and other disease symptoms, such 
as respiratory dysfunction). In clinic, should cognitive screening suggest dysfunction, a 
full neuropsychological assessment would be required to make a formal diagnosis of 
impairment. Currently, six categories of cognitive impairment are acknowledged in 
ALS. Here, only ALSci and ALSbi categories are introduced, but Table 1.4. illustrates 
the criteria for all subtypes of ALS–related cognitive dysfunction.  
   
A. ALSci  
 
ALSci characterises patients who do not fulfil current FTD dementia (or another 
dementia syndrome) but who perform at or below the 5
th
 percentile on at least two 
distinct standardised neuropsychological measures sensitive to executive functioning, 
when compared to age– and education–matched norms from healthy controls. The 
guidelines recommend the assessment of other cognitive domains such as language, 
memory, attention and visuoperception in order to exclude the possibility of other 




The ALSbi category describes patients who do not meet criteria for bvFTD, but who are 
rated by caregivers as having at least two non–overlapping behavioural changes, as 
measured by either the Neary et al FTD criteria (Neary et al., 1998; Neary et al., 1990) 
or Hodges et al bvFTD criteria (Gregory et al., 1999).  
 
In cases where patients present with both executive dysfunction and behavioural 
change, concurrent ALSci and ALSbi diagnoses may be warranted. These criteria have 
encountered criticism, mostly regarding their failure to address the heterogeneity of 
cognitive impairment that has been documented in ALS (Goldstein & Abrahams, 2013). 
Since the recommended assessment for impairment is weighted towards executive 
function, this might compromise the detection of deficits in other cognitive domains, 
such as language dysfunction which can occur alongside or independent of executive 
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dysfunction (Taylor et al., 2013). Furthermore, deficits in emotional processing and 
social cognition have been shown in ALS patients (see Chapter 2, Section 2.3.) but 
there is no consensus on whether or how these should be assessed. Finally, these criteria 






Table 1.4.: Criteria for cognitive and behavioural impairment in ALS (adapted  
from Strong et al, 2009)  
ALS–FTD ALS–bvFTD ALS patient meeting criteria for either 
Neary et al criteria or Hodges et al criteria 
for bvFTD  
 
 ALS–PNFA ALS patient meeting Neary et al criteria 
for PNFA 
 
 ALS–SD ALS patient meeting Neary et al criteria 
for SD 
 
ALSbi  ALS patient meeting at least two non–
overlapping supportive diagnostic features 
from either Neary et al criteria or Hodges’ 
et al criteria for bvFTD 
 
ALSci  ALS patient with evidence of cognitive 
impairment at or below 5
th
 percentile on at 
least two distinct tests of cognition that are 
sensitive to executive functioning 
 
FTD–MND–like  Patient with primary FTLD diagnosis with 
evidence of MND–type degeneration 
insufficient to be classified as ALS  
 




` ALS patient with concurrent dementia 
and/or parkinsonism occurring in 






1.5.4. Differential diagnosis 
 
There are many conditions with features that closely resemble ALS, further 
complicating the diagnosis process. These ‘mimic syndromes’ are suspected on the 
basis of unusual symptomatology, an atypical presentation of symptoms or a stable 
disease course (Traynor et al., 2000a). Population–based studies have estimated that up 
to 10% of ALS diagnoses may in fact be other disorders (Davenport et al., 1996; 
Traynor et al., 2000a). Here, two disorders which are most commonly misdiagnosed as 
ALS (Traynor et al., 2000a) are briefly described, but this does not exhaust the list of 
possible mimic disorders.  
 
Kennedy’s Disease, also known as X–Linked bulbospinal neuronopathy or spinal and 
bulbar muscular atrophy, is a genetic disorder caused by a trinucleotide repeat in the 
androgen receptor gene (Finsterer, 2010). Its clinical features include slowly 
progressive lower motor neuron signs in the bulbar and proximal limbs. Differentiation 
from ALS is demonstrated on nerve conduction examinations in which Kennedy’s 
disease does not show sensory nerve action potentials, characteristic of ALS (Hardiman 
et al., 2011). Genetic testing is also conducted to distinguish the two diseases. The 
disease is progressively slower than ALS and life expectancy is not greatly affected 
(Finsterer, 2009).  
 
Another ALS–like disorder is multifocal motor neuropathy with conduction block. This 
is a slowly progressive condition presenting as asymmetric muscle weakness, selective 
involvement of the finger extensors and in some cases the presence of antiganglioside 
antibodies. The condition can be remediated with the introduction of intravenous 
immunoglobulin (IVG) treatment (Federico et al., 2000). In practice, IVG may be 
prescribed to patients presenting with ALS symptoms to rule out an 
immunopathological mechanism (Radunovic et al., 2007). 
 
 
1.6. Neuropathology  
1.6.1. ALS 
 
As previously described in Section 1.4., ALS is characterised by relative degrees of 
upper and lower motor neuron degeneration of the motor system. UMN pathology may 
encompass astrogliosis (neuronal scarring) in the grey matter (GM) and subcortical WM 
of the motor cortices, as well as axonal loss and demyelination in the CST (Ince et al., 
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1998a). Early studies suggested depopulation of UMNs in the primary motor cortex 
(Brownell et al., 1970; Nihei et al., 1993). However, later stereological investigations 
found no significant difference in the number or size of these neurons in this region 
(Gredal et al., 2000; Toft et al., 2005). LMN pathology may manifest as neuronal loss 
in the brainstem and ventral horn of the spinal cord (Ince et al., 1998a). 
 
At the molecular level, pathological hallmarks include abnormal neuronal and glial 
cystoplasmic inclusions in surviving neurons. Hyaline conglomerate inclusions are one 
type of body which may dislodge neuron contents, such as the nucleus (Ince et al., 
1998b). These inclusions are rare and associated with SOD1 mutation carriers (Kokubo 
et al., 1999). More prevalent are Bunina bodies (BBs), inclusions which are specific to 
ALS and occur in approximately 86% of cases (Piao et al., 2003). They are granule–like 
bodies found in spinal anterior horn cells (Hirano, 1996). BBs tend to occur alongside 
ubiquitin–immunoreactive intraneuronal inclusion bodies, within the same cell (Mori et 
al., 2010). The relationship between these inclusion types is undetermined. In 2006, the 
protein TARDBP of 43 kDa (TDP–43) was identified as a major component of these 
ubiquitinated inclusions in a majority of ALS and FTLD cases (Arai et al., 2006; 
Neumann et al., 2006). TDP–43 is an amino acid nuclear protein encoded by the 
TARDBP gene and which functions for ribonucleic acid (RNA) metabolism (Buratti & 
Baralle, 2009). TDP–43 inclusions are principal protein deposits in a high proportion of 
ALS cases, occurring in all 102 cases in one report (Piao et al., 2003). Some familial 
ALS cases resulting from SOD1 mutations have shown absent TDP–43 pathology 
(Mackenzie et al., 2007), raising the possibility of distinct pathologies underlying the 
disease. TDP–43 inclusion bodies are morphologically and functionally similar to 
FUS/TLS inclusions. The displacement of either inclusion in the cytoplasm of neurons 
might lead to loss of typical function of the nuclear protein, a gain of toxic function in 
intracellular fluid (ICF) or both (Lagier-Tourenne & Cleveland, 2009). FUS/TLS 
inclusions have been reported in ALS patients with and without FUS/TLS mutations 
(Deng et al., 2010; Vance et al., 2009), implying a role of FUS/TLS in the pathogenesis 
of sporadic and other familial forms of the disease. 
 
Pathology is not necessarily restricted to the motor system in ALS. 
Immunohistochemical surveys of extra–motor pathology in ALS patients have revealed 
TDP–43 and other inclusions in regions such as the nigro–striatal system, the 
cerebellum, amygdala, hippocampus and neocortex (Geser et al., 2008; Geser et al., 
2009; Mackenzie et al., 2006; Neumann et al., 2006; Tan et al., 2007). Furthermore, 
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extra–motor functional and structural changes in non–demented ALS patients have been 
documented in the frontotemporal regions; the corpus callosum, hippocampus and 
amygdala. These observations support the proposal that ALS is a multisystem disorder 
extending beyond the motor system.  
  
1.6.2. ALS–FTLD and FTLD 
 
In FTLD, distinct neuropathological changes are associated with each variant. This 
pattern of change is replicated in the various subtypes of ALS–FTLD. In bvFTD, 
atrophy of the mesial and orbital frontal regions occurs early in the disease course, 
typically progressing to encompass the temporal pole, hippocampal formation, 
dorsolateral cortex and basal ganglia (Kril et al., 2005; Piguet et al., 2011). Similarly, 
ALS–bvFTD is associated with prominent neuronal loss, gliosis, spongiosis and atrophy 
of the frontal and temporal cortices, the hippocampus, amygdala, striatum and basal 
ganglia (Chang et al., 2005; Coon et al., 2012; Ferrer et al., 1991; Garraux et al., 1999; 
Mackenzie & Feldman, 2004; Yoshida, 2004). The extent of cerebral pathology in the 
frontal cortex, in particular, has been shown to differentiate ALS–bvFTD patients from 
ALS patients without dementia (Murphy et al., 2007a; Talbot et al., 1995; Wilson et al., 
2001).  
 
The PPA variants of FTLD are associated with differential pathology. PNFA is 
associated with predominant left fronto–insular degeneration, while SD is related to 
bilateral atrophy of the anterior temporal areas (Gorno-Tempini et al., 2011). Likewise, 
PNFA and SD in ALS patients show common patterns of neuropathology associated 
with each FTLD phenotype, in addition to the typical motor patterns of ALS (Bak et al., 
2001; Caselli et al., 1993; Davies et al., 2005; Kim et al., 2009; Yokota et al., 2006). 
 
Much like ALS, the molecular pathology of FTLD is heterogeneous. A proportion of 
FTLD patients show protein aggregations or deposits called tau (FTLD–tau). In other 
cases, tau deposits are undetected and instead inclusions which are immunoreactive to 
ubiquitin are present (FTLD–U) (Cairns et al., 2007; Josephs et al., 2011). As in ALS, 
TDP–43 forms the main component of these inclusions (FTLD–TDP) (Arai et al., 2006; 
Neumann et al., 2006). Subtypes of TDP inclusions are associated with different 
phenotypes of FTLD. Consequently, Mackenzie and colleagues offer an FTLD 
classification system based on ubiquitin pathology (Mackenzie et al., 2011). A small 
minority of FTLD patients have neither tau nor ubiquitin–positive inclusions 




A comparison of TDP–43 pathology between patients with ALS, ALS–FTD and 
FTLD–TDP showed an accordant pattern of pathology involving motor, frontotemporal 
and parietal regions. The extent and severity of neocortical pathology was greater in 
FTLD–TDP and ALS–FTLD patients compared to ALS patients. Clinical symptoms 
were related to predominant distribution and burden of TDP–43 pathology (Geser et al., 
2009). This continuum of TDP–43 pathology between the diseases substantiates the 
hypothesis that ALS and FTLD are expressions of the same disease process, with motor 
dysfunction and cognitive–behavioural impairment present on opposite sides of the 
clinical spectrum (Ince et al., 1998a; Mackenzie & Feldman, 2005). Similarly, 
FUS/TLS pathology has been indicated in ALS, ALS–FTLD and the bvFTD variant of 
FTLD (Deng et al., 2010; Neumann et al., 2009; Urwin et al., 2010), furthering the 
argument for a common pathogenesis. 
 
 
1.7. Neuroimaging in ALS  
1.7.1. Motor system dysfunction 
 
In keeping with neuropathological features of ALS, structural change along the CST 
and motor cortex has been observed using conventional and novel Magnetic Resonance 
Imaging (MRI) techniques (Abe, 1997; Charil et al., 2009; Cheung et al., 1995; Goodin 
et al., 1988; Roccatagliata et al., 2009). Involvement of the posterior limb of the 
internal capsule of the CST has been commonly noted in post–mortem and MRI studies 
of ALS patients (Goodin et al., 1988; Smith, 1960; Wang et al., 2006); a recent study 
suggests that measures of WM degeneration in this area acts as a prognostic indicator 
(Menke et al., 2012). Voxel–based morphometry (VBM) has reported grey matter (GM) 
loss in the precentral gyrus (Chen & Ma, 2010; Roccatagliata et al., 2009), which 
correlates with disease progression rate (Verstraete et al., 2010). GM volume loss in this 
region appears to correspond to functional disability, as a comparison of patient onset 
groups revealed that bulbar–onset and limb–onset patients showed differential atrophy 
in the bulbar segment and limb segment of the motor homunculus, respectively (Bede et 
al., 2012). 
 
Altered metabolite concentrations in primary motor cortex (PMC) and brain stem has 
also been documented. Magnetic Resonance Spectroscopy (MRS) allows for the non–
invasive measurement of tissue metabolites, such as N–acetlaspartate (NAA), choline 
(Cho) and creatine (Cr) (Turner et al., 2012). Studies have found decreased NAA and 
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Cr levels but increased Cho concentrations in the PMC of patients compared to controls 
(Bowen et al., 2000; Gredal et al., 1997; Mitsumoto et al., 2007; Pohl et al., 2001; 
Schuff et al., 2001). Altered metabolite concentrations, including glutamate, are also 
documented in the brain stem (Hanstock et al., 2002; Pioro et al., 1999). PMC 
metabolite concentrations correlate with disease severity, disease progression and UMN 
impairment (Abe et al., 2001; Mitsumoto et al., 2007; Pohl et al., 2001). Similarly, 
brainstem NAA/Cr ratios are found to be lower in patients with bulbar weakness  (Cwik 
et al., 1998).   
 
1.7.2. Extra–motor involvement 
 
Early imaging studies of extra–motor structural changes using Computerized 
Tomography (CT) in ALS produced inconsistent findings. One of the earliest studies to 
adopt CT alongside neuropsychological testing revealed that 57% of their ALS sample 
(8/14) displayed cerebral atrophy (David & Gillham, 1986). Later larger CT studies 
with samples including other MND variants (e.g. PMA, ALS–FTD) would challenge 
(n=18 ALS, n=17 PMA; Gallassi et al., 1989) and support these results (n=19 ALS, n=3 
ALS-FTD; Kato et al., 1993) concerning cortical atrophy. 
 
Studies of Single–Photon Emission Computed Tomography (SPECT) and Positron 
Emission Tomography (PET) were applied in ALS patients and obtained comparable 
results. Both techniques rely on the detection of radiation emitted from injected 
radioisotopes (e.g. glucose) in the brain, allowing the quantification of cerebral changes, 
such as oxygen or glucose metabolism and blood flow (Turner et al., 2012). Using 
SPECT, Ludolph, Elger & Böttger (1989) demonstrated global cortical reduction, as 
well as multifocal reduction in the frontotemporal areas, of 17 ALS patients. Findings 
of frontotemporal dysfunction correlates in non–demented ALS have since been 
corroborated by others using this technique (Abe et al., 1997; Abe et al., 1993; 
Waldemar et al., 1992; Waragai et al., 1997). One of the first comparative SPECT 
studies of ALS, ALS–FTLD and FTD patients found that, relative to controls, all patient 
groups showed a common pattern of reduced regional cerebral blood flow (rCBF) in the 
bilateral anterior and medial orbitofrontal cortex (OFC), anterior and medial frontal 
cortex and bilateral anterior temporal lobes. Neuropsychological impairment and 
cerebral abnormalities were present in ALS patients but both were more pronounced 
and widespread in the ALS–FTLD and FTD patients (Talbot et al., 1995), implying a 
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continuum of pathology between the diseases and suggesting a positive relationship 
between extra–motor dysfunction and cognitive impairment in ALS patients. 
 
Functional MRI (fMRI) data have also indicated multisystem involvement in ALS. 
Analysis of resting state brain networks in 20 ALS patients and controls found 
significant deactivation in both the sensorimotor and default–mode networks in patients 
only (Mohammadi et al., 2009). The latter network is an interconnected neural system 
comprising of frontal, parietal and temporal regions, showing high activity during rest 
and reduced activity during cognitive tasks (Raichle & Snyder, 2007). In this study, 
decreased volumes in the lateral and prefrontal cortex (PFC), the inferior parietal and 
posterior cingulate cortex in patients relative to controls were found, indicating 
significantly weaker functional connectivity.  Earlier studies have correlated activation 
patterns with neuropsychological indices in ALS patients. These studies are discussed 
alongside neuropsychological investigations of ALS in Chapter 2.  
 
Studies of GM in extra–motor areas complement fMRI findings in ALS. Chang and 
colleagues (2005) compared patients with ALS, ALS–FTD and controls using VBM. A 
reduction in GM volume in the frontal (left middle and inferior frontal gyri, frontal pole, 
ventromedial frontal cortex) and temporal (bilateral superior temporal gyri and right 
temporal pole) regions, as well as the left posterior thalamus was observed in all 
patients versus controls. On direct comparison of ALS–FTD patients with ALS patients, 
the former group showed a greater degree of atrophy in the left frontal gyri. Thus, in 
keeping with Talbot et al’s (1995) SPECT observations, a frontotemporal pattern of 
atrophy was found in both groups, supporting the purported pathological continuum 
between ALS and ALS–FTLD.  
 
Changes in WM were not reported in the above study. This is in contrast with previous 
MRI investigations (Abrahams et al., 2005a; Ellis et al., 2001; Kassubek et al., 2005; 
Senda et al., 2011), but in keeping with others (Agosta et al., 2009; Agosta et al., 2007; 
Filippini et al., 2010; Tsujimoto et al., 2011). These discrepant findings may be due to 
heterogeneous processes underlying ALS, resulting in no apparent distinct degenerative 
profile. Alternatively conventional MRI may lack sensitivity to WM changes compared 
to other advanced techniques. Diffusion Tensor Imaging (DTI) has been proposed as a 
more robust method of detection (Turner & Modo, 2010). This relatively new technique 
allows for the in vivo assessment of WM integrity by probing the diffusion of water 
molecules along WM tracts. Two indices are used to estimate diffusion. The first index, 
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fractional anisotrophy (FA), measures the degree of diffusion anistrophy and relates to 
the alignment of cellular structures. The second, Mean diffusivity (MD), is an index of 
the directionally averaged magnitude of diffusion and reflects the integrity of local 
neural tissue (Wang et al., 2011). A meta–analysis which pooled 8 whole–brain voxel–
based DTI studies that compared FA differences between non–demented ALS patients 
and controls revealed that, relative to controls, patients showed FA reductions in the 
bilateral frontal WM and cingulate gyrus. The results showed robustness and high 
replicability, remaining after jackknife sensitivity analysis was applied  (Li et al., 2012). 
Other DTI studies, which were not included in the meta–analysis, have supported 
changes to WM in the parietal lobes and corpus callosum, thalamus, hippocampal 
formation and insula (Ciccarelli et al., 2006; Filippini et al., 2010; Sach et al., 2004; 
Sage et al., 2007).  
 
1.8. Clinical management 
 
Although ALS remains incurable, many of the symptoms of the disease are treatable. 
Disease management is therefore focussed on symptom control, in order to provide the 
best level of patient functioning and quality of life (QoL). The variety of symptoms and 
treatment options available necessitates the involvement of clinicians from diverse but 
related fields. A multidisciplinary approach appears to prolong survival, decrease 
hospital admissions and enhance quality of life for patients attending tertiary clinics 
with such care models (Chio et al., 2006; Van den Berg et al., 2005).    
 
1.8.1. Musculoskeletal and otolaryngological symptoms 
 
In addition to muscle weakness and fasciculations, cramping and spasticity may also 
occur in ALS. Clinic or community–based physical therapy may be available to 
supplement symptom management alongside pharmacological treatments. Cramps may 
be relieved through prescription of quinine sulphate, phenytoin and carbamazepine, 
while baclofen, tizanidine, dantrolene sodium and benzodiazepines can be helpful to 
relieve spasticity. 
 
Sialorrhea or abnormal saliva production, which affects 50% – 70% of ALS individuals 
(Miller et al., 2009), may be moderated through the introduction of medications such as 
glycopyrrolate, hyoscyamine or amytriptyline, a tricyclic antidepressants. In addition, 
botulinum toxin injections into the parotid and submandibular glands are effective for 
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pronounced secretions (Jackson et al., 2009).  Radiation therapy applied to the salivary 
glands has also been trialled in ALS for sialorrhea control with satisfactory results, 
although side effects including nausea and throat soreness were reported in some 
patients (Harriman et al., 2001). 
 
1.8.2. Emotional lability  
 
Emotional lability (EL), also known as “pseudobulbar affect”, is described as 
involuntary episodes of contextually inappropriate or exaggerated outbursts of laughter, 
crying or smiling often without corresponding patient affect (Parvizi et al., 2009). The 
episode is often incongruent with the patient’s emotional state and/or incommensurate 
to the emotional valence of the eliciting stimulus. These inappropriate displays may be 
difficult to supress, causing patients social embarrassment. Further, the condition is 
largely misunderstood by the patients’ caregivers, causing secondary distress. The 
disorder is associated with various neurological conditions; in ALS an estimated 
prevalence as high as 71% has been reported (Palmieri et al., 2009). It is also more 
common in patients with bulbar symptomatology (Moore et al., 1997; Newsom-Davis 
et al., 1999; Palmieri et al., 2009). Various tools have been developed for the 
assessment of EL. The Emotional Lability Questionnaire (ELQ; Newsom-Davis et al., 
1999) has been developed for the specific assessment of EL in ALS for use in research 
or clinical settings (see Chapter 4).   
 
The exact pathophysiology of EL is unknown, but the available evidence implicates 
disruption to the cortico–pontine–cerebellar circuit, which includes motor, limbic and 
association cortices (Miller et al., 2011; Parvizi et al., 2009). Treatment of EL has 
primarily involved the prescription of selective serotonin re–uptake inhibitors (SSRIs) 
and tricyclic antidepressants which are thought to act on neurotransmitters involved in 
the relevant circuit. A novel agent, ‘Nuedexta’, which is a combination of 
dextromethorphan and quinidine sulphate, has been developed for the treatment of EL. 
The precise mechanisms of the drug’s action are undetermined but it is believed to 
modulate glutamatergic transmission (Miller et al., 2011). A placebo–controlled trial of 
the drug in ALS and Multiple Sclerosis (MS) patients experiencing EL found a 
significant reduction in episode rate and symptom severity over a 12 week period for 
both groups. In general the drug was well tolerated, but adverse effects did include 




1.8.3. Depression and anxiety 
 
The presence of depression and anxiety is understandable but not inevitable in the face 
of a terminal disease diagnosis such as ALS (See Chapter 2, Section 2.2.3.). No 
controlled studies of antidepressant benefit in ALS exist; however, in practice, tricyclic 
antidepressants or SSRIs may be prescribed for depression, while anxiety is treated with 
buproprion or benzodiazepines. Caregivers may also experience changes in mood state 
(see Chapter 3). Supportive counselling may benefit both patient and their families as 
they cope with the patient’s increasing disability.  
1.8.4. Cognitive and behavioural changes 
 
There is mounting evidence for cognitive and behavioural change in ALS. The degree 
of these changes may vary from mild to frank dementia (see Chapter 2). Detection of 
impairment is important as evidence suggests that executive dysfunction is a negative 
prognostic indicator in ALS (Elamin et al., 2011) and associated with reduced 
compliance with palliative care methods (Bede et al., 2011; Olney et al., 2011). 
Furthermore, behavioural impairments are associated with increased burden and 
reduced QoL of ALS caregivers (Chio et al., 2010).  
 
Screening tests for cognitive and behavioural impairment in ALS have been developed 
(e.g. Abrahams et al., 2013; Woolley et al., 2010b), and a verbal fluency task, which 
accounts for motor impairment (Abrahams et al., 2000), is available for use in clinical 
settings. Comprehensive neuropsychological testing is required to determine 
impairment or dementia comorbidity. Behavioural impairment can be assessed using 
self and informant–rated scales (See Chapter 2, Section 2.2.2). Management of 
behavioural symptoms might include behaviour modification and/or atypical 
antipsychotics and SSRIs in standard doses (Gordon, 2011). However, no studies have 
evaluated the effects of behavioural and pharmacological interventions on such 
symptoms.  
 
1.8.5. Respiratory function  
 
Respiratory dysfunction is a common feature in the majority of ALS cases at some stage 
of the disease duration. Incipient weakness of the respiratory muscles may be subtle but 
progress to more severe signs. These symptoms include dyspnoea (shortness of breath) 
on exertion or at rest; orthopnoea (shortness of breath when in the supine position) and 
nocturnal hypoventilation (associated with sleep disturbance; morning headaches; 
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daytime sleepiness and poor concentration). Defective swallow, weakened cough 
manoeuvre and bulbar symptoms may also be present, leading to excessive throat 
secretions and the blockage of the air passage, which in turn may lead to increased risk 
of pulmonary infection and aspiration. 
 
The management of respiratory symptoms comprises of invasive and non–evasive 
approaches. Forced Vital Capacity (FVC) is a standard physiological marker of 
respiratory function, however, this measure may be distorted for patients with bulbar 
weakness, as its assessment requires sufficient lip seal. For this reason, sniff nasal 
inspiratory pressure (SNIP), may be the preferred method for monitoring respiratory 
sufficiency in patients with moderate bulbar symptoms. Practice parameters recommend 
the introduction of non–invasive ventilation when FVC or SNIP measures fall below 
50% and 40cm H20, respectively (Andersen et al., 2007; Miller et al., 2009). At this 
juncture, Non–invasive Positive Pressure Ventilation (NIPPV) may be prescribed to 
alleviate respiratory symptoms. NIPPV simulates physiological function by artificially 
inflating the lungs and assisting with respiration.  NIPPV compliance of more than four 
hours per day was associated with enhanced quality of life (QoL) and a survival benefit 
of approximately seven months in patients without severe bulbar dysfunction (Bourke et 
al., 2006).   
 
Invasive procedures may be elected to compensate for advanced respiratory impairment 
when non–invasive ventilation is no longer effective. Tracheostomy insertion is such a 
procedure and requires a respiration tube to be implanted into the trachea for the direct 
oxygenation of the lungs. One–year survival rates after this treatment option vary 
between 65.0% – 78.9% and mean and median survival are reported as 10.6 and 21 
months, respectively (Sancho et al., 2011; Vianello et al., 2011). Perceived QoL of 
patients receiving this treatment is comparable to non–treated patients and patients 
receiving NIPPV (Kaub-Wittemer et al., 2003; Vianello et al., 2011). In contrast, 
caregivers of tracheostomy patients rate their own QoL lower than their patient’s QoL 
and report a high level of care burden compared to caregivers of NIPPV patients 
(Gelinas et al., 1998; Kaub-Wittemer et al., 2003), possibly reflecting the increased 
assistance required for tracheostomy in relation to non–invasive measures.  
 
As advances in technologies for respiratory management ensue, ALS patients may 
benefit from novel treatment options. Diaphragm Pacing Simulation (DPS) is a 
relatively new technique in which electrodes are implanted into the diaphragm and 
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routed percutaneously to a control unit. This unit provides the stimulus for diaphragm 
contraction thereby simulating ventilation (Onders et al., 2009a). An initial assessment 
of DPS safety in ALS patients showed encouraging results in patients with intact 
phrenic nerves, while trials to date indicate that DPS use may delay the need for a 
ventilator by two years (Onders et al., 2009b), DPS has also been associated with 
reduced apnoeas and hypopnoeas during REM sleep, improving sleep efficiency 
(Gonzalez-Bermejo et al., 2012). 
 
1.8.6. Nutritional status 
 
Maintenance of body weight and healthy nutritional intake forms an important care 
priority, as nutritional status represents a prognostic risk factor in ALS (Desport et al., 
1999; Stambler et al., 1998). Recently, a retrospective study reported that patients with 
a weight loss exceeding 10% of that at time of diagnosis was associated with shorter 
disease duration (Limousin et al., 2010), while a longitudinal analysis indicates that 
patients with a weight loss of only  5% from diagnosis experience a twofold increase in 
mortality risk (Marin et al., 2011). 
 
Many factors may contribute to malnutrition and weight loss including dysphagia; 
reduced upper limb strength which restricts eating function and consumption; 
suppressed appetite from anxiety or depression and constipation as a result of 
medication use, bowel immobility or reduced fluid intake. Additionally, 
hypermetabolism is often associated with the disease (Bouteloup et al., 2009), further 
complicating weight management. Moderate feeding difficulties may be overcome 
through the use of adaptive eating utensils; the modification of food or liquid 
consistency for easier swallow; postural advice to prevent asphyxiation or par–enteral 
feeding. As dysphagia and immobility become more problematic, enteric feeding by 
gastronomy becomes necessary to supplement oral intake.  
 
Percutaneous endoscopic gastrostomy (PEG) is an enteral procedure in which a tube is 
inserted directly into the stomach. Medication and crushed food can then be provided 
through the tube. A median survival benefit of 5 months has been demonstrated in ALS 
patients accepting this procedure compared to those declining it (Spataro et al., 2011).  
Since the procedure requires sedation, the insertion of an endoscopic tube and the 
ability to lie flat, it is not advised for patients experiencing pronounced respiratory 
insufficiency or sialorrhea. Morbidity risk increases if the procedure is performed when 
FVC is below 50% (Kasarskis et al., 1999); it is therefore advised that PEG is fitted 
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prior to the event of this threshold. Radiologically inserted gastrostomy (RIG) is a 
suitable alternative for patients with respiratory dysfunction as sedation and endoscopy 
is not required. Per–Oral Image Guided Gastrostomy (PIG), a hybrid technique of both 
PEG and RIG procedures, is a recent advance in enteric feeding procedures. Compared 
to PEG, no significant survival differences were observed for either procedure in one 
study, but no life–threatening complications were reported for patients in either 
procedure group (Chavada et al., 2010), suggesting the safety and efficacy of PIG as an 
alternative method of nutritional management in ALS.  
  
1.9. Disease modification  
 
An excess of the excitatory neurotransmitter glutamate is associated with several 
neurodegenerative disorders, including ALS (Lau & Tymianski, 2010; Shaw & Ince, 
1997). Riluzole, originally developed as an anti–epileptic drug, inhibits glutamate 
transmission and is the only approved disease modifying treatment for the disorder. 
Other pharmacological mechanisms of the drug have been posited to encompass the 
disruption of the N–methyl–D–aspartate (NMDA) receptor action, the blockade of CA2+ 
and NA
+
 channels and the modulation of gamma–amino–butyric acid (GABA) systems, 
although its precise neuroprotective actions are unknown (Cheah et al., 2010). A 
Cochrane Library meta–analysis of four randomised placebo–controlled trials including 
1477 ALS patients indicated that a dosage of 100mg/day of Riluzole was associated 
with a prolonged median survival of 2 – 3 months in patients experiencing symptoms of 
less than five years, a FVC greater than 60% and an age of less than 75 years (Miller et 
al., 2007). A deceleration in progressive muscle weakness was demonstrated in one 
study (Bensimon et al., 1994), but not replicated in subsequent trials (Bensimon et al., 
2002; Lacomblez et al., 1996). Another study reported a small positive benefit on limb 
function, which persisted when the data were combined in a meta–analysis (Lacomblez 
et al., 1996). Imaging data revealed an increase of 6% in the N–acetylaspartate/Choline 
(NAA/Cho) ratio in the primary motor cortex of 11 patients after three weeks 
administration of the drug. In comparison, untreated patients showed a 4% reduction in 
this ratio over the same period (Kalra et al., 1998). However, no corresponding 
improvement in functional or symptomatic indices in the treatment group was observed 
over the study period.  The drug is shown to be well tolerated, even in elderly or 
advanced–staged patients (Bensimon et al., 2002). Nonetheless, adverse effects may 
include fatigue, nausea, dizziness and diarrhoea. In addition, elevated liver enzyme 
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levels may also occur and thus regular monitoring of liver functioning is required 





ALS is a complex multi–system disorder, for which there remains no cure. The current 
chapter detailed the physical and clinical characteristics of ALS and related 
neurodegenerative diseases. It highlighted the on–going interdisciplinary efforts which 
have so far converged to support the suggestion of ALS relationships with FTLD at 
genetic, neuropathological and neuropsychological levels. The primary focus of the 
current thesis concerns the profile of neuropsychological change in non–demented ALS 
patients; Chapter Two provides a detailed review of the literature in this area. As a 
secondary focus, the thesis will examine the effect such change has on the ALS 
























2. Literature Review – Cognition and behaviour in ALS 
 
As highlighted by Chapter One, the evidence for ALS as a multisystem disorder is 
compelling; not least because of extra–motor involvement documented by 
neuroimaging and neuropathological studies, but also because of the apparent 
aetiological overlap with other neurodegenerative conditions, as indicated by genetic 
research. This chapter will provide further evidence to support this notion through a 
critical review of studies reporting neuropsychological change in ALS. A subsidiary 
focus of the review is the overlap of cognitive and behavioural symptoms in ALS with 
FTLD syndromes. With this in mind, Section 2.1. outlines the main findings of 
cognitive and behavioural changes in ALS–FTLD. The key objective of this chapter 
will be to delineate the cognitive (Section 2.2.1.) and behavioural (Section 2.2.2.) 
profiles of ALS and specifically the emotional processing and social cognition deficits 
(Section 2.3.) that have been reported in the disease. Evidence for a relationship 
between executive dysfunction and deficits in emotional processing and social cognition 
is also explored (Section 2.3.2.4.). An overview of the literature concerning caregiving 
in ALS is provided in Chapter Three.  
2.1. Cognitive and behavioural changes in ALS–FTLD  
 
As outlined in Chapter One, the criteria for the separate syndromes ALS–FTD are 
characterised by behavioural and/or language changes. This section will review 
neuropsychological findings of ALS–FTD. The few studies which have assessed 
neuropsychological function in ALS–FTD patients have included case reports or very 
small patient groups, leading to reduced generalizability of their findings. The majority 
of these studies predate the establishment of current ALS–FTD and FTD diagnostic 
criteria (e.g. Neary et al, 1998; Rascovsky et al, 2011; Strong et al, 2009) and the 
standards for dementia diagnosis vary between them. Furthermore, many lack controls 
for motor disability. Despite these caveats, a profile of neuropsychological change for 
these patients has emerged. Studies investigating profiles for behavioural and language 
variants of ALS–FTD will be considered separately.  
2.1.1. ALS–bvFTD  
 
Converging findings from studies of ALS–bvFTD patients support a predominant 
pattern of impaired executive functioning and behavioural change. In particular, 
cognitive impairments are elicited on measures of verbal fluency, attention, inhibition, 
set–shifting and concept formation. Table 2.1. summarises these findings by study and 
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year. Memory impairments are reported less consistently (Gentileschi et al., 1999; Liu 
et al., 2009; Neary et al., 1990). Visuoperception is consistently reported as intact 
(Gentileschi et al., 1999; Moretti et al., 2002; Neary et al., 1990; Peavy et al., 1992), 
while language dysfunction has been suggested using measures of confrontation naming 
(Gentileschi et al., 1999; Liu et al., 2009; Neary et al., 1990; Peavy et al., 1992). Errors, 
such as semantic and phonemic paraphasias, have been noted in some studies 
(Gentileschi et al., 1999; Neary et al., 1990; Vercelletto et al., 1999), suggesting 
overlapping symptoms of PPA. Although executive dysfunction dominates the 
cognitive profile of ALS–FTD, language dysfunction has been found in several recent 
studies of these patients (see Section 2.1.2). The relationship between executive and 
language impairment, and the overlap of ALS–bvFTD and PPA, within ALS–FTD is of 
on–going enquiry.  
Case reports have described ALS–bvFTD patients as showing marked personality 
change, becoming increasing socially disinhibited, irritable and aggressive. Increased 
egocentrism, sterotyped gestures, and reduced ‘warmth’ or empathy are also reported, 
alongside a lack of insight into or concern for their deterioration (Gentileschi et al., 
1999; Liu et al., 2009; Moretti et al., 2002; Peavy et al., 1992; Vercelletto et al., 1999). 
The more florid behavioural displays may, paradoxically, culminate in a period of 
inertia, apathy, emotional flatness and social withdrawal (Liu et al., 2009; Neary et al., 
1990; Peavy et al., 1992). These case descriptions of ALS–bvFTD patients resonate 
with those from the bvFTD literature (Neary et al., 1998; Neary et al., 2005; Tartaglia 
et al., 2008).  Three major behavioural subtypes of FTD have been proposed (see Figure 
2.1.), on the basis of clinical presentation and underlying neuropathological distribution 
of the frontal and temporal lobes (Snowden et al., 2001). A disinhibited subtype is 
characterised by overactivity, distractibility and disinhibition and associated with 
predominant pathology of the orbitofrontal lobes and anterior temporal neocortex. A 
second rare subtype shows predominant ritualistic and sterotyped behaviours 
(stereotypic–type), reflective of pathology in the striatum and temporal cortex. The 
apathetic subtype is characterised by apathy, inertia and loss of volition, associated with 
more widespread frontal lobe pathology including the DLPFC. Neary et al describe 
patients with disinhibited–type bvFTD as becoming increasingly more apathetic with  
time (Neary et al., 2000). This is similar to the pattern of behaviour described in ALS–
bvFTD patients above, suggesting early orbitofrontal pathology in the disease with 
increasing dorsolateral involvement at later stages. However, it is not certain if 
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increasing physical disability in these patients may partially explain this change from a 
disinhibited to apathetic disposition. 
2.1.2. ALS–PPA  
 
As already mentioned in Chapter One, many ALS patients present with prominent 
language dysfunction severe enough to warrant a diagnosis of ALS–PPA (Doran et al., 
1995; Mitsuyama, 1984; Watanabe, 1893), even after accounting for motor speech 
difficulties (Bak et al., 2001). Neuropsychological studies of aphasia in ALS have 
revealed distinguishable profiles of language impairment for patients with ALS–PNFA 
and ALS–SD, which have been described as more severe than those seen in the 
corresponding aphasic syndromes of FTD (Bak & Chandran, 2012).   
Both ALS–PNFA and ALS–SD patients show impairments in confrontation naming. 
ALS–PNFA patients show semantic and phonemic paraphasias, alongside word–
retrieval difficulty (Bak et al., 2001; Rakowicz & Hodges, 1998). In ALS–SD, object 
naming deficits are prominent (Kim et al., 2009; Yokota et al., 2006), reflecting  the 














Figure 2.1.: Behavioural subtypes of FTD (Snowden et al, 2001) 
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Table 2.1.: Neuropsychological studies of patients with ALS–bvFTD 
† impaired at follow–up; * borderline impairment. BNT: Boston Naming Test; D–KEFS: Delis–Kaplan Executive Function Scale; JLO: Judgement of Line Orientation, MMSE: 
Mini Mental State Examination, NPI: Neuropsychiatric Inventory, PASAT: Paced Auditory Serial Addition Task; VOSP: Visual Object and Space Perception Battery; WAIS: 
Weschler Adult Intelligence Scale, WCST: Wisconsin Card Sort Task, WMS: Weschler Memory Scale.
Authors  
 
n Neuropsychological tests indicating impairments  Neuropsychological tests indicating preserved performance 
Neary et al. 
(1990) 
4 BNT; Verbal Fluency; WCST; WAIS; Paired Associate 
Learning; Weigl’s Block Task; Proverbs interpretation test 
 
Money Road Map; Warrington Memory Test; Delayed Verbal Recall; Koh’s 
Block Figures 
  
Peavy et al, 
(1992) 
2 BNT; Verbal Fluency; WAIS; Stroop Test; Go–Nogo task; 
Mattis Dementia Rating Scale 
 
WMS; Parietal Lobe Battery; Cancellation Test; JLO 
Gentileschi 
et al (1999) 
1 BNT; Semantic Fluency; Stroop Test; MMSE; Verbal 
Judgements; Silly Sentences; Paired Word Learning, Corsi 
Supra–Span Spatial Learning;   Autobiographical Memory 
Questionnaire; Semantic Questionnaire; Digit Cancellation; 
Token Test; Facial Recognition Test 
 
JLO; Verbal Forward Span
†;  Forward Spatial Span, Raven’s Coloured 
Matrices; Arithmetic Judgements; Street’s Completion Test; Perceptual Maze 
Test; Overlapping Figures Test;  Dual Task; Long Story Recall; Associative 
Matching Task ;  Weigel’s Block Test†; Familiar Faces†; Famous Faces† 
 
Vercelletto 
et al (1999) 
5 Verbal Fluency; WCST; Stroop; Aphasia Test, MMSE WMS; Rey Words 
Moretti et al 
(2002) 
4 Phonemic Fluency; WCST; Stroop; PASAT; Proverbs 
interpretation test; Aphasia Test; MMSE; NPI 
 
WAIS–R Similarities; Digit Span; Raven’s Progressive Matrices; JLO; Koh’s 
Block Figures; Story Retrieval; Past Events Retrieval 
Liu et al 
(2009) 
1 BNT; D–KEFS verbal fluency; Pyramids and Palm Trees test: 
Words & Pictures; VOSP: number location; WAIS–III 
Similarities; WAIS–III Matrix Reasoning*; WCST; D–KEFS 
Trail Making; D–KEFS Colour–Word Interference; CVLT: 




; WAIS–III Block design; WAIS–III picture arrangement†; Modified 
Rey–O copy; WMS–2 Visual Reproductions†; WMS–3 Face Recognition; 




Dissociative impairment patterns between the two syndromes are observed. In ALS–
PNFA, although the comprehension of single–words remains intact, patients show 
agrammatism in production and difficulties with syntactic comprehension (Bak et al., 
2001; Caselli et al., 1993; Catani et al., 2004; Tsuchiya et al., 2000). Conversely, 
patients with ALS–SD show preserved syntactic comprehension, but impaired single–
word comprehension (Yokota et al., 2006). 
One of the hallmark features of ALS–PNFA is a selective deficit in the processing of 
verbs, both in production and comprehension tasks (Bak & Hodges, 2004; Bak et al., 
2001; Hillis et al., 2006). In an investigation of two ALS patients and four ALS–PNFA 
patients with variable degrees of FTD, a similar profile of impaired verb processing was 
observed across patient groups. Imaging data revealed atrophy and hypofusion of the 
frontotemporal cortices in these patients, while a post–mortem study of four of the 
demented patients showed pathological changes in areas of the inferior frontal gyrus, 
including Broca’s area (Bak et al., 2001).  This dissociation has been demonstrated in 
pure PPA patients (Hillis et al., 2006; Hillis et al., 2004; Hillis et al., 2002), but is 
opposite to the pattern shown in SD patients (Hillis et al., 2004). While SD patients 
have demonstrated a select deficit in the processing of nouns as opposed to verbs (Hillis 
et al., 2004), this is yet to be confirmed in ALS–SD patients. The verb processing 
deficit in ALS–PNFA is not restricted to words and includes abstract concepts of 
actions, as opposed to objects (Bak & Hodges, 2004).  
Other cognitive domains in ALS–PNFA and ALS–SD patients remain relatively 
preserved. Visuoperception and non–verbal memory in both disorders are reportedly 
intact (Catani et al., 2004; Kim et al., 2009; Rakowicz & Hodges, 1998; Yokota et al., 
2006). Topographagnosia (agnosia for landmarks) and prosopagnosia (agnosia for 
faces) have been noted in ALS–SD (Coon et al., 2012). Although language dysfunction 
dominates the clinical picture of ALS–PPA, dysfunction in attention and executive 
abilities have shown to progress with time (Catani et al., 2004).   
The presentation of behavioural features alongside PNFA and SD syndromes in ALS 
provides further evidence that ALS–bvFTD and ALS–PPA may overlap (Caselli et al., 
1993; Doran et al., 1995; Rakowicz & Hodges, 1998). Similar to PPA or bvFTD, the 
emergence of co–occurring syndromes might indicate a progression in disease stage 
(Gorno-Tempini et al., 2011; Marczinski et al., 2004). Changes in behaviour typical of 
ALS–bvFTD have been noted in ALS–SD patients, who show increased levels of 
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apathy, reduced empathy, insight and social disinhibition (Coon et al., 2012; Kim et al., 
2009). Behaviour in SD is believed to show a more compulsive quality than in bvFTD 
(Snowden et al., 2001). No formal comparison of behaviour in ALS–bvFTD and ALS–
SD patients has been made; as such the qualitative differences between these patients in 
undetermined. Patients with ALS–PNFA may also show behavioural change. Increased 
irritability and depressive symptoms are pronounced in the late stages of disease (Catani 
et al., 2004); a similar evolution of  behaviour  has been noted in PNFA patients 
(Marczinski et al., 2004; Snowden et al., 1992).   
2.1.3. The putative ALS – FTD cognitive continuum 
 
Recently, efforts from different disciplines have converged in an attempt to characterise 
the overlap between ALS, ALS–FTD and pure FTD. Debate surrounds whether the 
association between these disorders represents a continuum of clinical patterns of one 
single disease, reflects the co–occurrence of separate diseases or corresponds to distinct 
nosological entitles (Bak, 2010; Gentileschi et al., 1999). Compelling support for the 
‘continuum hypothesis’ is provided by studies documenting common molecular, genetic 
and neuropathological mechanisms between the disorders (Chang et al., 2005; DeJesus-
Hernandez et al., 2011; Neumann et al., 2006; Snowden et al., 2013). Notably, subsets 
of ALS patients show milder symptoms of cognitive and behavioural change which are 
characteristic of ALS–FTD (see Section 2.2.). Conversely, FTD patients may develop 
motor symptoms of ALS, accompanied by ALS–typical degeneration of the anterior 
horn and spinal cord (Lomen-Hoerth et al., 2002; Neary et al., 1998).   
The proposal of a unitary disease spectrum encounters some challenges. If the 
cognitive–behavioural profile of ALS patients mirrors that of ALS–FTD and FTD, it 
would follow that the FTD–like symptoms in ALS would progress with disease 
duration. However, several longitudinal studies have failed to detect significant 
cognitive change over time in these patients (see Section 2.2.1.7.), although longitudinal 
assessment of patients with progressive disease is difficult, and it may be that the 
decline in physical ability outpaces the initially subtle cognitive deterioration in ALS. 
Studies typically support comparable profiles of cognitive–behavioural dysfunction 
between the disorders; however, some dissimilarities have been noted. For example, 
ALS patients have demonstrated different patterns of affective decision–making 
(Girardi et al., 2011; Torralva et al., 2007) and differences between ALS–FTD and FTD 
patients in terms of the severity of language comprehension deficits exist (Bak & 
Chandran, 2012).  
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Nonetheless, the interpretation of similarities and differences between the three diseases 
is further complicated by the increasingly acknowledged genotypic and phenotypic 
heterogeneity within each disorder (Sabatelli et al., 2013; Snowden et al., 2013). 
Profiles of impairment similar to those associated with the three clinical syndromes of 
FTD, are indicated in ALS–FTD and ALS (see Sections 2.1. and 2.2.). However, 
changes in domains such as language and social cognition, which are consistently 
present in PPA and bvFTD respectively, have not been examined in great detail in 
ALS–FTD or ALS. It is unclear, for example, if the socio–emotional processing deficits 
reported in ALS (see Section 2.3.) correspond to those apparent in bvFTD; and if when 
present are attributable to similar cognitive or neural mechanisms. A more detailed 
characterisation of the extent of cognitive and behavioural change in ALS is required to 
build evidence in support of or against the continuum of the disease entities.  
2.1.4. Summary 
This section outlined the cognitive and behavioural profiles of patients with ALS–FTD. 
In brief, the separate syndromes of ALS–bvFTD and ALS–PPA are characterised by 
executive–behavioural or language dysfunction, respectively. These syndromes 
correspond qualitatively to those of bvFTD and PPA. Within ALS–PPA, distinct 
profiles of language impairment are evident. The presentation of executive or language 
dysfunction in ALS–FTD patients may present in isolation or co–occur. An emergence 
of overlapping deficits may be mediated by disease stage. Similar patterns of deficits in 
non–demented ALS, ALS–FTD and pure FTD suggest a cognitive continuum between 












2.2. Cognition and behaviour in non–demented ALS 
 
Following on from the proposed cognitive continuum between ALS and FTD outlined 
in Section 2.1., the current section will provide a critical overview of the literature 
pertaining to cognitive and behavioural changes in non–demented ALS patients.  
Studies investigating domains of cognition (Section 2.2.1.) behaviour (Section 2.2.2.), 
mood and personality (Section 2.2.3) are reviewed in turn. In addition, some researchers 
have extended the assessment of ALS cognitive impairment to include examinations of 
performance on emotion and social cognition tasks. Evidence for ALS–related 
impairments in these domains is reviewed separately (Section 2.3.), to reflect the overall 
focus of the thesis. Finally, the primary aims of the thesis are outlined (Section 2.4.). 
2.2.1. Cognition in ALS 
2.2.1.1. Executive function 
 
The term ‘executive function’ is an evolving concept in neuropsychology, which is yet 
to be fully delineated. In general, it is an umbrella term that refers to “higher–level” 
processes involved in the selection and supervision of “lower–level” mechanisms 
(Alvarez & Emory, 2006) that enable the planning and execution of behaviour in order 
to achieve prioritised goals (Lezak, 2004). Several theoretical models emphasise the 
dominant role of the frontal lobes in these functions, a position which  is supported by 
lesion and neuroimaging studies (see Robbins et al., 1996 for review). However, 
evidence also supports the involvement of more posterior and subcortical regions in 
executive ability (e.g. Alvarez & Emory, 2006; Simões-Franklin et al., 2010). Given the 
anatomical connectivity of the frontal lobes with non–frontal regions, some authors 
emphasise the involvement of ‘frontal–subcortical circuits’ in executive behaviour 
(Stuss, 2011). Throughout this thesis, the term ‘executive dysfunction’ will be used to 
refer to the presence of dysfunction in any one or a collection of these “higher–level” 
processes, while ‘dysexecutive behaviour’ will connote the corresponding behavioural 
syndrome that is associated with such dysfunction. Stuss & Alexander (2007) argue that 
the terms ‘executive dysfunction’ or ‘dysexecutive behaviour’ are misleading as they 
convey an undifferentiated disorder or syndrome. They contend that ‘dysfunction’ is 
better explained as deficits in a collection of anatomically and functionally independent 
but interrelated attentional control processes, an argument supported by evidence (see 
Stuss & Alexander, 2007). The current thesis offers these terms and definitions for 
simplicity and acknowledges the controversy surrounding the conceptualisation of the 
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executive function construct, or impairment thereof (see Banich, 2009). Non–demented 
ALS patients have shown difficulty on various indicators of executive function; each 
which will be considered in turn.  
Verbal Fluency 
Verbal fluency impairment is the most consistently reported cognitive deficit in ALS 
research, a finding which is substantiated by meta–analysis (Raaphorst et al., 2010). 
Fluency measures typically require participants to produce as many words as possible in 
a given time limit and under conditions in which the response is specified by a 
particular restriction, such as a letter (phonemic fluency test) or semantic category 
(category fluency test). In addition to linguistic processes, these tests are understood to 
rely heavily on executive resources and recruit several cognitive processes in order to 
initiate appropriate responses and engage retrieval strategies in quick succession while 
maintaining output to avoid repetition. The demands of the separate tests differ. 
Category fluency tests place less demand on executive processes and more demand on 
semantic knowledge connections (Laisney et al., 2009). Distinct neural regions for each 
test type have also been proposed, with category fluency performance being associated 
with temporal cortex and phonemic fluency performance primarily subserved by the 
frontal regions, in particular the DLPFC (Birn et al., 2010; Meinzer et al., 2009; 
Schlösser et al., 1998). Although variable across studies, both phonemic (see Table 2.2.) 
and semantic fluency deficits (e.g. Abe et al., 1997; Abrahams et al., 2000; Hanagasi et 
al., 2002; Rottig et al., 2006) have been found in ALS, suggesting an underlying 
vulnerability of the cognitive and neural processes associated with the tasks in ALS.  
 
Studies of verbal fluency in ALS have differed by task and modality (oral or written), 
which may influence the identification of deficits in patients. The most frequently used 
fluency tasks have included the Controlled Oral Word Association Test (COWA; 
Benton et al., 1978) and the (written) Thurstone’s Word Fluency Test (TWF; Thurstone 
& Thurstone, 1938). Both tasks are timed and do not account for motor impairment in 
scoring. A modified version of the TWF to accommodate physical disability (Abrahams 
et al., 1996) introduces a second condition whereby, after the completion of the 
standard letter fluency task, participants are timed as they copy the words they have 
previously provided. A verbal fluency index (VFI) may then be calculated by 
subtracting the time of the copy condition from the time of the standard generation 
condition and dividing this by the total number of words generated. This index 
represents the average time taken to generate each word; higher scores indicating longer 
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thinking times and more pronounced executive impairment. The formula is illustrated 
below:  
 
         VFI =     (time for generation condition) – (time for copy condition) 
                                              Total number of words generated 
 
Studies have varied in the adoption of this control measure, leading to a possible 
overestimation of fluency impairment in the disease. Abrahams et al (1996) applied 
these indices to their fluency measures and found that fluency impairments in the ALS 
group remained. The robustness of this procedure to detect fluency deficits in patients 
has been indicated by subsequent research (Abrahams et al., 1997; Abrahams et al., 
2004; Abrahams et al., 2005a; Abrahams et al., 2005b; Abrahams et al., 2000; 
Stukovnik et al., 2010), which also suggests a true fluency impairment in ALS 
independent of physical impairment.  
While some studies have not found semantic fluency impairments in ALS patients 
compared to controls (Talbot et al., 1995), others have found that patients are impaired 
at generating words for ‘animals’ but not for other semantic categories (Abe et al., 
1997; Abrahams et al., 2000; Hanagasi et al., 2002). Several studies have failed to 
replicate a specific ‘animal’ naming deficit in ALS patients (Abrahams et al., 2005b; 
Hartikainen et al., 1993; Palmieri et al., 2009); instead a few studies have shown patient 
fluency impairments for other categories such as, ‘fruits’, ‘vehicles’ (Abe et al., 1997) 
and ‘supermarket goods’ (Rottig et al., 2006). The semantic fluency deficits found in 
these patients may suggest corrupt semantic representation in ALS; however, they do 
not rule out executive impairment as a source of impaired response generation on these 
tasks.  
 
For example, Abrahams et al (2000) compared phonemic, semantic and design fluency 
between 22 ALS patients and 25 controls. Working memory and word retrieval were 
also compared between groups. Relative to controls, patients showed impairments on 
the written phonemic task and the ‘animal’ category of the oral semantic fluency test. 
These deficits were found in the presence of intact phonological function and word 
retrieval, but impaired working memory capacity in patients. This suggests that the 
impoverished fluency performance demonstrated by patients was attributable to 
dysfunction of the executive component of working memory rather than to impairments 
in phonological loop functions or simple linguistic abilities.  
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Several imaging studies have adopted fluency tasks as activation paradigms to 
investigate the relationship between cognitive dysfunction and abnormal cerebral 
responses in ALS. The comparison of regional Cerebral Blood Flow (rCBF) of patients 
with and without phonemic fluency deficits in addition to healthy controls was 
conducted in a PET study (Abrahams et al., 1996). Reduced activation in the DLPFC, 
anterior cingulate (AC) gyrus, insular cortex, thalamus and premotor cortex was evident 
for patients showing fluency impairments. ALS patients without fluency impairments 
showed normal rCBF activation patterns in line with healthy controls. These 
conclusions corroborated previous findings from an earlier PET study (Kew et al., 
1993b). The results are also in agreement with earlier PET and SPECT studies that have 
suggested an association between reduced glucose uptake in the frontal regions of ALS 
patients with impaired fluency performance (Abe et al., 1993; Ludolph et al., 1992).    
Widespread cortical involvement in fluency performance has been suggested in ALS 
using other neuroimaging techniques. Abrahams et al (2004) conducted an fMRI study 
comparing blood–oxygen–level–dependent (BOLD) changes between 28 patients and 
controls during a phonemic fluency task. Compared to controls, patients were impaired 
on this task and showed decreased BOLD responses in the PFC, such as the AC and the 
language–related Broca’s area. In addition, impaired activation in temporal regions and 
the supramarginal gyrus of the inferior parietal lobe was found. The latter region has 
been associated with the phonological store component of working memory (Paulesu et 
al., 1993; Salmon et al., 1996). The study therefore highlights the involvement of 
language–related processes in ALS fluency performance. 
Structural MRI has revealed that WM changes in the frontotemporal regions of ALS 
patients are associated with fluency performance (Abrahams et al., 2005a). Twenty–
three ALS patients were classified into two groups of cognitive status (impaired and 
unimpaired) on the basis of phonemic fluency performance. Relative to controls (n=12), 
cognitively impaired patients (n=11) showed WM reductions in regions encompassing 
the medial temporal lobe, as well as in regions surrounding association fibres within the 
superior and medial frontal lobes. These patients also showed impairments on naming 
and memory tasks, consistent with the pattern of structural abnormalities described. 
Compared to controls, patients without fluency impairment (n=12) showed WM 
changes in regions surrounding fibres that connect the frontal lobes to other cortical 
areas, demonstrating that structural abnormalities may precede noticeable cognitive 
impairment in ALS. Broadly consistent with these results, a DTI study found that longer 
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fluency index times for an oral phonemic fluency task were associated with reduced FA 
in WM in the inferior and superior frontal gyri, as well as the corpus callosum and CST 
in 30 ALS patients (Pettit et al., 2013). These results also corroborate the above fMRI 
data which showed a decreased BOLD response in patients in the anterior PFC and 
inferior frontal gyrus (which corresponds to Broca’s area) during a fluency task 
(Abrahams et al., 2004). Together, these studies propose that disruption to particular 
WM pathways in ALS may underlie the impaired verbal fluency performance observed 
in patients.   
Attention, inhibition and working memory 
Reports of attention difficulties in ALS patients exist. Two large studies of 
neuropsychological functioning in ALS (n=146, Massman et al., 1996; n=279, Ringholz 
et al., 2005) have used the Verbal Series Attention Test (VSAT, Mahurin & Cooke, 
1996), which includes several tasks, such as reciting the alphabet, counting backwards 
whilst subtracting a constant and recalling the days and months of the year in forward 
and reverse order. Using normative data, Massman et al (1996) found that patients’ 
mean VSAT completion time fell at the 25
th 
percentile. This result was unexpected, 
given the patients’ above average premorbid IQ estimates which predicted mean scores 
to fall within at least the average range. Using the same task, Ringholz et al (2005) 
found that impaired VSAT performance was common to all patient cognitive subgroups 
(mild, moderate and severe impairment). This might indicate an early vulnerability of 
attentional resources in cognitively impaired patients. However, the high verbal demand 
of the VSAT may have contributed to poor patient performance in both studies. Indeed, 
dysarthria scores correlated with task completion times in Massman et al’s study.        
On the other hand, they did not correlate with other verbal tasks, suggesting that 
patients were able to verbalise responses adequately under time restraints.  
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Table 2.2.: Phonemic verbal fluency impairment in ALS patients 
Measure Author                  Group 
    ALS               Controls                        
ALS impairment 
 
Thurstone’s Verbal Fluency 
 











Strong et al (1999) 
 
13 5                    yes  
COWA Gallassi et al (1985) 22 36                        yes 
 Gallassi et al (1989) 18 36                        yes 
 Ludolph et al (1992)* 17 17                        yes 
 Kew et al (1993)* 13 16                        yes 
 Talbot et al (1995) 19 10                        no 
 Massman et al (1996) 146 Normative Data 21% ALS patients below 5
th
 
percentile of norms 
 
 Frank et al (1997) 47 56                        yes 















    ALS               Control 
ALS impairment 
 
Modified Verbal Fluency Index / 
Abraham’s Protocol * 
 






ALS with PSP (n=20) significantly impaired 
relative to ALS patients without PBP (n=23) 
and controls 
 
 Abrahams et al (2000) 22 15 yes (but not for oral VFI*) 
 Abrahams et al (2004) 28 18 yes 
 Abrahams et al (2005) 20 18 yes 
 Wicks et al (2009) 41 35 no 
 Taylor et al (2013) 53 35 25% ALS patients below 5
th
 percentile of 
control group 
 
“L” “B” “S” (timed: 60 seconds) Rottig et al (2006) 15 15 no 
 *included control for motor impairment, PSP, Pseudobulbar Palsy 
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Studies which have incorporated non–verbal tasks of attention have also indicated 
attentional processing impairments in ALS (Gallassi et al., 1985). On a visual search 
matching task, 11 out of 50 ALS patients showed impaired attention compared to 27 
age–matched controls and 23 neurological control patients (Chari et al., 1996). 
However, impairments in ALS patients only emerged when the attentional demands of 
the task increased, indicating a graded impairment effect. Performance of ALS patients 
on less complex visual attention tests was comparable to the healthy control group.  
There is increasing evidence for eye movement (saccade) abnormalities in patients (see 
Donaghy et al., 2011 for review) which might offer an alternative explanation for ALS 
impairments on visually–based tasks. Saccades are rapid eye movements that bring 
stimuli to the fovea of the retina. Reflexive saccades require little cognitive control and 
occur automatically when participants look at external stimuli. Anti–saccades are 
voluntary movements made in the direction opposite to the side where the stimulus is 
presented. While the former saccades are associated with activation of  parietal lobe 
regions, the latter are thought to be mediated by the frontal eye fields of the PFC (Mort 
et al., 2003) and the DLPFC (Ford et al., 2005).  
Shaunak et al (1995) found that relative to controls, ALS patients showed longer 
latencies for correctly made anti–saccades and higher distractibility (greater error rates) 
on an anti–saccades task. More recently, higher distractibility in patients has been 
replicated, and this has correlated with performances on tasks of executive function, 
such as the Stroop and WCST, as well as dysarthria scores (Donaghy et al., 2010; 
Evdokimidis et al., 2002). Shaunak et al (1995) did not find evidence for abnormal 
reflexive saccades in their patient sample, but other studies have indicated these to be 
slower in ALS (Leveille et al., 1982; Ohki et al., 1994), particularly in patients with 
bulbar–onset disease (Donaghy et al., 2010). Other eye abnormalities, such as saccadic 
intrusions (involuntary saccades that disrupt fixation) and impaired smooth pursuit (eye 
movements involved in tracking moving stimuli) have also been noted in ALS patients; 
these have been interpreted as further evidence for frontal lobe involvement in ALS 
(Donaghy et al., 2011).         
Event Related Potential (ERP) studies allow the examination of attention in ALS 
through the adoption of physiological data alongside neuropsychological tasks. An 
advantage of these studies is that ERP components elicited by these tasks do not always 
necessitate an overt motor response. The first ERP study in ALS used an oddball task, 
in which participants are required to identify infrequent ‘target’ stimuli in a sequence of 
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promptly presented ‘standard’ stimuli. ERP recordings revealed prolonged latencies of 
the attention–sensitive N200 and P300 components in 60% of their patient sample      
(n=20, Gil et al., 1995). This was followed by findings of ALS patients demonstrating 
significant impairment relative to controls in detecting target stimuli during a visual 
serial search task, but not during a simple parallel search task (Munte et al., 1999), in 
keeping with Chari et al’s (1996) findings of a graded effect of attention impairment. 
Slower performance was accompanied by longer latencies and reduced amplitudes of 
the P300 in the complex task. On the parallel search task, no differences in P300 
amplitude were found between patient and control groups. However, the onset of the P3 
latency was 120ms slower for patients than controls. These results suggest that search 
behaviour in ALS may be corrupted by an attention deficit independent from motor 
impairment.  
Similarly, abnormal P300 subcomponents have been identified in auditory oddball 
tasks. Hanagasi et al (2002) found reduced amplitudes of P3a and P3b and longer P3a 
latencies in patients compared to controls using both active and passive versions of this 
paradigm. Abnormal P3a parameters are thought to indicate deficient novelty detection 
processes and are associated with frontal areas, such as the AC (Escera et al., 1998). 
The P3b component is evoked through effortful target detection and is thought to reflect 
memory storage mechanisms originating in the hippocampal formation (Polich & 
Criado, 2006). Patients in this study also showed impairments on neuropsychological 
tests of attention, working memory, inhibition and visuospatial processing. Together 
with the ERP data, these results were interpreted as evidence for underlying dysfunction 
of a frontally–mediated attentional network in the ALS group.      
Attention, as measured by digit span tasks, has been reported as impaired (Gordon et 
al., 2010) and, conversely, within the normal range (David & Gillham, 1986; Ludolph 
et al., 1992). A distinction between forward and reverse digit span performance is 
evident in studies with some patients demonstrating intact performance on the former 
and impaired performance on the latter (Hanagasi et al., 2002; Moretti et al., 2002; 
Rakowicz & Hodges, 1998). This dissociation may reflect intact global attention 
capacity but deficient working memory processes, which are each associated with the 
respective subtask. Recently, a study set out to delineate the specificity of reported 
working memory deficits (Hammer et al., 2011). Eleven ALS patients and healthy age–
matched controls performed several working memory tasks: digit span, reading span 
and two N–back tasks which required the storage of figural and spatial information, 
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separately. In the N–back task stimuli are presented serially and participants have to 
indicate whether the presented stimulus is identical to the one that was presented ‘N’ 
trials before  (see McEvoy et al., 1998). ALS patients showed comparable performance 
on the digit span, reading span and figural N–back tasks, but significantly impaired 
performance on the spatial N–back task, relative to controls. Previous evidence suggests 
the involvement of the right DLPFC in spatial working memory (Bor et al., 2006); 
further implicating impaired functioning of this region in ALS. In addition, ERP data, 
which accompanied the N–back tasks, revealed that the differentiation between stimuli 
(target and non–target stimulus–positions) in the spatial task was more prominent in 
ALS patients compared to controls and showed a frontoparietal gradient. The study also 
found significantly reduced COWA performance in ALS patients relative to controls, 
further supporting Abrahams and colleagues’ suggestion of a frontally–mediated 
working memory impairment (Abrahams et al., 2000).  
Selective attention and inhibition in ALS has been investigated using the Stroop Test 
(Stroop, 1935). In this test, participants are instructed to name the print colour of a 
semantically congruent (‘red’ written in red ink) or incongruent word (‘red’ written in 
blue ink). The task requires participants to selectively focus attention in order to inhibit 
the interference caused by the distracting information. In ‘incongruent trials’, naming of 
the ink colour typically takes longer than in ‘congruent trials’. This phenomenon is 
known as the ‘Stroop Effect’. Stroop performance is proposed to reflect functioning of 
frontal regions (Bench et al., 1993). Findings from this task in ALS samples have been 
mixed, with some studies reporting deficits (Frank et al., 1997; Gibbons et al., 2007; 
Hanagasi et al., 2002; Rusina et al., 2010; Sterling et al., 2010) and others showing 
comparable performance to healthy controls (Gordon et al., 2010). In particular, studies 
which have compensated for motor impairment or recorded alternative indices of 
performance, such as error scores, (Abrahams et al., 1997; Kew et al., 1993a; Ludolph 
et al., 1992; Ogawa et al., 2009; Pinkhardt et al., 2008; Stukovnik et al., 2010) have 
failed to identify group differences.  
Although Abrahams et al, (1997) failed to find group differences on the Stroop test, the 
study did find a strong trend (p=.051) for a group effect on a negative priming (NP) 
task, a derivation of the Stroop test. In this condition, participants were required to 
name the colour of the ink in which an incongruous colour word was presented; 
however, the colour of the ink was the same as the colour word on the previous trial. 
Thus in order to respond correctly the participant must inhibit the distractor response on 
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a trial and then produce the previously inhibited response on the subsequent trial. 
Reaction times in healthy adults are typically increased in this condition compared to 
control and Stroop conditions, indicating a higher cognitive load of the NP task (Steel et 
al., 2001). In the study, ALS patients did not show this typical pattern, suggesting that 
the patients showed difficulty with inhibiting a previously suppressed stimulus. 
However, the higher cognitive load associated with the NP task might itself have 
influenced ALS performance.    
 
An fMRI study which compared 14 ALS patients and 8 controls on the Stroop and NP 
tasks failed to demonstrate differences between the groups for either the Stroop or NP 
effects (Goldstein et al., 2011). However, the direction of the difference and a large 
effect size (d=0.809) for the Stroop effect suggested that the ALS group did show 
greater interference on the Stroop test compared to controls, but that the small sample 
size may have prevented finding a statistically significant difference. Relative to 
controls, the ALS group showed increased activation in the left temporal and AC areas 
during this task, reflecting greater difficulty in suppressing the distractor response. For 
the NP task, decreased activation in the left cingulate precentral gyrus and the left 
medial PFC was found in patients compared to controls, despite the behavioural data 
indicating no group difference in NP effect. These cerebral regions are associated with 
the working memory and articulatory aspects of the NP task (Steel et al., 2001). Lower 
activation of these areas during the NP task may therefore correspond to a reactivation 
of the previously suppressed distractor which is more readily available to ALS patients 
because of inefficient inhibitory processes or wider working memory difficulties.       
The Hayling Sentence Completion Test (see Chapter 4) has also been used in ALS to 
assess inhibition of prepotent responses. Participants are read aloud several sentences 
with the last word of the sentence missing. In the first condition, they are primed to 
complete the sentence with a sensible word as quickly as possible. In the second 
condition, they are asked to provide a word which is unconnected to the sentence in 
every way. Effective performance in the second condition requires cognitive inhibition 
as the participant must suppress a highly associated word. Errors in this condition have 
been associated with OFC dysfunction in lesion and dementia groups (Hornberger et al., 
2010; Volle et al., 2012). A comparison of errors on this condition between ALS 
patients and controls revealed a non–significant trend in one study (Wicks et al., 2009). 
Subsequent research has used this task to compare performance across control, ALS and 
FTD groups (Lillo et al., 2012b). Group differences for overall and error scores on this 
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task were statistically significant; and indicated a continuum of performance between 
the groups, with ALS patients performing worse than controls but better than FTD 
patients. Nonetheless, the overall score which was a composite of timed responses did 
not account for possible dysarthria of the ALS patients and so group differences on this 
score should be interpreted cautiously.    
Further support for disturbed response inhibition in ALS is provided by ERP methods. 
Thorns et al (2010) administered 13 ALS patients with the Stop–signal paradigm 
(Logan & Cowan, 1984), in which participants were cued by a stimulus to respond to a 
following target using either a left or right hand button press. On 25 % of the trials a 
stop–signal followed the target stimulus requiring the participants to abort the initiated 
motor response. The behavioural data indicated that compared to controls (n=13), 
patients showed less efficient stopping movements and a lack of behavioural adjustment 
(no reaction time adaption) after the stop–signal trials. These deficits were accompanied 
by reduced amplitudes for ERPs that index motor preparation, inhibitory control and 
error processing.  
Conception formation, problem solving, set–shifting 
Concept formation is the ability to identify relationships among environmental stimuli 
and group these stimuli into meaningful classes according to rules. This enables 
effective decision–making about objects and flexible responding to changes in 
contextual relationships (Hartman et al., 2004; Milton et al., 2009; Nyhus & Barcelo, 
2009). Difficulties in concept formation and mental flexibility are often assessed in 
ALS using the original and modified version of the Wisconsin Card Sorting Test 
(WCST, Grant & Berg, 1948; Milner, 1963; Nelson, 1976). Performance on this task is 
strongly, but not exclusively, associated with executive and frontal lobe function 
(Demakis, 2003; Milner, 1963; Nelson, 1976; but see Nyhus & Barcelo, 2009). An early 
neuropsychogical study of ALS, found impaired performance in patients relative to 
healthy controls on the WCST (David & Gillham, 1986). Subsequent studies have 
supported these findings (Abrahams et al., 1997; Evdokimidis et al., 2002; Frank et al., 
1997; Rusina et al., 2010; Strong et al., 1999); but not consistently (Gibbons et al., 
2007; Ludolph et al., 1992; Ogawa et al., 2009).  
Poor performance on the WCST can be attributed to impaired concept formation or a 
tendency towards perseveration; it is difficult to discern the relative contributions of 
these components (Levine et al., 1995). A similar test, the Card Sorting Task (CST, 
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Delis et al., 2000), examines these processes separately (Beatty et al., 1994). The CST 
possesses many unique features compared to the WCST, most notably additional sort 
recognition trials that assess sorting strategy under a motor–free condition.              
Libon et al, (2012) found a range of test performance in 41 ALS patients on the CST. 
Using age–corrected scaled scores, a K–means cluster analysis classified patients into 
three groups of impaired (n=9), average (n=20) and above average (n=15) sorting 
ability. Action naming and word meaning test scores predicted sorting performance on 
the free sorting and recognition sorting conditions, respectively. Previous reports of 
impaired action and object naming in ALS exist and posit the degradation of the 
action/semantic network in patients (see Section 2.2.1.2.). The study’s findings may 
support this position. Letter fluency scores were related to performance on both sorting 
conditions, suggesting the contribution of executive resources to task performance. 
However, the measure used did not control for motor impairment (i.e. Abraham’s 
protocol), and should be interpreted cautiously. Nonetheless, in a subset of 16 patients, 
sorting recognition scores correlated with cortical thinning in the left DLPFC and left 
parietal cortices. Since PFC regions are implicated in the executive components of 
sorting tasks (Badre et al., 2009), recognition sorting performance in ALS may depend 
in part on the executive retrieval and mediation of lexical and semantic knowledge.  
 
Ecologically–valid tests of executive function 
 
Investigations of executive function in ALS labour under the covert assumption that the 
measures used to assess this construct tap into patients’ everyday problem–solving and 
planning behaviour. This has, however, not been established. Concerns regarding the 
real–world application of some executive function tasks have been raised in the 
neuropsychology literature (Burgess et al., 2006; Chan et al., 2008; Chaytor & 
Schmitter-Edgecombe, 2003). With these reservations in mind, Stukovnik et al (2010) 
used a novel task which simulated the reality of everyday medication management. 
Participants were required to assemble coloured cards, each representing different 
medications, according to rules relating to each ‘card/medication–pill’ (e.g. take two 
different times a day; do not take with other medication) in as few steps as possible. 
ALS patients’ (n=22) overall performance was significantly worse than controls (n=22). 
Specifically, they placed fewer pills correctly, made more errors and broke more rules. 
Moderate to large effect sizes for group differences were observed. These were larger 
than those observed from other standard cognitive tests included in the battery, 
suggesting that tasks which imitate realistic problem–solving situations may be more 
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sensitive to the extent of cognitive impairment in ALS. Equivalently, a difficulty in    
co–ordinating multiple rules to achieve a familiar objective (medication scheduling) in 
the patient group indicates that executive dysfunction in ALS may bear real relevance to 
patient care and daily living.  
 
Decision–making under realistic conditions of increasing complexity has also been 
assessed in ALS using an adapted version of the Holiday Apartment Task (Fellows, 
2006). In this task, participants are required to choose the best apartment out of a range 
of alternatives (with differing attributes) for the purpose of a hypothetical holiday stay. 
Meier et al (2010) administered this task to 17 ALS patients and 18 controls. They 
found that while controls adopted an attribute–based strategy for all trials, the patients’ 
search strategy shifted from an attribute–based approach in the first trial to an 
apartment–based approach in the third trial, the highest level of complexity (more 
apartment options). An attribute–based approach is posited to reflect a ‘maximizing 
strategy’ where the best choice is the objective. An apartment–based approach is 
considered to represent a ‘satisfying’ strategy where an acceptable but not optimal (i.e. 
‘good enough’) alternative is chosen (Simon, 1956). This latter approach has been 
demonstrated by patients with OFC lesions on comparable decision–making tasks and 
possibly reflects a deficient representation of stimuli value (Fellows, 2006; Fellows & 
Farah, 2003). The study therefore provides indirect support for the presence of 
underlying OFC dysfunction in non–demented ALS patients, which might compare to 
the early OFC involvement present in bvFTD (Hornberger et al., 2010; Wittenberg et 
al., 2008). 
 
Meier et al (2010) included other tasks, which they designated as being either primarily 
OFC– or DLPFC–sensitive. Individual case analysis, using the control sample as a 
reference, revealed that impaired performance on tasks sensitive to OFC and DLPFC 
functioning were dissociated within the ALS group. Some patients (n=6) performed 
worse and showed classical dissociations on tasks sensitive to OFC function. In other 
patients (n=3) this pattern was apparent for DLPFC tasks only. Another subset of 
patients (n=5) showed dissociations on both sets of tasks. While caveats regarding the 
suggested specificity of these individual tasks are acknowledged, these findings 
implicate a broader involvement of the PFC in ALS cognitive dysfunction and that 
different patterns of cognitive impairment in patients might be associated with separate 







In addition to the relatively robust fluency deficits demonstrated in non–demented ALS 
patients, impairments in confrontation naming have been reported (Abrahams et al., 
2004; Cobble, 1998; Hanagasi et al., 2002; Kilani et al., 2004; Mantovan et al., 2003; 
Taylor et al., 2013; Wicks et al., 2009) , albeit less consistently (Abrahams et al., 2000; 
Kew et al., 1993a; Rakowicz & Hodges, 1998; Talbot et al., 1995). Phonemic and 
semantic paraphasias, errors which are associated with PNFA and SD (see section 
2.1.2.), have also been demonstrated in ALS patients on these tasks (Mantovan et al., 
2003; Rakowicz & Hodges, 1998; Strong et al., 1999). Both fluency and naming tasks 
involve executive and word–retrieval processes, but the latter is considered to be less 
dependent on executive resources, due to the available prompts of external stimuli 
(pictures of objects). It is regarded as a more direct assessment of language function 
than verbal fluency. Performance on the two tasks is associated with common and 
divergent underlying neural substrates; only confrontation naming activates the 
temporo–occiptal cortices (see Abrahams et al., 2003). However, fMRI data acquired 
during tasks of phonemic fluency and  naming  revealed reduced BOLD responses in 
the inferior frontal gyrus of patients relative to controls for both tasks (Abrahams et al., 
2004).  
Comprehension  
Much like ALS naming studies, the assessment of receptive language has produced 
mixed results. An early study found significant differences between 19 ALS patients 
and 10 controls on the Token Test which requires the adherence to verbal commands of 
increasing complexity (Talbot et al., 1995). Subsequent larger studies have failed to 
detect group effects using the same task (Mantovan et al., 2003; Rusina et al., 2010). 
Other means of assessment have included testing the ability of participants to match 
spoken sentences with pictures or line drawings, on trials of increasing grammatical 
complexity. Findings of impaired performance have like–wise been variable across 
small samples which have on occasion included patients with FTD–PPA (Cobble, 1998; 
Rakowicz & Hodges, 1998; Strong et al., 1999), thereby limiting inferences regarding 







Verb and noun processing  
 
The selective deficit in verb processing shown in ALS–FTD (see Section 2.1.), has also 
been demonstrated in non–demented ALS patients. Grossman et al (2008) compared 
knowledge of verbs and nouns in a sample of 34 ALS patients. Participants were 
required to select one of two available single word choices that best matched either a 
presented verb (associated with an action) or noun (associated with an object). In 
addition, participants were asked to match one of four available action verbs or object 
nouns with a phrase describing either an action or an object. A pattern of impaired 
action knowledge (verb processing) compared to object knowledge (noun processing) 
was revealed in 24 ALS patients. Participants also completed a brief assessment of 
executive functioning and grammatical comprehension. Performance on both verb and 
noun processing correlated positively with grammatical comprehension, suggesting that 
the latter did not influence the select deficit in verb processing in these patients. 
Patients' verb processing impairments correlated with the degree of atrophy in the 
premotor regions, while non–motor regions (including the bilateral DLPFC and inferior 
frontal cortex) correlated with both verb and noun processing ability. Previous imaging 
studies have revealed an association of verb processing and the motor cortices in 
healthy individuals (Hauk et al., 2004; Tettamanti et al., 2005). Grossman et al’s 
findings thus suggest that verb processing deficits in ALS may be related to the 
degradation of action knowledge associated with compromised motor regions. 
However, verb, and not noun, processing ability also correlated with executive function 
indices, indicating that the select impairment might be due in part to increased 
recruitment of executive resources on the verb processing component of the task.  
Writing Errors  
Increased writing errors in the form of syntactic and spelling mistakes and the omission 
and substitution of letters have been observed in ALS patients without overt dementia 
or aphasia compared to controls (Cobble, 1998; Ferguson & Boller, 1977; Ichikawa et 
al., 2010; Tsuji-Akimoto et al., 2010). These errors are qualitatively similar to the 
agraphia, paragraphia and spelling errors reported in aphasic ALS patients (Ichikawa et 
al., 2008). In non–demented ALS, writing errors have been proposed as predictive of 
frontotemporal degeneration (Ichikawa et al., 2011). Similarly, the severity of writing 





Discourse analysis has been used to investigate spoken language in non–demented ALS 
patients using the Cookie Theft picture description task (Goodglass et al., 2001) and a 
topic–directed interview. On both tasks, Strong et al (1999) found that ALS patients 
produced significantly fewer self–corrected utterances relative to controls at baseline 
and again at a 6 month follow–up. Using the Cookie Theft task, a 24 month longitudinal 
study found that ALS patients produced significantly fewer correct information units 
(CIU), a measure of content relevance and accuracy, compared to controls at baseline. 
Moreover, individual analyses revealed that 10/16 ALS patients scored greater than one 
standard deviation (1 SD) below controls at baseline on the CIU measure, a pattern 
which remained consistent throughout the study duration. Also at baseline, ALS 
patients produced fewer content units, an indicator of participants’ ability to deduce 
information from the picture. At this time period, 8/16 patients exceeded the 1 SD cut–
off; however, this pattern did not persist throughout the study (Roberts-South et al., 
2012). Patient performance was found in the context of preserved expressive 
vocabulary, comprehension and action naming, suggesting greater sensitivity of 
discourse methods over standard language measures to more subtle language 
impairments in ALS. Alternatively, discourse deficits may reflect underlying executive 
dysfunction rather than discrete language disruption in ALS patients. This suggestion is 
supported by studies which reveal a relationship between executive function and 
discourse production in several neurological conditions, including FTD (Ash et al., 
2006; Coelho et al., 1995). Unfortunately, measures of executive function were absent 
in this study, so a similar relationship in this ALS sample could not be examined.   
Language dysfunction and relation to executive dysfunction 
 
Meta–analysis supports the presence of language dysfunction in ALS, as a significant 
medium effect size for language deficits based on seven studies (n=155, d=0.53, p<.05, 
95% CI [0.09;-0.97]) has been demonstrated (Raaphorst et al., 2010). Population 
research indicates a higher prevalence of language dysfunction in patients (23.3%, 
n=232) than previously suggested by clinic–based investigations (Phukan et al., 2012). 
Nevertheless, these studies include restricted sets of language assessment, thereby 
limiting inference regarding the profile of impairment. Debate surrounds whether ALS 
language dysfunction is reflective of aphasic–type impairment or secondary to 
executive deficits (Bak & Hodges, 2004; Talbot et al., 1995).  
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Phukan et al (2012) showed that although executive dysfunction and language 
impairment tended to co–occur, the isolation of language impairment in some patients 
was also present. However, similar to previous studies, object naming served as the only 
measure of language function in the cohort. A relatively large clinic–based study    
(n=51 ALS; n=35 controls) which used a comprehensive assessment of language 
function found a similar pattern of results (Taylor et al., 2013). In this study separate 
composite scores based on executive and language items were constructed for each 
participant. Of the 51 patients assessed, 31% were classified as showing executive 
deficits and 43% qualified for language impairment, on the basis of performing at or 
below the 5
th
 percentile of the control group. In addition, established criteria for 
cognitive impairment (Strong et al., 2009) and an extension of these criteria to explore 
language deficits was applied to individual domain items. Thirteen patients (25%) were 
classed as ‘cognitively impaired’ based on executive deficits and 20 (39%) based on 
extended criteria including language. These results suggest that language dysfunction 
might be as prevalent if not more prevalent than executive impairment in ALS. 
Independence of language disruption was again evident, as seven of the 20 language–
impaired patients showed no executive dysfunction. Furthermore, within the ALS 
sample, regression analysis demonstrated that the Executive function composite scores 
accounted for only 44 % of the variance in the language composite scores. As 
neuropsychological testing was weighted more towards language than executive and 
non–executive function (i.e. memory), this may have produced a battery 
disproportionately sensitive to language impairment. Nonetheless, these findings 
challenge the opinion of exclusive or predominant executive dysfunction in ALS. 
Instead, they delineate a cognitive profile which could be characterised by either 
executive dysfunction, language impairment or both.  
2.2.1.3. Memory 
Recall Memory 
Immediate verbal recall has been shown to be impaired in some (Gordon et al., 2010; 
Hammer et al., 2011; Mantovan et al., 2003; Ringholz et al., 2005) but not all studies 
(Hanagasi et al., 2002; Rottig et al., 2006), on measures of verbal span, word and prose 
retrieval. Delayed verbal recall is, likewise, highly variable (Gallassi et al., 1989; 
Hanagasi et al., 2002; Hartikainen et al., 1993; Iwasaki et al., 1990; Kilani et al., 2004; 
Neary et al., 1990; Paulus et al., 2002).  
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Impaired cued verbal recall has been noted in ALS patients using the Paired Associative 
Learning task (David & Gillham, 1986; Phukan et al., 2012) and others assessing 
immediate and delayed cued recall (Hanagasi et al., 2002). However, some studies 
measuring similar processes have failed to replicate these results (Abrahams et al., 
1997; Abrahams et al., 2004; Abrahams et al., 2005b; Kew et al., 1993a).   
A comparable inconsistency exists for studies assessing immediate and delayed visual 
memory recall. ALS patients have displayed reduced immediate recall of visual stimuli 
(David & Gillham, 1986; Gallassi et al., 1989; Kew et al., 1993a; Mantovan et al., 
2003; Palmieri et al., 2009; Ringholz et al., 2005), but not consistently (Abe et al., 
1997; Abrahams et al., 1997; Evdokimidis et al., 2002; Lakerveld et al., 2008; Ludolph 
et al., 1992; Wicks et al., 2009). A minority of studies have investigated delayed visual 
recall, with some finding impairment (David & Gillham, 1986) but not others 
(Evdokimidis et al., 2002; Kilani et al., 2004).  
Recognition Memory 
Recognition for verbal information is largely reported as preserved (Abrahams et al., 
2005b; Hanagasi et al., 2002; Kew et al., 1993a; Massman et al., 1996; Rottig et al., 
2006), although some studies have noted impairments (Abrahams et al., 1997; 
Mantovan et al., 2003). Recognition of visual information has been assessed using 
varied non–verbal stimuli, such as faces (Abrahams et al., 1997; Hanagasi et al., 2002; 
Kew et al., 1993a; Ringholz et al., 2005; Strong et al., 1999; Talbot et al., 1995), 
figures and patterns (Chari et al., 1996; Frank et al., 1997; Gordon et al., 2010; 
Mantovan et al., 2003), again providing inconsistent results. 
Nature and mechanisms of memory impairment  
 
Published evidence on recall and recognition memory in ALS is highly variable. A 
better indication of the memory profile in ALS might be provided through meta–
analysis. Raaphorst et al (2010) found significant mean effect sizes for immediate (95% 
CI [0.16;0.86]) but not delayed (95% CI[-0.002; 0.97]) verbal memory domains. A 
significant mean effect size for visual memory impairment was also found (95% CI 
[0.01; 0.84]) (both immediate and delayed studies were amalgamated to represent one 
domain in order to circumvent the small number of studies available in the latter). 
Generally, immediate memory impairments are attributed to executive impairments 
related to the frontal cortex, while delayed memory recall is associated with medial 
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temporal–related processes (Lezak, 2004). The profile indicated by this study therefore 
implicates a frontally–mediated memory deficit in ALS.  
Notwithstanding, the proposed involvement of medial temporal lobe in memory change 
in ALS is not irrelevant. In Raaphorst and colleagues’ meta–analysis, the effect size for 
impairments in delayed verbal memory (n=371; d=0.47; p>.05, 95% CI [–0.002; 0.97]) 
was within the same range as that of the immediate verbal memory domain (n=497; 
d=0.51; p<.05, CI 95% [0.16; 0.86]). It is possible that delayed verbal memory did not 
meet statistical significance due to the smaller number of participants contributing to 
that domain (Raaphorst et al., 2010). Furthermore, Phukan et al’s (2012) recent 
population study compared memory performance between ALS patients with intact 
cognition; ALS patients with predominantly executive dysfunction (ALS–Ex) and 
patients with non–executive cognitive impairment (ALS–NEx). Compared to 
cognitively intact patients, the ALS–Ex group performed significantly worse on 
immediate and delayed recall trials, but not on the retention or recognition trials. 
Conversely, the ALS–NEx patients performed significantly worse on all four memory 
conditions. These results suggest a heterogeneous pattern of memory impairment in 
ALS which can occur alongside and independent of executive dysfunction.   
 
2.2.1.4. Visuoperception and visuocontructive skills 
 
Visuoperceptual function refers to a set of processes that include attention, object 
identification and recognition (Phukan et al., 2007). These processes are largely 
preserved in ALS, as suggested by individual studies (Kew et al., 1993a; Massman et 
al., 1996; Ringholz et al., 2005; Talbot et al., 1995; Wicks et al., 2009) and meta–
analysis (Raaphorst et al., 2010). However, mild impairments using a motor–free visual 
perception test (Strong et al., 1999); object decisions test (Robinson et al., 2006) and a 
line orientation task (Hanagasi et al., 2002) have been reported. Where impairments are 
found, it is possible that these deficits are secondary to the executive dysfunction 
inherent in the respective patient samples, rather than visuoperceptual difficulties per 
se. Findings of similar impairments reported sporadically in FTD patients are often 
interpreted in light of severe executive impairment (Zakzanis, 1998). Despite a lack of 
impairment findings, these tests are often included to eliminate the possibility of global 




2.2.1.5. Relationship between disease variables and cognition in ALS  
Studies supporting the existence of neuropsychological impairment in ALS must 
account for disease–related factors which could reasonably explain or at least contribute 
to cognitive change. Respiratory insufficiency is an inevitable consequence of the 
disease course and has been associated with cognitive dysfunction in ALS (Kimura et 
al., 1999; Newsom-Davis et al., 2001). Recently, comparable executive functioning was 
documented between patients with intact (n= 20) and compromised (n=24) respiratory 
function (an FVC score <80%). However, within the respiratory–impaired group, those 
not receiving pulmonary interventions did show greater executive impairment than 
those receiving treatment (Strutt et al., 2012). This supports earlier findings (Newsom-
Davis et al., 2001) that respiratory insufficiency may contribute to reduced cognitive 
functioning, but that once treated impairment may be less evident. Cognitive assessment 
in ALS should monitor and control for this potential confound, but in practice the use 
and methods of respiratory assessment do vary between studies, and is not consistently 
reported.  
The impact of mood and fatigue on cognitive performance has received little attention, 
despite demonstrable relationships in other neurodegenerative disorders (e.g. Diamond 
et al., 2008). In one study, depression differentially affected ALS patients and controls. 
Neither group means met cut–off criteria for clinical depression; depression scores 
overall were not associated with cognitive performance in one group more than the 
other. Instead, depressive symptoms were negatively associated with patients’ 
performances on delayed recall, naming and visuospatial ability, but were negatively 
associated with controls’ performances on immediate recall and verbal fluency (Jelsone-
Swain et al., 2012). Although group differences in cognitive performance were 
associated with the presence of depressive symptoms, they do highlight the importance 
of considering mood assessment alongside cognitive testing, as significant associations 
were found within the groups.  
In the same study, ‘vegetative’ symptoms (which comprised fatigue items) were not 
associated with cognitive performance in the ALS sample. However, only a subsample 
of patients completed the symptom questionnaire. Physical functioning in these patients 
was significantly higher than those without these data. Therefore the lack of effect 
might be attributed to better physical functioning in the group included in the analysis, 
although  a relationship between cognitive impairment and level of physical functioning 
has been inconsistently reported (Gordon et al., 2010; Jelsone-Swain et al., 2012; 
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Lakerveld et al., 2008). The rate of disease progression may be a more useful predictor 
of cognitive impairment, as clinic and population–based research has associated 
executive dysfunction with more aggressive disease course (Elamin et al., 2013; 
Gordon et al., 2010; Phukan et al., 2012).  
Site of disease onset may also be relevant to neuropsychological functioning in ALS. 
Patients with bulbar–onset disease have shown impaired cognitive performance relative 
to limb–onset patients and healthy controls in cross–sectional and longitudinal analyses 
(e.g. Abe et al., 1997; Portet et al., 2001; Schreiber et al., 2005; Strong et al., 1999).  
However, these findings are not always replicated (e.g. Kilani et al., 2004; Ringholz et 
al., 2005; Rippon et al., 2006; Stukovnik et al., 2010; Zalonis et al., 2012). The 
presence of pseudobulbar palsy may also be associated with cognitive dysfunction 
(Abrahams et al., 1997). 
Associations between the neuropsychological profile of ALS and emotional lability 
(EL) have been investigated sparingly. An early neuropsychological study found that 
total errors on the WCST predicted the presence of EL symptomatology with 75% 
accuracy (McCullagh et al., 1999), although a later study failed to identify any 
relationship using an abbreviated version of the same task (Palmieri et al., 2009). 
However, different measures of EL were used and the latter study’s sample comprised 
several MND variants (i.e. PMA, PLS patients), which may show variable EL severity 
and different profiles of neuropsychological change. Assessing the relationship between 
EL and cognitive change in ALS is confounded by the presence of other disease factors. 
Some evidence indicates a relationship between episodes of crying and depression 
(Moore et al., 1997; Newsom-Davis et al., 1999), while another study has shown an 
association of EL with anxiety and emotional fragility (Palmieri et al., 2009). Other 
studies have noted EL symptoms in non–depressed and non–anxious patients who show 
cognitive change (Girardi et al., 2011; Wicks et al., 2009).  Furthermore a relationship 
between EL and cognition may be a function of bulbar symptomatology, as EL is also 
more common in patients with bulbar presentation (Moore et al., 1997).  
2.2.1.6. Prevalence and incidence of cognitive impairment in non–demented ALS  
 
The reported prevalence of cognitive dysfunction in ALS varies among studies, 
presumably reflecting discrepancies in testing procedures, sample size and patient 
sampling. Furthermore, despite the introduction of methods to control for the confounds 
of motor impairment in testing, studies diverge on their adoption. Similarly, inconsistent 
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exclusion criteria across studies result in samples with variable co–morbid disease 
factors that may influence cognitive performance. Notably, different criteria of 
cognitive impairment are in use, further complicating comparisons between studies. In 
addition, referral bias from clinics which may have a specific interest in ALS cognitive 
change might further distort these estimates.  
 
The largest clinic–based neuropsychological study of ALS (n=279) to date reported that 
51% of their patient sample demonstrated subtle to severe cognitive impairment; the 
more severely impaired meeting criteria for dementia (Ringholz et al., 2005). The study 
distinguished patient performance along a continuum of impairment. Mild cognitive 
impairment was defined as performance below the 5
th
 percentile of the healthy control 
group performance on two or more neuropsychological tests. Moderate–severe impaired 
was specified as performance below the 2.3
rd
 percentile of the control group on three 
tests. DSM–IV and McKhann criteria (McKhann et al., 2001) were used to establish 
dementia diagnosis. Of the 142 patients classified as impaired, 32% and 19% met the 
criteria for ‘mild’ and ‘moderate–severe’ cognitive impairment, respectively. Of the 
‘moderate–severe’ patients, 15% were diagnosed with dementia. Forty–one ‘demented’ 
patients met criteria for FTD, while only 2 met criteria for AD. The study used a 
detailed neuropsychological battery of non–timed tasks that assessed several cognitive 
domains. However, measures of verbal fluency (COWA) and attention (VSAT) did not 
include a motor control condition, possibly inflating the prevalence of cognitive 
impairment obtained. Despite this limitation, the size of the study may provide a more 
reliable estimate of cognitive impairment in ALS than previous smaller investigations 
(e.g. Massman et al, 1996; Lomen–Hoerth et al, 2003; Rippon et al, 2006). The 
classification of patients into groups based on the severity of cognitive dysfunction 
underscores the continuum of impairment that can occur within the disease. Finally, the 
study supports the impression of a higher prevalence of FTD than other dementia 
syndromes, such as AD, in ALS.    
This study was followed by another relatively large (n=110) clinic sample that 
differentiated neuropsychological performance between bulbar (n=40) and limb–onset 
(n=70) patients (Flaherty-Craig et al., 2006). The study used only three tests of 
cognitive assessment (verbal reasoning, verbal judgement and verbal fluency) and 
relatively less stringent criteria of cognitive impairment than Ringholz et al’s study    
(1.5 standard deviations below total ALS group mean on the tests). Nonetheless, a 
comparison of patients with bulbar and limb onset revealed discrepant rates of 
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impairment between the patient groups. Limb–onset patients showed lower prevalence 
of impairment on all three tests; corroborating previous reports of an association 
between cognitive dysfunction and bulbar–onset disease. These results suggest that the 
prevalence of cognitive impairment in ALS may vary as a function of the ratio of bulbar 
versus limb–onset patients across patient samples.        
Cognitive dysfunction in ALS has been associated with shorter survival times and more 
aggressive disease (Elamin et al., 2013; Olney et al., 2005; Phukan et al., 2012; Rusina 
et al., 2010). This implies that clinic–based investigations which typically comprise 
prevalent cases may underestimate the incidence of cognitive dysfunction in the disease. 
A recent population–based study recruited 160 incident cases and found that 
approximately 40% of ALS sample showed cognitive impairment, predominantly but 
not exclusively in the form of executive dysfunction (Phukan et al, 2012). This estimate 
is lower than that reported by Ringholz et al’s large clinic study; however, more 
stringent impairment criteria were applied in this study. Performance below the 2.3
rd
 
percentile of the control group (n=110) on two domain–specific tests qualified for 
impairment. Patients were classified according to a domain–based system rather than 
according to a continuum of general cognitive performance, which may also account for 
the lower prevalence reported.  
2.2.1.7. Longitudinal assessment of cognition in ALS 
 
Only a few studies have assessed cognition over time in ALS. Due to the progressively 
debilitating nature of the disease, these studies are often confounded by high attrition 
rates, limited sample sizes, missing data and restricted compositions in which patients 
with more aggressive disease forms may be inadequately represented at follow–up. The 
first prospective study of cognition in ALS included 13 patients, of which only eight 
remained in the study at a six month follow–up (Strong et al., 1999). At baseline, only a 
test of visual perception distinguished patient and control performance. However, at 
follow–up the patient group showed relative impairments on tests of word generation, 
visual recognition of faces and visual perception. Bulbar–onset patients showed greater 
impairment than limb–onset patients at both testing points; impairments extended to 
working memory and cognitive flexibility for this group. Additionally, progression of 
cognitive impairment in the bulbar–onset group, but not the limb–onset group was 
evident, as involvement of cognitive domains increased between testing periods for 
these patients only.   
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In contrast to this first study, Kilani et al (2004) compared 18 patients and 19 controls 
over a period of 12 months and found generally preserved cognitive performance and 
lack of progression in their patient sample. At baseline, patients performed significantly 
worse than controls on a Trail–making test and the BNT, but these impairments were no 
more pronounced at subsequent follow–ups. Only two bulbar–onset patients were 
included in the study, which might explain the lack of deteriorated performance in this 
sample as opposed to Strong et al’s study. Further, bulbar severity scores were 
reportedly low in the ALS patients. Previous studies have noted a relationship of 
cognitive impairment with not only bulbar–onset location but severity of bulbar 
symptoms (Abrahams et al., 1997).   
A larger prospective study directly compared bulbar (n=15) and limb (n=37) onset 
patients over a course of 18 months, at 4 month intervals (Schreiber et al., 2005). 
Unsurprising for a study on this length, only 19 of the original 52 patients remained in 
final follow–up assessment. Nonetheless, at baseline, neuropsychological testing 
revealed relative performance decrements in bulbar–onset patients compared to limb–
onset patients on tests of word and design fluency. Although no profound deterioration 
was documented, these inter–group differences increased during follow–up, with the 
bulbar–onset group remaining significantly impaired. Due to the high attrition rate, 
longitudinal statistical analyses could not be applied to separate groups. 
Notwithstanding, the results, based on mean scores, do point to some decline in 
executive function for the bulbar–onset patients over the course of the study.     
A similar profile of cognitive stability in ALS was suggested by another study using a 
comprehensive neuropsychological assessment of executive function, memory, 
language and visuospatial ability (Abrahams et al., 2005b). Only verbal fluency 
impairments were found in patients (n=20) at inclusion, but indices remained stable 
relative to controls (n=18) at the six–month follow–up. Using a computerised sentence 
completion test, and controlling for motor speech impairment, the study found 
significantly slower word retrieval response times between testing sessions for the 
patient group. It was noted that 50% of the patients at the second test session showed 
clinical signs of pseudobulbar palsy. It was not reported whether the presence or 
emergence of bulbar symptomatology was associated with performance deterioration. 
Notwithstanding, these results suggest that cognitive deterioration in non–demented 
ALS progresses slowly relative to the overall disease and that language function may be 
more vulnerable than other domains to deterioration over the course of disease. These 
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conclusions are substantiated by Gordon et al (2010) who observed that only animal 
naming (semantic fluency) deteriorated in their six–month study of 50 ALS patients. At 
the first testing session, mild to moderately deteriorated performance for some patients 
(n=14) was shown on measures of executive function, memory and other language 
abilities (confrontation naming), but these did not show deterioration between time 
points. In this study, neuropsychological testing did not accommodate for motor 
disability, but neither bulbar–onset nor severity of bulbar signs predicted impairment at 
the initial testing session. Gordon et al (2010) did not investigate whether these 
variables predicted the progression of animal naming deficits.       
While previous investigations have found little evidence to suggest marked cognitive 
deterioration, the reliance of these studies on between–group analyses may have masked 
the potential heterogeneity of impairment progression within cohorts. Robinson et al 
(2006) used single–case methodology to compare 19 recently diagnosed patients and 
eight caregivers. As before, testing assessed multiple cognitive domains including 
executive function, memory, language and visuoperception. At the group level, 
comparisons of ALS performance at inclusion and six months later found no significant 
deterioration within or between groups. However, individual analysis revealed that 
seven ALS patients showed deteriorated cognitive performance over the test period. Of 
these patients, one patient showed progression of impairment on seven of the eight 
neuropsychological tests, while the remaining six patients showed abnormal 
performance on up to three of the tests at the six–month follow–up. Only three bulbar–
onset patients were recruited to the study, precluding informative comparisons of this 
subgroup with limb–onset patients or controls. However, of the seven patients showing 
cognitive deterioration, two were bulbar–onset; the third bulbar–onset patient showed 
cognitive stability. These findings underscore the potential of individual analysis in 
detecting subtle progression of ALS cognitive deficits over time in otherwise presumed 
homogenous samples. They also indicate that deterioration in cognitive function in ALS 
is not restricted to bulbar–onset patients. 
Clinic–based studies are not only restricted in size but may also be susceptible to 
referral and selection bias, thus limiting the generalizability of their findings. 
Population–based research which follows incident cases through the disease duration 
may provide a better indication of the prevalence of cognitive impairment in ALS and 
the nature of its progression. One such study recruited recently diagnosed patients 
(n=186; diagnosis<12 months) from the Irish ALS register (Elamin et al., 2013). 
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Patients and healthy controls (n=120) underwent comprehensive cognitive testing over 
a period of 18 months at four–month intervals. Patients who did not qualify for ALS–
FTD (n=164) were designated to one of three groups, on the basis of cognitive 
performance at baseline. These groups were as follows: cognitively intact patients 
(n=94), patients with predominant executive impairment (n=47) and patients with non–
executive impairment (i.e. memory and/or language dysfunction, n=28). Within the 
executive impairment group, some patients showed only executive impairment (i.e. 
single–domain executive deficit, n=17), while in other patients the impairment extended 
to memory and/or language dysfunction (i.e. multidomain executive deficits, n=30). 
The majority of cognitively intact patients remained stable throughout the study, 
although the emergence of non–executive cognitive abnormalities, in particular 
language dysfunction, was noted in this group. The emergence of executive dysfunction 
was rare. This result resonates with earlier reports suggesting a higher susceptibility of 
language faculties to compromise with advancing disease (Abrahams et al., 2005b; 
Gordon et al., 2010). The majority of patients presenting with only executive 
dysfunction developed deficits in other cognitive domains. Patients with multi–domain 
executive dysfunction at baseline showed little progression, except for one patient who 
developed bvFTD. Similarly, only a small proportion of the remaining patients in the 
non–executive dysfunction group developed executive impairment. These results 
demonstrate not only that cognitive dysfunction in ALS may deteriorate with time, but 
that these cognitive deficits vary in presentation and progression. That is to say that 
ALS cognitive impairment may be characterised by distinct subtypes, each with their 
own clinical trajectory.        
In summary, the longitudinal effects of ALS on cognition remain a controversial topic. 
Small clinic–based studies suggest that ALS patients show modest, if any, cognitive 
deterioration along the disease course. Some studies indicate cognitive symptoms 
progress only in bulbar–onset patients (Schreiber et al., 2005; Strong et al., 1999), but 
evidence of progression in limb–onset patients exists (Robinson et al., 2006). Findings 
from a population–based study (Elamin et al., 2013) may reconcile inconsistencies in 
the foregoing literature, by suggesting separate cognitive phenotypes with distinct 
patterns of symptom progression. Previous studies, in which only group–level data are 
compared, may obscure this proposed heterogeneity inherent in ALS samples.     
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2.2.2. Behaviour in non–demented ALS 
 
Relative to cognition, systematic study of behaviour in ALS has been slow in 
development. Unsurprisingly, the prevalence, incidence and nature of behavioural 
symptoms have not been fully ascertained (Lillo et al., 2010; Lillo & Hodges, 2010). 
Investigation is strongly influenced by the prevailing classification of the dementia 
subtypes associated with FTLD (see Chapter 1, Section 1.5.2.). This is underscored by 
current criteria proposing the application of FTD diagnostic features to the assessment 
of behavioural impairment in ALS (Strong et al, 2009). The term ALSbi is offered to 
denote those patients who do meet FTD diagnostic criteria, yet show mood–independent 
change from disease onset (see Chapter 1, Section 1.5.3.). Research studies differ in the 
format (self or informant rated; questionnaire–based or structured) and type of 
inventory used. Furthermore, differing diagnostic criteria are applied to corroborate 
impairment. Despite these discrepancies, a proposed behavioural profile in ALS has 
emerged. The following section will outline and discuss the principal findings from the 
main studies of behaviour in non–demented ALS.  
2.2.2.1. Commonly reported behavioural symptoms 
 
Direct comparisons of ALS and bvFTD patients show that, although behavioural 
symptoms are significantly less frequent in ALS, changes in behaviour are qualitatively 
similar between the two groups (Lillo et al., 2010). Apathy appears to be the most 
common behavioural feature, although dysexecutive behaviour, social disinhibition and 
increased irritability are also reported frequently. A study of 45 patients which used the 
informant FrSBe found clinically significant levels of impairment on all three 
behavioural domains (as determined by a T–score cut–off of ≥65) following disease 
onset. The prevalence of impairment was highest for apathy (55.6%), followed by 
dysexecutive behaviour (46.7%) and disinhibition (28.9%). Only a statistically 
significant difference between pre– and post–illness–onset ratings was found for the 
apathy subscale (Grossman et al., 2007). Of note, premorbid ratings for all domains also 
met clinically significant criteria, suggesting that behavioural change in ALS may 
precede the physical symptoms associated with the disease. Alternatively, they might 
reflect pre–existing personality characteristics that have been previously noted in ALS 
by caregivers (see Section 2.2.3.). The study design did not allow for the examination of 
these alternatives, but indicates an interesting avenue of investigation.     
 84 
 
The profile of apathetic behaviour has been noted in a larger study (n=225) using the 
same informant measure and clinical cut–off criteria. Relatively conservative 
frequencies of impairment for apathy (31.6%), dysexecutive behaviour (19.6%) and 
disinhibition (16.9%) were noted. Nonetheless, 40% of patients showed impairment on 
at least one domain subscale. Analyses of a subset of 39 patients with premorbid data 
revealed that all patients showed significant changes in the FrSBe subscales, including 
the total behavioural change score (Witgert et al., 2010). In another study, when more 
stringent criteria for behavioural change were applied (2 SD between premorbid and 
current FrSBe ratings) the results failed to find significant changes over time on any of 
the domains (Woolley et al., 2010a). However, in contrast to the previous study, ratings 
did not meet the cut–off criteria for significant behaviour in either pre–morbid or post–
illness–onset domains. Behaviour for all patients was characterised by caregivers as 
typical of the normal population. Thus, this small sample (n=17) may not have captured 
the proposed heterogeneity of behaviour in the ALS population. 
Gibbons and colleagues (2008) found a spectrum of behavioural change in 14 of their 
16 ALS patients using the Manchester Frontotemporal Dementia Behavioural Interview 
(Bathgate et al., 2001; Snowden et al., 2001), an inventory which taps into a broad 
range of behaviours associated with FTLD. In all 14 patients, at least some change in 
affect and/or social behaviour was present. The most commonly reported change was 
increased self–centeredness and a reduction in concern for others, with over two–thirds 
(69%) of patients displaying these features. The authors suggested that this might reflect 
ego–centric behaviour typical of bvFTD. Other bvFTD–like behaviours included apathy 
(38%), blunting of emotion (25%), socially disinhibited behaviour (13%) and lack of 
awareness and concern for their disease (13%). Notably, the study also detected altered 
responses to sensory stimuli (50%) and repetitive, sterotyped behaviours (19%), 
suggestive of temporal lobe pathology associated with SD. Functional imaging in 8 
patients did reveal frontal and temporal lobe abnormalities, although the imaging results 
were not formally examined alongside the behavioural scores. 
Temporal lobe–mediated behaviours have also been detected in ALS using the Frontal 
System Behaviour Scale (Kertesz, 1997). Caregiver ratings for 198 ALS patients were 
identified as moderate–to–severe on bvFTD–like behaviours relating to apathy (13.6%), 
indifference (4.5%), perseveration (9.1%) and utilization behaviour (1.1%). However, 
items indicative of PPA, such as verbal apraxia and logopenia, were also identified as 
moderate–to–severe in 13.6% and 20.4%, respectively (Flaherty-Craig et al., 2009). 
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The above studies delineate a heterogeneous nature of behavioural change in ALS 
which may encompass milder forms of those seen across all the FTLD syndromes; 
possibly in accordance with underlying neuropathology. Nonetheless, caution in their 
interpretation is warranted. None of the behavioural measures employed across these 
studies have been validated in the ALS patients or adapted for the motor impairment. 
Responses to instrument items may be influenced by disease–related symptoms, 
although some studies do describe attempts to overcome this weakness through 
emphasizing the distinction of behavioural and physical symptoms to respondents (e.g. 
Grossman et al., 2007; Witgert et al., 2010). Furthermore, these studies employed 
subjective report designs and thus conventional methodological issues, such as recall 
bias and social desirability, apply. The common reliance on informant–ratings indicates 
an assumption that informant reports are a reliable standard, but caregivers might 
underestimate patients’ behavioural impairment through denial coping mechanisms 
and/or a lack of discernment of slowly developing changes leading to lower caregiver– 
ratings (e.g. Woolley et al., 2010a). Alternatively, increased distress, burden and a 
lowered quality of life might lead to overestimation of impairment by caregivers (Chio 
et al., 2010; Lillo et al., 2012a). In addition, few studies using self–report data employ a 
healthy control sample (e.g. Girardi et al., 2011; Wicks et al., 2009).   
2.2.2.2. Prevalence of behavioural change in non–demented ALS 
Prevalence estimates of behavioural change in ALS vary by study, likely reflecting 
inconsistencies of the methodologies and diagnostic criteria used. A recent systematic 
review of 21 studies found that mild to moderate behavioural changes were shown in 
17% – 88% of ALS patients without overt dementia (Raaphorst et al., 2012). One 
cross–sectional study which applied Strong et al’s criteria to 23 patients and found that 
the prevalence of ALSci (31%) was higher than ALSbi (4%) and symptom co–morbidity 
(4%) (Consonni et al., 2013). However, as this sample size was small, generalisations 
about the relative prevalence of cognitive and behavioural dysfunctions in the ALS 
population are restricted. Larger studies, preferably with population–based designs, are 
warranted. 
2.2.2.3. Mood, disease parameters and behavioural change 
 
Whether behavioural symptoms in ALS are part of the degenerative process or simply a 
reaction or adaptation to the progressive and terminal nature of the illness is a matter of 
debate. For example, a sensible query is the contribution of depressive symptoms to 
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elevated levels of apathy as reported by caregivers. Evidence for mood–independent 
behavioural change is supported by studies which have found raised apathy in non–
depressed patients (Gibbons et al., 2008; Grossman et al., 2007; Lomen-Hoerth et al., 
2003; Wicks et al., 2009; Witgert et al., 2010). Furthermore, in one study, depressive 
symptoms were present in 30% of ALS patients (n=81), but regression analysis revealed 
no relationship between mood symptoms and the presence of apathy (which was 
moderate to severe in 41% of patients), or any other behavioural symptom (Lillo et al., 
2010).  
Again, some reported changes in ALS should be interpreted with caution due to the 
physically debilitating nature of the disease. Loss of functional independence may 
contribute to increased irritability or self–centeredness as reactive behaviours towards 
the illness (Gibbons et al., 2008). Similarly, increased apathy in patients may be a 
response to the progressive loss of ability to engage with previous activities. Moreover, 
there is little study of whether behavioural change in ALS is a manifestation of fatigue, 
sleep disturbance (see Lo Coco et al., 2011), or medication–use. Nonetheless, absent 
relationships between behavioural change and functional status or disease duration have 
been noted (Gibbons et al., 2008; Grossman et al., 2007; Terada et al., 2011; Tsujimoto 
et al., 2011; Witgert et al., 2010; Woolley et al., 2011). A recent study compared 
cognitive and behavioural functioning between ALS and PMA patients under the 
premise that the two cohorts would show similar motor dysfunction. The PMA group 
had longer disease duration, but groups were matched on motor disease severity. 
Greater frequency of impairment in both cognitive and behavioural domains was found 
for the ALS group. In particular, ‘aspontaneity’ (or apathy) significantly differed 
between the two groups, with ALS patients showing a higher prevalence. Since the 
cognitive and behavioural profile of the PMA group was comparable to that of a healthy 
control group, these findings lend support to the notion that cognitive–behavioural 
impairment in ALS is not exacerbated by the physical limitations imposed by the 
disease (Consonni et al., 2013). 
As with cognitive change, evidence for increased vulnerability of bulbar patients to 
behavioural impairment is suggested but not conclusive. The presence of bulbar 
symptomology has been associated with increased ratings of behavioural symptoms in 
some studies (Chio et al., 2010; Flaherty-Craig et al., 2009; Gibbons et al., 2008; 
Grossman et al., 2007), but not others (Consonni et al., 2013; Lillo et al., 2010; Witgert 
et al., 2010). Severity of bulbar symptoms did not show a relationship to behavioural 
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change in one study (Grossman et al., 2007), while another showed that apathy and 
executive dysfunction were strongly related to presence of bulbar symptoms, more than 
to a bulbar disease onset (Chio et al., 2010).  
2.2.2.4. Neuroanatomical basis of behavioural change in ALS 
 
Neural correlates specific to apathetic behaviour have been suggested using DTI. 
Woolley et al (2011) assessed WM changes in 24 patients, 16 of whom received 
informant FrSBe ratings. A significant negative correlation between apathy change 
scores and alterations in the right AC was noted. Similar DTI data were obtained by 
another group investigating behavioural change in early–stage ALS (Tsujimoto et al., 
2011). Twenty–one patients who were described as ‘functionally independent’ (defined 
by achieving at least a score of 2 or more on each subscore of the ALSFRS–R) showed 
WM changes in the right frontal gyrus. Additionally, VBM analysis revealed that the 
severity of apathy was significantly correlated with atrophy in the OFC and DLPFC 
prefrontal cortices. An association between apathy and frontal lobe abnormalities has 
also been reported in FTD (Zamboni et al., 2008). The above studies therefore affirm a 
view of continuity between ALS and FTD at the behavioural and neuropathological 
levels. 
 
Behavioural changes in ALS might also reflect underlying genetic variation (Wicks et 
al., 2009). While sporadic patients showed a normal range of behaviour on the FrSBe, 
familial ALS (fALS) patients with and without SOD1 gene mutations endorsed 
significant levels of apathy following symptom onset. Additionally, non–SOD1 fALS 
patients showed significant post–illness–onset executive dysfunction scores. Due to the 
limited number of behavioural–genetic studies in ALS, consistent replication of the 
results is lacking and thus generalizability of these findings is restricted.   
2.2.2.5. The relationship between cognitive impairment and behavioural change  
The nature of the relationship between cognitive and behavioural change in ALS is not 
fully characterized. Significant correlations between executive deficits and behavioural 
change have been found (Grossman et al., 2007; Witgert et al., 2010) and co–morbidity 
of symptoms is reported (Consonni et al., 2013; Strong et al., 2009). However, changes 
are also shown to occur independently (Witgert et al., 2010; Woolley et al., 2011).  
Murphy et al (2007a) compared cognitive function in behaviourally intact (n=11) and 
compromised (n=9) patients. Only patients in the latter group showed co–morbid 
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executive dysfunction, suggesting an association between the domains. Since the 
impaired group included five ALS–FTD patients, conclusions about the specific 
relationship between cognition and behaviour in non–demented ALS patients were 
limited.  
 
A larger study used K–means cluster analysis to classify a subset of 141 non–demented 
patients into three groups, namely intact, mildly impaired and moderately–severely 
impaired, on the basis of neuropsychological test performance. FrSBe scores for the 
three groups were compared. Greater levels of behavioural impairment were found in 
the moderately–severe patient group, but only apathy differed significantly between 
groups. Nevertheless, 68% of patients in this group showed no behavioural symptoms at 
all, while 16% of the cognitively intact patients exhibited behavioural dysfunction 
(Witgert et al., 2010). Behavioural and cognitive disturbance was therefore 
incompletely related, suggesting that changes apparent in non–demented ALS may 
occur in isolation or together.   
Determining the relationship between cognitive and behavioural change in ALS is of 
theoretical and clinical importance. If cognitive and behavioural impairment emerge 
independently this might imply distinct phenotypes; presumably with unique 
neuropathologies, within ALS. Alternatively, the possibility of symptom co–morbidity 
extends the proposed spectrum of neuropsychological change within the disease. 
Furthermore, the identification of separate or concurrent symptomology in ALS patients 
may present unique challenges to the care of patients, and consequently to their 
respective caregivers.    
2.2.2.6. Insight and awareness  
Few studies have examined insight and awareness into cognitive and behavioural 
change in ALS, despite anosognosia of this kind constituting a core criterion of FTD 
diagnosis  (Neary et al., 1998).  A lack of awareness for cognitive dysfunction has been 
indicated in one study which found that, despite impaired performance relative to 
controls on an executive function measure, non–demented ALS patients consistently 
rated their performance on the task as similar to or higher than controls (Stukovnik et 
al., 2010). It is not known whether these evaluations reflect reduced insight into 
cognitive difficulties, denial coping strategies or the fact that the patients’ executive 
dysfunction was not severe enough to affect their everyday cognitive performance and 
thus remained undetected by patients. Further research in this area is required. Most 
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studies have focussed on insight into behavioural change, possibly because of the 
availability of behaviour scales and their potential to gain patients and caregiver reports 
for comparison.    
Differences between patient and informant ratings on patient behaviour were noted in a 
study of 70 ALS patient–caregiver couples (Chio et al., 2010). Compared to patient 
evaluations, caregivers reported higher frequencies of clinically significant pre–morbid 
and post–illness behaviour on all FrSBe domain scores. Caregivers rated apathy as the 
most commonly impaired domain (55.7%), followed by executive dysfunction (45.7%) 
and disinhibition (25.7%). Patients, however, rated apathy as the least commonly 
impaired (8.6%), noting executive dysfunction (20%) and disinhibition (10%) as more 
frequent. These discrepancies might reflect a particular lack of awareness of apathetic 
behaviour in ALS or could be attributed to over–responding by the ALS caregivers.     
A direct comparison of insight for behavioural change between ALS patients with and 
without FTD suggested preserved insight in non–demented ALS patients only (Woolley 
et al., 2010a). Loss of insight was defined as impairments endorsed by caregivers that 
were at least two standard deviations greater than those endorsed by the patient on 
domain or total scores of the FrSBe. While ALS–FTD patients reported only mild 
changes on the apathy domain, their caregivers reported profound changes in apathy, 
executive functioning and total behaviour change. These rating differences between 
respondent groups satisfied the loss of insight criterion. In contrast, a comparison of 
ALS patients and their caregivers’ ratings showed high concordance, with the patient 
group reporting slightly but not significantly greater change over time on all 
behavioural domains.  
Recent CT scanning evidence has revealed possible topographical correlates of 
anosognosia in a small cohort of ALS and ALS–FTD patients (n=8 in each group, 
Ichikawa et al., 2013). Anosognosia scores (as determined by patient–clinician 
discrepancies for functional and cognitive impairments) in the ALS group were 
significantly lower relative to the ALS–FTD group. Scores from both groups were 
positively correlated with anterior and inferior horns sizes, suggesting an association 
between loss of insight and frontotemporal atrophy in both diseases.  Follow–up CT 
data available for non–demented patients only (n=7) showed a longitudinal increase in 
inferior horn size. Increases correlated with anosognosia scores, suggesting that mild 
anosognosia in non–demented ALS might predict inferior horn enlargement, a 
reflection of medial temporal atrophy.    
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2.2.3. Mood and personality in ALS 
 
Depression 
One of the earliest reports of psychological status in ALS patients reported an absence 
of depressive symptoms in their small cohort (n=10, Brown & Mueller, 1970). Despite 
subsequent failure to replicate these findings with larger samples (Houpt et al., 1977; 
Montgomery & Erickson, 1987, although see Clarke et al 2001), the view that ALS 
patients remain resilient to depression in the face of their illness persists. A 2007 review 
of 28 studies reported a range of depression prevalence, varying from 0% – 100%. The 
weighted means for studies reporting means and standard deviations indicated a normal 
or only mild level of depression, depending on the measure used (Averill et al., 2007).  
Another review in the same year noted that larger studies (n ≥100) reported estimates of 
between 11% – 15%, double that of the general age–consistent population (McLeod & 
Clarke, 2007).  
Most psychological studies in ALS rely on self–report measures which are not formerly 
diagnostic of a major depressive disorder. Where studies have employed structured 
clinical interviews, such as the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth edition , population rates of major depressive disorder are estimated between   
0%  – 11% (Ganzini et al., 1998; Hammer et al., 2008; Rabkin et al., 2005; Rabkin et 
al., 2000). A recent study using DSM–IV criteria estimated a much higher prevalence of 
major depression in their sample (n=37) at 21.6% (Ferentinos et al., 2011). This might 
have been due to the fact that patients were interviewed relatively sooner after diagnosis 
than in previous studies, as some evidence indicates that depressive symptoms are 
inversely related to time since diagnosis (Hillemacher et al., 2004).  
The great variability reported in the literature is likely an artefact of the methodological 
disparity between studies, as different psychometric tools, assessment procedures 
(questionnaire; structured interview; postal survey), diagnostic or cut–off criteria, 
sample sizes and composition (cognitive status; MND phenotype; disease duration) and 
designs (cross–sectional or longitudinal) have been employed. Indeed, a survey study 
comparing prevalence rates of depression using different mood questionnaires in the 
same ALS sample (n=104) found a greater severity of mild to severe depressive 
symptoms using the Beck Depression Inventory (56%) (BDI, Beck, 1996) than the 
Hospital Anxiety and Depression Scale (25%) (HADS, Zigmond & Snaith, 1983) 
(Wicks et al., 2007). A more recent study of Greek patients (n=37) obtained a similar 
pattern of results with their selection of inventories, which also included the BDI and 
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HADS  (Ferentinos et al., 2011). Discrepant estimates between generic assessment tools 
may reflect their dissimilar emphasis on physical symptoms of depression which share 
an overlap with ALS symptoms (e.g. fatigue, sleep disturbance). Some, but not all, 
studies have attempted to circumvent these confounds by omitting biased ‘somatic 
items’ from analyses (e.g. Abrahams et al., 1997; Goldstein et al., 2002; Wicks et al., 
2007), but the psychometric properties of these modified mood measures have not been 
examined. Recently, a Rasch Analysis of the original HADS conducted for 298 ALS 
patients, found that the removal of two items, one from each of the depression and 
anxiety subscales, improved  the fit of each remaining 6–item subscale to the Rasch 
model (Gibbons et al., 2011). The modified version showed satisfactory reliability and 
good internal construct validity, making it suitable for use in the ALS population. New 
cut–off criteria indicating “caseness” for depression and anxiety were also calculated.  
The suggested prevalence of case–level depression and anxiety was 11.1% and 22.5%, 
respectively. A comparison of these prevalence estimates with those that would have 
been derived from the original cut–off criteria (HADS D: 15.1%; HADS A: 18.8%) 
suggested that the original HADS slightly overestimated caseness for depression and 
slightly underestimated caseness for anxiety, relative to the modified version.   
The notion that severe depression is not a frequent feature of ALS is supported by 
indirect comparisons with other neurodegenerative conditions such as PD, MS and 
Huntington’s disease (HD). A caveat of comparing prevalence rates between these 
disorders is that the neuropsychological, physical and pathological differences between 
them might impact depression differently in each condition. Moreover, assessment of 
depression between these disorders encompasses the same methodological variability 
apparent in ALS research. To overcome these limitations, one study compared the 
prevalence and severity of depression in ALS patients to that of patients with similar 
disease profiles (Taylor et al., 2010). Prevalence rates obtained from the BDI–II, HADS 
and Major Depression Inventory (Olsen et al., 2003) were comparable between groups, 
although higher than that estimated in the general population (Mojtabai & Olfson, 2004; 
Steffens et al., 2000). These results challenge the assumption that ALS patients are 
exceptionally resistant to mood disorder.   
Depression is suggested to be unrelated to disease severity in the majority of studies 
(Atassi et al., 2011; Clarke et al., 2001; Grehl et al., 2011; Lule et al., 2008; 
Montgomery & Erickson, 1987; Rabkin et al., 2000; Tedman et al., 1997), although two 
early studies did find statistically significant but weak associations with physical 
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impairment (Hogg et al., 1994; Hunter et al., 1993). Recently, depressive symptoms 
were found to correlate negatively with ALSFRS scores (Oh et al., 2012). However, 
patients in this study were quite physically progressed and several were severely 
depressed, as measured by the BDI. Another study of 41 ALS patients found a 
significant relationship between depressive symptoms and the breathing and swallowing 
items of the ALSFRS, but not the total ALSFRS score (Hillemacher et al., 2004). This 
might suggest an increased vulnerability to depression for patients with bulbar or 
respiratory symptoms. Depressive symptoms correlated negatively with disease 
duration, indicating that the depression present in the sample may represent a 
psychological reaction to the diagnosis communication for some patients. By 
comparison, increased depressive symptoms have also been associated with limb 
dysfunction, even in high functioning ALS patients (n=22, Jelsone-Swain et al., 2012).  
Longitudinal studies typically fail to show increased depression and anxiety over the 
course of disease, even at the late–stage of illness (Cupp et al., 2011; Goldstein et al., 
2006b; Rabkin et al., 2005). One study did report increased depression from baseline to 
a 9–month follow–up in 31 patients, but symptoms remained in the non–depressed 
range (Gauthier et al., 2007).   
Although fatigue has been previously associated with depression (Lou et al., 2003), a 
recent study found that 65% of their sample of ALS patients (n=223) endorsing fatigue 
were not depressed (McElhiney et al., 2009), suggesting the two conditions may occur 
independently. Other correlates of depression include reduced quality of life (Kubler et 
al., 2005; Lule et al., 2008; Tramonti et al., 2012); lack of social support (Ganzini et al., 
1999; Goldstein et al., 2002; Rabkin et al., 2000); anxiety (Atassi et al., 2011), pain 
(Rabkin et al., 2000; Tedman et al., 1997);  reduced survival (McDonald et al., 1994) 
and perceived burden placed upon their respective caregiver (Gauthier et al., 2007; 
Rabkin et al., 2000). These relationships underscore the importance of on–going 
psychological assessment in ALS patients. Although inconsistent, they also point 
towards associated disease variables which may improve identification of patients at 
risk of developing depression.   
Anxiety 
The presence of anxiety has received little study in ALS. Prevalence estimates of ALS 
individuals meeting criteria for significant anxiety range from 11% – 26% (Clarke et 
al., 2001; Ferentinos et al., 2011; Goldstein et al., 1998; Goldstein et al., 2002; Moore 
et al., 1998). Findings parallel those in the depression literature, in which the varied use 
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of mood measures across studies lead to inconsistent estimates. Wicks et al (2007) 
compared estimates from the HADS with the State and Trait Anxiety Inventory  (STAI, 
Spielberger et al., 1968, 1977) and found that while only 8% of the 104 patients were 
classified as anxious on the STAI, 18% met criteria for ‘caseness’ of anxiety on the 
HADS. A more recent study which adopted the Brief Symptom Inventory (Derogatis & 
Spencer, 1993) found that anxiety subscale scores in ALS patients (n=51) were 
significantly higher than those of a non–clinical normative sample (n=685). In 
comparison to a psychiatric outpatient reference group (n=999), ALS anxiety scores 
were not statistically different. This suggests that anxiety in ALS patients might be as 
severe as that in psychiatric patients receiving treatment in outpatient mental health 
services (Felgoise et al., 2010). In contrast, another study found no difference between 
patients (n=40) and controls (n=40) using the STAI (Pagnini et al., 2012). However, as 
with depression, similar methodological differences between studies apply.  
A distinction is made between state anxiety, an unpleasant emotional reaction in 
response to perceived threat, and trait anxiety, stable anxious feelings in anticipation of 
threatening situations. Vignola et al (2008) examined both constructs in 75 ALS 
patients using the revised STAI (Spielberger, 1983) at the time of diagnosis and at a 
follow–up phase later in the disease course. Results from the diagnostic phase indicated 
that 31% qualified for high state anxiety and 14% showed high trait anxiety. At the 
follow–up phase, these figures decreased to 11% and 2% respectively. These results 
suggest that trait anxiety may be low in ALS patients and that state anxiety declines 
with disease progression, following high levels during the initial diagnosis period. State 
anxiety at the time of diagnosis was related to depression, lower life satisfaction and 
shorter survival. Both state and trait anxiety correlated with QoL at the two time points, 
highlighting the important relationship between anxiety and patient perceptions of 
wellbeing. Furthermore, anxiety has been correlated with speech and eating abilities, as 
well as the social consequences of experiencing impairments in these domains (Hogg et 
al., 1994). Other studies have noted associations between anxiety and emotional 
functioning, mental health, fatigue and pain (Olsson-Ozanne et al., 2011; Olsson et al., 
2010a; Tedman et al., 1997).  
Personality  
Personality is a complex concept, the definition of which is problematic. Here, it will be 
defined as the habitual patterns of cognitive, emotional and social behavioural traits 
(Sollberger et al., 2009). Several models of personality have been proposed, one of 
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which, the Five Factor Model (Digman, 1990), has received wide acceptance due to its 
universal replicability (McCrae & Terracciano, 2005; Rossier et al., 2005). This model 
postulates that personality arises from the covariation of five broad dimensions or traits, 
namely Neuroticism (‘N’), Extroversion (‘E’), Openness to experience (‘O’), 
Agreeableness (‘A’), and Conscientiousness (‘C’). These traits are seen to remain 
approximately stable throughout the adult lifespan (Costa & McCrae, 1988), although 
their permanence in the context of neurodegenerative disease is debatable. Personality 
change is noted in several neurodegenerative disorders and may differ qualitatively and 
quantitatively between conditions (Rankin et al., 2005; Sollberger et al., 2011), 
corroborating suggestions of a brain–personality relationship. Compared to other 
neurodegenerative conditions, personality in ALS has not been extensively studied.  
ALS studies have predominantly focussed on pre–existing traits rather than change after 
disease onset. This remains despite the growing support for a clinical overlap between 
ALS and FTD; the latter can include profound alterations in personality from disease 
onset (Neary et al., 2005). An early review of sixteen ALS case reports noted pre–
morbid traits of extraversion and ‘universal cheerfulness’ (Veit, 1947), in line with 
contemporary observations of ALS patients as being ‘warm and pleasant’ (Borasio et 
al., 2001).  
Studies that have directly assessed personality in ALS have drawn contradictory 
conclusions. An early report by Brown & Mueller (1970) described an autonomous, 
‘hard–working’ and ‘emotionally–controlled’ behavioural style in their 10 patients, 
based on self–ratings of the Internal–External locus of control scale (Rotter, 1971). 
Locus of control (LoC) refers to an individual’s perception of the relative contribution 
of external and dispositional factors to the outcome of situation (Rotter, 1975). The 10 
patients were characterised by high internal LoC and by the adoption of denial as a 
psychological defence mechanism against depressive thoughts. These findings were 
challenged by a larger study which found a low use of denial coping (30%) and 
depression (n=35%) in their sample (n=40). Instead, internal LoC was highest for 
patients in the mid–stage of disease (Houpt et al., 1977, n=38), suggesting internality 
may vary with length of illness. Another study found that male patients (n=21), but not 
female patients (n=17), demonstrated a tendency of increased neuroticism (Peters et al., 
1978). Compared to the general medical population, male participants showed elevated 
scores on hypochondriasis, depression, hysteria and schizophrenia scales. However, the 
composite personality profile of ALS patients did not differ from the medical reference 
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group. Together, findings from these early studies failed to identify a distinct profile of 
personality in ALS and attention in this area diminished.  
In recent years, interest in personality in ALS has returned. Grossman et al 2006 
compared caregiver ratings of premorbid personality between 47 ALS patients and 
those of a progressive disease control group (n=47; comprising of 15 MS, 22 lung 
cancer and 10 brain glioma patients). The study used the NEO Personality Inventory 
(NEO-PI, Costa & McCrae, 1992), a measure which operates under the FFM (McCrae 
& John, 1992). No differences between ALS patients and the control group on 
dimensions of ‘N’, ‘E’, ‘A’ and ‘C’ were observed. However, ALS patients were rated 
significantly lower on the ‘O’ dimension, believed to assess attentiveness to various 
forms of experience, such as intellectual curiosity, fantasy and emotional sensation. 
People who score low on this trait typically feel emotion less intensely than others and 
exert a higher level of emotional control (McCrae & John, 1992). The results of this 
study therefore resonate with Brown & Mueller’s earlier findings surrounding LoC. 
They may also partially explain why some patients evaluate aversive stimuli as less 
arousing or negative than healthy controls (see Section 2.3.2.). Moreover, scores on ‘O’ 
have been positively related to scores of depression (Wolfestein & Trull, 1997), raising 
the possibility that the low prevalence of mood disorder reported in ALS might be 
attributed at least in part to pre–existing personality characteristics.  
Some studies have suggested meaningful relationships between personality traits and 
cognitive and behavioural functioning in neurodegenerative disease. Premorbid 
neuroticism is associated with higher levels of memory impairment in AD (Wilson et 
al., 2004), while cognitive indices have predicted personality traits of warmth, 
extraversion and dominance in a large neurodegeneration sample (n=286), after 
controlling for demographic variables, diagnosis and premorbid trait scores (Sollberger 
et al., 2012). These associations suggest that personality traits in neurodegeneration 
may be subserved by specific neuropsychological functions; possibly mapping onto 
common neural networks. In ALS, the current study of personality factors alongside 






2.3. Emotional processing and social cognition  
 
Social interaction is integral to human life. Successful navigation of the social 
environment provides personal and evolutionary advantages (Adolphs, 1999; Gresham 
& Elliott, 1987; Silk et al., 2003). This interaction is reliant on two coinciding 
processes: the perception and processing of social cues in the environment; and the 
formulation and action of appropriate responses to these cues (Elamin et al., 2012). 
Social cues are embedded in language, paralinguistic information (such as intonation or 
emphasis) and non–verbal indicators (such as eye gaze, facial expression and gestural 
movement) (McDonald, 2012). In social neuroscience, the concepts of emotional 
processing and social cognition are intractably linked and overlap greatly; distinctions 
between them are not often emphasised in the literature. Here, the term socio–emotional 
processing will be used to encompass both meanings; however, each will be defined and 
discussed separately in relation to their study in ALS.  
Generally, emotional processing is described as the specific detection, representation 
and retrieval of affective information. Social cognition is a term used to refer to those 
cognitive processes that subserve the encoding and decoding of socially salient 
information in relation to the self and others (Beer & Ochsner, 2006). Important 
subcomponents of social cognition include Theory of Mind (ToM) and empathy. ToM 
is a construct that refers to the capacity to infer other peoples’ mental and emotional 
states, allowing the prediction of, and appropriate response to, their behaviour (Baron-
Cohen & Frith, 1985; Premack & Woodruff, 1978). Experimental and imaging evidence 
suggests a distinction between ToM for emotions (feelings) and cognitions (thoughts, 
beliefs) of others (Amodio & Frith, 2006). Empathy, on the other hand, can be defined 
as the ability to appreciate and experience the emotional states of others           
(Lacoboni, 2009). It is conceptually related to ToM, with some authors also 
distinguishing between ‘cognitive’ and ‘affective’ components (Davis, 1983). How 
these various facets of social intelligence converge to enable social behaviour is of on–
going scientific enquiry.  
2.3.1. Neural basis of socio–emotional processing  
A challenge in describing the underlying neuroanatomy of psychological processes is 
that no such process maps cleanly onto a particular structure working in isolation 
(Adolphs, 2010). A widely acknowledged position suggests that a set of distributed 
structures constitute specialised neural systems dedicated to the processing of social 
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information, referred to as the “Social Brain” (Brothers, 1990). Lesion and 
neuroimaging studies have implicated involvement of certain neural regions in the 
identification of emotions from faces. For example, the amygdala is suggested to 
support fear–processing, while anterior insula cortex is associated with recognising 
disgust (Adolphs et al., 2002). Other regions such as the basal ganglia, the temporal 
lobes, the AC and the right somatosensory cortices have also been implicated in 
emotional processing (Cancelliere & Kertesz, 1990; Ojemann et al., 1992). Some of 
these structures share reciprocal projections to other neural regions, residing in the PFC. 
Subdivisions of the PFC include the OFC, ventromedial (vMPFC) and DLPFC regions. 
The two former regions are often used interchangeably due to their partial overlap, but 
distinctly the OFC occupies the ventral surface of the PFC, while the VMPFC 
constitutes the inferior part the medial wall of the frontal lobe (Zald & Andreotti, 2010). 
Both have been noted for their roles in emotion processing (Heberlein et al., 2008; 
Hornak et al., 2003; Hornak et al., 1996), affective ToM and empathy (Gallagher et al., 
2000; Shamay-Tsoory et al., 2009; Shamay-Tsoory et al., 2005; Stone et al., 1998). The 
DLPFC, on the other hand, has mostly been associated with ‘pure’ executive 
functioning (Lamar & Resnick, 2004), but there is evidence that it may be involved in 
affective decision–making and cognitive aspects of ToM and empathy (Hynes et al., 
2006; Manes et al., 2002; Shamay-Tsoory & Aharon-Peretz, 2007).  
 
2.3.2. Emotional processing and social cognition in ALS 
The investigation of emotional processing in non–demented ALS has entailed the use of 
several paradigms sensitive to the recognition and memory for emotional and social 
stimuli. The use of divergent measures and the application of variable impairment 
detection methods (e.g. group versus individual–level analysis) across studies have 
presumably led to inconsistent conclusions about the prevalence and nature of the 
reported deficits. The impact of traditionally small sample sizes and diverse sample 
compositions should also not be underestimated in this regard. Nonetheless, a 
heterogeneous profile of impairment has been indicated. Here, studies investigating 
ALS impairments in emotional processing and social cognition will be critically 





2.3.2.1. Emotional Processing 
Emotional responding 
Altered emotional response to emotive material is suggested in ALS. Compared with 
healthy participants, ALS patients evaluated emotional images as more positive and 
reported a balanced state of subjective arousal when viewing scenes that contained 
social situations and facial expressions (i.e. they rated calm pictures as more exciting 
and exciting pictures as more calm) (Lule et al., 2005). A second study used fMRI to 
measure participants’ neural response patterns to similar emotive stimuli (Lule et al., 
2007). The data revealed that ALS patients showed increased activation in the right 
supramarginal gyrus, a region which has previously been noted for its involvement in 
the recognition of basic emotion from faces (Adolphs et al., 2000) and its recruitment in 
the cognitive reappraisal of aversive stimuli (Ochsner et al., 2002). The enhanced neural 
response pattern became more pronounced at a six month follow–up, indicating 
increased recruitment of this area along the disease progression. Intriguingly, other 
areas, such as the amygdala and AC which are typically associated with altered 
response patterns for valence and arousal (Anders et al., 2004) did not contribute to 
group differences. However, 11 of the 13 ALS patients from the study showed reduced 
amygdala volume in a separate analysis (data were not reported). A possible 
interpretation of these findings may be that the progressive recruitment of 
somatosensory regions acts as a compensatory mechanism in the context of other 
compromised emotion–processing substrates.  At the follow–up, patients also showed a 
reduction in brain responses from baseline in the anterior insula, an area strongly 
associated with arousal and subjective emotional awareness (see Craig, 2009, for 
review). Moreover, these reduced responses correlated with the subjective arousal 
reports at the initial assessment, indicating that the subjective experience of attenuated 
arousal may precede the underlying progressive neuropathology.  
The relevance of altered socio–emotional processing in ALS is highlighted by findings 
of altered social perception in the context of hypothetical social situations. In a social 
judgement task, participants were asked to imagine a scenario in which a presented face 
is available to them for travel directions and to rate how approachable they believe that 
face to be (i.e. how likely they were to ask them for directions). Although an earlier 
study found no difference in ratings for faces between non–demented patients and 
controls (Papps et al., 2005), a later study comprising of ALS and ALS–FTD patients 
did show evidence for altered responding relative to controls (Schmolck et al., 2007). 
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Faces were rank ordered according to the control–group ratings of approachability. 
Ratings for the 10 most approachable faces did not differ between groups; however, 
ratings for the 10 least approachable faces were rated as more approachable by the 
patient group than controls. All participants were categorised into ‘Trusters’ or 
‘Conventional’ responders based on their average rating of the 10 least approachable 
faces. There were significantly more ‘Trusters’ in the patient group than in the control 
group. Within the patient group, performance on the paradigm task was not associated 
with cognitive status. In fact, six of the 11 cognitively intact patients fell into the 
‘Trusters’ category, while only two of the seven cognitively compromised patients, one 
mildly impaired patient and one ALS–FTD patient, also fell into this category. The 
authors suggest that the rating behaviour was therefore not associated with frontal 
dysfunction in patients, and that since similar rating behaviour is apparent in amygdala–
damaged patients (Adolphs et al., 1998), these results could likely be due to amygdala 
involvement. However, only vague descriptions of cognitive testing and diagnostic 
criteria were provided for 18 of the 26 patients, questioning the exclusion of frontal 
dysfunction involvement.  
 
Emotional memory 
Reduced arousal for affective material may be related to impaired recall of emotional 
stimuli, which has also been demonstrated in ALS samples. Papps et al (2005) found 
that ALS individuals failed to demonstrate enhanced recognition of emotional words 
relative to neutral words, a pattern of performance typically observed in healthy 
individuals (Bradley et al., 1992; Brierley, 2004; Kuriyama et al., 2010). These results 
could not be explained by general memory impairment or fatigue effects, as the ALS 
individuals showed enhanced memory for neutral words relative to controls. However, a 
recent study which included a standardized measure of verbal memory found that a 
subgroup of ALS patients who failed to demonstrate enhanced emotional word 
recognition on the same task did display general memory impairment (Cuddy et al., 
2012). In contrast to Papps et al, this study failed to find overall group differences, 
although heterogeneous ALS performance within a small sample size, greater 
equivalence in mood levels between groups and a methodological departure in measure 
administration, may have contributed to the dissimilar results obtained.  
If the impairments found in Papps et al’s study are reflective of an exclusive difficulty 
in the encoding, consolidation and/or retrieval of emotionally–toned material, they may 
implicate underlying neuropathology of the limbic structures in ALS. Enhanced 
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memory for emotional stimuli has been associated with amygdala activation in healthy 
individuals (Canli et al., 2000), while selective deficits in emotional memory 
recognition have previously been noted in patients with amygdala damage (Cahill et al., 
1995). Although neuroimaging studies have documented amygdala abnormalities in 
ALS patients (Anderson et al., 1995; Kawashima et al., 2001), corresponding 
neuroimaging data is required to determine if the selective deficit observed is associated 
with damage to or dysfunction of this or other neural processes. Furthermore, it remains 
to be seen whether recognition deficits for emotional words can be replicated for 
memory of other types of emotional stimuli, such as prose and scenes or whether it is 
representative of memory changes for personal emotional events.  
In keeping with Papps et al’s findings, an fMRI study which incorporated an emotional 
decision task and a subsequent recognition memory test also found a failure of ALS 
individuals to display the normative pattern of enhanced memory for emotional words 
(Palmieri et al., 2010). Both the decision task and the memory test were associated with 
reduced right hemispheric activation and increased left hemispheric activation for 
unpleasant words versus neutral words in ALS patients compared to controls. No 
positively–valenced words were presented in the study, so it is not clear if a similar 
atypical lateralisation in ALS individuals would have occurred for pleasant words. The 
abnormal functioning of the right hemisphere in these ALS patients may have led to 
difficulties in the processing of the unpleasant words, possibly leading to their poorer 
recognition. Notably, during the recognition memory task, ALS patients showed 
reduced activation compared to controls in the right posterior cingulate gyrus. This area 
has been implicated in the interaction of emotional and memory–related processes as 
well as the reception of inputs from frontal cortical regions pertinent to the regulation of 
emotional and social behaviour (Maddock et al., 2003). However, since the 
neuropsychological battery did not include behavioural inventories, an examination of a 
relationship between the apparent dysfunction and behaviour could not be conducted. 
Nonetheless, these results do complement other findings of right hemisphere 
dysfunction in ALS patients with FTD and mild cognitive and/or behavioural symptoms 
(Murphy et al., 2007b). Structural MRI showed significantly reduced right hemisphere 
grey matter volume for patients with cognitive and behavioural symptoms in 
comparison to those patients without such symptoms. The structural distinctions 
between the ALS groups led the authors to suggest that right hemisphere atrophy in 
ALS patients might represent a biomarker for cognitive and behavioural change in the 




Studies of emotion recognition for prosodic stimuli, albeit limited, have produced 
varied results. An initial study found that, relative to controls, ALS patients showed a 
generally absent impairment for emotionally–intoned sentences (except for the 
recognition of surprise) in the context of significantly reduced recognition accuracy for 
emotional faces (Zimmerman et al., 2007). This dissociation in performance between 
the two tasks might suggest a selective impairment for facial information only in ALS 
or imply a relative insensitivity of prosodic tasks in detecting emotional processing 
dysfunction in these patients. In contrast to these findings, Meier et al (2010) did 
demonstrate a deficit using the Aprosodia Battery (Ross et al., 1997), a task requiring 
the identification and discrimination of emotion from asyllabic utterances and syllables 
in addition to sentences. This task may be more difficult or sensitive than the one used 
in the former study. Notably, these patients showed a deficit in recognising emotion but 
not discriminating between them, indicating that difficulties reflected impaired 
recognition of the emotions themselves, rather than perceptual deficits. 
 
Findings from studies examining the recognition of emotion from faces have been 
similarly inconsistent (see Table 2.3.). While an early investigation found no evidence 
of impaired facial emotion recognition in 19 ALS individuals (Papps et al., 2005), later 
studies have documented significantly worse performance of patients in comparison to 
healthy controls (Girardi et al., 2011; Lillo et al., 2012b; Zimmerman et al., 2007). Lillo 
et al (2012b) employed a modified version of combined facial recognition tasks, with 
some faces morphed to display different intensities of affect. The authors did not 
analyse, or at least report, any effects of emotion intensity on recognition accuracy in 
their sample. Since emotional intensity has been shown to influence accuracy of 
emotion identification across different stimuli (Hess et al., 1997; Kumfor et al., 2011), 
such an analysis may have provided better insight into the degree of the recognition 
deficit that was found. Nonetheless, the study did include a cohort of FTD patients for 
comparison with ALS and healthy control samples. It was found that the ALS group 
performed significantly worse than controls but significantly better than FTD patients, 
indicating a continuum of performance across the three groups and suggesting a 
comparable if not attenuated recognition deficit in ALS relative to FTD.  
 
A subsidiary consideration is whether the recognition of specific emotions is affected in 
ALS. In one study, basic emotions such as sadness, disgust, angry and surprise showed 
statistically significant group differences (Zimmerman et al., 2007), while in other 
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studies only group effects for overall performance accuracy have been noted (Girardi et 
al., 2011; Lillo et al., 2012b). In FTD studies, a selective deficit in recognising negative 
facial expressions is commonly reported (Fernandez-Duque & Black, 2005; Werner et 
al., 2007). However one study which compared subgroups within their FTD cohort 
found that the selective deficit was shown only for patients with predominantly 
temporal–lobe involvement. Patients with disproportionately more frontal–lobe atrophy 
showed impairments for both negative and positive facial expressions (Rosen et al., 
2004). These findings suggest that frontal–lobe pathology in FTD may correspond to 
more profound or global impairment in emotion recognition than regionally restricted 
temporal–lobe atrophy. Given that ALS patients have shown simultaneous deficits in 
identifying positive and negative emotions and that most studies have documented 
impairments in overall performance accuracy rather than in specific emotions or 
valence–type, it is possible that the nature of the ALS deficit is in keeping with that of 
FTD patients with prominent frontal–lobe atrophy. Alternatively, the acknowledged 
anatomic heterogeneity within ALS samples in terms of the degree and pattern of 
patient neurodegeneration may itself have influenced the behavioural results obtained in 
these studies.   
 
Affective decision–making 
Decision–making under conditions of reward, punishment, ambiguity and risk has also 
been studied in non–demented ALS. Although no group effect was observed in one 
study using a similar probabilistic reversal learning task (Meier et al., 2010); differences 
between ALS participants and healthy controls have been observed using the Iowa 
Gambling Task (IGT, Bechara et al., 1994; Bechara et al., 2000). This task requires the 
selection of cards from four alternative decks, with the objective to maximise monetary 
reward. However, the distribution of reward and penalties between decks is such that 
selection from some decks leads to an overall gain, while selection from other decks 
leads to an overall loss; these latter decks being associated with increased risk.         
 
Using an abbreviated version of the IGT, Girardi et al (2011) found that, in contrast to 
controls, ALS participants continued to select from high–risk decks despite the negative 
consequences associated with monetary loss. Notably, ALS individuals did not display 
increased selection from high–risk decks with task progression, a response style noted 
in FTD patients (Torralva et al., 2007). Instead, performance was uniform throughout 
the task, indicating an executive failure to learn reward–penalty contingencies rather 
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than a heightened risk–taking preference (Clark & Manes, 2004). In support of an 
executive dysfunction contribution to task performance, correlational analyses revealed 
a positive relationship between this selection behaviour and higher self–reported rates 
of executive and overall behavioural dysfunction. However, no relationship with 
objective measures of executive function was found. 
2.3.2.2. Social Cognition 
 
ToM 
Impairments in the recognition of basic emotion extend to more socially complex 
emotions in ALS. Basic emotions (such as sadness, happiness, fear, etc.) have been 
distinguished from complex emotions (such as guilty, arrogant, or flirtatious, etc.) on 
the basis that the latter require the attribution of mental or emotional states that bear a 
social relation (Adolphs et al., 2002). Girardi and colleagues found significant group 
differences on both a basic emotion recognition task and the complex Reading the Mind 
in the Eyes (RME) tasks in 19 patients (Girardi et al., 2011). The latter task requires an 
attribution about mental or emotional states from immediate cues in the eye region of 
the face and is a well–established ToM or “mentalising” measure (Baron-Cohen et al., 
1997). A subgroup of patients in the Girardi et al (2011) sample performed in the 
impaired range on both measures; performance on these tasks correlated strongly with 
each other (r=-.76, p<.05). A relationship between executive dysfunction and social 
cognition performance was also observed, as verbal fluency indices (thinking latencies 
for word generation), correlated negatively with both tasks (r=-.83, p<.005 and r=-.66, 
p<.05, respectively). Deficits on the RME have not been reported consistently; 
however, as a recent study of 15 ALS patients found no impairment on this measure, 
despite showing a deficit on a measure involving the prospective social interaction of 
cartoon characters (Cavallo et al., 2011a). While the RME is a widely used measure of 
ToM, it does not entail the depiction of social situations. ToM in ALS might be 
differentially impaired, with some patients displaying difficulty with mental attribution 
regardless of social (or non–social) context and others showing a select difficulty with 
interpreting elaborate social interactions between individuals; this could account for the 
incongruous result on the RME in the latter study.  
 
Impairments on less complex ToM tasks, involving a simple social cue such as eye 
gaze, have also been reported. Using the Judgement of Preference task (JOP, Baron-
Cohen et al., 1995). Girardi et al found that ALS patients failed to correctly identify 
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which picture a character “liked best”, as determined by the orientation of the 
character’s gaze (Girardi et al., 2011). No group effect was found on a condition task in 
which participants determined which picture the character was looking at, thereby 
eliminating the possibility of visual processing deficits. Distracter trials, in which an 
arrow pointed to a different picture than to which the face was orientated, were 
introduced in both control and experimental conditions. Although ALS impairment was 
more pronounced when distracters were present (64% of patients impaired), over a third 
of patients (36%) showed impairment on the less executively demanding trials 
involving no distracters. Error analysis revealed that patients relative to controls 
selected more items which were indicated by the distracting arrow. This suggests an 
attentional component underlying the impairment found on these trials. Notably 
however, patients also selected non–target items based on their personal preference (as 
indicated by a pre–experimental personal preference condition) on distracter and non–
distracter trials. These error responses may imply a failure to override their egocentric 
responding, contributing to reduced inferential performance. Performance on this task 
was related to self–perceived change in levels of apathy, a frontally mediated behaviour.         
 
The assessment of ToM in ALS has also included the use of cartoons and written 
scenarios from which the intentions and beliefs of characters can be inferred (see Table 
2.4.). Gibbons et al (2007) found a spectrum of ToM ability in their sample of 16 ALS 
individuals on the Happé Cartoon and Scenarios task (Happé et al., 1999). The ALS 
group performed significantly worse than controls on the scenario subtask, but only a 
trend of impaired performance was observed for the two cartoon subtasks. Lack of 
group differences were attributed to variation in ALS performance, which ranged from 
normal to significantly impaired. Impairments were more prominent in patients with 
bulbar symptomology, which converges with studies that posit bulbar signs as a 
potential susceptibility factor for cognitive decline (see Section 2.2.1.5.).
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Table 2.3.: ALS impairments in basic emotion recognition from faces 
†Anger, Disgust, Fear, Happiness, Sadness, Surprise. * Dynamic videos. FEEST, Facial Expressions of Emotions Test; TASIT, The Awareness of Social Inference Test; EEA, 
Emotional Evaluation Assessment. 
Author Measure                    Group 
     ALS                        HC  
ALS impairment 
 
Papps et al (2005) Ekman Faces Test 20 18 Statistical trend for Surprise 
     
Zimmerman et al (2007) The Emotional Faces Task 13  
 
12 Sad, Disgust, Surprise only 
     
Girardi et al (2011) FEEST 14 20 Lower mean accuracy scores for all basic emotions† Two 
patients performed within the abnormal range of controls 
 
Lillo et al (2012b) Modified Ekman Faces Test 20 20 
20 bvFTD 
Lower mean total accuracy score than controls 
Higher mean total accuracy score than bvFTD patients 
 
     
Staios et al (2013)* 
 
 
















No differences between positive and negative emotions 
 
 





Error analysis revealed that ALS participants as a group provided more descriptive 
responses, lacking abstract inferences. The subgroup of bulbar patients committed more 
concrete errors than controls; an error pattern noted in FTD patients on the same task 
(Snowden et al., 2003). Notably, patients displayed no evidence of a differential 
impairment for ToM compared to control conditions across all subtasks. This profile of 
performance might indicate a general impairment in inferential ability related to 
executive dysfunction, rather than a specific ToM deficit. Support for this suggestion is 
provided by the finding that both total accuracy scores and the proportion of errors 
correlated significantly with measures of executive functioning, in particular with tests 
of mental set–shifting and abstraction (i.e. the WCST).  
 
Evidence for a selective ToM deficit has been indicated by one study which employed 
the Social Faux Pas test (Stone et al., 1998). This task consists of written scenarios 
containing characters saying and committing socially inappropriate comments or 
actions. Participants are required to identify and explain the faux pas through a series of 
questions which tap into the participant’s ToM ability and awareness of social 
proprieties. Performance on this task by a group of ALS individuals indicated 
impairment in identifying faux pas scenarios, as well as an inability to qualify a 
correctly identified faux pas. In contrast, on scenarios not involving faux pas, ALS 
participants were unimpaired, indicating specific compromise in ToM ability. 
Performance on an oral fluency task had been co–varied out in these analyses, leading 
the authors to conclude that performance was not attributable to executive dysfunction 
(Meier et al., 2010). Although, a caveat of this procedure is that it assumes the single 
fluency measure entered as a covariate represents all constituents of executive function 
or that the nature of executive involvement is similar between tasks.        
 
Further delineation on the nature of ToM deficits in ALS is provided by a study which 
investigated ToM ability under conditions of private (individual) and social (group) 
intentionality (Cavallo et al., 2011a). A theoretical distinction among varieties of 
intentions posits that private intentions necessitate individually–driven behaviour to 
secure a goal while social intentions involve a social goal requiring action from several 
individuals. Disproportionately wider prefrontal engagement in social relative to private 
intentions has been observed in neuroimaging paradigms (Ciaramidaro et al., 2007; 
Enrici et al., 2011). Using a cartoon completion task, Cavallo et al (2011a) found that 
ALS individuals showed a dissociation of ToM ability. Patients accurately inferred 
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private intentions of individual characters but failed to demonstrate understanding of 
social intentions. This selective impairment has previously been shown in FTD patients 
(Cavallo et al., 2011b), further suggesting a similar nature of ToM deficits between the 
two diseases. Individual analysis of performance supported group comparisons with the 
same direction of effect in 12 of the 15 patients. The focus on distinct types of 
intentions under social compared to non–social contexts is a novel departure from 
previous studies which have typically compared general inferential ability to specific 
ToM ability under social and non–social contexts within the same experimental 
categories. As Cavallo and colleagues suggest, this may explain the heterogeneous 
results obtained across these studies. On the other hand, ceiling performance on the 
non–social (private intention) items was found in both participant groups, implying that 
the social stories may have been relatively more complex than the non–social items and 
perhaps required greater executive demand. Executive dysfunction, therefore, may have 
been a source of the observed selective deficit, rather than specific difficulty with 
inferring social intentions.  
 
A further dissociation of ToM ability in ALS was explored using a non–verbal cartoon 
completion task that entailed emotional and cognitive attribution under separate 
conditions (Cerami et al., 2013). Twenty ALS patients and 56 healthy controls were 
presented with comic strips comprising three pictures depicting a story. Participants 
were asked to complete the story with a picture from a choice of three possible 
alternatives. These alternatives depicted plausible, implausible or plausible but incorrect 
endings. One condition required the identification of characters’ emotional states 
(emotional attribution), while a second condition involved the identification of 
characters’ intentions (cognitive attribution). A control condition depicted pictures 
which required the application of causal knowledge relating to the physical properties of 
objects. No differences were found between participant groups on the control or 
cognitive attribution conditions. However, significantly reduced performance in patients 
relative to controls was noted for the emotional attribution items. Two patients showed 
impairment (at or below 5
th
 percentile of controls performance) on this aspect of the 
task. Of these patients, one was cognitively and behaviourally intact, based on 
established criteria (Strong et al, 2009). Furthermore, performance on all the task 
conditions showed no relationship to measures of executive function. A subset of 14 
patients and 20 controls underwent whole brain VBM imaging procedures. In ALS 
patients, emotion attribution scores correlated positively with grey matter density in the 
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right fronto–insular cortex and the AC. Relative to controls, patients also showed 
reduced grey matter density in the ventromedial PFC, although these did not show a 
statistical association with experimental scores. All three regions have been implicated 
in empathic ability in healthy and neurological populations (for review, see Bernhardt & 
Singer, 2012). The results align with those from previous studies noting socio–
emotional processing impairments which are isolated from executive dysfunction in 
patients. This selectivity corroborates suggestions of a variable vulnerability to 
cognitive change within the disease. Previous investigations which have used ToM 
measures that do not formally distinguish between emotional and cognitive aspects of 
ToM may contribute to the apparent discrepancies in patient performance across these 
studies. Performance differences may be explained by the heterogeneous quality of ALS 




While some behavioural inventories include items which assess empathic responding 
(e.g. NPI), to date, there have been no formal attempts to directly assess levels of self– 
or caregiver reports of empathy in non-demented ALS. This is surprising given the 
growing evidence for reduced empathic ability in FTD (Fernandez-Duque et al., 2009; 
Rankin et al., 2005), which has shown to correlate with performance on measures of 
social cognition (Shany-Ur et al., 2012). If changes in socio–emotional processing are 
indeed reflective of those apparent in bvFTD, it would follow that empathic ability in 
ALS might also be compromised. Further, its relationship to other constructs of social 
cognition, such as ToM, and emotion processing is of theoretical and methodological 
interest to future ALS studies. Determining the presence of reduced empathy in ALS 
may also benefit current understanding of behavioural change within the disease, and in 
addition its impact of the patient–caregiver relationship. 
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Author Type of  
measure 













character’s beliefs, feelings 








Absence of select ToM deficit 
in ALS patients.  
 
Patients showed heterogeneous 
impairment relative to controls, 
ranging from normal to 








Social Faux  
Pas Task 
‘faux pas’ 





(no faux pas) 
 
Presence of select ToM deficit 
in ALS patients.  
 
Relative to controls, ALS 
patients tended to misidentify 
the faux pas and showed an 
inability to explain a correctly 
identified faux pas in the 











‘social contexts’  
(actions for social 
 goal)  
 
‘non–social contexts’ 
(actions for private 





     
 
Presence of select ToM deficit 
in ALS patients.  
 
Relative to controls, ALS 
patients performed worse on the 


















physical properties of 
objects) 
 
Presence of select ToM deficit 
in ALS patients.  
 
ALS patients performed worse 
on the emotional attribution 
condition. No group differences 
were observed for cognitive 




2.3.2.3. Ecologically–valid measures of socio–emotional processing  
   
A limitation of previous socio–emotional studies in ALS is the reliance on static faces 
or unanimated social scenarios to assess processing impairments. These measures may 
fail to capture the complexity of everyday social interaction. Emotion recognition in the 
“real–word” typically includes the processing of transient facial expressions, alongside 
other contextual information, such as prosody of speech. Equally, drawing accurate 
inferences about the intentions and beliefs of a speaker requires the appreciation of the 
actual and subliminal content of what is being said. The inclusion of more realistic 
measures of social cognition might determine the extent of processing deficits reported 
in ALS and whether they are likely to represent everyday patient difficulties with 
interpreting social exchanges. 
 
Only two ALS studies have incorporated realistic measures of emotion recognition in 
ALS (Savage et al., 2013; Staios et al., 2013). Both have used the dynamic emotion 
recognition subtest of The Awareness of Social Inference Test (TASIT, McDonald et 
al., 2002, see Chapter 4). On this task, participants are asked to identify an emotion 
portrayed by an actor in a scene, from a possibility of seven basic emotions. In the first 
study, performance for individual emotions were combined into positive (happy, 
surprised, neutral) or negative (sad, angry, anxious, revolted) emotions and compared 
between non–demented ALS patients (n=35) and controls (n=30). No significant 
differences were found between the groups for these combined scores. The inspection 
of group means for individual emotions revealed that controls outperformed patients on 
all emotion categories, except for the neutral and anxious items; but these differences 
were too small to contribute to a statistical effect (Staios et al., 2013). Savage et al 
(2013) found similar results for their non–demented ALS patient group. This study 
compared emotion recognition performance between groups of ALS, ALS–FTD, FTD 
and control participants using the TASIT subtest and a static emotion recognition task. 
Initially, the non–demented ALS patients (n=13) and the ALS–FTD patients (n=16) 
were combined to form one group (ALS/ALS–FTD). Both the ALS/ALS–FTD (n=29) 
and the bvFTD (n=25) patient groups recognised significantly fewer emotions on the 
separate tasks relative to healthy controls (n=30). However, when the ALS group was 
divided into those with and without FTD, only the ALS–FTD patients showed 
impairment on these tasks. Non–demented ALS patients, by contrast, showed preserved 
emotion processing relative to controls. These results indicate that deficits in this 
domain may be specific to ALS patients with comorbid FTD. They might also reconcile 
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the inconsistent findings across previous studies of emotion recognition in non–
demented ALS, since these studies have included ALS and ALS–FTD patients in the 
same sample (e.g. Zimmerman et al, 2007) or possibly recruited patients with 
undiagnosed dementia.     
 
Staios et al (2013) also compared non–demented ALS patients with control participants 
on a second subtask of the TASIT which comprises enacted social situations. 
Participants watched vignettes in which actors made sincere, simple sarcastic or 
paradoxically sarcastic statements. Under the sarcastic statement conditions, one of the 
actors means the opposite of what he is saying and intends for his interlocutor to 
accurately interpret his true meaning. On the simple sarcasm items, it is only through 
reading the paralinguistic cues of the actors that the participant is able to discern the 
sarcasm. On the paradoxical sarcasm items, the dialogue between the two actors makes 
no literal sense, unless it is assumed one of the actors is being sarcastic. Following these 
scenes, participants were asked a series of questions which assessed their interpretation 
of the actors’ meaning, intentions and feelings.  
 
Staios et al found no difference between groups for sincere items, but patients were 
significantly impaired relative to controls on both sarcastic conditions. This implies that 
patients have a relative difficulty in discerning more socially complex exchanges in 
which the literal meaning of a conversation is superseded by covert paralinguistic cues 
that convey the intended meaning. That is to say, patients show impairment for high–
order social cognitive abilities. Patients also performed worse than controls on a test of 
cognitive flexibility. When the effects of performance on this task were co–varied out 
statistically, patients remained significantly impaired on the sarcastic items. This 
suggests that patients’ social cognition deficits were not related to their apparent 
executive dysfunction. However, because only one measure of cognitive flexibility was 
administered, the relationships between patients’ executive functioning and their 
apparent social processing deficits may have been obscured. A broader battery of 
executive function might have uncovered a role of executive impairment in the results 
obtained. Furthermore, no behavioural measures were included in the study. As a result, 
it lacks sufficient evidence to conclude that patients’ performance on these measures 
correlate with their real–life social behaviour, such as a tendency to respond 
compassionately towards others or perceive others’ perspectives. Nonetheless, the study 
is novel in its adoption of more ecologically–valid tasks which provides greater insight 
into the scope of the apparent social cognition deficits in ALS. 
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2.3.2.4. Executive dysfunction, behaviour and socio–emotional processing in ALS 
 
While there is evidence to suggest that deficits in emotional processing and social 
cognition are less marked than those observed in FTD patients, it is uncertain if, when 
present, these deficits are associated with cognitive or behavioural change. Moderate to 
strong correlations between behavioural scores and social–emotional tasks are reported 
(Girardi et al., 2011); but in general, behaviour is not commonly assessed alongside 
these measures. Performance has been correlated with executive function indices 
(Cavallo et al., 2011a; Gibbons et al., 2007; Girardi et al., 2011; Meier et al., 2010; 
Staios et al., 2013), suggesting that executive dysfunction may partially underlie the 
observed impairments. Although, studies adopting individual–case analysis have 
revealed some patients may be exclusively impaired on cognitive or socio–emotional 
tasks, while others show an overlap of dysfunction on these measures (Cavallo et al., 
2011a; Cerami et al., 2013; Girardi et al., 2011; Meier et al., 2010). In both the Giradi 
et al (2011) and Cavallo et al (2011a) studies, patients’ aggregate performance was 
within the normal range on several executive function tasks, but was significantly 
impaired on tests of socio–emotional processing (Cavallo et al., 2011a; Girardi et al., 
2011). Cerami et al (2013) also found no association between executive dysfunction 
and impaired emotion attribution.  
 
In bvFTD, traditional cognitive tests may fail to detect frontal dysfunction in the early 
stages of disease (Gregory et al., 1999), while socio–emotional processing impairments 
can be profound and easily identified (Adenzato et al., 2010). Some authors have 
argued for the inclusion of social and emotion measures to consolidate a prediction of 
bvFTD diagnosis (Sarazin et al., 2012; Schroeter, 2012). In ALS the mechanisms 
underlying socio–emotional processing deficits are unclear. It is possible that these 
impairments reflect executive dysfunction, secondary to DLPC pathology, which in turn 
leads to impaired inferential ability (Bechara, 2002; Gibbons et al., 2007). 
Alternatively, they may reflect an isolated impairment similar to early bvFTD, 
implicating early OFC pathology. Should these findings in ALS patients prove robust, it 
may imply that socio–emotional tests serve as a more sensitive indicator of ALS frontal 
dysfunction than traditional executive function measures. This could hold implications 
for neuropsychological assessment of ALS patients, and more broadly, for the 




2.3.2.5. Summary  
In conclusion, there is some evidence to indicate that a subset of ALS patients show 
impairment across a variety of tests of emotional processing and social cognition. The 
nature of these deficits is similar and milder to the impairments observed in FTD. 
However, the evidence is neither consistent nor conclusive. Studies have predominantly 
relied on static stimuli and abstract social situations, which may limit inferences 
regarding the everyday difficulties patients experience with social interaction. Study 
sample sizes are typically small, further limiting generalizability to the ALS population.  
Other aspects of social cognition, such as empathy, are yet to be explored in the disease. 
In addition, the role of executive function in these impairments is controversial. 
Detailed investigation of the relationship between executive dysfunction and socio–
emotional processing change in ALS would improve understanding of the underlying 
mechanisms of these reported deficits. 
 
2.4. Primary aims of the thesis 
As the current review has emphasised, there is growing evidence for cognitive and 
behavioural change in non–demented ALS patients, which may correspond to the 
milder changes apparent in ALS–FTD and FTD patients. In particular, ALS patients 
have demonstrated impairments in the ability to recognise emotion and interpret social 
information. The current study will incorporate a range of static and dynamic tasks of 
socio–emotional processing in order to assess the scope of these reported deficits in 
ALS. In addition, the study will examine the relative impact of patients’ executive 
(dys)function, mood, personality, empathy and behaviour on socio–emotional 
processing performance. Hypotheses relating to the second component of the thesis 
(caregivers of ALS patients) are outlined in Chapter Three.  
 
2.4.1. Hypothesis One: Profile of executive impairment and changes in emotional 
processing and social cognition in ALS 
The current study tests the hypothesis that patients with ALS will show impairments 
relative to controls in executive functioning and the processing of emotional and social 
information. To test this hypothesis, comparisons between patients and healthy controls 





2.4.2. Hypothesis Two:  Profile of behavioural change in ALS 
The current study tests the hypothesis that ALS patients will show higher levels of 
premorbid and current behavioural dysfunction on domains of apathy, dysexecutive 
behaviour and disinhibition.  
 
2.4.3. Exploratory Research Question One: Mood, personality, empathy in ALS 
The current study explores whether differences in ALS patients and healthy controls on 
measures of mood, personality and empathy exist.   
 
2.4.4. Hypothesis Three: The contributions of executive function, behaviour, mood, 
personality and empathy to emotional processing and social cognition in ALS 
The current study tests the hypothesis that executive (dys)function will be the main 
predictor of performance on tests of emotional processing and social cognition, with 
smaller contributions from behaviour, mood, personality and empathy (above and 














3. Caregivers of ALS patients 
The progressive and incapacitating nature of ALS means that patients require increased 
assistance as they progress towards the end–stage of the disease. Day–to–day disease 
management is more often than not undertaken in the patient’s home and provided by a 
family member (Chio, 2010; Mockford et al., 2006). The majority of psychosocial 
studies in ALS have investigated the patient’s experience of their disease, in terms of 
their mood and quality of life. A growing area of research focuses on the impact ALS 
may have on the family caregiver. Initially, the effects of the patients’ physical status 
and mood on caregivers’ wellbeing dominated research in the area. Recently, the 
evidence for cognitive–behavioural change within the disease has shifted attention 
towards the additional challenges such changes might pose to caregivers of ALS 
patients (Merrilees et al., 2010). This chapter will present an overview of research 
findings of the psychological consequences of ALS on the primary caregiver. A primary 
caregiver is defined here as the person most involved in the patient’s care on an 
informal basis.  
 
A challenge in interpreting the caregiver literature comes from the multiple domains 
used to characterise the caregiver experience. Furthermore, debate surrounds the 
boundaries of its constituting constructs (see Hunt, 2003). In ALS, the topic of caregiver 
experience is broad and encompasses several factors, such as general health (Jenkinson 
et al., 2000), quality of life (Gelinas et al., 1998; Lo Coco et al., 2005; Trail et al., 
2003) and religiosity (Bremer et al., 2004; Calvo et al., 2011) among others. This 
chapter will limit the discussion to three indices of caregiver experience, namely mood, 
perceived strain or burden and marital satisfaction, as these outcomes are examined 
within the current thesis. The constructs underlying these indices are generally poorly 
defined in ALS studies (Aoun et al., 2013). Here, definitions and studies of each 
construct will be discussed in turn; however, this arrangement does not mean to imply 
that these concepts are unrelated or isolated in their contribution to caregivers’ 
experiences. Particular emphasis will be placed on the effects of mild–moderate 
cognitive–behavioural change on caregivers of non–demented ALS patients. 
Furthermore, the impact of ALS on spousal (or partner) caregivers will be of focus. This 
is in keeping with the secondary objectives of the thesis, which is to understand the 
relative impact of executive function, socio–emotional processing, and behaviour in the 
patient with ALS on their spousal caregivers.   
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3.1. Caregiver outcomes 
3.1.1. Mood  
Mood is defined here as anxiety and/or depression. Estimates of depressive symptoms 
in ALS caregivers  vary between 10% – 61% across studies (Chio et al., 2005; Chio et 
al., 2010; Goldstein et al., 2006a; Lillo et al., 2012a; Rabkin et al., 2009; Rabkin et al., 
2000; Trail et al., 2003). However, using DSM–IV criteria, Rabkin et al (2009) found 
only 13% of 71 ALS caregivers satisfied criteria for major depressive disorder at their 
study baseline. This is lower than a previous study using the same criteria (18%, n=31, 
Rabkin et al., 2000). Studies of ALS caregivers show similar methodological 
discrepancies to those apparent in the patient literature, such as inconsistent assessment 
methods, which might account for the variable mood estimates reported between 
studies. Gender of the informant may also be important, as higher rates of depression 
have been reported in female compared to male ALS caregivers (Chio et al., 2010), but 
not consistently (Goldstein et al., 2006a). Women are typically over–represented in 
spousal ALS caregiver samples due to the disproportionate disease incidence rates 
between genders. As a result, gender comparisons in ALS caregiving are restricted by 
unequal group sizes. 
There is evidence to suggest lower levels of depression in caregivers than patients 
(Gauthier et al., 2007; Goldstein et al., 2000; Goldstein et al., 1998; Rabkin et al., 
2000); however, it is not certain if this is an artefact of the somatic items found in 
several depression inventories, inflating patient scores (see Chapter 2, Section 2.2.3.). 
Nonetheless, caregiver scores are higher than that of control participants (Pagnini et al., 
2012; Tedman et al., 1997; Trail et al., 2003), suggesting a greater prevalence of 
depression in caregivers than the general population.   
Some cross–sectional studies have reported positive correlations between caregivers’ 
and patients’ levels of depression (Chio et al., 2005; Rabkin et al., 2000). In a 
longitudinal study of 31 ALS couples, scores for the severity of patients’ and 
caregivers’ depressive symptoms were positively related at the study’s baseline; 
however, this association disappeared at a nine–month follow–up assessment of the 
same couples (Gauthier et al., 2007). Instead, the data indicated that while the 
caregivers’ depression scores significantly increased over time, the patients’ depression 
scores remained stable. Nonetheless, absolute scores for the caregiver group remained 
lower than that of patients throughout the study duration.  
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The relationship between caregiver depression and patient physical status is also 
inconsistent. Higher depressive symptoms in caregivers has been associated with 
greater functional impairment in patients (Adelman et al., 2004; Gauthier et al., 2007; 
Pagnini et al., 2010), and in particular with greater limb severity (Chio et al., 2005; 
Goldstein et al., 1998). However, other studies have not found these relationships (Chio 
et al., 2005; Olsson et al., 2010b; Rabkin et al., 2009; Rabkin et al., 2000) and another 
indicates that caregivers’ depression may be less dependent on patients’ level of 
disability than caregivers’ perceptions of the effect ALS has on their partner’s life 
(Goldstein et al., 1998). The impact of cognitive–behavioural symptoms in ALS 
patients on caregiver mood has received little attention to date. Gordon et al (2007) 
observed that cognitive–behavioural changes in 49 ALS patients were associated with 
increased depressive symptoms in caregivers. However, the specific behaviours that 
contributed to caregiver depression were not reported and the study did not control for 
patients’ disease symptoms. A later study also found a positive relationship between 
caregivers’ depression and levels of patients’ apathy and dysexecutive behaviour but 
not disinhibition, as measured by the informant FrSBe. Stepwise regressions found that 
the FrSBe Executive Dysfunction domain was independently related to caregivers’ 
depression, after controlling for patient parameters, such as disease severity and site of 
onset (n=70 couples, Chio et al., 2010).  
Compared to depression, anxiety in ALS caregivers has not been studied in detail. Like 
depression, the level of anxiety apparent in participants is often defined by cut–off 
criteria specific to the mood assessment used in a particular study. Using the HADS, 
medium or higher levels of anxiety (HADS A ≥ 8) have been shown in 42% of 
caregivers (n=19) of patients with variable disease duration (Goldstein et al., 1998). By 
comparison, a study which used the STAI to assess 46 caregivers after at least 1 month 
of their spouse’s diagnosis, found that 58.7% and 13% met criteria for medium (total 
score: 40 – 59) and high (total score: 60 – 80) levels of state anxiety, respectively 
(Vignola et al., 2008).  
Comparable levels of anxiety have been noted between patients and their caregivers 
(Pagnini et al., 2012; Rabkin et al., 2000) and greater caregiver anxiety has been related 
to reduced physical functioning of the patient in some (Bolmsjö & Hermerén, 2003; 
Jenkinson et al., 2000; Pagnini et al., 2010), but not all studies (Pagnini et al., 2012). 
Greater anxiety has also been associated with shorter time since disease onset 
(Goldstein et al., 1998) and might be related to the caregiver’s acceptance of the 
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diagnosis. Longitudinal research found that anxiety rates in ALS caregivers showed a 
slight decrease from the diagnostic stage at a nine month follow–up (Vignola et al., 
2008). Both studies indicate moderate caregiver anxiety early in the disease course, 
possibly reflecting the uncertainty of the disease trajectory.  
3.1.2. Burden and strain 
The concepts of burden and strain are used interchangeably in ALS research (Aoun et 
al., 2013; Chio, 2010; Mockford et al., 2006). In the general caregiving literature, 
separate, albeit similar, definitions are provided by some authors, suggesting conceptual 
specificity between the two terms. Burden has been stated as the oppressive or 
worrisome load arising from caring for the chronically ill, while strain has been referred 
to as the excessive physical or mental exertion required of, and the associated tension 
felt by, persons providing such care (Hunt, 2003). However, references to both concepts 
in established assessment scales, such as the Zarit Burden Interview (ZBI; Zarit & Zarit, 
1987), suggest that these concepts are not generally interpreted as distinct (Goldstein et 
al., 1998). In this review, burden will be used to encompass both terms except where 
‘strain’ is described in individual studies as distinct. Burden is defined here as the sum 
of the objective (physical; practical) and subjective (psychological; existential) strains 
caregivers encounter through caring for their relative (Chio, 2010).    
 
Several studies of ALS caregivers have noted relationships between levels of caregiver 
burden and the severity and progression of the patient’s functional impairment 
(Adelman et al., 2004; Chio et al., 2005; Hecht et al., 2003; Pagnini et al., 2010). In 
addition, greater caregiver burden is associated with higher levels of depression and 
anxiety (Chio et al., 2005; Gauthier et al., 2007; Goldstein et al., 1998; Pagnini et al., 
2010; Rabkin et al., 2000). In the general caregiving research, filial caregiving is topical 
due to the ageing population (Stuifbergen & Delden, 2011); however, in ALS, spousal 
caregivers still form the largest group of informal caregivers in Europe and the UK 
(Chio, 2010; Mockford et al., 2006). Despite this, caregiver samples in ALS studies 
often comprise both filial and spousal caregivers (e.g. Chio et al., 2010; Hecht et al., 
2003; Lillo et al., 2012a). Since no comparative studies between ‘caregiver–types’ have 
been conducted, it is not known whether this might affect the generalizability of study 
findings to the wider ALS caregiver population. However, there are presumably 
differences between caregiver groups in terms of their relationship with or attachment to 
patients which may affect the level of burden or strain felt (e.g. Conde-Sala et al., 
2010). Goldstein et al (1998) found that reduced marital satisfaction following disease 
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diagnosis correlated positively with perceived strain in 19 spousal caregivers. Studies 
which have recruited heterogeneous caregiver samples and neglected to include 
measures of perceived relationship quality with the patient might have overlooked an 
important contributor to caregiver strain. 
 
Restriction of personal time due to caregiving duties is frequently associated with 
burden (Chio et al., 2005; Hecht et al., 2003; Pagnini et al., 2010). In particular, Hecht 
et al (2003) found that in their sample of 37 ALS caregivers, higher burden scores were 
associated with increased ALS disease severity and greater hours per day devoted to 
care provision. Personal and social restrictions, alongside perceived physical and 
emotional problems associated with providing care, were the main components of 
burden. For a subgroup of caregivers who endorsed substantial ‘problem behaviour’ in 
their respective partner (n=14), total burden scores were significantly higher than in the 
remaining respondents. This suggests that burden scores obtained from the group 
overall might have been influenced by a small frequency of ‘problem behaviour’ in 
some ALS patients. The nature of ‘problem behaviour’ was not explicitly stated, so it is 
not possible to determine if this referred to patients’ mood, personality and/or ALS–
related cognitive–behavioural change. 
 
Subsequent research has examined the relationship between patients’ frontally–
mediated symptoms and burden. A study of 70 ALS caregivers found that greater 
behavioural impairment (higher FrSBe scores) were associated with higher scores 
(greater burden) on components of the Caregiver Burden Inventory (CBI, Novak & 
Guest, 1989), as well as worse caregiver mood and reduced quality of life (Chio et al., 
2010). Caregiver burden was positively related to the total FrSBe score and the 
subscales of apathy and dysexecutive behaviour but not disinhibition. Of the CBI 
domains, emotional and developmental burden (feeling ‘out of step’ with one’s peers) 
correlated most strongly with patients’ behavioural symptoms. Lillo et al. (2012a) used 
a different set of measures to assess burden and patient behaviour in 140 caregivers and 
found a dissimilar pattern of results. The revised Cambridge Behaviour Inventory (Wear 
et al., 2008) was used to assess patients’ behaviour, while the Zarit Burden Interview 
(ZBI) was used to classify caregivers into two groups: those experiencing low burden 
and those showing high burden scores (n=67 with cut–off burden score ≥17). In contrast 
to Chio et al’s (2010) findings, logistic regression found that caregiver ratings of 
disinhibition and impulsivity, along with caregiver stress (measured on a separate 
scale), were the main predictors of caregiver group status. Apathy, although reported in 
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80% of the patients by caregivers, did not explain caregiver burden in the statistical 
model.  
 
The discrepant findings between the studies might be explained by the different tools 
used to measure burden in caregivers. The CBI is a multidimensional scale that includes 
objective (physical health; time−dependence) and subjective (social relationships 
outside of caregiver–patient relationship; emotional health) components of burden. The 
ZBI is unidimensional, emphasising the caregiver’s subjective feelings towards their 
caregiving role and the care recipient. It is possible that distinct behaviours are more 
pertinent to certain aspects of caregiver burden than others. For example, increased 
apathy in patients might be more burdensome to caregivers who require greater caring 
time or effort for patients who are less motivated to do things for themselves (reflected 
in time–dependence score on the CBI). Disinhibited and impulsive behaviours may be 
more relevant to caregivers’ feelings towards the patient (reflected on the ZBI) than 
objective measures of the caregiver role, such as time and caregivers’ physical health. 
In addition, Chio et al (2010) found that compared to other domains, disinhibition was 
relatively lower, with fewer patients meeting criteria for clinical impairment on this 
domain; offering another possible explanation for the lack of relationship between 
disinhibition scores and the CBI scores in this study. Moreover, the use of different 
measures to assess patients’ behaviour and, more obviously, possible differences in the 
patient and/or caregiver characteristics between the studies’ samples might have 
contributed to the divergent results obtained.    
Both studies found that caregivers’ burden scores were not associated with patients’ 
physical status following logistic (Lillo et al 2012a) or stepwise (Chio et al 2010) 
regression analyses. These results are a departure from previous studies without 
behavioural data (Chio et al, 2005; Pagnini et al, 2010), implying that the influence of 
behavioural change in patients may dominate their disease symptoms in the prediction 
of caregiver burden in ALS.  
Cross–sectional research has indicated factors associated with burden in ALS 
caregivers; however, the determination of causal relationships for caregiver outcomes is 
only possible through successive assessment over the duration of care provision. 
Goldstein et al (2006a) assessed the longitudinal impact of ALS on 21 spousal 
caregivers over the course of 12 months at six month intervals. Psychological distress (a 
global outcome score which combined measures of caregiver’s mood, perceived strain 
and burden) increased significantly over this period. At baseline, the psychosocial 
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impact of their partner’s functional impairment, the number of other dependents and the 
extent to which caregiver’s perceived their partners as showing emotional lability (EL) 
best predicted the outcome score. ALS symptom severity was not related to the 
caregiver outcome score at this time–point, indicating that psychosocially–salient 
features of disease, such as EL, might be more pertinent to caregiver distress in the 
initial stages of disease. A patient’s EL may be a source of social embarrassment for the 
caregiver or a cause for alarm for caregivers who might interpret EL as evidence for 
overt mood or behavioural change. Subsequent assessments revealed that the perception 
of negative aspects of social support and satisfaction with social relationships best 
predicted psychological distress at the penultimate and final stages of the study, 
respectively. These findings suggest dynamic trajectories of caregivers’ mood, strain 
and burden with progression of their partner’s disease. They also corroborate a previous 
cross–sectional study which found that caregivers’ ratings of their ability to cope with 
future anticipated strain and distress was influenced positively by the number of social 
groups to which they belonged (Goldstein et al., 1998).  
 
3.1.3. Marital satisfaction 
A shift in the marital dynamic between ALS–affected couples is expected as the 
patient’s physical status deteriorates (Oh & Schepp, 2013). Issues relating to sexuality 
(Oh & Schepp, 2013; Wasner et al., 2004), verbal communication difficulties (Joubert 
et al., 2011) and shared decision–making regarding palliative care (Bolmsjö & 
Hermerén, 2003) are only a few examples of factors that may influence the patient–
spouse relationship. Although marital intimacy has been found to correlate with 
caregivers’ psychological distress (Goldstein et al., 2006a), little ALS research has 
investigated predictors contributing to caregiver perceptions of their marital 
relationship.   
Caregivers of ALS have reported a change in marital satisfaction following the onset of 
their spouses’ disease (Goldstein et al, 1998). Reduced satisfaction did not correlate 
with measures of caregiver mood but showed a strong relationship with levels of strain 
(r=.50, n=19, p<.005). Notably, caregivers’ ratings of their spouses’ behavioural and 
communication changes together accounted for approximately 40% of the variance in 
the change between premorbid and post–illness–onset scores of marital satisfaction. 
This finding resonates with caregiving studies of patients with dementia and mild 
cognitive impairment that indicate an association between reduced caregiver–ratings of 
marital quality and the cognitive–behavioural difficulties the diseases present (Ascher et 
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al., 2010; de Vugt et al., 2003; Garand et al., 2007). Despite similar implications for 
ALS caregivers, no research has since investigated caregiver perceptions of 
neuropsychological change on the marital relationship.   
    
In a further study, Atkins et al (2010) assessed patients’ and caregivers’ perceptions of 
their marital relationship over the course of 12 months (three interviews; six months 
apart). While the study’s attrition of ALS couples (n=50 dyads at baseline; n=33 dyads 
second interview; n=27 dyads at conclusion) might limit the interpretations of the 
results obtained, the study did highlight possible contributors to marital satisfaction in 
ALS. Ratings of marital satisfaction did not change over the duration of the study for 
ALS patients or their spouses. However, spouse–caregiver ratings of their marital 
relationship at each assessment were lower than their retrospective ratings of their 
relationship before the onset of their partner’s ALS. Further, after adjusting for the pre–
illness relationship score, caregivers’ marital satisfaction scores at the first and second 
interview were predicted by their ratings of the patients’ psychosocial function. At the 
final interview feelings of burden additionally predicted current marital satisfaction. For 
patients, ratings of their own psychosocial function predicted their marital relationship 
at the first interview only. These results indicate that the early reduction in everyday 
interpersonal activities between patient and caregivers may contribute to caregiver 
perceptions of reduced marital quality. Whether a reduction in these interpersonal 
exchanges could be partly attributable to cognitive–behavioural changes in the patient is 
unknown. The inclusion of objective and/or subjective measures sensitive to ALS–
related cognitive–behavioural impairment might have enabled an exploration of this 
question.  
3.1.4. Directions for future research  
The findings of the above studies underscore the importance of the non–physical 
aspects of ALS in understanding caregiver wellbeing. As this review has demonstrated, 
caregivers’ perceptions of behavioural and psychosocial changes in patients appear to 
play an integral role in caregivers’ experiences of the disease. However, little progress 
has been made in expanding the understanding of caregivers’ perceptions of patients’ 
cognitive–behavioural change and the impact these may have on them in terms of their 
mood, perceived burden and, in the case of spousal caregivers, marital satisfaction. 
Where these have been assessed, there have been no objective measures of patients’ 
neuropsychological performance to corroborate caregivers’ perceptions of cognitive–
behavioural change. Objective measures of cognition have been shown to predict stress 
 123 
 
and burden in FTD caregivers (Greve et al., 1994; McCade et al., 2013; Miller et al., 
2013; Nelis et al., 2011). Considering the overlap of cognitive symptoms between ALS 
and FTD patients, it would be of interest to examine if milder cognitive changes in non–
demented ALS patients are similarly able to predict caregivers’ experiences.  
In FTD research, behavioural abnormalities, such as personality change, social 
inappropriateness, reduced empathy and emotional reactivity, are associated with 
caregiver burden, depression and compromised marital quality (Ascher et al., 2010; 
Ballard et al., 2000; Davis & Tremont, 2007). Social disinhibition and reduced 
empathic concern in patients have been noted by ALS caregivers. Moreover, studies 
have associated certain personality characteristics with ALS patients using caregiver 
reports (see Chapter 2). Studies of ALS caregivers have yet to explore if perceived 
changes in personality and behaviour are associated with caregivers’ wellbeing and/or 
marital satisfaction. In addition, studies of patients’ awareness of cognitive–behavioural 
changes in ALS are limited (see Chapter 2, Section 2.2.2.6.), with some studies 
assuming reduced awareness in ALS patients on the basis of discordant ratings between 
caregivers’ and patients’ reports (e.g. Chio et al, 2010). No ALS studies to date have 
examined dyadic discrepancies alongside caregivers’ self–ratings of their wellbeing. 
Exploration of possible relationships between perceived changes in the patient or 
discordant caregiver–patient perceptions with caregiver outcome variables might 
implicate other factors important to caregivers’ experiences in ALS. Alternatively, since 
dyadic discrepancies can also be influenced by caregiver mood and burden themselves 
(Pfeifer et al., 2013), such relationships might indicate potential confounds in caregiver 
reports of patients’ behaviour.  
 
3.2. Secondary aims of the thesis 
Following previous caregiving research in ALS and the limitations discussed in this 
review, the current study explores relationships between patients’ (objective) cognitive 
dysfunction, (caregiver–rated) behavioural impairment and caregivers’ wellbeing  
(mood, burden, strain) and marital satisfaction. Changes in personality and behaviour, 
as perceived by the caregiver, as well as discrepancies between caregivers’ and patients’ 
perceptions of patients’ personality and behaviour will be examined; their relationship 




3.2.1. Hypothesis Four: Predictors of caregiver wellbeing 
The current study tests the hypothesis that objective measures of cognitive function and 
caregiver–perceived behavioural impairment in patients with ALS will contribute 
significantly to caregiver wellbeing (in terms of mood, perceived burden and strain), 
above and beyond patients’ disease status and symptoms.  
 
3.2.2. Hypothesis Five: Predictors of caregiver marital satisfaction  
The current study tests the hypothesis that objective measures of cognitive function and 
caregiver–perceived behavioural impairment in patients with ALS will contribute 
significantly to caregivers’ perception of marital satisfaction, above and beyond 
patients’ disease status and symptoms.       
                                                                                                                                 
3.2.3. Exploratory Question Two:  Comparisons between patients’ and caregivers’ 
perceptions of patients’ behaviour, empathy and personality 
This study explores differences between patients’ and caregivers’ perceptions of 
patients’ behaviour, empathy and personality and whether such differences are 
associated with caregiver outcomes (in terms of caregiver mood, perceived burden, 
strain and marital satisfaction). The study will also explore if caregivers’ perceived 

















A between–group cross–sectional design was used to investigate emotional processing 
and social cognition in patients with ALS compared to healthy control participants. A 
within–subjects design was employed to investigate predictors of emotional processing, 
social cognition and behavioural change in patients with ALS. See Section 4.6.3 for 
details of statistical procedures.  
 
4.2. Participants 
4.2.1. Ethical approval 
 
Ethical approval was obtained from the National Research Ethics (NRES) South East 
London Research Ethics Committee (REC) 4 (formerly The Joint South London and 
Maudsley and Institute of Psychiatry Research Ethics Committee) on 22 March 2011 
(11/H0807/1). A substantial amendment to the study protocol (see below) received 
ethical approval from the NRES Committee London – Camberwell St Giles (formerly 
known as The Joint South London and Maudsley and Institute of Psychiatry Research 
Ethics Committee) on the 2 August 2011. A minor amendment was granted by the same 
committee on 17 May 2012. Please see Appendix I for copies of respective approval 
letters. R&D approval was obtained from the following sites: King’s College Hospital 
NHS Trust, East Kent University NHS Foundation Trust; NHS Medway Community 
Healthcare; Cambridge University Hospitals NHS Foundation Trust; and The National 
Hospital for Neurology and Neurosurgery, University College London NHS Trust.   
 
A. Substantial amendment 
 
Under the original study Protocol (version 2.0, dated 06.12.10); patients who possessed 
a Forced Vital Capacity (FVC), a measure of respiratory function, of less than 70% 
were excluded from invitation to the study. In practice, it was found that this measure 
was not consistently available or updated in patients’ medical notes at the various 
research sites. The use of a proxy measure the, Epworth Sleepiness Scale (ESS; Johns, 
1991, 1992), was submitted as an amendment to replace FVC, under the revised study 
Protocol (version 3.0, dated 13.07.11). This alternative scale allowed the researcher to 





B. Minor amendment 
 
The application for a second amendment was in two parts. First, the study applied for 
approval to modify a criterion concerning patients’ psychoactive mediation use. 
Originally participants receiving psychoactive medication were excluded from the 
study. In practice, many patients at the research sites were being prescribed such 
medication for the treatment of disease symptoms and not mood disorder per se. This 
measure was preventing otherwise eligible and suitable participants from taking part in 
the study. The amendment only allowed the recruitment of those patients prescribed 
psychoactive medication for palliative treatment (i.e. not for mood disorder). Control 
participants remained ineligible for psychoactive medication use.  
 
Second with respect to this amendment, the study applied for approval to modify the 
recruitment process. A revised study Protocol (version 4.0, dated 27.04.12) was 
submitted alongside this amendment. This modification would allow one patient, who 
fell outside of the care of the NHS sites from which the study operated, but who had 
contacted the researcher directly to enquire about potential participation, to take part in 
the study. This patient received the same treatment and ethical protection as stipulated 
in the approved ethical opinion letter. This patient was screened with the same criteria 
as patients recruited via the research sites (See Section 4.2.3.) and received the same 
consent procedure. Access to the patient’s medical information was arranged, following 
the patient’s formal written consent and with the co–operation of the patient’s GP.  
 
4.2.2. Recruitment and obtaining consent 
 
4.2.2.1. Patients & caregivers 
 
Patients were recruited from the MND clinics or teams at the following sites:  King’s 
College Hospital and The National Hospital for Neurology and Neurosurgery, both in 
London; William Harvey Hospital, Ashford, East Kent; Addenbrooke’s Hospital, 
Cambridge and the Wisdom Hospice, Rochester, Kent. Clinical notes of patients 
attending the clinics or teams were screened regularly for eligibility (See section 4.2.3.). 
This process was facilitated by the principal investigator and clinical teams at each site. 
The Dementia and Neurodegenerative Diseases Research Network (DeNDRoN) 
research co–ordinators, based at MND centres at King’s College and Addenbrooke’s 




The recruitment procedure was the same at each site, except at Addenbrooke’s Hospital. 
Here, patients who were identified as eligible by the DeNDRoN research nurse or MND 
clinic co–ordinators were posted a letter from the clinic staff informing them about the 
research study at the centre (see Appendix I.2.). The letter informed the recipient to 
make contact with the clinic team to indicate their consent for their address details to be 
released to the researcher. This enabled a formal recruitment pack (an invitation letter 
signed by the principal investigator at the relevant site, an information sheet, a consent 
form and a proposed schedule of the testing sessions, see Appendix I.3.a.) to be posted 
to patient who indicated an interest in the study. Once the patient had received the 
recruitment pack, the same recruitment process established at the other research sites 
ensued.      
 
At all other research sites the recruitment procedure was the same. Patients who met the 
inclusion criteria (see Section 4.2.3.1.) were posted a recruitment pack on behalf of the 
principal investigator at the relevant site. Patients were instructed to return a signed 
consent form to the researcher or her academic supervisors if they did want to 
participate. If they did not want to participate, they were instructed to notify either the 
principal investigator or the research team. In this instance, the patient’s details were 
subsequently removed from the contact list and their personal information 
confidentially destroyed. Participants were also offered the researcher’s telephone 
contact number should they wish to discuss the study before consent. If no response was 
received within two weeks of the invitation, the researcher telephoned the participant to 
gauge interest in participation and answer any outstanding queries regarding the 
research. If a patient expressed willingness to participate they were contacted via 
telephone or email to arrange appointments for the testing sessions. At this time and if 
possible, a final screening measure was administered to ensure eligibility (see Section 
4.4.1.2.). They were also asked if they would agree to the researcher contacting their 
partner or spouse to invite them to participate in the study. If the participant agreed, a 
caregiver recruitment pack (an invitation letter signed by the researcher, an information 
sheet, a consent form and a summary of interview content, see Appendix I.3.b.) was 
sent to the participant’s relative. Spouses or partners were not invited to participate if 
the patient declined participation. Patients who accepted an invitation to participate 
were still recruited to the study even if their relative declined invitation. Again, the 
spouse or partner was requested to return a signed consent form to the researcher or her 
academic supervisors if they did want to participate. They were also invited to 
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telephone or email the researchers should they wish to discuss the study before giving 
their consent. The spouse interview was arranged once the spouse expressed willingness 
to participate. Written consent was obtained prior to the interview in all cases. 
 
Ninety–one ALS patients were invited to participate. Sixty–one patients consented to 
participate in the study, giving a recruitment rate of 67%. Of the 61 patients, two failed 
final screening criteria at the phone interview (see Section 4.4.1.2.), one consented to 
the study but later withdrew from participation prior to testing, two became ineligible 
due to suspected dementia and one became ineligible due to diagnostic uncertainty. This 
left a total of 55 ALS patients in the study.  
 
Of the 55 ALS patients, seven were either widowed, divorced or single and thus no 
spouse or partner was available for interview; one patient declined to give their consent 
to allow their spouse to be invited to take part; one spouse was ineligible due to a 
dementia diagnosis and two partners were ineligible as they had not known the patient 
for at least two years prior to the ALS diagnosis (see Section 4.2.3.1.). This left 44 
spouses or partners available for invitation to the study. Of the invited 44 spouses or 
partners, 35 consented to take part in the study, giving a recruitment rate of 79.5%.  
 
4.2.2.2. Control group 
 
Healthy control participants were recruited via the ‘Mindsearch’ database 
(http://www.mindsearch.iop.kcl.ac.uk) at the Institute of Psychiatry, King’s College 
London. Participants were selected at random from the database on the basis of 
specified criteria (see Section 4.2.3). Eligible participants were sent a control 
recruitment pack (an invitation letter, an information sheet and a consent form, see 
Appendix I.3.a.).   
 
Control participants were also recruited via recruitment posters (see Appendix I.5.) 
placed in an around the region of Camberwell, Dulwich and Streatham. In addition, 
advertisements were placed on the online classifieds website, ‘Gumtree’ 
(http://www.gumtree.com/), as well as local online forum websites: ‘East Dulwich 
Forum’ (http://www.eastdulwichforum.co.uk/) and ‘West Dulwich Forum’ 
(http://www.westdulwichforum.co.uk/). All advertisements provided the researcher’s 
contact details and basic eligibility criteria. Potential control participants who contacted 
the researcher were assessed for eligibility before a formal invitation letter and an 
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information sheet were sent to them.  Written consent was obtained at the time of the 
initial assessment session for all control participants.   
4.2.3. Inclusion/exclusion criteria 
 
4.2.3.1. Inclusion criteria 
 
ALS Patients were only included if they fulfilled Revised El Escorial Criteria 
(ALSFRS-R; Brooks et al., 2000) for clinically definite, probable or 
laboratory−supported probable ALS. Patients had to have received a diagnosis at least 3 
months prior to being contacted in order to remain sensitive to, and mitigate possible 
confounding effects of, immediate emotional reactions to the diagnosis. Patients with 
cognitive impairment were included, provided the impairment did not interfere with 
their capacity for informed consent (i.e. they did not have a formal diagnosis of 
dementia). 
 
All patients and controls had to be under the age of 75 years. An upper age limit 
reduced the likelihood of recruiting patients with age–related illnesses associated with 
cognitive decline.  All participants’ first language was English, as several of the tests 
included to assess language and executive function assumed English as a first language. 
Only patients and controls with an estimated IQ greater than 70 were included since a 
lower IQ may make the detection of focal cognitive deficits difficult. 
 
Inclusion criteria specific for caregiver participants were as follows: caregiver 
participants were required to be identified by the patient as the 'primary caregiver' and 
were required to be the patient’s spouse or long–term partner as the study concerned the 
effects of behavioural change within the disease on marital relationships. Caregivers 
were required to have known the respective patient for at least 2 years prior to the 
diagnosis; this is because some of our questionnaires examined pre–morbid behaviours 
and personality.   
 
4.2.3.2. Exclusion criteria 
 
Exclusion criteria specific for patient participants included the following: patients with 
respiratory insufficiency (score >10 on the Epworth Sleepiness Scale, Johns, 1991; 
Johns, 1992; see Section 4.4.1.2.), since poor respiratory may exaggerate cognitive 
impairment (Newsom-Davis et al., 2001) and potentially confound the study’s findings. 
Patients were also excluded if they were in the advanced stage of the disease where a 




For all participants the following exclusion criteria applied: participants with a 
diagnosis of another neurological or a psychiatric condition (including drug or alcohol 
abuse) or diabetes that may affect cognition, affect and behaviour; participants with a 
formal diagnosis of dementia, since they would be unlikely to undertake our 
neuropsychology protocols and would not be able to give informed consent; participants 
whose first language was not English. Originally, participants who were receiving 
psychoactive medication were excluded, but this criterion was later withdrawn (see 
Section 4.2.1).  
 
4.3. Test administration 
 
Assessment of patients was carried out over two sessions of approximately 3½ hours 
each. Patient participants carried out these sessions over the course of at least two days, 
to mitigate possible fatigue. Controls participants were given the option of completing 
the two sessions in the course of one day with an extended break in between sessions. 
Participants were encouraged to take breaks as they required and were informed that 
they could suspend or end testing at any time without consequence. Tests were 
prioritised in order of importance to the objectives of this study. This allowed for at 
least the most important data to be recorded in cases where missing data was present. 
Due to the physical disability of ALS patients, a number of patient participants were 
unable to complete all tests of the neuropsychological battery. The number of 
participants with data missing on each test is outlined in Appendix II. Due to physical 
disability, some patients were either unable to use a pen or speak for long periods of 
time. In these instances, and where possible or appropriate, responses would be given 
verbally or by alternative communication methods (such as paper and pen or ‘tablet’) to 
prevent loss of data and participant fatigue; in these cases responses were recorded by 
the researcher. All participants received £30 gift vouchers for their participation.   
 
4.4. Assessment of patient and control groups 
 
4.4.1. Demographic and clinical variables 
 
4.4.1.1. Clinical status 
 
ALS participants’ clinical history and particular demographic details were ascertained 
from a brief interview prior to participation. The Revised Amyotrophic Lateral Sclerosis 
Functional Rating Scale (ALSFRS-R; Cedarbaum et al., 1999) was administered in an 
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interview format to asses physical functioning. The ALSFRS–R is an ALS–specific 
clinical rating scale that measures patients’ activities of daily living and global 
functioning according to 12 items. It is a revision of the previous ALSFRS which 
underestimated the weight of respiratory dysfunction associated with the disease. The 
set of items relate to the following abilities: speech, salivation swallowing, handwriting, 
cutting food and handling utensils (for patients with and without gastrostomy), dressing 
and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, 
dyspnea, orthopnea, and respiratory function. Participants evaluated these items on a 4–
point likert scale; lower scores indicating a higher level of disability. The maximum 
score achievable upon completion is 48; reflecting no physical disability.  
 
Good construct validity for this measure is demonstrated in one study (n=387) which 
showed strong correlations between the ALSFRS–R and other clinically relevant 
measures, namely an objective measure of FVC (r=.58, p<.001) and the Sickness 
Impact Profile (SIP; Bergner et al., 1981) (rho=-.58, p<.001). Good inter–rater 
(ICC=0.93, 95% CI [0.84; 0.98]) and intra–rater reliability (ICC=0.95, 95% CI [0.92; 
0.98]) and an acceptable level of internal validity were also reported (α=.73) (Kaufmann 
et al., 2007). Furthermore, the measure has shown to predict survival time (Kaufmann 
et al., 2005; Kollewe et al., 2008) and a survey of ALS clinicians and researchers 
endorsed its efficacy in monitoring clinically meaningful changes to patient functional 
status over time (Castrillo-Viguera et al., 2010).  
4.4.1.2. Daytime sleepiness 
 
The Epworth Sleepiness Scale (ESS; Johns, 1991) was used as a proxy of respiratory 
function. The scale provides a measurement of participants’ general level of daytime 
sleepiness. Participants are asked to rate on a scale of 0 – 3 how likely they are to dose 
off or fall asleep in eight everyday situations, generating a maximum possible score of 
24. A cut off score of 10 indicates abnormal sleepiness. For the purposes of screening, 
participants were administered this study via telephone or by post prior to the final 
recruitment stage. Patients who exceeded the cut–off score were not invited to 
participate.  
 
The ESS was shown to successfully distinguish healthy individuals (n=30) from sleep–
disordered patient groups (n=150), such as obstructive sleep apnoea syndrome (OASA), 
narcolepsy and idiopathic hypersomnia in an initial development study (Johns, 1991). 
Moreover, ESS scores were significantly correlated with sleep latency as measured by 
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overnight polysomnography. Within the OSAS group, ESS scores were significantly 
correlated with the respiratory disturbance index, calculated as the number of apnoeas 
and hypopnoeas which caused a decline of greater than 3% in arterial oxygenation 
saturation per hour of sleep. High and satisfactory internal consistency for sleep–
disordered patients (Cronbach’s α=.88) and healthy controls (Cronbach’s α=.73) has 
been shown for the measure (Johns, 1992).   
 
4.4.1.3. Estimated premorbid and current Intelligence Quotient (IQ)  
 
Premorbid and current levels of IQ were estimated by means of the Wechsler Test of 
Adult Reading (WTAR; Holdnack, 2001) and the Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler, 1999), respectively.  
 
The WTAR is a reading test that provides an indication of crystallized intelligence; 
stored knowledge and skills, such as vocabulary acquirement and reading pronunciation 
ability. The test was used as an estimate of premorbid function (Green et al., 2008; 
McGurn et al., 2004; Paque & Warrington, 1995). The test is based on a reading–
recognition paradigm, whereby the stimuli words have anomalous grapheme–to–
phoneme translations. This reduces the likelihood of superior test performance being a 
result of the application of learned pronunciation rules. Participants were presented with 
a page of 50 written words and asked to read them aloud. Accuracy of pronunciation 
was recorded. The test is untimed.  
 
A high degree of consistency within and across assessments is shown for this measure. 
Internal consistency coefficients ranging from .87 – .95 in a British standardization 
sample and stable test–retest correlations ranging from .90 – .94 in a healthy population 
are reported in the test manual (Holdnack, 2001). Further, stable test performance has 
been shown for patients recovering from traumatic brain injury (Green et al., 2008).  
The WTAR was designed in keeping with the format and task demands of the National 
Adult Reading Test (NART; Nelson, 1982), another well accepted instrument for 
predicting premorbid intelligence. Correlations with other measures of reading 
recognition, including the NART, are high, indicating good convergent validity 
(Holdnack, 2001). It was co–developed and co–normed with the Wechsler Adult 
Intelligence Scale–Third Edition, (WAIS-III, Wechsler, 1997) making its selection 




Current IQ was measured using the WASI, which comprises four subtests: Vocabulary, 
Block Design, Similarities and Matrix Reasoning. Only two subtests of the WASI, 
namely ‘Vocabulary’ and ‘Matrix Reasoning’ were used, as they did not require limb 
motor function and could be completed relatively quickly. These subsets, one verbal 
and one non–verbal, combine to yield a two–subset estimate of full–scale IQ score 
(FSIQ–2).  
 
The use of the WASI is advantageous due to its relative concision compared to other IQ 
measures. It has demonstrated exemplary internal consistency (WASI FSIQ-2 r=.96; 
Axelrod, 2002) and test–retest reliabilities (WASI FSIQ-2 r=.88; Wechsler, 1999). It 
also correlates highly with other IQ tests: a correlation coefficient between WAIS–III 
FSIQ and WASI FSIQ–2 of .87 has been observed (Wechlser, 1999). In addition, good 
construct validity of the WASI is suggested by an exploratory factor analysis of adult 
standardisation and clinical samples (Ryan et al., 2003).  
 
4.4.2. Emotional processing and social cognition 
 
4.4.2.1. Emotion recognition and social inference: dynamic vignettes   
 
The Awareness of Social Inference Test (TASIT; McDonald et al., 2002) was used to 
examine the ability to perceive basic emotions in dynamic facial displays, as well as the 
ability to determine a speaker’s intention, meaning and attitude in everyday social 
scenarios. The TASIT comprises video vignettes, lasting between 15 – 60 seconds, in 
which professionally trained actors portray a variety of emotional and social exchanges. 
The test includes two versions, Form A and Form B, which each comprise three subtests 
(Emotion Evaluation; Social Inference – Minimal; Social Inference – Enriched) 
presented in consecutive order. Forms A and its three subtests were adopted for this 
study.   
 
A. The Emotion Evaluation Test (EET)  
 
This task comprises 28 video vignettes, in which actors portray positive (happiness, 
surprise), neutral and negative (anger, disgust, fear and sadness) emotions. Prior to 
testing, each participant was questioned about the definition of each emotion to ensure 
accurate understanding of emotion labels. Participants were instructed to indicate which 
emotion they believed was most strongly portrayed by the targeted actor in each scene 
by selecting one emotion from a response card presented alongside the vignette. The 
targeted actor was announced prior to each item. Answers were recorded on the record 
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sheet out of view from the participant. There was an initial practice item with a practice 
response card to familiarise the participant with the task format. Thereafter, participants 
made their selections from a possibility of four response cards, all displaying the same 
emotions in a multiple–choice array but in different order. These response cards were 
presented in a consecutive cycle from the first test item. Responses were scored as 
either correct or incorrect (1/0), yielding a maximal overall score of 28 and maximal 
subscores of 4 for each emotion.  
 
B. The Social Inference – Minimal task (SI–M)  
 
This subtest comprises 15 vignettes which included sincere, simple sarcastic and 
paradoxical sarcastic exchanges between two actors. In the sincere exchanges the 
dialogue and paralinguistic cues are consistent (the speaker’s thoughts and feelings are 
congruent with what he is saying). In the sarcastic exchanges, the targeted speaker 
means the opposite of what he is saying but intends his/her interlocutor to understand 
the real meaning. There are two types of sarcastic exchanges. In the simple sarcastic 
exchanges, one of the actors is being sarcastic, but only through successful 
interpretation of the paralinguistic cues, can the participant discern the sarcasm. In the 
paradoxical sarcastic exchanges, the dialogue between two actors is paradoxical and 
does not make sense unless it is understood that one actor in the scene is being 
deliberately sarcastic.  
 
After viewing each item, participants were required to answer four questions relating to 
the scene. Each question required a ‘Yes’, ‘No’ or ‘Don’t Know’ answer, which was 
recorded on the record sheet. The four questions were designed to assess understanding 
of four different elements of the exchange, for example: 
 
a) the first question asks what one of the actors was doing to the other actor – i.e. what 
he/she was trying to make another person do, think or feel (second order Theory of 
Mind, ToM). 
 
b) the second question asks what a targeted actor was trying to say to the other person  
    – i.e. what is the message he/she is trying to get across (meaning). 
 
c) the third question asked what a targeted actor was thinking – i.e. what was his/her  
    underlying belief which may have differed from what he/she was actually saying  
   (first order ToM). 
 
d) the fourth question ask what a targeted actor was feeling – i.e. what is the emotion  
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    he/she was feeling or how did he/she feel towards the other actor or situation    
    (emotion).  
 
Examples of question types are provided in Appendix III.a.  
 
Each probe question was scored as correct or incorrect or omission (1/0/0). This yielded 
a maximum score of 60 for the subtask, a maximal score of 20 for each exchange type 
(Sincere, Simple sarcasm, Paradoxical sarcasm) and a maximal score of 15 for each 
element (Do, Say, Think, Feel).    
 
C.  The Social Inference – Enriched task (SI–E) 
      
This subtest comprises 16 vignettes. In each of the scenes one of the actors is saying 
something contrary to his/her thoughts or feelings. Eight vignettes depicted actors 
attempting to conceal his/her true thoughts and feelings by telling either a “white” or 
“sympathetic” lie.  A further eight of the vignettes depicted an actor deliberately using 
sarcasm to highlight the contradiction between his speech and thoughts and feelings.   
 
Of the 16 scenes, eight scenes made use of visual cues (such as a physical object) to 
reveal the true state of affairs, while the remaining eight scenes used verbal cues (a 
prologue or epilogue) to provide this information. In four of the ‘visual cue’ scenes, the 
actor is telling a lie but the visual evidence is only apparent to the speaker and not 
his/her interlocutor. The participant has to attend to the physical object to which the 
speaker refers and observe which character can directly perceive that object. In the other 
four ‘visual cue’ scenes, the visible evidence of one actor’s obvious sarcasm is available 
to both parties in the scene. In four of the scenes which provided either an epilogue or 
prologue, the actor is telling a lie; whilst in the remaining four scenes an actor is being 
sarcastic. However, in these eight scenes only the speaker is aware of the true state of 
affairs. This is revealed in the prologue or epilogue.  
 
After viewing each item, participants were required to answer four questions relating to 
the scene. The four questions were designed to assess understanding of four different 
elements of the exchange, as above in the second subtest. Examples of these question 
types are also provided in Appendix III.a.  
 
Each question required a ‘Yes’, ‘No’ or ‘Don’t Know’ answer, which was recorded on 
the record sheet. As before, each probe question was scored as correct or incorrect or 
don’t know (1/0/0). This yielded a maximum score of 64; maximal scores of 32 for each 
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exchange type (Lie or Sarcastic); maximal scores of 16 for each of the elements (Do, 
Say, Think, Feel) and maximal total scores of 32 for each cue type (visual, verbal).  
 
Ecological validity for the TASIT has been indicated in a study of 21 patients with 
Traumatic Brain Injury that related performance on the TASIT with measures of social 
behaviour (McDonald & Flanagan, 2004). Patients’ use of humour in spontaneous 
conversations with a study confederate correlated positively with the EET (r=.46), the 
SI-M (r=.58) and the SI-E (r=.67) of the TASIT. Social manners (politeness, 
interruptions), egocentric behaviour and ‘partner involvement behaviour’ (e.g. 
encouraging the interlocutor to talk about himself) also correlated positively with the 
SI-E of the TASIT (r=.57; r=.77; r=.49, respectively). Convergent validity for the 
TASIT is supported by another study of adult brain injury in which TASIT performance 
was compared with specific tests of social perception (McDonald et al., 2006). 
Significant correlations ranging between .37 < r < .69 were revealed for all parts of the 
TASIT and emotion identification performance on the Ekman and Friesen series 
(Ekman & Friesen, 1976). The SI-M of the TASIT was also associated (r=.68) with 
second–order ToM stories (Bibby & McDonald, 2005), but not simple first–order ToM 
stories or control stories requiring only physical inference. Performance of the TASIT 
has been shown to discriminate bvFTD patients with and without pronounced 
neuropathology in an fMRI study. Poor performance, particularly in interpreting 
sarcastic items and emotions, was associated with damage to the lateral orbitofrontal 
cortex, insular and the temporal poles (Kipps et al., 2009).  
 
Most social cognition studies that have used the TASIT have compared participants’ 
performance on the Sarcasm or Lie conditions with their performance on the Sincere 
condition. Little research has investigated dissociations in performance between the 
‘Do’, ‘Say’, ‘Think’ or ‘Feel’ domains of the TASIT subtasks. One study used the SI-E 
subtask to compare performance across these domains between 77 healthy controls and 
102 neurodegenerative patients (n=39 bvFTD; n=32 AD; n=16 progressive supranuclear 
palsy; n=15 cerebrovascular disease) (Shany-Ur et al, 2012). Patients with AD and 
cerebrovascular disease performed similarly to controls across all domains under the 
three conditions of the task (Sincere; Lie; Sarcasm). Relative to controls, patients with 
bvFTD were impaired on all four domains for both the Lie and Sarcasm conditions, 
suggesting a generalised mentalising deficit contributing to the bvFTD group’s impaired 
overall performance on these conditions. Notably, patients with progressive 
supranuclear palsy performed similarly to controls on all domains with the exception of 
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the ‘Think’ domain under the Lie condition. The results indicated that the impaired 
overall performance on the Lie condition demonstrated by these patients was driven by 
an isolated impairment in making inferences regarding characters’ true beliefs in 
exchanges involving deception. These findings highlight possible advantages in 
comparing performance across the domains of the TASIT scenarios (e.g. ‘Do’; ‘Say’, 
‘Think’, ‘Feel’) to reveal specific difficulties underlying overall performance deficits on 
the TASIT conditions (e.g. Sincere, Sarcasm, Lie). Nonetheless, the specific reliability 
and validity of using these domains have, as yet, not been examined.  
4.4.2.2. Mental state attribution: static facial images  
 
The ability to identify feelings and thoughts of others was also assessed using the 
Reading the Mind in the Eyes Test – Revised version (RME; Baron-Cohen et al., 2001). 
The RME consists of 36 facial images depicting only the eye region. Each image is 
surrounded by 4 words; one target word and three distracters (foils), all similar in 
valence. The words describe complex mental states which require the attribution of a 
belief or intention to the pictured person. Word examples are as follows: annoyed, 
cautious, hostile, tentative. Participants were asked to select which word they believed 
best described the mental or emotional state of the person in the picture, either orally or 
by pointing to the word. In the control condition, participants were asked to judge the 
gender of the target person. The researcher recorded each answer on the record sheet, 
out of view of the participant. A glossary of terms for the word items was provided for 
participants to refer to throughout the test if they were unsure of the word definitions.   
 
The RME was originally developed for the detection and measurement of subtle 
impairments in mentalising ability of adults with autistic spectrum disorders. The 
current test is a revision of an earlier version (Baron-Cohen et al., 1997). Normative 
data for this test is based on typical data from a study in which performance of healthy 
participants was compared to participants with Asperger’s syndrome (AS) or High–
functioning Autism (HFA). In this study, the test demonstrated successful 
discrimination between the three participants groups; the AS and HFA groups showing 
impaired performance. The test has also demonstrated impaired performance in patient 
groups with bilateral lesions of the orbitofrontal region (Stone et al., 1998)  and 
amygdala (Stone et al., 2003)  
 
The RME was selected on the basis of its widespread use as a ToM measure and brevity 
of administration. We also wished to replicate previous findings of impairment on this 
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measure in an ALS sample (Girardi et al., 2011) within the context of the present 
investigation of social cognition in ALS. 
 
4.4.2.3. Mental state attribution: static cartoons 
 
The Happé Cartoons and Written Scenarios task (Happé et al., 1999) was adopted to 
investigate mental state attribution for characters in humorous illustrations. These 
materials were the same as those described in Gibbons et al (2007)  and Snowden et al 
(2003). The task comprises two separate subtasks with separate materials: a cartoon 
interpretation exercise and a forced–choice task. Both subtasks compare comprehension 
of two types of cartoons: ‘mental’ and ‘physical’. Both cartoon types require the 
integration of visual information and the drawing of inferences. However, only the 
‘mental’ cartoon type requires the attribution of mental states. The ‘physical’ cartoon 
set therefore constitutes the control condition in which mental state attribution is not 
required. In the ‘mental’ cartoon set, the humour related to a character’s ignorance, false 
belief, intention or act of deception, while in the ‘physical’ cartoon set, the humour was 
based on physical absurdity or impossibility. Illustrative examples of cartoons are 
shown in Appendix III.b.  
 
Scoring and classification of responses for each subtest were undertaken by two raters 
for 30 items of each subtest (15 patient items; 15 control items). One of the raters was 
blinded to the participant’s group status. Inter–rater reliability for the ratings are 
described in the Results sections (Chapter 5; Section 5.2.2.4.) and shown in Appendix 
VI.2.  
 
A. Cartoon Inference subtask  
 
Participants were shown 12 single–frame cartoons, which were presented in random 
order. Cartoons were presented consecutively with the instruction to describe what was 
funny about each one. Six of the cartoons (three ‘mental’ and three ‘physical’) included 
captions, which the participant was required to read aloud. The cartoon remained in 
view until the participant had finished responding. Time taken to respond (the time from 
presentation of the cartoon to the first offer of a response) was recorded. Responses 
were recorded verbatim. Participants who gave vague answers were prompted with 




Scoring of the responses was in accordance with the scheme used by Gibbons et al 
(2007) and Snowden et al (2003). Performance accuracy of responses was rated on a 
three–point system, as follows: 
 
a) 3 points = full and explicit explanations 
b) 2 points = partial or implicit responses 
c) 1 point = reference to relevant parts of the cartoon but without further explanation 
d) 0 points = omissions and responses that provided irrelevant or inaccurate detail 
 
Responses awarded less than a perfect score of three, were classified under the 
following error categories:  
 
a) Omissions (‘don’t know’ responses) 
b) Concrete responses (itemisation of elements of cartoon without integration) 
c) Descriptions (description of relevant parts of cartoon or involving integration of 
elements but without inferences outside of the cartoon content) 
d) Misconstructions (responses that provide inferences outside of the cartoon’s content 
but that which are faulty or inaccurate) 
e) Partial responses (responses that involve accurate inferences but are incomplete and 
not explicitly stated) 
 
B. Cartoon Forced–Choice task (Cartoon Pairs) 
 
In this subtask, participants were presented with 10 cartoon pairs, both identical except 
for one cartoon having had the humorous element removed. Cartoon pairs were 
presented juxtaposed with the position of left and right cartoon being counterbalanced 
across items. Participants were instructed to select which cartoon they believed to be the 
humorous one of the pair. Accuracy of selection and time to respond (time from cartoon 
presentation to the first offer of a response) were recorded. Participants were also asked 
to explain what was humorous about the cartoon they had selected. Responses were 
recorded verbatim. Vague responses were, as above, prompted with “anything else?” to 
encourage an explicit answer. Cartoons remained in view of the participant until they 
indicated completion of their response.  
 
The response scoring and error classification schemes were identical to that of the 
Cartoon Inference task.  
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4.4.2.4. Mental State Attribution: written scenarios 
 
Sixteen written scenarios (adapted from Happé et al., 1999) were used to assess mental 
state attribution of characters in prose. The passages were the same as those used by 
Gibbons et al (2007) and Snowden et al (2003). Sixteen passages, depicting characters 
in everyday situations, were presented on cards to participants, followed by a question. 
The passages comprised two types of scenarios, eight cards in each set type, which 
constituted two separate conditions. The ‘mental’ condition involved stories which 
depicted double bluffs, mistakes, persuasion and white lies on the part of a character in 
the passage. These stories required an inference about the characters thoughts, feelings, 
desires and intentions in order to respond to the passage question. The ‘physical’ 
condition, involved stories also depicting characters within a scenario but were followed 
by questions relevant to inferences of physical causation or logical sequence. This set of 
scenarios thus constituted the control condition. Examples of these scenarios are shown 
in Appendix III.c. 
 
Participants were instructed to read each passage silently and indicate reading 
completion by turning over the card. The respective item question was revealed on the 
other side of the card and was read aloud by the experimenter. This question remained 
in full view of the participant until they moved on to the next item. Participants were 
informed beforehand that once the card was turned over they could not refer to the 
content again. ‘Mental’ and ‘physical’ items were completed in blocks; blocks were 
presented in counter–balanced order. Reading time (from the receipt of card to turning 
over of the card) was recorded. Responses were recorded verbatim.   
 
Scoring and classification of responses for each subtest were undertaken by two raters 
for 30 items for this subtest (15 patient items; 15 control items). One of the raters was 
blinded to the participant’s group status. Inter–rater reliability for the ratings are 
described in the Results sections (Chapter 5; Section 5.2.2.4) and shown in Appendix 
VI.2.  
 
The scoring scheme adopted by Gibbons et al (2007) and Snowden et al (2003) was 
used. Performance accuracy of responses was rated on a two–point system, as follows:  
 
a) 2 points = explicit and full responses 
b) 1 point = partial or implicit responses 




In addition, responses receiving a less than perfect score of two were classified under 
the following error categories: 
 
a) Omissions (‘don’t know’ responses) 
b) Concrete responses (reiterations of parts of the passage without integration) 
c) Descriptions (identification of relevant parts of the story or integration of elements 
but without drawing inferences) 
d) Misconstructions (inaccurate inferences) 






The Interpersonal Reactivity Index (IRI; Davis, 1980) was selected to determine 
empathic behaviour of patients as perceived by themselves, through self–report, and 
their caregivers, through informant report. The IRI is a 28–item questionnaire in which 
respondents endorse statements with regards to themselves or another according to a 5–
point Likert scale (0: Does not describe me/him/her very well; 5: Describes me/him/her 
very well). It comprises four scales (each containing seven items) namely, Perspective 
taking (PT); Empathic Concern (EC); Fantasy (F) and Personal Distress (PD). The PT 
scale measures the tendency to spontaneously assume the psychological perspective of 
others; F assesses the tendency to identify oneself with the feelings and behaviour of 
fictitious characters from novels or film; EC assesses sympathetic feelings towards 
others; and finally, the PD scale evaluates feelings of anxiety in emotionally–tense 
interpersonal situations. This latter scale has been suggested as a measure of emotional 
self–control rather than a facet of empathy (see Baron-Cohen & Wheelwright, 2004). 
Each subscale has a maximum total score of 28.  
  
Empathy is defined as a multidimensional construct, comprising of both cognitive and 
emotional aspects. The cognitive component reflects the comprehension of another’s 
point of view without necessarily simulating that person’s emotion. The emotional 
component, on the other hand, refers to the recognition of another’s emotional 
experience as a result of congruent emotional reactions induced by witnessing their 




This scale was adopted for its comprehensive measurement of both cognitive (PT) and 
emotional (EC) components of empathy. The IRI subscales have shown good internal 
consistency (.71<<.77) and acceptable test–retest reliability (test–retest correlation 
coefficients ranged from .62 to .71) (Davis, 1980). A validation study also showed that 
the IRI subscales correlated strongly in magnitude and in the anticipated direction with 
measures of social functioning, self–esteem, emotionality, and sensitivity towards 
others (Davis, 1983).  




The modified version of Thurstone’s written fluency test was used as a measure of 
orthographic fluency (Abrahams et al, 1997). Thurstone’s written fluency test has been 
shown to have good test–retest (.79) and inter–rater reliability (.98) (Cohen & Stanczak, 
2000). Impairment in this domain is a widely reported in MND (see Chapter 2, Section 
2.2.1.1.) and this test has been shown to be effective in detecting executive dysfunction 
whilst mitigating confounds of physical disability in MND patients (Abrahams et al., 
1997; Abrahams et al., 2004; Abrahams et al., 2005a; Abrahams et al., 2005b; 
Abrahams et al., 2000). The test comprised two parts. The first part, the ‘generation 
condition’, required participants to write down as many words as possible in a given 
time limit and under conditions in which the response was specified by a particular 
restriction, such as a letter. The first restriction required participants to produce words 
beginning with “S” in five minutes; the second restriction required four–letter words 
beginning with the letter “C” in four minutes. Participants were instructed against the 
production of suffixes, proper nouns or plurals.  In the second part, the ‘copy condition’, 
participants were timed as they copied out the words that they had previously provided.  
A Verbal Fluency Index (VFI) was then calculated by subtracting the time of the copy 
condition from the time of the standard generation condition and dividing this by the 
total number of words generated. This index represents the average time taken to 
generate each word; higher scores indicating longer thinking times and more 
pronounced executive impairment. The formula is illustrated below:  
 
            VFI =     (time for generation condition) – (time for copy condition) 





If participants were unable to write they were asked to give responses verbally while the 
examiner wrote down the answers in front of them. In the ‘copy condition’, these 
participants were given the list they had generated and asked to read it aloud. The time 
taken to read the list was recorded and a VFI was subsequently calculated.  
 
4.4.3.2. Response inhibition  
 
Response inhibition was examined by means of the Hayling Sentence Completion Test 
(Burgess & Shallice, 1997). The task is also believed to provide a measure of response 
initiation and strategic thinking (Burgess & Shallice, 1996) 
 
The test comprised two sections. The first section, the Sensible Completion (SC) 
condition, required participants to complete 15 statements with an appropriate missing 
word as quickly as possible. For example, “He scraped the cold food from his …” 
(acceptable response: ‘plate’). Latency of the response was recorded as a measure of 
response initiation. The second section of the test, the Unconnected Sentences (US) 
condition, required participants to replace the missing word with an inappropriate word 
that was unrelated to the sentence meaning in every way. As in the first section, there 
were 15 statements. For example, “The dog chased our cat up the …” (an acceptable 
inappropriate response: ‘spoon’). This component of the test required participants to 
inhibit an appropriate and easily accessible response (‘tree’) in favour of the generation 
of a novel unrelated one (‘spoon’), thereby acting as a measure of cognitive inhibition. 
Error scores were also recorded. Category A errors constituted sensible and appropriate 
responses, while category B errors were recorded as responses which are indirectly 
related to the sentence. Normal performance on SC but impaired performance on US 
(longer latencies and more errors), may indicate anterior frontal lobe damage (Burgess 
& Shallice, 1996). However, since scores are calculated from summing the timed 
responses in each condition, dysarthria in some of the patients might exaggerate 
impairment. Therefore, the current study calculated the difference in total latency 
between the two sections of the task (US total time – SC total time), allowing for an 
index of cognitive inhibition that controls for motor disability (i.e. slowed speech).  
 
Acceptable split–half reliability (SC=.63; US=.78) has been reported in a study of 
response suppression and initiation abilities in patients with frontal lesions (Burgess & 
Shallice, 1996), suggesting the measure is sensitive to frontal dysfunction. Further, the 
US condition has shown to correlate significantly with the informant version of the 
Dysexecutive Questionnaire from the Behavioural Assessment of Dysexecutive 
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Syndrome (Wilson et al., 1996), supporting the ecological validity of the measure 
(Wood & Liossi, 2006). The Hayling error score has also been correlated with initiation 
time on the Tower of London test (r=.40, p<.001; Andrés & Van der Linden, 2000), 
suggesting convergent validity of this measure of executive function.  
4.4.3.3. Rule detection & concept formation 
 
A visuospatial rule attainment task was used to examine rule detection, concept 
formation and cognitive flexibility. The Brixton Spatial Anticipation Test (Burgess & 
Shallice, 1997) constitutes a 56–page stimulus booklet. Each page presents an 
arrangement of 10 circles divided equally into two rows and which are numbered 1 – 
10.  On each page, one circle is coloured blue. The position of the blue circle alters from 
page to page, according to a set of rules that change abruptly. Participants were 
presented with each page in sequence and asked, on the basis of the rule learned in 
previous pages, to indicate where they anticipated the position of the coloured circle to 
be on the following page. The total number of errors provided the outcome measure, 
with higher scores indicating worse performance. The test does not require a limb motor 
response, as participants can call out their predictions.   
 
Split–half reliability and test–retest reliability for this test were originally reported as 
.62 and .71, respectively (Burgess & Shallice, 1997). A more modest test–retest 
reliability of .61 has since been cited; however, these coefficients are comparable with 
those reported for other accepted executive function measures, such as the Wisconsin 
Card Sorting Test (WCST) and the Behavioural Assessment of Dysexecutive 
Syndrome. Further, an investigation of the applicability and validity of the measure in a 
clinical sample revealed adequate sensitivity and specificity for executive function 
when comparing Korsakoff’s syndrome and healthy controls (AUC=.74, 95% CI [.66; 
.82]). Stroke and psychiatric disorder samples also performed in the “below average” 
range more frequently, suggesting the measure is sensitive to subtle cognitive deficits 
(Van den Berg et al., 2009).  
 
Category formation was examined by means of The Card Sorting Test, one of nine 
subtests of the Delis–Kaplan Executive Functioning Test (D-KEFS; Delis et al., 2000). 
The task requires participants to sort cards into mutually exclusive categories based on 
the verbal or visual information of the cards; it recruits mental operations that rely on 
working memory and mental search ability (Libon et al., 2012), as well as conceptual 
flexibility and monitoring capacity (Latzman & Markon, 2010). This test is endorsed by 
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sufficient validity and reliability data of the D–KEFS (Delis et al., 2004) and good test–
retest ability (Homack et al., 2005).  
 
Prior to test administration, all participants underwent a screening pre–test. This 
entailed the presentation of a list of stimulus words. Participants were required to read 
aloud each word and inform the researcher of any word for which they did not know the 
meaning. Participants were also asked if they had any difficulties in perceiving shapes 
and/or colours. Finally, an orientation set was conducted using practice cards in which 
the researcher demonstrated the rules of the task and the targeted arrangement and 
description of sorts. 
 
The test was administered and scored according to the standard protocol described in 
the task manual. This comprises a Free Sort condition, followed by a Recognition Sort 
condition. In the first condition participants were instructed to sort six cards into two 
groups, three cards per group, according to as many different concepts or rules they 
could identify. There are a maximum of eight sorting rules for each of the two card sets. 
Three of these rules are determined by verbal–semantic information from words printed 
on each card. The five other rules are determined by visuospatial patterns on the cards. 
Participants were required to provide the sorting rule that they used to group the cards. 
The manual stipulates that a maximum free sorting time of 4 minutes should be allotted 
for each card set. Due to the physical impairment of the patient participants, this 
restriction was not observed. Instead, the administration of each card set was 
discontinued when either the participant had completed 10 attempted sorts, attained all 
target 8 sorts, or indicated that he or she could not generate any sorts for the second 
time (i.e. after one prompt from the researcher). Cumulative sorting times were 
recorded by the researcher but not used in analyses. Participants were encouraged to 
work as quickly as possible.  Where the participant was unable to sort the card by hand 
due to limb disability, he or she would instruct the researcher to place the card into 
groups.   
 
In the recognition condition, cards were sorted into groups by the researcher and 
participants were asked to identify or describe the rule that the researcher used.  The 
discontinuation of each trial occurred when 45 seconds elapsed from the sort 




In the first condition, cards sorts were awarded a score of 1 if they were correctly made. 
A score of 0 was awarded for incorrect sorts, repeated sorts and sorts which were 
unconfirmed by the description response (i.e. a correct sort but incorrect description).  
 
Description responses for both conditions were scored according to a 2–point system:  
 
a) 2–points were awarded when a target or appropriate general concept was identified 
(e.g. “they are all animals”). 
 
b) 1–point was awarded when a specific feature of the stimuli (e.g. “they all have legs”) 
or a correct description was provided for only one of the card groups.  
 
c) 0–point was awarded for omissions (e.g. “don’t know”), a repetition of a previously 
correct description, an incorrect response (e.g. “these are happy” for animal groups) or 
an overly inclusive description which applied to both groups (e.g. “they are things 
found in a planet” for animal and transport group). 
The current study calculated a sorting score (maximum possible sorting score – score 
obtained) and a description score (maximum possible free sorting description score – 
description score obtained) to be used in the computation of a composite score of 




The Graded Naming Test (GNT; McKenna & Warrington, 1983) was used to assess 
object naming ability, as an indication of language function.   
 
Pictures of 30 objects were presented consecutively and in ascending difficulty to 
participants (i.e. items are ordered in terms of progressively lower frequency, such as 
‘kangaroo’ to ‘retort’). Participants were required to name the object on each page 
before proceeding. Where a participant was unable to produce an intelligible response 
(due to dysarthria), they were allowed to indicate a response through written 
communication. All answers were recorded verbatim. Items were scored “1” if the 
object was named correctly, and “0” if otherwise. In some cases, participants 
misperceived an item altogether (e.g. ‘broom’ for ‘tassel’) or gave a generic response 
(e.g. ‘animal’ for ‘boar’). In these cases, the researcher prompted the participant with 
“What is another name?” or “What else could it be?” The raw score served as a measure 




The GNT was first standardised in a group of 100 subjects in the late 1970s  (McKenna 
& Warrington, 1980). A subsequent restandardisation study (n=710) provides revised 
norming data. The test has shown excellent test–retest reliability study in healthy and 




The short form of the Californian Verbal Learning Test 2
nd
 Edition (CVLT-SF; Delis et 
al., 2000) was used to assess verbal memory. This is an abbreviated version of the 
original test battery with a shortened wordlist (9 words instead of 16), only one list to 
remember (instead of two) and fewer recall trials. Participants were required to recall a 
list of nine words under different conditions. These conditions included free recall, cued 
recall and recognition. Responses were recorded verbatim throughout the trials.  
 
In the immediate free recall condition, the researcher read the list of nine words to the 
participant, who was then asked to recall as many of the listed words as possible (in any 
order). This process was repeated three times, creating four trials. After the fourth trial, 
a 30–second distractor task occurred, in which participants counted backwards from 100 
until the researcher asked them to stop. After this distractor task, a short–delay free 
recall condition followed. Here, participants were asked to name as many words from 
the list that the researcher had read in the preceding trials. Upon completion of this 
condition a 10–minute delay interval followed during which the researcher administered 
a non–verbal task to the participant. Following this interval, the long–delay free recall 
condition occurred. Participants were asked again to name as many words as possible 
from the original list. Following this condition, a long–delay cued recall condition was 
administered, in which the researcher asked the participant to name all the words from 
the list pertaining to separate categories (‘Fruits’, ‘Clothing’, ‘Fruits’). Following this 
condition, a long–delay yes/no recognition condition followed. The researcher read 
aloud a list of 27 words, nine of which were items from the preceding trials. After each 
word was read aloud by the researcher, the participant indicated if the word was from 
the original word list.     
 
The CVLT–II and its predecessor, the CVLT, have been widely adopted in memory 
research in both clinical and non–clinical populations. Criticisms of the original CVLT, 
which were directed mainly at its norming procedure (see Elwood, 1995; Randolph et 
al., 1994; Wiens et al., 1994), led to the restandardisation and development of the 
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revised edition, using a larger (n=1087) and more representative reference sample. 
Reliability data are provided in the test manual for the normative sample and a small 
mixed neuropsychiatric sample (n=124), for which internal consistency estimates range 
from .78 – .89 and .80 – .96 respectively. Further, a non–clinical sample (n=62) which 
was administered both editions in a counterbalanced order, showed comparable 
performance and satisfactory correlations between the tests. The authors argue the 
validity of the CVLT–II on the basis of its close association with its well validated 
predecessor. The short version of the test was developed for quick administration and to 
identify memory problems without overly taxing participants. We chose this measure 
with our patient participants in mind. Normative data for the ‘short version’ is provided 
in the manual, however, how this data was derived is not specified.  
 
Previous research has shown that CVLT–SF recall data contributed effectively in 
discriminating between the memory profiles of patients with AD, bvFTD and SD 
following discriminant analysis (Kramer et al., 2003) 
4.4.6. Mood and personality  
 
4.4.6.1. Anxiety and depression 
 
The revised version of the Hospital Anxiety and Depression Scale (HADS; Gibbons et 
al., 2011) was used to determine depression and anxiety. This modified version is a 12–
item questionnaire, subdivided equally into two separate scales of anxiety (HADS–A) 
and depression (HADS–D). Items are scored 0 – 3; with a higher score indicating 
greater levels of anxiety or depression. The original version of the HADS (Zigmond & 
Snaith, 1983), which included seven items on each subscale, shows satisfactory internal 
validity (Dagnan et al., 2000), reliability and discriminant validity (Cameron et al., 
2008). However, Rasch analysis of the original version in 298 ALS patients, found that 
the removal of two items, one from each subscale, improved the fit of each remaining 
6–item subscale to the Rasch model. The items removed from each subscale were: “I 
feel restless as I have to be on the move” (HADS–A) and “I feel slowed down” 
(HADS–D).  
 
The authors suggest that the modified version is suitable for MND patients in clinic and 
research, following satisfactory reliability. Both subscales showed good internal 
construct validity, as Person Separation Indices (PSI) for HADS–A=.84 and HADS–
D=.79 were obtained. The modified subscales possessed no gender– or age– related 




New cut–off criteria for the modified version, which accounts for the reduced number 
of items of the scale, have been provided (Gibbons et al., 2011). These criteria are as 
follows:  
 
i) HADS–D ≥ 8 ;  case level of depression 
ii) 5 ≥ HADS–D ≤ 7 ;  borderline level of depression 
iii) HADS–D ≤ 4;  normal / non–case  level of depression 
iv) HADS–A ≥ 9 ;  case level of anxiety 
v) 7 ≤ HADS–A ≤ 8;  borderline level of anxiety 
vi) HADS–A ≤ 6;  normal / non–case level of anxiety  
 
Although these revised criteria have not been validated against clinical diagnostic 
interview, the suggested prevalence of case–level depression in the Gibbon’s et al 
(2011) sample (11.1%) was similar to the pooled prevalence estimate of three other 
MND studies (9.7 %; range 9 % – 11%) which used DSM–IV criteria to diagnose the 
presence of major depression in MND patients (Ganzini et al., 1998; Rabkin et al., 




The NEO–Five Factor Inventory (NEO-FFI, Costa & McCrae, 1992) self–report adult 
version was used to assess current personality in patient and control participants. This 
scale is an abridged version of the NEO Personality Inventory (NEO–PI) instrument and 
was developed to provide a comprehensive measure of personality for greater 
convenience and concise completion.  
 
Participants were required to read a series of statements and to endorse these statements 
along a five–point scale. The scale response options included Strongly Agree; Agree, 
Neutral, Disagree of Strongly Disagree. Participants made their selection by 
highlighting one option on the record sheet or calling out their selection to the 
researcher who recorded it on their behalf. The gender–specific norms reported in the 
manual to derive T–scores for each domain were used.  
 
All NEO–PI versions are based on the Five–Factor Model (FFM; Digman, 1990; 
McCrae & Costa, 1987), an established dimensional model of personality structure. The 
model describes five domains of personality, namely Neuroticism (N), Agreeableness 
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(A), Conscientiousness (C), Extraversion (E) and Openness (O), identified from factor 
analysis of adjectives or ‘traits’ used in common English language.      
 
The NEO–FFI comprises 60 items from the 180 items of the NEO–PI, which were 
selected upon identifying those items which most strongly contributed to the five 
domains, using principal component analysis and a varimax rotation procedure. These 
items received minor substitutions in order to vary item content, eliminate items with 
joint loadings and safeguard against potential acquiesce response bias, by including 
forward and reverse scored items (Costa & McCrae, 1992). The short version provides a 
single domain score for each factor only, whilst the longer version comprises six facet 
scores within each of the domains. The NEO–FFI was therefore not designed to provide 
a complete measurement of the five personality factors, but reasonable estimates of 
each domain (McCrae & Costa Jr, 2004).  
 
Correlations between the NEO–FFI scales and the NEO–PI validimax factors reportedly 
range from .75 to .89. Correlations with the revised NEO–PI (NEO–PI–R) scales are 
reported as ranging from .77 to .92 (Costa & McCrae, 1992). Test–retest reliability for 
the five scales is high and internal consistency is adequate (ranging from .68 - .86; 
Costa & McCrae, 1992). 
4.4.7. Behaviour 
 
4.4.7.1. Executive / Frontal system mediated behaviour 
The Frontal Systems Behavioural Scale (FrSBe; Grace & Malloy, 2001) was selected to 
assess frontal–lobe mediated behaviours. The questionnaire contains 46–items which 
may be rated on a scale of 1 (almost never) to 5 (almost always); with respect to 
behaviour both before (premorbid baseline) and after the onset of illness. The 
questionnaire yields a Total score and three subscale scores, which correspond to three 
behavioural syndromes, namely ‘Apathy’, ‘Executive Dysfunction’ and ‘Disinhibition’.  
It may be administered as either a self–rating scale or in an informant–rating format. 
Both ALS participants and controls were asked to complete this measure on the basis of 
current behaviour. In addition, ALS participants were instructed to rate their behaviour 
two years prior to their disease diagnosis; control participants were asked to rate their 
behaviour two years prior to the testing session. Raw scores for each subscale and a 
Total score were calculated for both before and after response scales. These were then 
converted into standardized scores (T–scores) using normative data presented in the 
manual. The normative data provided in the manual is derived from a sample (n=436) 
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of men and women ranging in age (18 – 95 years) and educational attainment (10 years 
to doctoral level). The normative tables are stratified for gender, age and education; 
providing T–scores for self–rating and family–rating versions.   
 
As described in the manual, scores above 65 were considered to indicate clinically 
significant impairment; scores between 60 – 64 were considered to show borderline 
clinical impairment and scores below 60 were considered to indicate no behavioural 
impairment at all. An index of behavioural change was calculated by comparing the       
T–scores based on the normative data of ratings for current and premorbid behaviour.   
 
High internal consistency of the self–report version of this scale is reported with 
adequate  coefficients for ‘Total’ (.88), ‘Apathy’ (.72), ‘Disinhibition’ (.75) and 
‘Executive Dysfunction’ (.79) in normative samples (Grace & Malloy, 2001).  Similarly 
impressive  coefficients have been demonstrated in a large (n=324) neurological 
sample, 63% of which were neurodegenerative disease patients (Stout et al., 2003). In 
this study, a factor analysis supported a factor structure corresponding to the three 
subscales representing frontally–mediated behaviour. Good construct validity has also 
been shown in a study comparing patients with frontal lobe damage (n=24) to those 
without frontal lesions (n=15) as well as healthy controls (n=48). Scores for the frontal 
lesion group were significantly higher than those of the comparative groups. A 
significant behaviour change for the lesioned group was shown when comparing 
premorbid and post lesion behaviour (Grace et al., 1999).   
 
Convergent validity of this measure has been shown in a study comparing the FrSBe 
with another well validated measure, the Neuropsychiatric Inventory (NPI; Cummings 
et al., 1994). Significant correlations between the NPI Total and FrSBe Total score; the 
NPI and FrSBe Apathy subscales; and the NPI and FrSBe disinhibition subscales in 30 
dementia patients and their caregivers were found. Furthermore, the FrSBe Executive 
Dysfunction and Apathy subscales were associated with deterioration in instrumental 
activities of daily living, suggesting ecological validity for the measure (Norton et al., 
2001).  
 
4.4.7.2. Emotional lability 
 
Emotional lability (EL), was measured by the Emotional Lability Questionnaire (ELQ; 
Newsom-Davis et al., 1999) Both the self–rated and informant–rated versions of this 
scale were used.  This measure comprises 33 items encompassing three subscales 
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measuring ‘Laughter’, ‘Crying’ and ‘Smiling’ on a 4–point Likert scale. Higher scores 
indicate higher levels of perceived EL. Participants were asked to consider their 
‘emotional and behavioural condition’ over the four weeks preceding the interview. 
Each subscale was preceded by a screening question, in which the participant was asked 
to respond if, and how often, the patient experienced any sudden episodes of 
laughing/crying/smiling in the past four weeks. If the participant responded “never”, the 
subsequent subscale was excluded, otherwise the participant responded to the subscale 
questions.  
 
The ELQ was developed as a modification of the Pathological Laughter and Crying 
Scale (Robinson et al., 1993) for the specific assessment of EL in MND populations. A 
validation study, using a sample of ALS patients and matched healthy controls (n=43 in 
each group) showed both patient and informant versions of the questionnaire to have 
good internal validity as good concordance between total scores and the separate 
subscales scores was found for each. Construct validity was corroborated by good 
agreement between patients and their caregivers for total score (r=.37, p=.02), crying 
(r=.44, p=.006) and laughing subscales (r=.34, p=.04). There was a greater number of 
significant correlations within and between ELQ versions for the patients as compared 
to the controls, indicating high sensitivity to EL pathology (Newsom-Davis et al., 
1999).  
 
4.5. Assessment of spouses or partners 
 
4.5.1. Caregiver mood  
 
In keeping with the patient and control participant assessments, the modified HADS 
(Gibbons et al., 2011) was used to determine depression and anxiety in spousal 
caregivers. The modified version was used instead of the original HADS version 
(Zigmond & Snaith, 1983) because the study sought to compare patients’ and 
caregivers’ depression and anxiety scores.  
 
4.5.2. Perceived strain & burden 
 
The Morris Strain Scale (MSS, Morris et al., 1988) was administered to assess the 
perceived strain felt by the spouse or partner in relation to their relative’s illness. 
Numerous issues which potentially may represent a source of strain for the caregiver are 
assessed, such as the amount of control they feel they possess over their reactions to 
their partner’s disease and their expectations regarding their ability to cope with the 
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future.  Caregivers indicated the level of strain they felt on a seven–point bipolar rating 
scale (a minimum score of 1 representing no strain; a maximum score of 7 representing 
severe strain) following each of the six items. A total range of scores for the scale was 6 
– 42, with higher scores reflecting greater perceived strain.  
 
At present no published data regarding the validity or reliability of the scale is available. 
However, the scale has been used in previous research investigating the psychological 
impact of ALS on patients and their caregivers (Goldstein et al., 1998; Goldstein et al., 
2006a) 
 
The Zarit Burden Inventory (ZBI, Zarit et al., 1980; Zarit & Zarit, 1987) was 
administered to caregivers in order to measure the perceived burden associated with 
their partner’s illness and the negative consequences of their caregiving role. The 
inventory comprises 22 items reflecting themes such as health, finances, interpersonal 
relations and social functioning. Spouses or partners were asked to respond to each item 
according to a five–point scale of “Never” (0); “Rarely” (1); “Sometimes” (2); “Quite 
Frequently” (3) and “Nearly Always” (4). A global score was obtained by summing all 
the items; a higher score indicating greater perceived burden.  
 
The ZBI has been validated across different cultural and ethnic populations (Hébert et 
al., 2000; Taub et al., 2004). High internal consistency (α=.91) and test–retest reliability 
(α=.71) are reported (Hébert et al., 2000; Vitaliano et al., 1991). Predictive ability for 
caregiver QOL has also been shown in a sample of dementia caregivers (Schreiner et 
al., 2006). 
 
4.5.3. Perceived marital satisfaction 
 
Marital satisfaction, from the perspective of the caregiver, was measured using the 
Marital Intimacy Scale (MIS; Morris et al., 1988). This measure was based on the 
operational definition of ‘intimacy’ produced from research by Warring and colleagues 
(Waring & Patton, 1984; Waring et al., 1980). The scale consists of 25 statements and 
is designed to measure 8 dimensions of the marital relationship, namely: affection, 
cohesion, expressiveness, compatibility, conflict resolution, sexuality, autonomy and 
identity. Caregivers were asked to indicate their level of agreement with each statement 
along the following scale: 0=‘strongly agree’, 1=‘agree’, 2=‘undecided’, 3=‘disagree’ 
or 4=‘strongly disagree’. Alternate items are reverse scored. Of the 25 items, one item is 
a global measure of marital satisfaction and is not included in the calculation of the total 
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MIS score. The remaining 24 items constitute the marital satisfaction subscale; a higher 
total score indicating greater marital satisfaction (a maximum of 96).   
 
Caregiver participants were required to complete this measure over two time scales: at 
the time of the interview and approximately two years before the onset of their spouse’s 
ALS symptoms. This provided a measure of ‘present’ and ‘past’ intimacy, respectively.  
 
As with the MIS, the validity and reliability of this measure remains unreported. This 
measure was adopted for this study on the basis of its use in previous studies of 
caregiving in ALS (Atkins et al., 2010; Goldstein et al., 1998; Goldstein et al., 2006a). 
 
4.5.4. Perceptions of behaviour in their spouse with ALS 
 
The informant version of the FrSBe was used to assess spousal caregivers’ perceptions 
of frontal–lobe mediated behaviour in the respective patient. Caregiver participants 
were asked to complete the form with respect to their spouse’s behaviour at the time of 
testing and two years preceding their disease diagnosis. Scoring of this version involved 
a similar procedure to the self–rating version, as described above. An estimate of the 
change in perceived executive function following the ALS symptoms was obtained 
from subtracting present scale scores from the past scale scores. Normative data for the 
family–rated version are also provided in the manual. Estimates of perceived behaviour 
change in patients following their ALS symptoms were obtained from subtracting 
caregivers’ present behaviour T–scores from their past behaviour T–scores. In addition, 
patient–caregiver discrepancy scores for patients’ behaviour for each time point 
(premorbid or current) were also calculated by subtracting the patients’ 
premorbid/current T–scores from the caregivers’ premorbid/current T–scores.   
 
Internal consistency for the informant–rating format has shown to be high; with 
adequate  coefficients for ‘Total’ (.92), ‘Apathy’ (.78), ‘Disinhibition’ (.80) and 
Executive Dysfunction’ (.87) in normative samples (Grace & Malloy, 2001).  
 
4.5.5. Perceptions of emotional lability 
 
An informant–version of the ELQ was administered to caregiver participants. This 
measure was identical to the patient and control questionnaire, except that the responses 
were presented from the perspective of a third party. Good internal validity of both 
scale versions has been found, as described in Section 4.4.7.2. (Newsom-Davis et al., 




4.5.6. Caregiver perceptions’ of patients’ current empathy  
 
The IRI was modified so that responses were presented from the perspective of a third 
party. Scoring remained the same as the patient version. This modified IRI version has 
previously been adopted for caregivers of FTD and AD patients (Hsieh et al., 2013). 
Patient–caregiver discrepancy scores for patients’ current levels of empathy were 
calculated for each domain by subtracting the patients’ current ratings from the 
caregivers’ current ratings.   
4.5.7. Caregiver perceptions’ of patient personality 
 
Informant–versions of the NEO–FFI were administered to the spouse or partner of the 
patient. Caregivers were asked to endorse statements about their partner’s personality 
over two time–frames: at the time of testing and approximately two years before the 
onset of their spouse’s symptoms. This provided measures of ‘past’ and ‘present’ 
perceived personality on the part of the caregiver. Estimates of perceived personality 
change in patients following their ALS symptoms were obtained from subtracting 
caregivers’ present personality T–scores from their past personality T–scores. In 
addition, patient–caregiver discrepancy scores for patients’ current personality were 
also calculated by subtracting the patients’ current T–scores from the caregivers’ current     
T–scores.   
 
Data from spouse ratings (n=91) suggest that the informant NEO–FFI scales correlate 
well with the domain scales from the full revised version, as correlations ranging from 
.88 to .94 have been found (Costa & McCrae, 1992). The five domains of the 
retrospective informant version of the NEO–FFI has shown good to excellent inter–rater 
reliability (average ICC 95% CI [.68; .78]), excellent intra–informant reliability 
(average ICC 95% CI [.84; .96]) and good internal consistency (.68<α<.91) in a sample 
of AD caregivers, indicating that it is a reliable measure of premorbid personality 
(Archer et al., 2006).    
4.6. Data Handling and statistics 
 
Collected data were analysed using The IBM Statistical Package for the Social Sciences 
(SPSS) Version 21.0.; the R Statistical Programme Version 3.0.1 and STATA Version 




4.6.1. Data protection and confidentiality 
 
Demographic sheets and consent forms, as well as letters of correspondence to 
participants, were separated from record forms or performance data and locked in a 
separate filling cabinet. Copies of consent forms for patient and spouse participants 
were sent to the respective research sites for inclusion in the site–file or the patients’ 
medical files (as determined by the specific R&D protocols at each site). Hard copies of 
performance data were anonymised and stored in a locked filing cabinet at the Institute 
of Psychiatry. Data were inputted into password–protected databases which were stored 
on security–controlled computer networks.   
4.6.2. Power analysis 
 
Gpower® was used to conduct power analyses.  Sample size was estimated on the basis 
of a between group (ALS, Controls) comparison of scores on the TASIT. To detect a 
medium effect size f=.25 (GPower 3.0.8), for a 2x2 ANOVA [group (ALS, controls)] x 
task; [(e.g. lies, sarcasm)] with 80.76 % power and α=.05, a sample size of 49 
participants per group would be required.  
 
Based on this sample size for ALS patients, the study set out to recruit a similar size for 
caregivers. For a linear regression with three predictor variables, this would have had 
>85% power with α=.05 to detect a medium effect size of f2=.25 (R2=.20, GPower 
3.0.8). 
4.6.3. Statistical protocol and procedures  
 
4.6.3.1. Outliers and normality 
 
Parametric and non–parametric analyses were used to analyse the data. Univariate 
normality was assessed using the D’Agostino–Pearson Omnibus Test (D'Agostino et 
al., 1990), histograms, Q–Q plots, and the examination of skew and kurtosis values. 
Where multivariate normality was required for multivariate analyses (e.g. MANOVA), 
this was assessed using Shapiro–Wilk multivariate normality test (Royston, 1983).  
 
Since parametric data are sensitive to the presence of outliers, all outliers were detected 
using, histograms, box–plots and the robust Median Absolute Deviation (MAD) method 
(Hampel, 1974; Leys et al., 2013). Multivariate outliers were assessed using the 
Mahalanobis D
2  
statistic (Mahalanobis, 1936). Each outlying value was re–coded with a 
score one unit higher than the next highest non–outlying score in the distribution 
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(Tabachnick & Fidell, 2013). After outliers were re–coded, normality was re–assessed. 
When recoded distributions showed skewness values ≥|2|, they were submitted to 
Naperian log transformation. As some distributions contained values that were negative 
or less than one, a constant was added to each score before the transformation. The 
constant was equal to the absolute value of the minimum score within the distribution 





A. Parametric analyses 
 
In addition to the assumptions of normality, other assumptions specific to the 
parametric tests used were assessed. For t–tests and ANOVAs, homogeneity of variance 
(HOV) was assessed for grouped distributions using the Levene’s HOV test (Levene, 
1960). For ANOVA with repeated measures, the sphericity assumption was assessed 
using Mauchley’s test  (Mauchly, 1940) and the covariance–variance matrix was 
consulted to determine the degree of compound symmetry. Where sphericity was not 
upheld, the Greenhouse–Geisser correction (Greenhouse & Geisser, 1959) was applied. 
For MANOVA, the linearity assumption was examined using scatterplots. Box’s M 
(Box, 1954) was used to assess the homogeneity of covariance assumption; an adjusted 
significance level of p<.001 was applied (Tabachnick & Fidell, 2013). A comparison of 
the covariance matrix for the variables across the groups was also conducted. When 
covariates were included in any of the above analyses, the homogeneity of regression 
slopes assumption was assessed using scatterplots and the interaction term method 
(SPSS>Univariate>Model>Custom).    
 
For the Multiple Regression (MR) analyses, multicollinearity was assessed by 
consulting the respective correlation matrix (ideally r<.80); Variable Inflation Factor 
(VIF) scores (ideally VIF<10.0) and the inverse Tolerance scores (ideally 
Tolerance>0.10) (Field, 2009). Cook’s Distance (CD) was used to screen for influential 
cases (ideally CD<1.0) (Cook, 1977). Linearity and homoscedasticity of residuals were 
assessed using scatterplots.  
 
B. Non–parametric analyses 
 
Certain non–parametric tests (e.g. Mann–Whitney U test) assume HOV (Sheskin, 
2003); this was assessed using the non–parametric Levene’s HOV test (Nordstokke & 
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Zumbo, 2010). Where HOV was not upheld, the Moods’ Medians test (Mood, 1954) 
was used. Group differences for nominal and ordinal variables were assessed using the 
Pearson’s Chi–Square test (see Agresti, 2002) or McNemar test (McNemar, 1947). 
Where the expected count was less than 5 (20%) in 2x2 designs, the Fisher–Boschloo 
exact test (Lydersen et al., 2009) was used.  
 
4.6.3.3. Treatment of missing data 
 
Due to the physical disability and fatigue of the ALS participants, a number of patients 
were unable to carry out tasks that involved handwriting and prolonged speech. The 
number of participants with data missing on each test is delineated in Appendix II and 
noted throughout the Results section. For group comparisons, missing data were 
excluded from individual analyses but cases remained in the dataset. For the within–
group multiple regressions, only participants with data for all the relevant variables 
were included in the analyses.  
4.6.3.4. Correcting for multiple testing  
 
Composite scores combining several related variables were calculated for between–
group and multiple regression analyses. This was undertaken with the objective of 
reducing the likelihood of making Type I errors through conducting multiple 
comparisons using individual neuropsychological test or questionnaire scores. Where 
exploratory between–group comparisons for individual tests were conducted, 
Bonferroni corrections (see Abdi, 2007) were applied to account for the number of 
comparisons and inflated risk of Type I errors. For correlational analyses, a p–value of 
p<.01 was adopted to correct for multiple correlations. Where these corrections are not 
applied, this is noted in the text.   
 
4.6.3.5. Effect sizes and confidence intervals  
 
Where possible, tables in the Results section provide effect size estimates and 
confidence intervals (CI). Formulas for effect size estimates are shown in Appendix IV. 
For parametric group comparisons, such as the t–test, Cohens’d and the 95% CI for the 
mean difference are reported. For ANOVA and MANOVA analyses, partial–eta 
squared, ηρ², is used to represent the proportion of variance in the outcome variable that 
is attributable to the predictor variable in question (excluding the variance explained by 




2, Beta coefficients (B), standardised Beta coefficients (β) and the 95% CI 
for B.    
 
For non–parametric analyses and where medians are compared, Pearson’s r correlation 
coefficient is used as a measure of association for the Mann–Whitney U test. For 
Mood’s Median test, Pearson’s Chi–Square Test and Fisher–Boschloo tests, Cramer’s V 
(φc) represents the strength of association between variables. The Hodges–Lehmann 
95% CI (Hodges & Lehmann, 1963) is reported as an estimate of the difference in 
population medians (both independent and paired group analyses). The Newcombe–
Wilson hybrid 95% CI (Newcombe, 1998) is reported for an estimate of differences in 





























5.1. Introduction and hypotheses  
 
Chapter Two outlined studies reporting the presence of mild to moderate cognitive 
change in patients with non–demented ALS. Executive dysfunction is the most 
consistently reported cognitive impairment, although changes in other domains, such as 
attention, memory and language, are reported. More recently, attention has shifted to 
patient performance on tasks assessing the processing of emotional and social 
information. Although some studies suggest impairments in emotion recognition and 
Theory of Mind (ToM) in non–demented patients, findings are neither consistent nor 
conclusive. In addition, the study of social cognition in ALS has so far not included 
empathy. The presence of a relationship between these changes and ALS–related 
executive dysfunction is contentious. It is possible that these impairments reflect a 
primary deficit in executive function or, alternatively, are independent of patients’ 
executive abilities. Furthermore, little is known about the contributions of additional 
factors such as mood, personality traits and behaviour to these reported deficits.    
 
5.1.1. Hypothesis One: Profile of executive impairment and changes in emotional 
processing and social cognition in ALS 
 
The current study tests the hypothesis that patients with ALS will show impairments 
relative to controls in executive functioning and the processing of emotional and social 
information. To test this hypothesis, comparisons between patients and healthy controls 
on measures of executive function and an extended battery of social cognition were 
conducted. The relevant findings are reported in Section 5.2.2.  
Overview  
The current chapter reports a detailed study of neuropsychological change in 
patients with non–demented ALS. A primary focus of this chapter is the 
investigation of the profile and prevalence of executive impairment and changes in 
emotional processing and social cognition in patients. Performance on measures of 
memory and language is also examined. As a secondary focus, this chapter will 
explore profiles of behavioural change, mood, personality and empathy in ALS. 
Finally, the chapter will describe the relative contributions of executive function, 
mood, personality, empathy and behaviour to emotional processing and social 





5.1.2. Hypothesis Two:  Profile of behavioural change in ALS 
 
The current study tests the hypothesis that ALS patients will show higher levels of 
premorbid and current behavioural dysfunction on domains of apathy, dysexecutive 
behaviour and disinhibition. A comparison of behaviour between patients and healthy 
controls is reported in Section 5.2.3   
 
5.1.3. Exploratory Research Question One: Mood, personality, empathy in ALS 
 
The current study explores whether differences in ALS patients and healthy controls on 
measures of mood, personality and empathy exist.  The relevant findings are reported in 
Sections 5.2.4 – 5.2.7.  
 
5.1.4. Hypothesis Three: The contributions of executive function, behaviour, mood, 
personality and empathy to emotional processing and social cognition in ALS 
 
The current study tests the hypothesis that executive (dys)function will be the main 
predictor of performance on tests of emotional processing and social cognition, with 
smaller contributions from behaviour, mood, personality and empathy (above and 
beyond patients’ demographic variables and disease symptoms). Findings from this 
investigation are reported in Section 5.2.9.  
 
5.2. Results 
5.2.1. Participant characteristics 
 
A. Sample Size 
Testing took place between April 2011 and June 2013. In total, 57 ALS patients and 50 
control participants were recruited to the study. Of these, two ALS participants were 
excluded due to suspicion of co–morbid FTD which only became apparent during the 
initial assessment. A further ALS patient was excluded due to diagnostic uncertainty 
which only became apparent after the testing sessions. One control participant was 
excluded on the basis of a recent diagnosis of depression and neurological illness which 
was withheld from the researcher at screening and disclosed only after testing.  
Therefore data is reported on 55 ALS patients and 49 control participants. These final 
group numbers exceed, in the case of patients, and meet, in the case of controls, the 
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numbers required per group, as determined by the a priori power analysis (see Chapter 
4, Section 4.6.2.).  
 
B. Clinical variables 
Table 5.1. summarises the disease profile of the ALS patients. Patients had an average 
disease duration (months since symptom onset) of less than three years. The average 
diagnostic delay (months between symptom onset and diagnosis date) was 
approximately 16 months. The average age at time of symptom onset was 
approximately 58 years. Disease progression rate was estimated using the decline in the 
patient’s ALSFRS–R total score since symptom onset (48 minus ALSFRS–R score 
divided by time from symptom onset to date of assessment). Approximately 76% of 
patients had limb–onset, which is similar to population estimates (Haverkamp et al., 
1995). The majority of patients were receiving Riluzole, while 15 patients were 
receiving medication with psychoactive properties. These included antidepressants, 
benzodiazepines and analgesics for the management of disease symptoms, such as 
sialorrhea, emotional liability, spasticity and pain (i.e. not for mood disturbance). Please 
refer to Appendix V.a. for details of participant medication (patients and controls) and 
Appendix V.b. for details specific to participants using psychoactive medication. A 
comparison of medicated and non–medicated patient subgroups is conducted in Section 
5.2.8. 
 
C. Epworth Sleepiness Scale scores 
Both patients and controls completed the above questionnaire as a screening measure 
before testing (see Chapter 4, Section 4.4.1.2.). A cut–off score of ≤10 was used to 
indicate respiratory sufficiency and thereby ensure eligibility. Some control participants 
(n=15) did not complete this measure as it was introduced into the neuropsychological 
battery after initial testing had commenced. There were no differences between patient 
(M=3.5, SD=3) and control (M=4.2, SD=3) scores on this measure as revealed by a 








Table 5.1.: Clinical profile of disease for ALS patients 
∞ ALSFRS–R: bulbar=items 1–3; Limb=items 4–9; respiratory=items 10–12. † Disease progression rate 








 Mean   (SD) 
Months since symptom onset 
Months since diagnosis 
Age at symptom onset (years) 
 
ALFSFRS–R total score (max 48)∞ 
ALSFRS–R bulbar severity score
 
ALSFRS–R Limb severity score 
ALSFRS–R Respiratory severity score 
 
Median Disease progression rate† 
31.8      (18.5) 
16.3      (16.4) 
57.8      (8.8) 
 
34.1      (7.8) 
9.0        (3.0) 
14.2      (6.5) 
10.8      (1.8) 
 
0.48      (0.0/0.3)* 
 
 N         (%) 
Region of onset                                           Limb 
                                                                    Bulbar 
 
Currently receiving Riluzole  
 
Currently receiving psychoactive medication 
 
42       (76.4) 
13       (23.6) 
 
43       (78.2)  
 




D. Demographic variables 
Table 5.2. summarises participants’ demographic characteristics.  The two groups were 
matched with regard to age and years of education; two–tailed t–tests revealed no 
significant differences between groups on these variables. Similarly, non–parametric 
Mann–Whitney U tests revealed no between group differences on the revised HADS 
Depression and HADS Anxiety scores (Gibbons et al., 2011). A two–tailed Pearson’s 
Chi–squared analysis revealed that the ratio of males to females was not significantly 
different across groups. In addition, the number of participants who had had previous 
contact with a GP or psychiatrist was not significantly different across groups. There 
was a significant association between group and marital status. Inspection of the 
standardised residuals revealed that single status contributed to this significance; more 
controls than patients were single. The ratio of single and non–single participants 
between groups was not considered to be clinically relevant. All participants were white 
Caucasian, except for two participants (one control and one patient) who were of 
African descent, as determined by the researcher.  
 
E. Estimated premorbid IQ and current IQ 
Between group comparisons of IQ measures are shown in Table 5.3.  Four ALS patients 
did not receive premorbid IQ estimates as they were unable to complete the WTAR due 
to dysarthria. Full–scale IQ estimates were not calculated for seven ALS patients as 
they did not complete both subtests of the WASI. Six patients were unable to complete 
the Vocabulary subtest due to dysarthria and/or fatigue. One patient participant did not 
complete the Matrix Reasoning subtest due to lack of time. Non–parametric Mann–
Whitney U tests showed no between–group differences for the obtained estimates of 
premorbid and current IQ.  The median premorbid and current IQ estimates were within 
the High Average range for both patients and controls.  
 
F. Treatment of demographic covariates 
No group differences on demographic or IQ variables were found between groups. 
However, correlations between these variables and the neuropsychological test scores 
were assessed for the overall data and within groups (adjusted p<.01 for multiple 
correlations). Identified covariates were entered into the analyses either alone or in 
combination to examine the effect on the outcome of significance testing. Instances 
whereby this procedure changed the outcome of the results are noted in the text; 
otherwise results are presented without the inclusion of the covariate(s).  
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Table 5.2.: Demographic characteristics of participants 
 Mean (SD) t(df)  p 
 ALS (n=55)   HC (n=49)   
Age (yrs.)            60.3 (8.5) 
14.5 (3.5) 
   60 (9.7) 
   14.5 (2.7) 
-0.14 (102.00) .89 
Education (yrs.) -0.00 (100.13) .10 
 Median (MAD/IQR) U(z) p 
 ALS (n=55)         HC (n=49)   
HADS Depression† 2 (1/3)                       1 (1/4)     
4 (2/4)                       3 (2/4) 
1109.5 (-1.58) .12 
HADS Anxiety† 1307.0 (-0.27) .79 
 N (%) χ2 (df) p 
 ALS  (n=55)   HC (n=49)   
Gender*
 
  Men  
                  Women 
40 (72.7%) 
15 (27.4%)                   
  34 (69.4%) 
  15 (30.6%) 
 












  13 (26.5%) 
  30 (61.2%) 
  4 (8.2%) 
  2 (4.1%) 
 
17.55 (3)  <.001 
Mental Health** 11 (20%)                        8 (16.3%) 0.53 (1) .82 
p–values from two–tailed t–tests except † Mann–Whitney U test; * Pearson’s Chi–square test. Significant 
results are shown in bold–p<.05. **Mental health=previous contact with a GP or psychiatrist regarding 








Table 5.3.: Premorbid and current IQ measures 
IQ Measures Median (MAD/IQR) U(z) p r   




112 (4/9) 114 (4/11) 1111.5  (-0.95) .34 -.10  
 ALS (n=48) HC (n=49)    
WASI Full Scale 
IQ 
 
117 (7.5/14)           119 (6/13) 1004.00 (-1.24) .21 -.13 
p–values from Mann–Whitney U  tests. r, Pearson’s correlation coefficient. †WTAR and demographic 




5.2.2. Executive function and emotional processing and social cognition 
5.2.2.1. Group comparisons on composite scores 
 
To compare executive and socio–emotional functioning between ALS patients and 
healthy controls, composite scores for each domain were created. This was carried out 
with the objective of reducing the likelihood of making Type 1 errors through multiple 
comparisons of test scores. Composite scores were created as follows: test scores were 
standardised by subtracting the mean score of the control group from each participant’s 
score on an individual test and then dividing the difference by the corresponding 
standard deviation of the control group. The resulting standardised scores were then 
summed according to theorized function and divided by the number of component tests 
constituting the composite. All scores shared the same direction; a higher score 
represented poorer performance. If scores did not share this direction, they were 
reflected (maximum possible score – obtained score). When participants did not 
complete all measures in the composite, the measures that were completed were 
standardised and averaged as above. Missing data for each task are shown in Appendix 
II. Since language and memory assessment included only one test, composite scores 
were not computed for these domains. Performance on these measures is explored in 
Section 5.2.2.4.  
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The measures included in the composite scores
1
 were:  
 
 Executive function score: D–KEFS free sorting; D–KEFS free sorting 
description; Phonemic VFI–S words; Phonemic VFI–C words;  Brixton errors  
(5 measures) 
 
 Emotion Processing and Social Cognition (EMOSOC) score: TASIT EET 
errors; TASIT SIM errors; TASIT SIE errors; Happé Cartoon Inference (C–
Inference); Happé Cartoon Pairs Forced choice (C–Pairs); Happé Written 
Scenarios (Scenarios);  RME errors  (7 measures) 
 
Verbal fluency involves both language and executive components (see Chapter 2, 
Section 2.2.1.1.). However, both phonemic fluency indices showed stronger total–item 
correlations when included within the Executive function composite than within a 
language score (i.e. with the GNT score) (see Table 5.4.). Both measures therefore 











Table 5.4.: Total–item correlations with Executive function and Language scores 
 
           r values     Executive  function                       Language 
VFI–S words 
 
.58                      .45 
VFI–C words .68                      .31 
 




 D–KKEFS, Delis–Kaplan Executive Function System; VFI, Verbal Fluency Index; TASIT, 
The Awareness of Social Inference Test, EEA ,Emotion Evaluation Test, SIM, Social Inference 




A. Internal consistency of composite scores 
 
Table 5.5. summarises the results of the analysis of the internal consistency of 
composite scores. Both composite scores demonstrated satisfactory internal consistency 
with Cronbach’s alpha coefficients of greater than .7 (DeVellis, 2003; Nunnally, 1978). 
The inter–item correlations for each composite were above the recommended threshold 
of .20 (Briggs & Cheek, 1986), except for Brixton errors which showed only a small 
correlation with verbal fluency–S words (r=.14) within the Executive function 
composite. However, the corrected inter–item correlation of the Brixton error 
component reached the acceptable benchmark level (r=.30) (DeVellis, 2003). 
Furthermore, removal of this component from the composite did not substantially 
improve Cronbach’s alpha (from .78 to .80). Therefore, the component remained in the 
composite. Initially, the Hayling latency and error scores were considered as 
components for the Executive function composite; however, these items correlated 
poorly with the total score of the respective composite (r<.30), despite contributing to a 
near sufficient level of internal consistency (α=.69). These components were 
subsequently dropped from the model, leaving five items making up the final 
composite. Performance on the Hayling Test is examined separately in Section 5.2.2.4. 
 













Emotional Processing and Social 
Cognition  (EMOSOC) 











B. Group differences on composite scores 
 
A one–way MANOVA revealed a statistically significant difference between patients 
and controls on the combined dependent variables (composite scores) [F(2,101)=4.68, 
p=.01, Wilks’ Lambda=0.92, ηρ²=.09]. Univariate contrasts revealed that the patient 
mean scores were significantly higher (more impaired) for the executive function 
composite [F(1,102)=8.6, p=.004, ηρ²=.08] and the EMOSOC composite 
[F(1,102)=5.53, p=.02, ηρ²=.05]. As advised by Harris (1975), a Bonferroni correction 
was applied; results remained significant (adjusted p=.025). 
 
A one–way MANOVA was also conducted on the untransformed data and detected 
significant differences [F(1,102)=4.036, p=.02, Wilks’ Lamba=0.93, ηρ²=.07]. 
However, between–group differences on the EMOSOC composite did not remain 
significant, following a Bonferroni correction. These results are compared in Table 5.6, 
which presents original means and standard deviations (SD) alongside back transformed 
means with corresponding confidence intervals (CI).    
 
For exploratory purposes and to help interpret the statistically significant MANOVA 
effect, the standardised discriminant function coefficients were consulted. These 
coefficients were derived from the untransformed data for ease of interpretation, and are 
therefore interpreted cautiously. One canonical variate was extracted from the 
MANOVA. As can be seen in Table 5.7 the standardised discriminant function 
coefficients suggest that group membership was maximally differentiated by the 
Executive function composite, which showed a greater weighting than the EMOSOC 
composite. However, the correlation between the EMOSOC composite and the 
canonical variate was of appreciable magnitude (r=.77). The Executive function 











Table 5.6.: Composite scores untransformed and transformed data 
Composite ALS (n=55)         HC (n=49) 
 
F(df) p ηρ² 






0.5 (1)                   0.0 (0.7) 
 
















0.80 (0.74; 0.88)    0.67 (0.61; 0.73)   
 










 p–values are from ANOVAs. Uncorrected significant results shown in bold–p<.05. Results significant 
following Bonferroni correction are shown in bold*–p<.025. † Untransformed original data. ††Back 
transformed data. EMOSOC, Emotional Processing and Social cognition; ηρ², partial–eta squared. Note: 
higher scores indicate worse performance 
 
 
Table 5.7.: Discriminant function coefficients associated with MANOVA† 
Dependent variable 
 





















N=104;†untransformed composites as dependent variables. B=unstandardized coefficients; Standardised 
β=standardised coefficients; Structure β=structure coefficients/ Pearson’s r correlations between 







5.2.2.2. Group differences on component scores 
Following the identification of group differences on the composite scores, performance 
on individual tests constituting these composites was explored in more detail. Once 
outliers were identified they were re–coded according to the procedure specified in 
Chapter 4, Section 4.6.3.1. Not all distributions met this assumption according to the 
statistical normality test; transformations did not improve distributional characteristics. 
However, these distributions did not show strong skew or kurtosis values (Skew<|2|, 
Kurtosis<|4|) and inspection with histograms confirmed this.  Furthermore, the means, 
5% trimmed means and medians within each group were similar, suggesting 
approximate symmetry. Under these conditions, distributions were deemed reasonably 
normal and parametric tests were used.  
 
A. Executive function measures 
 
Results are shown in Table 5.8. Two–tailed t–tests revealed significant group 
differences on the D–KEFS sorting; D–KEFS description and Phonemic VFI–C words 
tests. A trend was found for the Phonemic VFI–S word task. When a Bonferroni 
correction (adjusted p<.01) was applied, only group differences on the D–KEFS sorting 
and description tasks remained.  
 
Sensitivity analyses using non–parametric tests on the data distributions with outliers 
revealed between group differences for D–KEFS sorting and D–KEFS description tests. 
Results remained significant following a Bonferroni adjustment (adjusted p<.017) for 
these measures. No between groups difference was found for the Phonemic VFI–C test. 
Results are shown in Table 5.9.  
 
Eleven ALS patients completed the VFI measures orally to accommodate motor 
disability. Index scores were compared between these patients and those who completed 
the written version of the task using Mann–Whitney U tests on non–recoded raw data. 
No significant differences between patients in the oral version group (Mdn=4.6) and 
written version group (Mdn=4.2) were found for the VFI–S words task, U=199.5,       
z=-0.89, p=.37, r=-.12. Furthermore, no significant differences between patients in the 
oral version group (Mdn=9.5) and the written version group (Mdn=11.3) were found for 
the VFI–C words task, U=205, z=-0.78, p=.44, r=-.12. These results justify the 




Table 5.8.: Measures of executive function 
Test  Mean (SD) t(df) 
 
p d 95% CI 
 ALS  
 
HC      






























-4.3; 0.4  
p–values from t–tests. Uncorrected significant results shown in bold–p<.05. Results significant following 
Bonferroni correction are shown as bold*–p<.01. desc., description; d, Cohen’s d; 95% CI, confidence 




Table 5.9.: Non–parametric sensitivity analysis 
Measure Median (MAD/IQR) U(z) p r 95% 
CI 

























p–values from Mann–Whitney U tests. Results significant following Bonferroni correction are shown as 
bold*–p<.017. desc., description. r, Pearson’s correlation coefficient; 95% CI,  Hodges–Lehmann 







B. Emotional processing and social cognition measures  
 
Results are shown in Table 5.10. Two–tailed t–tests revealed significant group 
differences on the Happé Cartoon Inference test (C–Inference), Happé Cartoon Pairs 
test (C–Pairs) and the Happé Written Scenarios test (Scenarios). These differences 
remained significant following a Bonferroni correction (adjusted p<.007). No group 
differences were found for any of the TASIT subtest scores or the RME errors score.  
 
Sensitivity analyses using non–parametric tests on the non–normal data distributions 
with outliers revealed between group differences for C–Inference, C–Pairs test and 
Scenarios Test. Results remained significant following a Bonferroni adjustment 
(adjusted p<.017) for all tests except the Happé Cartoon Pairs test.  Results of these 
analyses are displayed in Table 5.11. 
 
 
Table 5.10.: Measures of emotional processing and social cognition 
Test  Mean (SD) t(df) 
 
   p d 95% 
CI 
 ALS  HC      
RME  
TASIT EET  
TASIT SIM  











-.64 (101)   .52 0.13 -2.3; 1.2 
5.9 (2.5) 
10.6 (6.7) 
12.7 (6.6)  
12 (5.2)  
11.6 (4.6)  







  .23 
  .15 
  .98 
<.001* 
  .002* 













p–values from t–tests. Results significant following Bonferroni correction are shown as bold*–p<.007. d, 







Table 5.11.: Non–parametric sensitivity analysis 
Measure Median (MAD/IQR) U(z)/ X
2
 (df) p r / φc  95% 
CI 














  .018 









p–values from Mann–Whitney U tests except † Medians test. Uncorrected significant results shown in 
bold–p<.05. Results significant following Bonferroni correction are shown as bold*–p<.017. r, 
Pearson’s correlation coefficient; φc, Cramer’s V;  95% CI,  Hodges–Lehmann  confidence interval for 
difference between medians, ∞ CI interpreted with caution due to asymmetrically skewed distributions. 




5.2.2.3. Single–case analysis: deficits and dissociations 
 
As suggested by previous research, group level analysis may mask the heterogeneity of 
cognitive performance that exists within ALS samples (Bak & Hodges, 2004; Gibbons 
et al., 2007; Girardi et al., 2011; Rippon et al., 2006). For this reason, single–case 
methodology was applied to explore individual performance on the composite scores 
and their individual components. The Bayesian Tests for Deficits and Dissociations 
were used (Crawford et al., 2011). These methods are extensions of classical tests 
(Crawford & Garthwaite, 2002) which have already been adopted in ALS research (e.g. 
Gibbons et al, 2007; Meier et al, 2010), but which allow for the control of covariates. In 
common with the original methods, they test the null hypothesis that the case’s score is 
an observation from the scores in the control population, but the control population is 
redefined as controls having the same value(s) on the covariate(s) as the case (Crawford 





a) The case’s score is significantly lower/higher2 than controls (controlling for  
    covariates) 
 
ii) Dissociation: 
a) The case’s score on Task X is significantly lower/higher2 than controls 
(controlling for covariates) and 
 
b) The case’s score on Task Y is not significantly lower/higher2 than controls 
(controlling for covariates) and 
 
c) The standardised difference between the case’s scores for Tasks X and Y are 
significantly different from the standardised difference for the same tasks in 
the control group (controlling for covariates)  
 
Deficits and dissociations were inferred by consulting the effect size for the difference 
between case and controls (including the 95% Credible Interval, CIb) and the point 
estimate of the abnormality of the case’s score(s) (again, including the 95% CIb of the 
same quantity). The point estimate of the abnormality of a case’s score is the estimated 
proportion of controls, with the same values on the covariates, that will obtain a score 
lower than the case. In situations where error and reflected scores were entered, the 
point estimate of abnormality of the case’s score reflected the percentage of the control 
population, with the same values on the covariates, expected to obtain a higher score 
than the case. Participants were defined as meeting criteria for impairment on composite 
or component scores if the point estimate of abnormality was at or above 95% of the 
controls and the CIb indicated confidence in this estimate (i.e. if 90% <CIb< 100%).
2
 
Criteria for dissociation included a point estimate of abnormality at or below 5% of the 
controls and if the CIb indicated confidence in this estimate (i.e. if 0% <CIb <10% ). The 
proportions of participants meeting criteria for impairment or dissociation were 
compared between the groups using two–tailed Pearson’s Chi–square test or two–tailed 
Fisher–Boschloo’s exact tests (Lydersen et al., 2009), where appropriate.    
 
A. Selection of covariates 
 
Three covariates were included in the analyses: age, gender and education (number of 
years in formal education). The selection of these covariates was primarily theory 




 For error or reflected scores, case’s score is significantly higher than controls 
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driven. Age has shown robust relationships with executive function (MacPherson et al., 
2002; Salthouse & Miles, 2002; Vaughan & Giovanello, 2010; Verhaeghen & Cerella, 
2002; Wecker et al., 2000; West et al., 2010; Zelazo et al., 2004) and social cognitive 
abilities (Calder et al., 2003; Isaacowitz et al., 2007; Keightley et al., 2006; Maylor et 
al., 2002; Orgeta & Phillips, 2007; Seddon & Waller, 2000; Sullivan & Ruffman, 
2004). Gender differences on performance of measures of emotional processing and 
social cognition are well documented (Bradley et al., 2001; Hall, 1978; Hall & 
Matsumoto, 2004; Hoffmann et al., 2010; Schulte-Rüther et al., 2008); and have been 
shown for some measures of executive function (Halpern et al., 2011; Lezak, 2004; 
Mathuranath et al., 2003; van Hooren et al., 2007). The effects of education, premorbid 
and current IQ on executive function and social cognition are also indicated (Lezak, 
2004; Nisbett et al., 2012; Riggio et al., 1991; Shanley et al., 1971). In the current 
study, these three variables correlated moderately with the composites scores and 
several of the components; however they also correlated moderately to strongly with 
each other (.4< rho<.7).  Since not all patient participants were able to complete both IQ 
measures due to physical disability, years of formal education acted as a proxy for 
intellectual functioning for all participants.  
 
B.  Composites 
Results for the relative proportion of impairment in each group for the composites are 
shown in Table 5.12. Proportionately more patient participants showed impairments on 
the Executive and EMOSOC composites. However, two–tailed Fisher–Boschloo exact 
tests revealed that the differences in these proportions were not significant for either 
composite. The number of patients and controls who showed isolated impairment on 
either the Executive or EMOSOC composite, as well concurrent impairment on both 
composites is shown in Table 5.13. Dissociations between performance on the separate 
composites (including the direction of the dissociation) were examined for cases in 
which isolated impairments on either composite was found (also in Table 5.13).  
 
C. Individual component scores 
Results for the relative proportion of impairment in each group on the components of 
the Executive function composite are shown in Table 5.14. Two–tailed Pearson’s Chi–
squared analyses revealed significant between–group differences regarding proportion 
of participants impaired on the VFI–S words and VFI–C words tasks. Inspection of the 
percentages revealed that ALS patients were more likely to be impaired on these 
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measures than healthy control participants. When a Bonferroni correction was applied 
(adjusted p<.01), only the between–group difference on the VFI–S words remained 
significant. Results for the relative proportion of impairment in each group on the 
components of the EMOSOC composite are shown in Table 5.15. A two–tailed 
Pearson’ Chi–squared test revealed a significant between–group difference regarding 
the proportion of participants impaired on the C–Inference task only. Inspection of the 
percentages revealed that ALS patients were more likely to be impaired on this task 
than healthy control participants. When a Bonferroni correction was applied (adjusted 
p<.007), this difference remained significant.  
 
Table 5.12.: Single–case analysis – composite scores 
Composite N (%) P φc 95 % CI 













p–values from two–tailed Fisher–Boschloo test. φc, Cramer’s V; 95% CI, Newcombe–Wilson hybrid 
confidence interval for difference between proportions.  
 
Table 5.13.: Profile of impaired performance across composites 
                         N impaired                        
 ALS (n=55) HC (n=49) 
Executive  & EMOSOC  
Executive only 
EMOSOC only 







Impaired on Executive; not impaired on 
EMOSOC 
 













Table 5.14.: Single–case analysis: Executive function composite components 
Composite N (%) χ2 (df) P φc 95 % CI 
 ALS  HC      



































p–values from two–tailed  Pearson’s Chi–square test except † two–tailed Fisher–Boschloo exact test. 
Uncorrected significant results shown in bold–p<.05. Results significant following Bonferroni correction 
are shown as bold*– p<.01. φc, Cramer’s V. 95% CI, Newcombe–Wilson hybrid confidence interval for 
difference between proportions. desc., description.  
 
 
 Table 5.15.: Single–case analysis: EMOSOC composite components 
Composite N (%) χ2 (df) p φc 95 % CI 





























  .10 
>.99 
  .56 
  .32 
<.001* 
  .15 















p–values from two–tailed Fisher–Boschloo exact test except † Pearson’s χ2 test. Results significant 
following Bonferroni correction are shown as bold*– p<.007. φc, Cramer’s V. 95% CI, Newcombe–
Wilson hybrid confidence interval for difference between proportions.  
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D. Number of components impaired 
 
Figures 5.1. and 5.2. show the proportion of participants from each group that 
demonstrated impairments on the Executive function and EMOSOC components, 
respectively.  
 
For the Executive function components: 30 (54.5%) patients were unimpaired on all 
components compared to 42 (85.7%) controls; 16 (29%) patients were impaired on one 
component compared to 2 (4.1%) controls; 4 (7.3%) were impaired on two components 
compared to 3 (6.1%) controls; 3 (5.5%) patients were impaired on three components 
compared to 2 (4.1%) controls; 2 (3.6%) patients were impaired on four components 
compared to no controls. No patients or controls were impaired on all five components. 
This means that, 45.4% of ALS patients and 14.3% of controls were impaired on at least 
one executive component.  
 
For the EMOSOC components: 32 (58.2%) patients were unimpaired on all components 
compared to 43 (87.8%) controls; 15 (27.3%) patients were impaired on one component 
compared to 2 (4.1%) controls; 4 (7.3%) patients were impaired on two components 
compared to 3 (6.1%) controls; 1 (1.8%) patient and 1 (2.1%) control were impaired on 
three components; 2 (3.6%) patients were impaired on four components compared to no 
controls. No patients or controls were impaired on five or six components only; 
however, 1 (1.8%) patient was impaired on all seven components compared to no 
controls. This means that 41.8% of patients and 12.3% of controls were impaired on at 













Figure 5.1.: Participants demonstrating impaired performance on the Executive   
function composite components by number of impaired components  
  
 
HC, healthy controls (n=49), ALS, patients (n=55).  
 
 
Figure 5.2.: Participants demonstrating impaired performance on the EMOSOC     
components by number of impaired components 
 
 
  HC, healthy controls (n=49), ALS, patients (n=55); EMOSOC, emotional processing and social  
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5.2.2.4. Performance on individual tests of neuropsychological function 
5.2.2.4.1. Language 
 
The Graded Naming Test (GNT) was used to ascertain naming ability. At the group 
level, a Medians test found no between–group differences for patients and controls. 
When the single–case methods were applied, ALS participants showed proportionally 
more impairments than the control participants. However, this difference did not reach 
statistical significance as revealed by a Fisher–Boschloo Exact test. Table 5.16. displays 
results for group and individual level analyses.   
 






 (df) p φc 95% CI 





    
GNT (max 30) 23 (2/3) 24 (2/4) 0.6 (1) .44 .08 -1.0;  2.0 






    
GNT  4 (7.3) 1 (2) — .32 .12 -0.1;  0.2 
p–values from Medians test (Group level analysis) and Fisher–Boschloo test (Single–case analysis). φc, 
Cramer’s V;  95% CI,  Hodges–Lehmann  confidence interval for difference between medians except     
* 95% CI, Newcombe–Wilson hybrid confidence interval for difference between proportions. Note: 





The short form of the California Verbal Learning Test (CVLT) was used to examine 
immediate and delayed verbal recall. Results for this task are presented in Table 5.17.  
T–scores and standardized scores, normed for age and gender, from the CVLT manual, 
were used. At the group level, two–tailed t–tests and median tests revealed no 
significant between–group differences on any of the CVLT measures. Single–case 
analyses were also performed for the memory measures. Raw scores were used for both 
participant groups. Age, gender and education were entered as covariates, as before. 
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The proportion of impairments per group was not found to be statistically significant 









Mean (SD)  t(df) p d 95% CI 
Standardized 
scores  






    
Immediate free  
recall ** 
 
Short delay free 
recall 
 
Long delay free 
recall† 
 

















































 φc 95% CI* 
Standardized 
scores 



















 0.0 (0/1)  
 0.0 (0.5/2) 


















 0.0; 0.0 






p–values from two–tailed t–tests except p† Median tests. ** T–score (min 5; max 95); † Naperian log 
transformed data (original means and SDs). d, Cohen’s d; φc, Cramer’s V; 95% CI, confidence interval 
for difference between means except * 95% CI,  Hodges–Lehmann confidence interval for difference 
between medians, ∞ ,CI interpreted with caution due to asymmetrically skewed distributions. Note: 






Table 5.18.: Percentage of impaired performance on CVLT 
 N (%)    
Single–case analysis  ALS             HC 
(n=51)         (n=49) 
p φc 95% CI 
Immediate free recall  
Short delay free recall 
Long delay free recall 
Long delay cued recall 
Total intrusions 
Total repetitions 


















  .65 
>.99 
>.99 
  .69 
  .31 
>.99 
>.99 

















p–values from two–tailed Fisher–Boschloo test. φc,  Cramer’s V;  95% CI, Newcombe–Wilson hybrid 
confidence interval for difference between proportions. HC, healthy controls. 
 
 
5.2.2.4.3. Executive function: Hayling Sentence Completion Test 
 
The following section compares participant groups on error scores from the Hayling 
Sentence Completion Test. Differences on the D–KEFS, the Phonemic VFI tasks and 
the Brixton test were previously compared in Sections 5.2.2.2 and 5.2.2.3.   
 
Three measures of performance were obtained from the Hayling Test: a latency score; 
the number of Category A errors committed and the number of Category B errors 
committed. The latency score was calculated by subtracting the time taken for the 
Response Initiation trial (‘Sensible Sentence’) from the Response Suppression trial 
(‘Unconnected Sentence’). Since these three variables did not correlate positively 
and/or strongly with other items entered under the Executive function composite                      
(see Section 5.2.2.1), they were not adopted as component measures within that score. 
Group–level and single–case analyses were conducted for these measures.                   
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For the group–level analyses, correlations between demographic variables and the three 
measures were assessed. No significant correlations were present between performance 
and demographic variables for either the overall or grouped data; only analyses without 
covariates are reported. For the single–case analyses, variables age, education and 
gender were entered as covariates. Results for group and single–case analyses are 
shown in Table 5.19.  
 
For the group–level analyses, two–tailed t–tests on Naperian log transformed data 
revealed significant between–group differences for the Category A and Category B 
errors only, with controls outperforming patients on both trials. When a Bonferroni 
correction was applied (adjusted p<.017), group differences remained for the error 
conditions. No significant group differences were found for the Hayling Latency score. 
 
Sensitivity analyses on the error scores using Mann–Whitney U tests with 
untransformed non–recoded data (non–normally distributed) revealed between group 
differences for both conditions. For the Category A condition, controls (Mdn=1.0) 
committed significantly fewer errors than patients (Mdn=3.0), U=826.00, z=-3.34, 
p=.001, r=-.33. For the Category B condition, controls (Mdn=1.0) committed 
significantly fewer errors than patients (Mdn=3.5), U=932.50, z=-2.61, p=.009, r=-.26.  
 
For the single–case analyses, proportionally more patients met criteria for impairment 
than controls on all conditions of the task. These differences were significant as 
revealed by two–tailed Pearson’s Chi–squared test. However, when a Bonferroni 













Table 5.19.: Hayling Test: group–level and single–case analysis 
Group–level  
analysis 
Mean (SD) t(df) p d 95% CI 





    
Hayling Latency 
 
Category A ∞ 
(max 15) 
 
Category B ∞  
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2





    
Hayling Latency  
Category A  



















p–values from two–tailed t–tests except p† two–tailed Pearson’s Chi–square test.Uncorrected significant 
results shown in bold–p<.05. Results significant following Bonferroni correction are shown as bold*–
p<.017; ∞ Naperian log transformed data. d, Cohen’s d; φc, Cramer’s V; 95% CI, confidence interval for 
difference between means except  95% CI*, Newcombe–Wilson hybrid confidence interval for difference 




5.2.2.4.4. Emotional processing and social cognition  
 
A. TASIT task 
i) The Emotion Evaluation Test (EET) 
Recognition scores for positive (happy, surprised) and negative (sad, angry, anxious, 
disgust) emotions were combined to form two superordinate variables: positive and 
negative. The scores of these new variables were normalised to a maximum score of 1 




Normalised (ei) =     ei — Emin         where                   ei = score for case in the i
th
 row 
                                       Emin = the minimum value for variable E 
                                   Emax — Emin                     Emax = the maximum value for variable E 
 
Neutral items were not included in this analysis. A split–plot ANOVA, with Group as 
the between–subjects factor and Valence–type as the within–subjects factor was 
conducted. There was no interaction effect for the factors [F(1,102)=0.32, p=.58, 
ηρ²=<.001], no main effect of Group [F(1,102)=0.31, p=.58, ηρ²=<.001] and no main 
effect of Valence–type [F(1,102)=0.03, p=.88, ηρ²=<.001]. 
 
Performance on separate emotions (including neutral) was compared between groups. A 
split–plot ANOVA, with Group as the between–subjects factor and Emotion–type as the 
within–subjects factor, was conducted. The was no interaction effect for the factors 
[F(5.34,544.4)=0.92, p=.47, ηρ²=.01]. There was no main effect for Group 
[F(1,102)=2.08, p=.15, ηρ²=.02]. There was a significant main effect for Emotion–type 
[F(5.34,544.4)=41.1, p<.001, ηρ²=.30]. Figure 5.3. displays group means for each 
emotion category. 
 
Figure 5.3.:  TASIT EET performance 
ALS, patients (n=55); HC, healthy controls (n=49). Errors bars represent 95% CI for mean; max score   






























ii.) The Awareness of Social Inference – Minimal (TASIT SIM)  
Participant performance on items of sincere, simple sarcasm and paradoxical sarcasm 
was explored. A split–plot ANOVA, with Group as between–subjects factor and 
Statement–type (sincere; simple sarcasm; paradoxical sarcasm) as the within–subjects 
factor, was conducted. There was no evidence for an interaction between Group and 
Statement–type [F(1.43,146)=1.76,  p=.18, ηρ²=.02]. Although there was a main effect 
for Statement–type [F(1.43,146)=7.45, p=.003, ηρ²=.07], no main effect for Group was 
present [F(1,102)=2.1, p=.15, ηρ²=.02].  Figure 5.4. displays group means across the 





Figure 5.4.: TASIT SIM Statement–type performance      
 
ALS, patient (n=55); HC, healthy controls (n=49). Error bars represent 95% CI for mean; max score for 
































Participants’ interpretations of the four elements of the social exchanges were also 
assessed between groups. A split–plot ANOVA, with Group as the between–subjects 
factor and Element (Do, Say, Think, Feel) as the within–subjects factor, was also 
conducted. There was no interaction effect [F(2.73,278.3)=0.66, p=.57, ηρ²=.01].  
Although there was a main effect for Element [F(2.73,278.3)=4.52, p=.005, ηρ²=.04], 
there was no main effect of group [F(2.73,278.3)=1.74, p=.19, ηρ²=.02]. Figure 5.5. 






Figure 5.5.: TASIT SIM Element condition performance                             
ALS, patients (n = 55); HC, healthy controls (n = 49); Error bars represent 95% CI for mean; max score 
































iii.) The Awareness of Social Inference – Enriched (TASIT SIE) 
Performance on the lie and sarcastic items from the enriched subtask of the TASIT was 
compared between groups. A split–plot ANOVA, with Group as between–subject factor 
and Statement–type (Lie; Sarcasm) was conducted. There was no interaction effect 
[F(1,102)=0.68, p=.41, ηρ²=.01]. There was a main effect of statement–type 
[F(1,102)=88.32, p<.001, ηρ²=.46] but not for group [F(1,102)=0.009, p=.92, 





Figure 5.6.: TASIT SIE Statement–type performance 
ALS, patients (n = 55); HC, healthy controls (n = 49). Error bars represent 95% CI for mean; max score 


































Participants’ interpretations of the four elements of the enriched social exchanges were 
also examined. A split–plot ANOVA with Group as between–subjects factor and 
Element (Do, Say, Think, Feel) was conducted. No interaction between factors was 
indicated [F(2.4,246)=19.54, p=.17, ηρ²=.02]. Although there was a main effect of 
Element [F(2.4,246)=19.45, p<.001, ηρ2=.16], there was no main effect of Group 






Figure 5.7.: TASIT SIE Element–type performance  
ALS, patients (n = 55); HC, healthy controls (n = 49). Error bars represent 95% CI for mean; max score    




































Performance on items which contained visual (physical objects) or verbal cues was 
assessed between groups. A split–plot ANOVA, with group as between–subjects factor 
and Cue–type (visual; verbal) as the within–subjects factor, was conducted. No 
interaction between factors was present [F(1,102)=0.94, p=.34, ηρ²=.01]. Although 
there was a main effect for inference–type [F(1,102)=73.73, p<.001, ηρ²=.42], there 
was no main effect of group [F(1,102)=0.004, p=.95, ηρ²<.001].  Figure 5.8. displays 




Figure 5.8.: TASIT SIE Cue–type performance 
ALS, patients (n =55); HC, healthy controls (n = 49). Error bars represent 95% CI for mean; max score 































Visual Verbal  
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B. The Happé Cartoon Inference and Written Scenarios Task (Happé Task) 
 
Sections 5.2.2.2 and 5.2.2.3 indicated that significant differences existed between 
patients and controls on the total scores for the three subtest of the above task. Here, 
each subtest will be analysed in more detail.  
 
Several ALS patients (n=10, Cartoon Inference subtests; n=17, Scenarios subtest) and 
controls (n=1, Cartoon Inference subtests; n=3, Scenarios subtest) were unable to 
complete this task due to fatigue and/or time constraints (see Appendix II). The groups 
of participants that did complete these tasks were compared on demographic data      
(see Appendix VI.1). For the Cartoon Inference subtests, no group differences were 
found for any demographic variables.  For the Scenarios subtest there was significant 
group difference for the WASI IQ measure only. Controls’ scores (Mdn=120, n=45) 
were significantly higher than patients’ scores (Mdn=116, n=35) on this scale   
(U=581.0, z=-2 p=.05, r=-.20). However, this difference did not remain significant 
following a Bonferroni correction (adjusted p<.03) and the effect size estimate (r=-.20) 
was small according to the Cohen (1988) conventions. Therefore the difference between 
the group median scores was considered insufficient to affect the between-group 
analyses conducted on the experimental tasks.     
 
i.) Inter–rater reliability 
 
The researcher trained a second rater in the scoring scheme for the cartoon and scenario 
subtasks, outlined in Chapter 4, Section 4.4.2. The second rater was unaware of the 
diagnostic status of participants throughout the rating period. Training included 
familiarisation, discussion and clarification of the classification schemes for accuracy 
and errors. The training also included a pilot inter–rater consultation of 10 responses 
from each subtest (5 patient items; 5 control items). These data were not used in the 
final inter–rater reliability analyses. Thirty participants’ responses (15 patient items, 15 
control items) from each subtest, which were coded by both raters, were used to assess 
inter–rater reliability. Percent agreement scores were calculated for each item by 
dividing the number of agreements by the number of agreements plus disagreements. 
For the classification of the accuracy of responses, Cohen’s linear weighted Kappa 
coefficients values were calculated for each item. For the classification of error 
responses, Cohen’s unweighted Kappa coefficients were calculated for each item. 
Percent agreement and Kappa coefficients for items of each subtest are shown in 
Appendix VI.2. Interpretation of the strength of agreement was based on the system 
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proposed by Landis & Koch (1977): <0, Poor agreement; .00 –.20, Slight agreement; 
.21 – .40, Fair agreement; .41 – .60, Moderate agreement; .61 – .80, Substantial 
agreement; >.81, Almost perfect agreement. The majority of the ratings (84.2%) 
demonstrated agreement of .70 or above and none had agreement values of less than 
.60.        
 
ii.) Response times for subtests 
 
Mean response times for each subtest were compared between groups. The patients and 
controls did not differ significantly in terms of time taken to respond to either mental or 
physical conditions for any of the subtests (see Appendix VI.3.).  
 
iii). Cartoon Inference subtask  
 
Accuracy scores for the above task were compared between groups using a Group x 
Cartoon–type (physical; mental) split–plot ANOVA. There was no Group by Cartoon-
type interaction [F(1,91)=1.36,  p=.25, ηρ² =.02]. However, there was a main effect of 
Group [F(1,91)=21.61, p<.001, ηρ²=.19] and a main effect of Cartoon–type (physical; 
mental) on performance accuracy [F(1,91)=6.38, p=.01, ηρ²=.07]. Figure 5.9. displays 
group means by cartoon condition.  
  
Five types of errors were recorded for responses that did not meet criteria for 
full/explicit explanation (i.e. an accuracy score < 3). The error categories were: partial, 
misconstruction, description, concrete and omission. The number of total errors per 
error category was summed and compared between groups (see Table 5.20). For both 
groups, most errors constituted partial (or incomplete) inferences and descriptive 
responses.  There was a significant difference between groups for the number of partial 
errors and descriptive responses given, with ALS patients committing more errors for 
both error categories. These differences remained significant following a Bonferroni 
correction (adjusted p<.01).  
 
A break-down of errors over the conditions revealed that both groups made significantly 
more partial errors in the physical condition [F(1,91)=10.32, p=.002, ηρ²=.10]; both 
groups made significantly more misconstructions on the physical condition 
[F(1,91)=5.47, p=.02, ηρ²=.06]. While the ALS group made significantly more 
description errors on the mental condition compared to the physical condition, the 
reverse was true for the control group [F(1,91)=6.51,p=.01, ηρ²=.07]; the ALS group 
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showed significantly more description errors on the mental condition compared to 










Figure 5.9.: Cartoon Inference subtask performance across cartoon conditions 
ALS, patients (n=45); HC, healthy controls (n=48). Error bars represent 95% CI for mean. Max score for 































Cartoon Type  
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Table 5.20.: Cartoon Inference subtask errors 
 
Error Type         Mean (SD) t(df)      p d 95% CI 
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p–values from two–tailed t–test. Results significant following Bonferroni correction are shown in 
bold*–p<.01. d, Cohen’s d; 95% CI, confidence interval for difference between means. Note: higher 
score indicates worse performance.  
 
 
iv.) Cartoon Pairs subtask 
 
The number of correct choices made by patients and controls for physical and mental 
cartoons were compared using a split–plot ANOVA. There was no Group by Cartoon–
type (physical; mental) interaction for choice accuracy [F(1,91)=0.3, p=.93, ηρ²=.01]. 
The two groups did not differ in their ability to select the ‘funny’ cartoon from the two 
alternatives [F(1,91)=0.008, p=.93, ηρ²<.001]. Both groups tended to make more 
correct choices for the mental cartoons than for the physical cartoons [F(1,91)=4.02,  
p=.05, ηρ²=.04].  
 
Accuracy scores for this subtest were also examined using a split–plot two–way 
ANOVA. There was no Group by Cartoon–type (physical; mental) interaction effect 
[F(1,91)=0.85, p=.36, ηρ²=.01]. A main effect for Group on performance accuracy was 
revealed [F(1,91)=9.44, p=.003, ηρ²=.09] but no main effect of Cartoon–type on 
performance accuracy was found [F(1,91)=0.04, p=.85, ηρ²<.001]. Figure 5.10. displays 




As with the previous subtask, the number of errors per error category was compared 
between groups using two–tailed t–tests (see Table 5.21).  Again, for both groups most 
errors constituted partial and descriptive errors. There was a significant difference 
between groups for mean number of misconstructions and descriptive responses, with 
ALS participants committing more of these error types than controls. However, only the 
difference for the misconstruction category remained significant following a Bonferroni 
correction (adjusted p<.01).  
 
A break-down of errors over the conditions revealed that both groups made significantly 
more partial errors in the mental condition [F(1,91)=38.46, p<.001, ηρ²=.29]; no other 
error types were influenced by condition, or influenced by the interaction of participant 
group and condition.  
  
 
Figure 5.10.: Cartoon Pairs subtask performance across cartoon conditions 
 
ALS, patients (n=45); HC, healthy controls (n=48). Error Bars represent 95% CI for mean. Max score  



































Table 5.21.: Cartoon Pairs subtask errors  
 
Error Type         Mean (SD) t(df) p d 95% CI 






































































p–values from two–tailed t–test. Uncorrected significant results shown in bold–p<.05 Results significant 
following Bonferroni correction are shown in bold*–p<.01. d, Cohen’s d; 95% CI, confidence interval for 
difference between means. Note: Higher score indicates worse performance.  
 
 
v) Written Scenarios subtask   
 
Accuracy scores for the above task were compared between groups using a split–plot 
two–way ANOVA. No Group by Scenario–type (physical; mental) interaction effect 
was found [F(1,81)=0.44, p=.51, ηρ²=.01]. A main effect for Group [F(1,81)=9.56, 
p=.003, ηρ²=.12] and a main effect of Scenario–type on performance accuracy were 
found [F(1,81)=49.33, p<.001, ηρ²=.38]. Figure 5.11. displays group means by scenario 
condition. 
 
Errors were recorded for responses that did not meet criteria for full/explicit 
explanations (i.e. an accuracy score <2). The error categories were the same for the 
previous subtasks. The total errors per error category were summed and compared 
between groups (see Table 5.22). Partial errors constituted the most errors for both 
groups. Once again, patients committed significantly more misconstructions than 
controls; this difference remained significant following a Bonferroni correction 
(adjusted p<.01).   
 
A break-down of errors over the conditions revealed that both groups made significantly 
more partial errors in the mental condition [F(1,81)=15.36, p<.001, ηρ²=.12]; both 
groups made significantly more omission errors on the physical condition 
[F(1,81)=4.71, p=.03, ηρ²=.06]. Both groups made significantly more misconstruction 
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errors on the mental condition [F(1,91)=15.36, p<.001, ηρ²=.12], but patients showed a 
strong trend for more errors on this condition than controls [F(1,91)=4.05, p=.05, 
ηρ²=.05].  
 
          
 
 
                            
                                                                                                                                                                                                                                     
Figure 5.11.: Written Scenarios subtask performance across scenario condition 
   
ALS, patients (n=45); HC, healthy controls (n=38). Error Bars represent 95% CI for mean. Max score for 






































Table 5.22.: Scenarios subtask errors 
 
Error Type         Mean (SD) t(df)      p d 95% CI 














































   .10 
 
   .53 
 



















p–values from two–tailed t–test. Results significant following Bonferroni correction are shown in bold*–





vi) Happé Task: Single–case analysis 
A previous ALS study that used the current task found a spectrum of performance in 16 
patients, ranging from normal to impaired (Gibbons et al., 2007). In light of those 
findings, the number of individual deficits for the physical and mental cartoon 
conditions in each group was examined using the single–case methods as described in 
Section 5.2.2.3. Significantly more patients than controls showed impairments on both 
conditions for the Cartoon Inference (C–Inference) subtask and the physical condition 
of the Scenario subtask. When a Bonferroni correction was applied (adjusted p<.008), 
significant differences remained for the physical condition of the C–Inference subtask 
only. A trend for a difference in proportions was shown for the mental condition of the 
Cartoon Pairs (C–Pairs) subtask. These results and the number of impairments per 
group for each condition are shown in Table 5.23.    
Dissociation of performance between physical versus mental conditions was examined 
at the individual level. Although proportionally more patients than controls showed 
dissociations on all three subtasks, none of these differences were significant. A 
summary of these results is presented in Table 5.24.  The number of participants per 
group who showed isolated impairments on either the physical or mental conditions, as 
well as those who showed simultaneous impairment on both conditions is summarised 
in Table 5.25. 
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Table 5.23.: Number of impairments on conditions of Happé Cartoon and  
Scenario subtasks 
 
               N (%) X
2











 2 (4.2) 




















 3 (6.3) 




















 3 (6.7) 
 2 (4.4) 








p–values from two–tailed Chi–square tests except † Fisher–Boschloo exact test. Uncorrected significant 
results shown in bold–p<.05. Results significant following Bonferroni correction are shown in bold*–
p<.008; 95% CI, Newcombe–Wilson hybrid confidence interval for difference between proportions.  
 
 
Table 5.24.:  Dissociation of performance on conditions of Happé Cartoon and  
Scenario subtasks 
 
 N (%)     p φc 95% CI 
Dissociation ALS HC 
  










  .09 
>.99 







C–Inference and C–Pairs ALS (n=45), HC (n=48); Scenarios ALS (n=38), HC (n=45). p–values from 
two–tailed Fisher–Boschloo exact test. φc, Cramer’s V; 95% CI, Newcombe–Wilson hybrid confidence 





Table 5.25.: Summary of impaired performance across conditions of Happé 
Cartoon and Scenario task 
 
                                            N                     
Cartoon Inference ALS (n=45) HC (n=48) 
 
Physical & Mental 
Physical only 









Cartoon Pairs   ALS (n=45)                  HC (n=48) 
 
Physical & Mental 
Physical only 









Scenarios ALS (n=38)                  HC (n=45) 
 
Physical & Mental 
Physical only 













Means for the self–rated FrSBe T–scores are presented in Table 5.26. Contrary to 
expectation, controls rated themselves as having a higher premorbid level of 
behavioural dysfunction than ALS patients. Differences between patients and controls 
for premorbid T–scores were significant for the Total premorbid score, the Apathy 
subscale and the Executive Dysfunction subscale. These differences remained 
statistically significant following a Bonferroni correction (adjusted p<.006). However, 
patients reported a higher level of current apathy compared to controls. For current 
behaviour T–scores, a significant difference between groups for the Apathy subscale 
was found, although this did not remain significant following a Bonferroni correction.  
No significant differences between groups were found for the remaining current 
subscales or total score.  
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Split–plot ANOVAs, with Group as the between–subjects factor and Time (premorbid; 
current) as the within–subjects factor were conducted on FrSBe total and subscale 
scores: 
 
T–scores differed as a function of Time for the Total score [F(1,97)=32.94, p<.001, 
ηρ²=.25], Apathy [F(1,97)=66.88, p<.001, ηρ²=.41] and Executive Dysfunction 
[F(1,97)=10.43, p=.002, ηρ²=.10] subscales. Current T–scores on the Disinhibition 
subscale were not significantly different from premorbid levels [F(1,97)=0.36, p=.55, 
ηρ²=<.001]. No main effects of group were found for the total score [F(1,97)=2.57, 
p=.11, ηρ²=.03] or Apathy [F(1,97)=0.1, p=.76, ηρ²<.001] and Disinhibition 
[F(1,97)=1.98, p=.16, ηρ²=.02] subscales. However, there was a group effect for the 
Executive Dysfunction subscale [F(1,97)=5.19, p=.03, ηρ²=.05]. 
 
A significant Group by Time interaction for the Total FrSBe score was found 
[F(1,97)=36.23, p<.001, ηρ²=.27]. This interaction is illustrated in Figure 5.12. While 
the patients’ total behavioural scores increased significantly over time, the control group 
showed a reduction on the total score scale. 
 
A breakdown of scores across the subscales revealed Group by Time interactions for all 
three subdomains: Apathy [F(1,97)=49.98, p<.001, ηρ²=.34], Disinhibition 
[F(1,97)=7.03, p=.01, ηρ²=.07] and Executive Dysfunction [F(1, 97)=17.44, p<.001, 
ηρ²=.05]. The direction of change for the Apathy subscale was the same for both 
groups, but a greater increase in apathy was indicated for patients on this domain. The 
interaction for Apathy is illustrated in Figure 5.13. For the Disinhibition and Executive 
Dysfunction subscales, both patient subscale scores increased over time. Although 
premorbid and current scores were higher than the ALS group, the control group 
showed reduced scores over time for both domains. The interactions for these domains 









Table 5.26.: Self–rated FrSBe T–scores 
































































Exec. Dys. (pre.)      



















Note: Participants were asked to rate their behaviour at present time and approximately 2 years prior.  p–
values are from two–tailed t–tests; Uncorrected significant results shown in bold–p<.05. Results 
significant following Bonferroni correction are shown as bold*–p<.006; d, Cohen’s d; 95% CI, 
confidence interval for difference between means. Disinhib., Disinhibition; Exec.Dys., Executive 
Dysfunction; pre., premorbid; cur., current. 
 
 
In both groups, mean domains scores did not meet criteria for “caseness” according to 
standard cut–off criteria (T–score ≥65).  Nonetheless, the relative proportions of each 
group satisfying criteria for “caseness” was examined (see Table 5.27.). A two–tailed 
Chi–square test revealed a significant difference between the ratio of cases in each 
group for the premorbid total FrSBe score only. Proportionally more controls than ALS 
patients were classified as a ‘case’ for this domain. This difference did not remain 
significant following a Bonferroni correction (adjusted p<.006). Proportionally more 
controls than patients satisfied these criteria for all the other domains, with the 
exception of the current Apathy subscale. However, the differences in proportions were 





Figure 5.12.: Line graph representing a significant interaction for FrSBe Total 
    
ALS, patients (n=51); HC, healthy controls (n=48).  
 
Figure 5.13.: Line graph representing a significant interaction for Apathy  
 





































































Figure 5.14.: Line graph representing a significant interaction for Disinhibition  
 
ALS, patients (n=51); HC, healthy controls (n=48). 
 
Figure 5.15.: Line graph representing a significant interaction for Executive   
Dysfunction  
 














































































Table 5.27.: Proportions of groups satisfying FrSBe ‘caseness’ criteria 
FrSBe N (%) X
2
 (df) p φc 95 % CI 















Exec. Dys. (pre.)      



































































p–values from two–tailed Chi–square test. Uncorrected significant results shown in bold–p<.05. φc, 
Cramer’s V. 95% CI, Newcombe–Wilson hybrid confidence interval for difference between proportions. 





The number of participants for which behavioural ratings changed from ‘non–case’ 
levels to meeting ‘caseness’ criteria, and vice versa, over the two time points are shown 
in Table 5.28. Proportionally more patients than controls progressed from the ‘non–
case’ level to meeting ‘caseness’ status from premorbid to current time points for all 
FrSBe scores.  Conversely, proportionally more controls than patients, who reported 
premorbid levels of ‘caseness’ on the FrSBe domains, showed a downward direction of 
change from ‘caseness’ to ‘non–case’ levels. Between group differences for these 
proportions were not significant (results not shown). Within the patient group, 
McNemar tests found that the percentage of patients satisfying ‘caseness’ increased 
significantly between time points for Total FrSBe and Apathy (see Table 5.29). These 
differences remained significant following a Bonferroni correction (adjusted p<.013). 
For the control group, there were no significant changes in the proportions of ‘cases’ 




Table 5.28.: ‘Caseness’ status over time points 






Total: pre. ‘non–case’ to curr. ‘caseness’ 
Total: pre. ‘caseness’ to curr. ‘non–case’ 
 
Apathy: pre. ‘non–case’ to curr. ‘caseness’ 
Apathy: pre. ‘caseness’ to curr. ‘non–case’ 
 
Disinhib.: pre. ‘non–case’to curr. ‘caseness’ 
Disinhib.: pre. ‘caseness’ to curr. ‘non–case’ 
 
Exec. Dys.: pre. ‘non–case’ to curr. ‘caseness’ 
























Disinhib., Disinhibition; Exec.Dys., Executive Dysfunction; pre., premorbid; cur., current. ‘caseness’, T 
score ≥ 65; ‘non–case’; T score ≤ 65.  
 
 
Table 5.29.: Comparison of the proportion of patients satisfying ‘caseness’ 
between premorbid and current time points 
 
FrSBe N (%) X
2
(df) p 95% CI 













































p–values from McNemar tests. Results significant following Bonferroni correction are shown in bold* – 
p<.013. Exec.Dys., Executive Dysfunction; 95% CI, Newcombe–Wilson hybrid confidence interval for 




5.2.4. Mood  
 
Section 5.2.1. displayed group medians for HADS A and HADS D scores. No 
significant differences were reported between groups. A further examination of these 
scores was conducted to investigate the relative proportions of patients and controls 
who satisfied revised criteria for ‘caseness’ on these measures (Gibbons et al., 2011). In 
addition, a HADS Total score was calculated for inclusion in subsequent analyses. 
Previous studies have found that the HADS subscales are highly correlated and have 
recommended the summation of subscale scores to create a single factor as an index of 
psychological distress (Crawford et al., 2001; Smith et al., 2002). This suggestion has 
been supported statistically by studies in non–ALS populations (Marinus et al., 2002; 
Martin et al., 2004; Pallant & Tennant, 2007). Support for the use of the modified 
HADS Total score for the purposes of research in ALS exists (Gibbons et al., 2011). 
Here the HADS Total score will be referred to as a measure of overall mood rather than 
psychological distress, in order to avoid confusion with alternative definitions that exist 
in the ALS literature for this latter term (e.g. Rabkin et al, 2009 vs. Goldstein et al, 
2006). The Gibbons et al (2011) revised HADS criteria for case level, borderline case 
level and non–case level of anxiety and depression are shown in Table 5.30. HADS 
Total score cut–offs for ‘possible’ mood disorder and ‘probable’ mood disorder is also 
shown in this table
3
. According to these criteria, the HADS D medians for patients 
(Mdn=2) and for controls (Mdn=1) are within the non–case level range for depression. 
The HADS A medians for patients (Mdn=4) and controls (Mdn=3) are within the non–
case level range for anxiety (see Section 5.2.1).   
 
Table 5.30.: Gibbons et al (2011) revised HADS criteria for caseness 
Scale          Case Level       Borderline Case Level          Non–Case Level 
HADS Total
3
            ≥ 21                              17 – 20                                 ≤ 16 
HADS A                    ≥ 9                                 7 –8                                      ≤ 6          
HADS D                    ≥ 8                                 5 –7                                      ≤ 4 




 Gibbons et al (2011) refer to criteria cut-off points for the HADS Total as ‘probable’ and ‘possible’ 




HADS A and HADS D scores (which were highly correlated, rho=.56, p<.001, n=104) 
were summed to create HADS Total scores. A Mann–Whitney U test revealed no 
significant difference between patients (Mdn=6) and controls (Mdn=6) on this score,                    
U(-0.7)=1240.5,  p=.49,  r=.07. According to the criteria, medians for both groups are 
not indicative of mood disorder.  
 
The group proportions of participants satisfying criteria for case level and borderline 
case level for depression and anxiety are shown in Table 5.31. There were no significant 
differences between the ratio of patients and controls satisfying the revised criteria.  
 
 
Table 5.31.: Proportions of participants by group meeting HADS criteria 
 N (%) X
2











































































































p–values from two–tailed Chi–square test except † Fisher–Boschloo test. φc, Cramer’s V. 95% CI, 










T–scores for the Big–Five personality dimensions (Neuroticism, N; Extraversion, E; 
Openness, O; Agreeableness, A; Conscientiousness, C) were calculated according to 
gender–corrected norms from the questionnaire’s manual (See Chapter 4). Group means 
for the domain T scores and the results of two–tailed t–tests for group comparisons on 
these domains are presented in Table 5.32. Controls reported significantly higher levels 
of N than patients, while patients reported significantly higher rates of C than controls. 
These differences did not remain significant following a Bonferroni correction (adjusted 
p<.01).   
 
Cut–off scores for levels of each domain T–score are also provided by the manual. The 
proportions of patients and controls falling into the extreme cut–off categories (Very 
high; Very low) are presented in Table 5.33. Significantly more controls than patients 
fell within the Very high N categories and the very low E categories. Differences in 
these proportions did not remain significant following a Bonferroni correction (adjusted 
p<.005).  Significantly more controls than patients fell within the very low C category; 
the difference in case ratio remained significant following a Bonferroni correction.  
 
According to the NEO–FFI manual, the N domain measures traits of anxiety, hostility, 
depression, self-consciousness, impulsiveness and ability to cope with stress. The four 
control participants who showed very high levels of N met criteria for case level HADS 
A and one also met criteria for borderline HADS D, suggesting that the high scores on 
N might be capturing these participants’ elevated mood levels. When the four control 
participants showing very high levels of N were removed from the analyses, the trend 
for between–group differences on this domain disappeared, t(94)=1.26, p=.21, 95% CI 















Mean (SD) t(df) p d 95% CI 








































 p–values from two–tailed  t–tests; d , Cohen’s d; 95% CI for difference between means. Uncorrected 
significant results shown in bold –p<.05. 
 
Table 5.33.: Self–reported NEO–FFI cut–off categories 
NEO–FFI N (%) X2 (df)     p φc 95% CI 
Very high (range 66: 75) 






    
N – Very high† 
N – Very low 
 
E – Very high† 
E – Very low† 
 
O – Very high 
O – Very low† 
 
A – Very high† 
A – Very low† 
 
C – Very high† 











































  .04 
  .66 
 
>.99 
  .04 
 
  .17 
>.99 
 
  .68 
>.99 
 
  .22 





























 p–values from two–tailed Chi–square test except † Fisher–Boschloo testφc, Cramer’s V; 95% CI, 
Newcombe–Wilson hybrid confidence interval for difference between proportions. Uncorrected 




5.2.6. Empathy  
 
Mean scores on the IRI subscales are shown in Table 5.34. T–tests did not find any 
significant differences between patients and controls on any of the subscales.  
 
Table 5.34.: Self–reported IRI ratings 
IRI subscales Mean (SD) t(df) 
 
p d 95% CI 
(min 7; max 35) ALS 























































































5.2.7. Emotional lability 
 
Each domain (Laughing, Crying, Smiling) has a maximum score of 31 yielding a total 
maximum score of 93 (ELQ Tot), with higher scores reflecting higher levels of 
emotional lability.  Median tests found significant differences between groups for the 
ELQ Tot and the Crying and Smiling domains. The ELQ Tot and Crying domains 
remained significant following a Bonferroni correction (adjusted p<.013). No 
differences were found between groups for the Laughing domain. Medians are 








Table 5.35.: Self–reported ELQ ratings 
 Medians (MAD/IQR) X
2























  .001* 
  .10 
<.001*       









p–values from Medians Test. Uncorrected significant results shown in bold – p<.05. Results significant 
following a Bonferroni correction are shown as bold* – p<.013 φc, Cramer’s V; 95% CI, Hodges–
Lehmann confidence interval for difference between medians. 
 
 
5.2.8. Patient Subgroups: medicated patients vs. non medicated patients  
 
The patient group comprised a subgroup of patients who were receiving psychoactive 
medication for disease management (n=15, see Appendix VII). Since psychoactive 
substances have shown to influence cognitive performance and the processing of 
emotionally–salient information in healthy participants (Delaveau et al., 2011; Pringle 
et al., 2011), it is plausible that the overall patient group performance might have been 
influenced by the presence of medicated patients. For this reason, the two patient 
subgroups (n=40, ‘not medicated’; n=15, ‘medicated’) were compared on measures of 
cognitive and emotional processing, personality, behaviour and empathy. A summary of 
these analyses follow:  
 
A. Demographic and Disease variables 
The subgroups did not differ significantly for any of the demographic variables (see 
Appendix VII.a.).   
 
B. Executive function and EMOSOC composites 
A one–way MANOVA found no significant difference between patients and controls on 
the combined dependent variable (composite scores) (see Appendix VII.b.).  The 





(1)=0.68, p=.41, φc=.11] or the EMOSOC composite [Fisher–
Boschloo exact test; p=.41, φc=.05].    
 
C. Executive function component scores and Hayling task 
No significant differences between subgroups were found for any of the executive 
function components scores. Similarly, subgroups did not differ on the error and latency 
scores of the Hayling task (see Appendix VII.c.). The proportions of patients impaired 
on the executive components and Hayling scores in each subgroup were compared; no 
significant differences were found (see Appendix VII.d.).  
 
D. EMOSOC components 
Subgroups were compared on the components of emotional processing and social 
cognition (see Appendix VII.e.). A significant difference was found for the TASIT EET 
component (emotion evaluation), with medicated patients performing significantly 
worse than non–medicated patients. This difference was not significant following a 
Bonferroni correction (adjusted p<.007). According to Cohen’s (1988) conventions, the 
effect size for the difference in means was within the medium range. No significant 
differences between subgroups were found for any of the other components. The 
proportions of patients impaired on the EMOSOC components were compared between 
subgroups; no significant differences were found (see Appendix VII.f.).  
 
E. Language and Memory  
Subgroups did not differ significantly on the GNT score or the CVLT measures (see 
Appendix VII.g.), with the exception of the CVLT delayed cued recall trial on which 
medicated patients showed superior performance relative to non–medicated patients. 
This difference was not significant following a Bonferroni correction (p<0.013). On the 
basis of Cohen’s (1988) conventions, effect sizes associated with the immediate recall, 
short delay recall and delayed cued recall trials of  the CVLT were within the range of 
medium to large. The proportion of impaired patients (n=5, non–medicated patients; 
n=0, medicated patients) on this trial was not statistically different between subgroups 






F. Behaviour, mood, personality, empathy and emotional lability  
Ratings for the IRI (empathy) domain scores
4
 were compared between subgroups (see 
Appendix VII.h.). Once again, no significant differences were found between subgroups 
on these scores. Ratings for premorbid and current FrSBe T–scores were also compared 
between subgroups (see Appendix VII.i.). No differences between subgroups on any of 
the FrSBe domains were found for either time period. In addition, there were no 
differences between groups for the ELQ domains (see Appendix VII.j.).  
 
Ratings for NEO–FFI domain T–scores5 were compared between subgroups (see 
Appendix VII.k.). Initially, subgroup differences for N were found at the uncorrected 
significance level, with medicated patients (M=49, SD=8.7, n=13) showing higher 
levels of N than non–medicated patients (M=42.7, SD=8.6, n=39), t(50)=-2.27, p=.03, 
d=0.73, 95% CI [-11.8; -0.72]. However when mood (HADS Total scores) was entered 
as a covariate in an ANCOVA, the difference between groups was no longer significant, 
F(1,49)=3.37, p=.07, ηρ²=.06. Correlational analyses did not find a significant 
relationship between variable N and any of the measures of interest. No significant 





















5.2.9. Inter–relationship between executive functioning and emotional processing 
and social cognition in ALS  
 
In order to examine Hypothesis Three that executive (dys)function will be the main 
predictor of performance on tests of emotional processing and social cognition, with 
smaller contributions from behaviour, mood, personality and empathy (above and 
beyond patients’ demographic and disease symptoms) a multiple regression (MR) 
analysis was conducted.   
 
Composite scores were recalculated using the patients’ scores, instead of the healthy 
control participant scores as had been done in Section 5.2.2.1. This was undertaken in 
order to investigate the relationship between these two domains in ALS patients, rather 
than with respect to healthy control participants. The composite scores were computed 
by subtracting the mean score of the ALS group from each ALS participant’s score on 
each test and then dividing by the standard deviation for the ALS group. The creation of 
these composites, as before, aimed to reduce the likelihood of making Type 1 errors that 
might occur if regressions of each individual neuropsychological score were 
undertaken.  
 
The composite scores were constructed using the same component scores outlined in 
Section 5.2.2.1.  The Cronbach’s alpha coefficients for these composite scores are 
shown in Table 5.36.; both were greater than .70, suggesting satisfactory internal 
consistency of each score.  
 








Emotional Processing and Social 
Cognition  (EMOSOC) 







The selection of predictors  
 
The selection of possible predictors was based on theory and statistical criteria. A list of 
the potential predictors under the domains of interest is shown in Table 5.37.  Bivariate 
correlational analyses were conducted to determine the presence of significant 
relationships between potential predictor variables and the EMOSOC composite 
(unadjusted p<.05). These variables were then entered into a MR with the EMOSOC as 
the outcome, controlling for demographic variables.  
 
Demographic variables: The correlations between EMOSOC and demographic variables 
were as follows: Age (r=.44, p=.001, n=55); Education (r=-.29, p=.03), WASI FSIQ 
(rho=-.48, p=.001, n=48) and WTAR–predicted FSIQ (rho=-.4, p=.004, n=51). 
However, Education was moderately to strongly correlated with WASI FSIQ (rho=.48, 
p=.001, n=48) and WTAR–predicted FSIQ (rho=.59, p<.001, n=51). Moreover, not all 
patient participants were able to complete both IQ measures due to physical disability. 
Therefore, Education acted as a proxy for intellectual functioning in the analyses. 
Gender did not correlate significantly with the EMOSOC score. 
 
Disease variables: Disease symptom severity, disease duration and disease progression 
rate did not correlate with the EMOSOC outcome.   
 
Executive: A significant association between the Executive and EMOSOC composite 
scores was found in the ALS group (r=.61, p<.001, n=55). Neither of the Hayling error 
scores nor the latency score correlated with the EMOSOC composite.  
 
Behaviour: The FrSBe Total score correlated significantly with the EMOSOC 
composite (r=.3, p=.04, n=51), as did the Apathy (r=.33, p=.02, n=51) and Executive 
Dysfunction (r=.41, p=.003, n=51) subscales. These three variables correlated strongly 
with each other (.7 < r < .9). The FrSBe Total score showed the strongest correlation 
with the EMOSOC score. Therefore, only the FrSBe Total score was used in the final 
regression model.   
 
Mood: The HADS Total score correlated significantly with EMOSOC (r=-.28, p=.04, 















WASI FS IQ 




ALSFRS–R: Total, bulbar severity, limb severity, respiratory 
severity subscale scores.   
 
Disease duration (months since ALS onset) 
Disease progression rate   
 
Executive  Executive function composite score 
Hayling Error and latency scores 
 
 





Mood HADS Total 
 
Personality NEO–FFI: Neuroticism, Extraversion, Openness, 
Agreeableness, Conscientiousness T–scores.  
 
Empathy IRI: Perspective Taking, Fantasy Thinking, Empathic Concern, 
Personal Distress scores.  
 
For abbreviations see pgs. 13-16.   
 
Personality: Only the Openness T–score of the NEO–FFI correlated significantly with 
EMOSOC (r=-.32, p=.02, n=52).   
 





Some patients did not complete the FrSBe (n=4) and NEO–FFI (n=3) measures due to 
fatigue and time constraints. A MR to determine the relative contributions of the 
Executive function composite, the FrSBe Total, the HADS Total and the Openness T–
score to the EMOSOC composite, controlling for age and years of formal education was 
conducted. Since the hypothesis expected a higher contribution from executive 
functioning than behaviour, personality and mood to the outcome, the variables were 
entered in a hierarchical design in the following blocks:  
 
Block 1: Age and education (control variables) 
 
Block 2: FrSBe Total, HADS Total and Openness T–score 
 
Block 3: Executive function Composite 
 
Results of this analysis are shown in Table 5.38. When variables Age and Education 




=.206) was significantly different 
from zero, F(2,45)=7.11, p=.002. Both Age and Education significantly predicted the 
EMOSOC scores (Age: t(46)=2.99, p=.004; Education: t(46)=-2.23, p=.03). 
 
In the second model, the addition of the behaviour, mood and personality variables did 






=.250), F(3,42)=1.87, p=.15, but the 
model remained significantly different from zero, F(5,42)=4.13, p=.004. Only Age 
remained a significant predictor of EMOSOC scores, t(46)=1.65, p=.04.  
 







=.445), F(1,41)=15.81, p<.001. At this final model, 
with all predictor variables entered into the equation, R
2
=.516 was significantly 
different from zero, F(6,41)=7.29, p<.001. The adjusted R
2
=.445 value indicated that 
44.5% of the variability in the EMOSOC composite was explained by the model. 
Inspection of the standardised regression coefficients indicated that as the Executive 
function composite scores increased by 1 SD (0.68), the EMOSOC composite scores 
increased by 0.49 SD. Executive function was the only significant predictor of 
EMOSOC, t(46)=3.98, p<.001.  
These results support Hypothesis Three that executive function would contribute more 
to performance on emotional processing and social cognition in ALS, than behavioural 




Table 5.38.: Predictors of EMOSOC composite 
 




95% CI for B 
1. Constant 
    Age 









   .39* 
-.29 
-2.6; 0.3 
 0.01; 0.1 
-0.1; -0.01 
2. Constant 
    Age 
    Education (years) 
    FrSBe Tot 
    HADS Tot 
    Openness 
  -1.03 
   0.02 
  -0.03  
   0.01 
  -0.03         


















-0.0; 0.0   
3. Constant 
    Age 
    Education (years) 
    FrSBe Tot 
    HADS Tot 
    Openness 





















    .49* 
-1.9; 0.9 
 0.0; 0.0 




 0.2; 0.7 









=.250; 3.  R
2 





5.3. Summary of results 
This section provides a review of the chapter’s findings. Results which were significant 
following a Bonferroni correction for multiple comparisons will be outlined. 
Uncorrected significant findings (significant at p<.05) will be described as trends or 
tendencies towards group differences.  
 
5.3.1. Participant characteristics 
The ALS (n=55) and control (n=49) participants were well matched for demographic 
variables, such as age, years of education and gender. There was no between–group 
difference for the HADS depression and anxiety subscales. Similarly, there was no 
between–group difference regarding the number of participants in each group who 
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reported having previously seen a GP or psychiatrist regarding mental health problems.  
Proportionally more controls than patients were single, but this was not considered 
clinically relevant. Participants were also matched on IQ estimates; no group 
differences on the WASI Full–scale IQ estimate or the WTAR premorbid Full–scale IQ 
estimate were found.    
 
5.3.2. Composite scores 
 
ALS patients showed greater impairment (higher scores) than controls on the canonical 
variate created by the multivariate procedure. In support of Hypothesis One, univariate 
analyses conducted on transformed data revealed that patients showed higher scores 
compared to controls on the Executive function and EMOSOC composite, indicating 
worse performance in these domains. Inspection of the discriminant function 
coefficients from untransformed data indicated that the Executive function composite 
showed greater weighting than the EMOSOC composite and maximally differentiated 
the group membership. This suggests that the Executive function composite contributed 
more to group differences on the canonical variate than the EMOSOC composite.   
 
A. Individual executive function component scores  
 
Following the finding that ALS patients showed greater impairment on the Executive 
function composite than controls, performance across individual components of the 
composite was explored. Between–group differences were found for the D–KEFS card 
sorting tasks. Relative to controls, patients showed greater impairment for the number 
of card sorts made and the descriptive responses provided on this task. A between–
group trend was also observed for one measure of verbal fluency; patients showed 
poorer performance for generating four–letter C–words than control participants. 
 
B. Individual EMOSOC component scores    
 
Relative to the control group, ALS patients performed significantly worse on the 
EMOSOC composite, when transformed data was compared between groups. For the 
untransformed EMOSOC composite data, a trend for poorer patient performance was 
observed. Further investigation was conducted to examine the nature of differences 
between the participants groups on individual measures of the composite. Significant 
group differences were found for the Happé cartoon and scenarios subtasks only, with 
patients performing significantly worse than controls for all three subtasks.       
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5.3.3. Single–case analysis 
 
A. Composites  
 
Single–case analyses revealed that proportionally more patients than controls showed 
impairments on the Executive and EMOSOC composites; however, the differences in 
proportions were not significantly different. The profile of impaired performance across 
composites was compared between groups. Proportionally more patients than controls 
showed concurrent impairments on the Executive and EMOSOC composites; 
proportionally more patients than controls showed isolated impairments on the 
Executive composite and proportionally more patients than controls showed isolated 
impairments on the EMOSOC composite. None of the differences in these proportions 
were significantly different. Dissociations of performance between the Executive and 
EMOSOC composites were found for three patients (none were found for controls). For 
all three patients, the directions of these dissociations indicated that patients were 
impaired on the Executive composite but unimpaired on the EMOSOC composite.     
 
B. Executive and EMOSOC components 
 
Single–case analyses revealed that proportionally more patients than controls showed 
impairments on all of the Executive function components; however, only the proportion 
between groups for the S–words verbal fluency index was significant following a 
Bonferroni correction. The proportions of patients impaired on the C–words verbal 
fluency index tended to be higher than the control participants, but this was not 
significant following the correction. In the ALS sample, 45.4% of patients were 
impaired on at least one executive component. This is contrasted with 14.3% of the 
participants from the control sample.   
 
Of the EMOSOC components, the proportion of impaired cases for the patient group 
was significantly greater than that of the control group for the Cartoon Inference 
subtask only. In the ALS sample, at least 41.8% of patients were impaired on at least 
one EMOSOC component. This is contrasted with 12.3% of the participants from the 









5.3.4. Individual tests of cognition 
 
A. Language and Memory 
 
No between–group differences were found for either the GNT or CVLT measures. 
Similarly, the proportion of impaired participants was not significantly different 
between groups.   
 
B. Executive function:  Hayling task 
 
Since the Hayling task did not correlate positively or strongly with the components of 
the Executive function composite, group performance on this measure was examined 
separately. Patients committed significantly more Category A and Category B error 
responses than controls, but the group means for the latency score were not statistically 
different. Single–case analyses revealed a tendency for the patient group to show 
proportionally more impairments than the control group on all the Hayling measures, 
including the latency score.  
 
C. Emotional processing and social cognition: TASIT and Happé  
 
More detailed analyses were conducted on the TASIT and Happé Cartoon and Scenario 
subtests. Between–group analyses conducted on performance of the TASIT subtasks 
revealed no group differences for the emotion evaluation test or the social inference 
tests (minimal and enriched social information subtests). 
 
Analyses conducted on the performance of the Happé Cartoon and Scenario subtests 
showed between–group differences for performance accuracy for all three subtests, with 
the patient group performing worse than the control group. Within–group analyses 
found that both groups performed better on the mental cartoon trials than the physical 
cartoon trials. Conversely, for the scenarios subtest, both groups performed better on the 
physical scenario trials than the mental scenario trials.  
 
Error scores were also compared between groups for the three subtests. On the Cartoon 
Inference subtask, ALS patients committed significantly more partial and descriptive 
errors than controls. Both groups made significantly more partial errors on the mental 
compared to the physical condition. While ALS patients made significantly more 
descriptive errors on the mental condition relative to the physical condition, the reverse 
was true for control participants. On the Cartoon Pairs subtask, ALS patients made 
significantly more misconstruction errors, and showed a trend for more descriptive 
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errors than controls participants. On the Scenarios subtask, patients committed 
significantly more misconstruction errors than controls. Both groups made significantly 
more misconstruction errors on the mental condition, but patients showed a strong trend 
for more errors on this condition than controls.  
 
Individual case analysis revealed the proportions of participants in each group showing 
impaired performance for the physical and mental conditions of each subtask. 
Significantly more patients than controls showed impairments for the physical condition 
of the single cartoon inference subtask. ALS patients also showed more impairments 
than controls for the mental condition of the same task; however this did not remain 
significant following a Bonferroni correction. Similarly, a greater proportion of 
impairment was found in the ALS group for the physical condition of the Scenarios 
subtask; however, this difference also did not remain significant following the 
correction.   
 
Dissociation of performance between the physical and mental condition was examined; 
although proportionally more patients than controls showed dissociations on all three 




Behaviour, as measured by the FrSBe, was compared between groups. Contrary to 
Hypothesis Two, patients did not report higher behavioural symptoms than the controls 
for either the premorbid and current time period. Controls reported significantly higher 
premorbid behavioural symptoms for the Apathy, Executive dysfunction and Total 
FrSBe domains. There was a trend for patients to report higher levels of current Apathy.  
Significant interactions of group membership and time were found for all the domains 
of the FrSBe. For the FrSBe Total domain, patients’ scores increased significantly over 
time while the controls’ total behavioural scores decreased. Both groups reported an 
increase in Apathy over time, but the magnitude of increase for this domain was larger 
in the patient group. For the Executive dysfunction and Disinhibition domains, patients’ 
scores increased over time while control scores decreased.  
 
The proportions of participants who satisfied criteria for ‘caseness’ (T ≥65) were also 
compared between groups. There was a trend for proportionally more controls than 
patients to satisfy ‘caseness’ criteria on the premorbid FrSBe Total domain. Within the 
patient group, the proportion of patients that satisfied ‘caseness’ for Apathy and the 
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FrSBe Total domains increased significantly from the premorbid to the current time 
point. This pattern was not demonstrated in the control participant group.  
 
5.3.6. Mood, personality, empathy and EL 
 
Patients and controls did not differ significantly on median HADS A and HADS D 
scores. A composite score of the two mood measures, HADS Total, also did not differ 
between groups. None of the medians for the mood scores were indicative of mood 
disorder according to the revised criteria (Gibbons et al., 2011). The proportion of 
participants satisfying ‘caseness’ and ‘borderline case level’ was compared between 
groups; no significant group differences were found.  
 
Personality domains of the NEO–FFI were also compared between groups. There was a 
tendency for controls to report higher levels of neuroticism than patients. There was a 
tendency for patients to report higher levels of conscientiousness than controls. The 
proportions of patients and controls meeting criteria for ‘extreme levels’ of the 
personality domains (very high; very low) were also compared between groups. There 
was a trend for more controls than patients to fulfil criteria for very low levels of 
extraversion. Significantly more controls than patients fulfilled criteria for very low 
levels of conscientiousness. There was also a trend for more controls (n=4) than patients 
(n=0) to fulfil criteria for very high levels of neuroticism. However, the four controls 
who met criteria for very high levels on the Neuroticism (N) domain, also met criteria 
for ‘caseness’ on the HADS A, suggesting that the high scores on N might be capturing 
these participants’ elevated mood levels. When the four control participants showing 
very high levels of N were removed from the analyses, the trend for between–group 
differences on this domain disappeared. No between–group differences were found for 
any of the empathy domains of the IRI measure. 
 
Patients and controls were compared for the presence and degree of emotional lability. 
Patients showed significantly higher scores on the crying subscale of the ELQ. The 
overall ELQ score was also significantly higher for patients compared to control 
participants. There was a tendency for patients to report higher levels of pathological 








5.3.7. Patient subgroups: medicated and non–medicated patients 
 
A subset of patients were receiving psychoactive medication for disease management 
(n=15). Since psychoactive medication may affect cognitive performance, this subset of 
patients was compared with non–medicated patients on the cognitive composites; 
components and measures of language, memory, behaviour and personality. The patient 
subsets did not differ significantly on demographic variables. There were no between–
group differences for the Executive function or EMOSOC composites. In addition, no 
differences were found between patient subgroups for any of the Executive function 
components or the Hayling error measures. Moreover, there were no differences 
between subgroups for the proportion of patients impaired on the Executive function 
components or Hayling scores.  There was a trend for medicated patients to perform 
worse on the emotion evaluation subtask of the TASIT than non–medicated patients; the 
associated effect size was within the medium range, according to Cohen (1988) 
conventions. The proportion of impaired patients per group on this measure was not 
significant. There were no significant group differences for any of the remaining 
EMOSOC components and no group differences for the proportions of patients 
impaired on these measures.  
 
There were no differences between patient subsets on measures of empathy, behaviour 
and personality. There was no significant difference between patient groups on the 
language measure. There was a trend for medicated patients to perform better than non–
medicated patients on the delayed cued recall trial of the CVLT. Although not 
significant, medicated patients also performed better on the immediate recall and short 
delay recall trials. According to Cohen’s (1988) conventions, the effect sizes associated 
with these three trials ranged from medium to large. Single–case analysis did not find 
significant differences between the proportions of impaired patients in each subset for 
either the language score or the memory trials.     
 
5.3.8. The relative contributions of executive function, personality, mood, empathy 
and behaviour to emotional processing and social cognition in ALS patients 
 
Correlational analyses identified the following predictors which were entered into a 
final hierarchal regression model: Age; years of formal education (control variables); 
Executive function composite; FrSBe Total score, HADS Total and NEO–FFI 
Openness. The results of the final regression analysis support Hypothesis Three. 
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Executive function contributed most to the performance of ALS patients on measures of 
emotional processing and social cognition, with smaller, albeit non–significant, 
contributions from behavioural, personality and mood factors.  
 
5.4. Discussion of findings 
 
This chapter reports an investigation of cognitive functioning in ALS patients with a 
focus on executive function and the processing of emotional and social information. It 
also explores differences in mood, behaviour, personality and empathy between ALS 
patients and control participants. Finally, it examines the relative contribution of 
executive function, mood, personality, empathy and behaviour to emotional and social 
cognition in ALS. This section will consider the position of the study’s findings within 
the current ALS cognitive literature and discuss its theoretical implications. The 
limitations specific to the study design are also discussed. Clinical implications, general 
limitations and recommendations for future research are addressed in the General 
Discussion (Chapter 7).      
 
5.4.1. Hypothesis One: Profile of executive impairment and changes in emotional 
processing and social cognition in ALS 
 
It was hypothesised that, consistent with previous reports, the neuropsychological 
assessment of participants would reveal (i) impaired performance of ALS patients 
relative to controls on domains of executive functioning and (ii) the processing of 
emotional and social cognition. The results of the multivariate analyses in Section 
5.2.2.1. support this hypothesis by demonstrating that, as a group, ALS participants 
performed significantly worse than control participants on a super–ordinate variable of 
the two domains. Univariate analyses showed that patients showed significantly higher 
(more impaired) domain composite scores than controls. Further support for the 
hypothesis was provided by the single–case analysis in Section 5.2.2.3. which found 
significantly higher proportions of patients than controls meeting criteria for impairment 
across the component scores constituting the composite indices. In addition, Section 
5.2.2.4. reports ALS deficits on separate executive function tasks not included in the 
Executive function composite and also describes impaired ALS performance on a task 






A. Executive function  
 
Analyses of the individual components of the Executive function composite score 
showed that ALS patients demonstrated significant performance decrements on the      
D–KEFS card sorting test relative to controls. The D–KEFS measures several factors of 
executive function, such as the ability to perceive, form and express conceptual 
relationships; the initiation of problem–solving behaviour and the ability to inhibit prior 
behavioural responses so as to abandon established sorting rules in search of novel ones. 
All participants were screened prior to the test administration with a screening pre–test 
(see Chapter 4, Section 4.4.3.3.), making it unlikely that these impairments were due to 
language comprehension or visuoperception difficulties. Instead, the impaired patient 
performance might reflect generalised deficits in concept formation and/or response 
initiation alongside a tendency to provide more concrete descriptions of conceptual 
relationships. Previous studies of concept formation and sorting behaviour in ALS have 
used the WCST and found inconsistent results (see Chapter 2, Section 2.2.1.1.). Where 
group differences have been found on the WCST, ALS impairment has been attributed 
to difficulties with cognitive set–shifting and inhibition. Similarly, the impaired sorting 
behaviour demonstrated by patients on the current task may provide further evidence for 
an inability to engage cognitive and behavioural flexibility. Libon et al (2012) reported 
that patients’ free sorting behaviour on the D–KEFS was associated with scores on tests 
of verbal fluency and action naming, suggesting that impairments in executive resources 
and semantic knowledge might contribute to sorting performance. Previous evidence for 
impaired action knowledge in ALS has been suggested (Grossman et al., 2008); 
however, the current study did not assess action naming, so was unable to examine if a 
degraded action/semantic network contributed to patients’ poorer sorting scores.  
 
Further evidence for executive dysfunction in the ALS participants is supported by the 
findings of proportionally more patients than controls showing impairments on the 
verbal fluency indices. ALS patients as a group showed a trend for longer latencies 
(thinking times) on the C–word condition compared to controls, although this trend 
disappeared when non–parametric data were analysed in a sensitivity analysis. The 
study supports previous research which has identified verbal fluency impairments in 
ALS patients after controlling for motor dysfunction (Abrahams et al., 1997; Abrahams 
et al., 2004; Abrahams et al., 2005a; Abrahams et al., 2005b; Abrahams et al., 2000; 
Stukovnik et al., 2010), even though group differences were not significant following 
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the Bonferroni adjustment. More correctly, the results indicate heterogeneity in fluency 
performance within the ALS group, with only a subset of patients showing impairments. 
  
ALS patients demonstrated normal performance on the Brixton Test, a measure of rule 
attainment, concept formation and cognitive flexibility (Burgess & Shallice, 1997). The 
Brixton Test has not been widely used in ALS research, but impairments have been 
noted in two previous ALS studies (Staios et al., 2013; Taylor et al., 2013), as well as 
FTD patients (Lough et al., 2006). It is possible that participant characteristics (both 
patients and controls) in the current study differed from those of other studies which 
have found group differences on the VFI and Brixton Tests. Chapter 7 explores this 
issue in more detail as a possible study limitation.   
 
Analyses of the three scores of the Hayling Test revealed variable patient performance 
across these indices. The latency score is a measure of the difference in the times taken 
to generate words in the ‘Sensible Completion’ (SC) condition and the ‘Unconnected 
Sentences’ (US) condition. It offers an index of inhibitory ability for prepotent 
responses, while controlling for confounds of possible dysarthria. No group difference 
for this score was found, in keeping with a previous study (Wicks et al., 2009). 
However, single–case analysis revealed a trend for proportionally more patients than 
controls to exhibit impairments on this measure. In addition, on average, patients 
committed significantly more Category A and Category B errors than controls, a finding 
which has been reported elsewhere (Lillo et al., 2012b). Single–case analysis also 
revealed a trend for proportionally more patients than controls identified as impaired on 
the basis of these scores. The presence of Category A responses indicates that patients 
more often than controls failed to suppress a logically appropriate response upon 
completing sentences in the US condition. The Category B errors suggest that patients 
avoided responding with an obviously sensible word but completed sentences with 
words that were connected in meaning with the subject of the sentence or the sensible 
word to be suppressed. The presence of these errors further suggests that, compared to 
controls, patients experienced more difficulty with the response suppression demands of 
the task. Their presence might also explain why no between–group impairment for the 
latency score was found: patients may have responded impulsively (i.e. quickly) at the 
expense of suppression effort. The results corroborate previous findings of inefficient 
inhibitory process in ALS patients which have used other paradigms, such as the Stroop 
(Frank et al., 1997; Gibbons et al., 2007; Hanagasi et al., 2002; Rusina et al., 2010; 
Sterling et al., 2010) and negative priming (NP) tasks (Abrahams et al., 1997; Goldstein 
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et al., 2011). However, these studies vary in their use of controls for motor impairment 
and the adoption of the latency score in the current study suggests that a subset of 
patients may show true inhibition impairments, independent of motor slowing.    
 
B. Emotional processing and social cognition  
 
Following the identification of a between–group effect for the transformed EMOSOC 
composite score, performance on the individual components of the composite was 
compared between groups. More detailed analyses comparing between–group 
performance on individual tests of emotion and social cognition were also conducted. 
The present investigation revealed that, as a group, ALS patients demonstrated 
comparable performance with healthy controls on the RME and TASIT subtests. The 
proportions of impaired cases on these measures were also comparable between groups. 
However, group differences for all three subtasks of the Happé task were found; single–
case analyses revealed proportionally more ALS impairments for the single cartoon 
abstraction subtask.    
 
Regarding the RME, the current findings are in keeping with those of Cavallo et al, 
(2011a), who also found that group– and individual–level analyses did not reveal 
significant differences between ALS patients and controls. Together, these studies’ 
findings are inconsistent with a smaller study from Girardi et al (2011) who reported a 
strong trend for between–group differences on this measure. Cavallo et al (2011a) 
explain that since the RME is a ToM measure that requires the comprehension of social 
emotions but not social situations, unlike their other experimental task in which group 
differences were found, normal ALS performance on the RME might be attributed to 
the measure’s inability to detect select deficits in the understanding social scenarios. A 
similar argument might suffice for the interpretation of the current study’s findings of 
RME performance, particularly since group differences were found for the Happé social 
cartoons and scenario task. However, the TASIT task, which includes subtests that 
simulate everyday social interaction, did not elicit group differences. Alternatively, 
intact RME performance for patients in this and Cavallo et al’s (2011a) study might be 
explained by a lack of impaired emotional processing in patients. Girardi et al (2011) 
found that patient performance on the RME correlated strongly with performance on a 
basic emotion recognition task, a measure on which the patient group was also impaired 
relative to controls. In the current study, ALS patients performed similarly to controls 
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on the emotional evaluation task (EET) of the TASIT; suggesting the appraisal of basic 
emotions to be intact in the current patient group.  
 
The lack of group difference for the emotion recognition task in the current study is 
consistent with recent studies using the same dynamic TASIT EET task in non–
demented patients (Savage et al., 2013; Staios et al., 2013). Savage et al (2013) found 
that within their ALS group which comprised demented and non–demented patients, 
only the ALS–FTD patients showed impaired emotion recognition on this measure, 
relative to controls. Although the current study did not directly compare non–demented 
and demented ALS patients, it lends some support to the notion that emotion processing 
deficits are not a feature of the non–demented form of the disease. That said, these 
findings are in contrast with earlier studies that have reported impaired emotion 
recognition in non–demented patients on static measures of facial emotion (Girardi et 
al., 2011; Lillo et al., 2012b; Zimmerman et al., 2007), but consistent with others that 
report no such deficit (Papps et al., 2005; Savage et al., 2013; Staios et al., 2013).  
 
Studies in ALS vary by method and criteria used for screening of cognitive impairment. 
The inconsistencies across ALS studies might therefore be the result of undiagnosed 
ALS–FTD patients contributing to mean performance in studies finding positive results.  
Moreover, the use of psychoactive substances for disease management by some patients 
might also influence the performance of patient samples, as the current study found a 
trend for impaired performance of medicated compared to non–medicated patients on 
this measure (the implication of this finding is discussed more broadly in Chapter 7). 
Studies of emotional processing in ALS often do not specify psychoactive use as an 
exclusion criterion, or report and control for such substances. Alternatively, the nature 
of the TASIT task might aid emotion recognition in patients who would otherwise 
perform poorly on traditional static emotion tasks. The TASIT task includes other 
contextual information, such as dialogue and speaker’s intonation, which may assist 
patients in determining the correct emotion portrayed by the actors.  That is to say, non–
demented patients may indeed have a select difficulty in decoding ‘rudimentary 
emotion’ from faces on the basis of structural information alone, but that this difficulty 
is mitigated in their real–world experiences of emotion recognition through auxiliary 
cognitive processes that are sensitive to other aspect of emotional display. More studies 
using both static and dynamic measures of basic emotion identification in non–
demented ALS patient samples (e.g. Savage et al, 2013) are needed to substantiate this 
suggestion.    
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The current study failed to find evidence that ALS patients are impaired at interpreting 
higher order social interactions, such as those which incorporate sarcasm and deceit, on 
measures of realistic social scenarios. This is at variance with Staios and colleagues’ 
(2013) findings that ALS patients were impaired relative to controls in interpreting 
simple and paradoxical sarcastic statements. The inconsistent findings might have 
resulted from differences in sample characteristics between the studies. A comparison 
of demographic and disease symptom data does not suggest gross discrepancies 
between patient groups. Furthermore, similar sampling methods and exclusion criteria 
were applied in both studies. Since Staios and his colleagues did not include a 
comprehensive measure of executive functioning, it is difficult to compare the relative 
profiles of cognitive impairment between the patient samples. Nonetheless, distinct 
executive difficulties existing between the patient groups may have been present and 
could account for the incompatible results. For example, the previous study found that 
patients were significantly impaired on the Brixton Test; a result which was not 
replicated in the current study. Instead, ALS patients in the current research showed 
impaired performance on the D–KEFS card–sorting task. Both tests are sensitive to rule 
attainment, adherence and switching; but the rules of the former task are more abstract 
and responses are not prepotently determined by the stimulus situation (Shallice et al., 
1996). The contextual processing required by the Brixton Test (e.g. the anticipation of 
future pattern sequences) might therefore be more analogous to social rule attainment 
and adherence in real world environments than that of the D–KEFS. Thus the nature 
and/or degree of executive dysfunction in patients may have differed between studies, 
possibly contributing to the different results obtained on the TASIT.     
 
The current study found that the patients showed impaired performance relative to the 
controls on a task requiring the interpretation of humorous cartoons and social stories. 
This replicates previous research using the same task in a smaller group of non–
demented ALS patients (Gibbons et al., 2007), although in that study group effects on 
the cartoon subtasks were masked by the heterogeneity of performance within the ALS 
group. It also resonates with an early study which used the task to assess mental 
attribution in FTD patients (Snowden et al., 2003). In the current study, between–group 
effects for accuracy were found for all three subtasks. Unlike the previous studies, 
effects for the cartoon condition were also found for the single cartoon inference and 
scenarios subtests: both groups performed worse on the physical compared to the 
mental condition on the single cartoon task but for the scenarios task, the reverse was 
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true. This might indicate that the physical cartoon stimuli were more difficult than the 
mental cartoon stimuli, while the mental stories may have been more difficult than the 
physical stories. On the paired cartoon subtask, both groups identified the correct 
(‘funny’) cartoon on a forced–choice trial more often under the mental condition, 
further indicating disproportionate difficulty between the conditions. Moreover, single–
case analyses revealed that proportionally more ALS patients than controls showed 
impairments on the physical cartoons of the single cartoon subtask. For the same task, 
only a trend for proportionally more impairments on the mental cartoons was found for 
patients compared to controls. Patients also showed a trend for proportionally more 
impairments than controls on the physical story condition compared to controls. 
Notably, no select ToM deficit was demonstrated by the ALS patients for any of the 
subtasks, in keeping with patterns of impairment previously found in ALS (Gibbons et 
al., 2007) and FTD patients (Snowden et al., 2003) on the task. A lack of isolated ToM 
deficit specific to ALS participants suggests that the poorer overall performance by the 
ALS participants might be attributed to a general impairment in executive, or 
inferential, ability in these patients. The contribution of executive function to social 
cognition in ALS is discussed in Section 5.4.4.  
 
The analyses of errors provided an insight into the qualitative differences in responses 
between the groups. For both groups, the largest proportion of errors for all three 
subtests were partial errors, in which participants gave accurate inferences but which 
were incomplete or not explicitly stated, even after prompting from the researcher. 
Proportions between groups for these errors were not significantly different. For the 
single cartoon inference subtask, patients provided proportionally more descriptive 
responses than controls; indicating that they were able to describe and integrate the 
contents of the cartoons but failed to draw inferences beyond their contents. This 
replicates the pattern of errors previously shown by ALS patients (Gibbons et al., 2007). 
A trend for this error type was again demonstrated by patients relative to controls on the 
paired cartoon abstraction subtask. In addition, patients showed proportionally more 
misconstruction errors (faulty inferences) on the paired cartoon and social stories 
subtasks. Notably, for the cartoon pairs task, both groups committed more 
misconstruction errors on the physical condition. This affirms the earlier suggestion that 
the physical cartoons might be harder than the mental cartoons. On the scenario task, 
while both groups made more misconstructions on the mental condition, there was a 
strong trend for patients to commit more of these errors on this condition relative to 
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controls. This indicates that while both groups showed more difficulty with drawing 
accurate inferences regarding the thoughts, feelings and intentions of characters in the 
stories than those regarding logical rules of the situations, patients showed a tendency 
for more difficulty with these ‘mental’ inferences than the controls. This pattern differs 
from that of the previous studies which showed that FTD and bulbar ALS patients’ 
errors were characterised by concrete responses, in which participants failed to integrate 
the contents of the cartoons or stories into a thematic narrative regardless of cartoon or 
story condition (Gibbons et al., 2007; Snowden et al., 2003). By comparison, concrete 
responding was relatively rare for both participant groups in the current study. The 
qualitative differences between these studies may be due to more impaired cognitive 
status of the FTD and bulbar ALS groups. In the Gibbons et al (2007) study, for 
example, bulbar patients performed significantly worse than non–bulbar patients and 
controls (who did not show concrete responding) on background tests of 
neuropsychological function.   
 
The misconstructions demonstrated by the patient group might relate to the impulsive 
responding demonstrated by the pattern of errors found for patients on the Hayling task. 
On items where patients were unable to comprehend the ‘joke’ or the story content fully 
they may have provided their ‘best guess’ before sufficient reflection. Mean response 
times did not differ between groups, but time to respond may not be the best index of 
reflection quality. The descriptive errors found on the cartoon subtasks may relate to the 
presence of deficient concept formation skills or impaired cognitive flexibility, as 
indicated by patients’ performance on the D–KEFS. For example, a lack of mental 
flexibility might prevent patients from conceiving alternative meanings, such as the 
non–literal interpretation of the stories or cartoons, thereby preventing inferences to be 
drawn beyond their contents. This might similarly account for the misconstruction 
errors as patients offer their own idiosyncratic interpretation instead. For the scenarios 
subtask, misconstructions might have resulted from the memory demands of the task as, 
unlike the cartoon trials, stimuli were not presented in full view during participant 
responding. Patients may have confabulated erroneous inferences because they could 
not remember specific details of the story, although this is not compatible with the 
presence of mainly partial errors shown by patients on all three subtasks. On the other 
hand, these findings might be the result of scoring bias; however, the second rater was 
blind to the participants’ diagnoses and inter–rater agreements for error responses were 




The Happé task has previously been criticised for using humour as well as social and 
non–social situations in the same experimental category (i.e. across both mental and 
physical conditions) (Cavallo et al., 2011a; Meier et al., 2010). In addition, within the 
mental condition, the cartoons and stories require both cognitive (thoughts) and 
emotional (feelings) attribution, with an emphasis on the former. The condition also 
does not distinguish between first–order and second–order mental state attributions. 
Selectivity of ToM ability has been shown in ALS patients using other cartoon tasks. 
Patients have demonstrated deficits in attributing emotional rather than cognitive states 
to cartoon characters (Cerami et al., 2013), as well as a difficulty inferring the mental 
states of characters involved in social as opposed to private situations (Cavallo et al., 
2011a). The lack of specificity between conditions in the Happé task may render it a 
less sensitive assay of ToM ability. The use of alternative ToM measures, which 
differentiate between the subcomponents of ToM or social contexts, might have 
provided greater scope to identify select deficits in the patients or qualify the 
relationship between ToM and executive dysfunction in ALS.  
 
The finding that impairments were elicited on the Happé task and not the TASIT social 
inference subtasks might be due to the greater complexity of the former measure. The 
Happé task requires the integration of information presented in the abstract form of 
static cartoons and scenarios; it also requires the effortful expression of this integration 
into a coherent narrative. The TASIT, by comparison, is a more passive experience. It 
provides the physical (i.e. visual and auditory) context of the presented situation and 
requires a simple ‘yes’, ‘no’ or ‘don’t know’ answer. This closed–ended question 
format may prevent detailed examination of erroneous responses. For example, patients 
and controls in the current study might have committed errors on the same items, but for 
distinct reasons. Open–ended questions, such as those from the Happé task, provide a 
qualitative account of differences in the inferences drawn between the participant 
groups. The drawback of the open–ended format; however, is that this is more verbally 
demanding and time–consuming which might preclude participation from patients with 
severe bulbar symptomology and fatigue. This was applicable to non–participation in 
the Happé task of the current study.   
 
Furthermore, although stimuli from both tasks include situations of deceit and false 
belief, the TASIT includes items in which characters are being deliberately sarcastic 
(i.e. verbal irony), while the Happé task includes stimuli in which characters find 
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themselves in ironic situations (i.e. situational irony), but not necessarily experiencing 
another character’s ridicule. The manipulation of ridicule has been found to affect 
healthy participants’ ratings of sarcasm but not irony in written passages of social 
conversation (Lee & Katz, 1998). The presence of a ‘victim’ in the TASIT scenarios 
may therefore have aided the detection that sarcasm was at play in the enacted 
exchange, whereas the detection of irony on some items of the Happé subtasks relied on 
the participant’s appreciation that the outcome of the scenario was incongruous to what 
is generally expected; i.e. that the ‘order of things’ had been violated (Lucariello, 1994). 
Without the benefit of additional cueing, the latter detection exercise might have been 
more difficult or required more effortful abstraction.  
 
C. Other cognitive domains 
 
Although not a focus of the current research, memory and language were also examined 
as part of the neuropsychological battery. The ALS group did not differ significantly 
from the control group on either domain at the group or individual level. 
 
Findings of memory impairments in ALS patients have been inconsistent for both 
verbal and visual stimuli (see Chapter 2, Section 2.2.1.3.). Where they are present, they 
are often interpreted as secondary to executive impairment. This position is supported 
by a meta–analysis which found a significant effect size for immediate but not delayed 
verbal memory (Raaphorst et al., 2010), a pattern of performance typically associated 
with frontally–mediated executive dysfunction (Lezak, 2004). However, recent 
evidence from a population study suggests that global memory impairment, independent 
of executive dysfunction, may exist in ALS (Phukan et al., 2012). While the current 
results provide evidence for executive dysfunction in the patient group, there is no 
evidence of executive–related memory disturbance. Although, the study relied on only 
one attenuated measure of verbal memory; a more thorough assessment of both verbal 
and visual memory may have rendered a different set of results. 
   
The study did find a trend for performance differences on a delayed cued recall trial 
between medicated and non–medicated patients, with medicated patients performing 
better on this trial. The enhancing effects of antidepressants on memory processes in 
healthy participants have been indicated by meta–analysis (Repantis et al., 2009). Thus, 
SSRIs may have influenced patients’ performance on the CVLT in the current study. 
Alternatively, these findings might be influenced by the presence of an unexamined 
variable or interaction. Single–case analysis found no indication of memory impairment 
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in the medicated group, suggesting that the effects of medication on performance for 
this trial, if any, were minimal. The inclusion of patients using psychoactive medication 
as a limitation specific to this study, as well as its implications for future ALS research 
are discussed in Chapter 7.    
 
Language was assessed using a measure of confrontation naming. No ALS impairment 
was indicated, a result that contributes to the variability in findings associated with ALS 
performance on such measures (see Chapter 2, Section 2.2.1.2.). The use of only one 
language test in ALS cognitive research is pervasive; presumably due to the emphasis 
on executive dysfunction within the disease and the limitations imposed by patients’ 
disability and fatigue on testing procedures. These reasons were, at least, applicable to 
the current study’s design. The few language studies in non–demented ALS have 
identified impairments on measures of comprehension, syntax and spelling, verb 
processing and discourse (see Chapter 2, Section 2.2.1.2.). Further, recent evidence 
which used a comprehensive battery of language and executive function tasks suggested 
that language impairment in patients may be as prevalent if not more prevalent than 
executive dysfunction (Taylor et al., 2013). The use of only one language measure in 
the current investigation may therefore have limited its efficiency in identifying more 
subtle language deficits and should not be over interpreted. 
 
5.4.2. Hypothesis Two:  Profile of behavioural change in ALS 
 
It was hypothesised that ALS patients would show higher premorbid and current 
behavioural dysfunction than controls. The results reported in Section 5.2.3. do not 
support this hypothesis. Patients self–ratings of premorbid behaviour were lower (less 
impaired) than controls’ retrospective self–ratings for the domains of Apathy, Executive 
Dysfunction and the Total FrSBe score. For the current scores, only a trend for a 
significant difference between groups for the Apathy subscale was observed. However, 
while patients reported increased behavioural dysfunction from premorbid to current 
ratings for the Total score and the domains of Executive Dysfunction and Disinhibition, 
the opposite direction of change was observed for controls. In both groups, levels of 
Apathy increased in the same direction, but patients reported a greater increase on this 
domain.  
 
A comparison of the current patients’ mean self–rated FrSBe domain scores with other 
studies using self–report data are shown in Appendix VIII.a.. Apart from one study 
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(Chio et al., 2010), a pattern of predominant apathy characterises patients’ current 
behaviour across the samples (Girardi et al., 2011; Woolley et al., 2010a). The 
proportions of patients’ self–ratings meeting behavioural impairment on the current 
domain scores are greater than that reported by Witgert et al (2010), the largest study of 
behaviour in ALS to date (n=225, see Appendix VIII.b.). However, only informant data 
were used in that study and lower proxy ratings relative to patients has been indicated in 
other research (Girardi et al., 2011; Woolley et al., 2010a). The current finding of 
higher retrospective self–ratings for controls relative to patients has previously been 
noted in a UK study (Girardi et al., 2011). This might reflect pre–existing personality 
traits in the control participants which differ in some way from patients (see Section 
5.4.3. and discussion in Chapter 7). Alternatively, it might suggest that the available 
FrSBe (American) norms are not appropriate for use in British samples as they may 
overestimate impairment.  
 
A key finding from the behavioural results was that the direction and magnitude of 
change from retrospective to current behaviour differed between groups on the FrSBe 
domains. The greatest change for patients occurred on the Apathy domain, which 
examines initiation, motivation, persistence, interest in others and blunted affect. 
Increased apathy is one of the most commonly reported behavioural symptoms in ALS 
patients (see Chapter 2, Section 2.2.2.1.), but concern has been raised regarding some 
apathy items on the FrSBe which may load on motor disability or mood (Gibbons et al., 
2008; Girardi et al., 2011; Witgert et al., 2010). In the current study, the patients’ 
increased ratings over time were unlikely affected by anxiety and depression, as median 
current mood scores did not differ from the control group and did not indicate mood 
disorder. Previous studies have also demonstrated raised apathy in non–depressed ALS 
patients (Gibbons et al., 2008; Grossman et al., 2007; Lillo et al., 2011; Lomen-Hoerth 
et al., 2003; Wicks et al., 2009; Witgert et al., 2010). All participants in this study were 
instructed to rate their behaviour independent of their physical (dis)ability; however, for 
patients responding to certain items (e.g. “Am slow moving, lack energy, inactive” or 
“Sit around doing nothing”) this may have been unrealistic, given the physical and 
practical consequences of the disease.  
 
Smaller changes in patients’ self–ratings over time were shown on the Executive 
Dysfunction and Disinhibition subscales. The former domain assesses attention, 
planning, shifting responding and self–monitoring while the latter domain examines 
impulsivity and inappropriate social behaviour. These domains are less likely to be 
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affected by motor dysfunction (Witgert et al., 2010), thus the endorsements of raised 
post–illness levels by patients on these domains may substantiate the presence of true 
behavioural change in ALS. For the Executive Dysfunction and Disinhibition subscales, 
a decrease on these measures in the healthy control participants might reflect a tendency 
to attribute positive effects of ageing (i.e. experience and wisdom) on behaviours which 
have connotations of immaturity (e.g. “Do risky things just for the heck of it”). Another 
more obvious explanation for these patterns of results, applicable to both participant 
groups, is the influence of recall bias, the effect of which is impossible to measure.  
 
Although not a formal investigation of the study, patients’ increased FrSBe scores over 
the course of their disease might correspond to their performance on tests of executive 
functioning. The D–KEFS card sorting task, a measure on which patients’ group 
performance was impaired relative to controls, requires participants to sustain attention, 
initiate and shift responding while maintaining motivation to persevere with the task 
demands; similar processes to those believed to be measured by the Apathy and 
Executive Dysfunction subscales. Further, the pattern of errors shown by ALS patients 
on the Hayling Test may indicate a tendency for impulsiveness and/or difficulty with 
inhibitory control, processes to which the Disinhibition subscale is believed to be 
sensitive. The relationship between patients’ behavioural change and performance on 
measures of emotional processing and social cognition is discussed in Section 5.4.4.  
The profile of the ALS patients’ cognitive and behavioural profile is discussed more 
broadly in Chapter 7.    
 
In summary, patients’ self–rated scores on the FrSBe in the current sample do not 
indicate greater levels of behavioural dysfunction in relation to controls. However, 
changes in behaviour scores for patients over the course of their disease appear to be 
more substantial and in some cases differ in direction from controls over time. The 
behavioural change in the current patients is characterised by raised levels of apathy 
since before the onset of their disease, with more subtle changes in dysexecutive and 
disinhibited behaviours in the same direction.  
 
5.4.3. Exploratory Research Question One: Mood, self–reported personality and 
empathy in ALS 
 
Patients and controls were matched for mood, an aim to ensure that identified between–
group differences on neuropsychological tests or responding on behavioural inventories 
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were not an artefact of differences on this variable. Median scores were not indicative 
of mood disorder and the proportions of participants per group meeting revised criteria 
for ‘caseness’ did not differ. Studies investigating mood in ALS have reported 
inconsistent estimates of elevated depression and anxiety in patients (see Chapter 2, 
Section 2.2.3.). Despite the variability in findings, the view that mood disturbance is 
rare in ALS persists. The current results would appear to support this view; however, 
the influence of selection bias should not be underestimated as patients who self–select 
themselves for research studies are unlikely to be suffering from low or disturbed mood. 
Further, it is possible that the study may have underestimated the prevalence of 
psychological change in the ALS sample due to the exclusion of patients with severe 
disability (Hogg et al., 1994; Hunter et al., 1993). Moreover, although the revised 
HADS measure used in this study shows satisfactory reliability and validity for use in 
ALS patients (Gibbons et al., 2011), it is not formally diagnostic of mood disorder. 
Furthermore, while a Rasch analysis supported the suitability of the revised HADS for 
the ALS population (Gibbons et al., 2011), there is no data on its appropriateness for 
use in the healthy adult population. Consequently, this might affect the application of 
the revised ‘caseness’ criteria to this participant group as well as comparisons of 
‘caseness’ between the groups.   
    
Patients’ self–rated scores on the Big Five personality domains did not differ 
significantly from those of control participants. A trend for higher levels of neuroticism 
in controls than patients was found. Similarly, a trend for more controls scoring within 
the very high range of the Neuroticism scale was observed. Four controls and no 
patients met criteria for very high levels of neuroticism. High scores on this scale 
suggest susceptibility for psychiatric problems but are not a measure of 
psychopathology per se (Costa & McCrae, 1992). Congruously, the four controls who 
scored in the very high range on this domain showed ‘caseness’ levels of anxiety on the 
HADS mood measure, suggesting that the personality scale may have captured the 
anxious dispositions of these participants. When these cases were eliminated from the 
analysis, the trend for between–group differences disappeared.  
 
Patients showed a trend for higher levels on the domain of Conscientiousness than 
controls. This scale assesses facets of personality, such as self–discipline, work ethic 
and diligence (Costa & McCrae, 1992). Initially these results appear to resonate with 
findings from Brown & Mueller (1970) who described the ten patients in their study as 
showing a high level of internal locus of control and ‘hard–working’ behavioural styles.  
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However, proportionally more controls than patients showed very low levels of 
conscientiousness in further analyses. This suggests that the between–group difference 
in mean ratings for the Conscientiousness domain arose from more controls reporting 
very low levels of conscientiousness, rather than from a high proportion of patients 
displaying high levels of this trait. Therefore the study fails to support Brown & 
Mueller’s early finding. Of note, the results also do not replicate a previous study using 
the NEO–PI, which found that ALS patients’ mean scores for levels of openness were 
lower than those of a progressive disease control group (Grossman et al., 2006). Scores 
on this domain correlated with performance on the EMOSOC composite score; this 
relationship is discussed in Section 5.4.4.  
 
The IRI subscales were designed to capture different facets of empathy (Davis, 1980); 
no differences between patients and controls on any of the domains were found. This 
may indicate that, unlike ALS–FTD, reduced empathic ability is not a feature of non–
demented ALS. However, premorbid and current scores were not compared in the 
current sample, so the results are limited in their ability to infer individual patient 
changes since the onset of ALS. 
 
Some caveats concerning the assessment of personality and empathy in the current 
study deserve consideration. The NEO–FFI is based on the Five–Factor Model (FFM) 
which, although widely accepted, has faced criticism for its adoption of a data–driven 
rather than a theory–driven approach to personality (a clustering of trait adjectives 
under factor analysis) and its limited scope of personality traits (see Block, 2010 for 
review). As such, personality characteristics which might be specific to the ALS 
patients (e.g. egotism, risk–taking) but not considered within the model (Paunonen & 
Jackson, 2000) were not assessed. In addition, the NEO–FFI is an abbreviated version 
of the NEO–PI, and collapses different facets of personality under each domain. This 
might have obscured differences or associations occurring at the lower–order levels of 
the scale (Schnabel et al., 2002).  
 
The IRI was chosen in preference to other empathy measures, such as The Empathy 
Quotient (Baron-Cohen & Wheelwright, 2004), because it differentiates empathy into 
‘cognitive’ and ‘emotional’ components, in keeping with neuroscience models of the 
construct (Decety & Jackson, 2006; Shamay-Tsoory et al., 2009). Criticisms regarding 
the ecological–validity of the questionnaire have been raised (Dziobek et al., 2008). 
Some of the items ask respondents to appraise their feelings towards hypothetical 
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situations involving fictional characters from novels or films rather than everyday 
personal exchanges involving other people (e.g. “After seeing a play or film, I have felt 
as though I were one of the characters”). Some responses therefore may not accurately 
reflect patient’s empathic behaviour in everyday life.  
 
As already suggested, the FrSBe may be confounded by items which load on physical 
ability, a caveat which extends to the IRI and NEO–FFI. In addition, none of the 
measures assessed social desirability which may have attenuated, inflated or mediated 
relationships within the data obtained from participants. Furthermore, other biases 
which may have influenced responding in the patient group, such as psychological 
coping or denial mechanisms, were not assessed.  
 
5.4.4. Hypothesis Three: The contributions of executive function, behaviour, mood, 
personality and empathy to emotional processing and social cognition in ALS 
 
Hypothesis Three predicted that emotional processing and social cognition in ALS 
would be best predicted by executive function relative to behaviour, mood, personality 
and empathy. The results of Section 5.2.9. support this hypothesis.   
 
The study demonstrated that executive dysfunction was the only predictor of socio–
emotional processing in ALS when entered into a model comprising mood, personality 
and behaviour, while controlling for age and years of formal education. Correlational 
analyses did find that measures of apathy and dysexecutive behaviour correlated with 
the EMOSOC composite score, resonating with a previous study which found an 
association between apathy scores and a preference judgement task (Girardi et al., 
2011). The study is also the first to consider the influence of personality and empathy 
on performance on social cognitive measures. The NEO–FFI Openness T–score was the 
only personality domain to correlate significantly with the EMOSOC composite. People 
who score low on this trait typically feel emotion less intensely than others and are less 
attentive to forms of experience, such as fantasy and intellectual curiosity (McCrae & 
John, 1992). The presence of this relationship is therefore meaningful. Surprisingly, 
levels of empathy did not correlate with the composite score; a relationship between 
empathy and socio–emotional impairments has been demonstrated in FTD patients 
(Shany-Ur et al., 2012). An absence of a significant correlation between these scores 
might indicate that self–perceived current empathic ability does not underlie socio–
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emotional processing in non–demented ALS. Alternatively, the components of 
EMOSOC composite may not have measured empathy.  
 
When personality and behaviour were entered into the model along with a measure of 
overall mood, the addition of these variables did not improve the variability explained 
in the composite and needless to say none were found to be significant predictors of the 
EMOSOC score. These findings may imply that ALS–related executive dysfunction, 
may sufficiently explain variability in socio–emotional processing above and beyond 
individual differences in mood, personality and behaviour. However, patients in the 
current sample did not show scores indicating clinical behaviour, mood disturbance or 
gross personality change. The interpretation of the outcome created by the regression 
procedure is therefore restricted to those ALS patients who do not show impairment on 
these domains.   
 
The interpretation of the influence of executive function on emotion processing and 
social cognition in ALS is controversial. Several studies of non–demented ALS have 
noted moderate to strong relationships between patients’ executive dysfunction and 
impairments on measures of emotion recognition and ToM. Nonetheless, evidence from 
individual–case analysis suggests that patients may be exclusively impaired on either 
domain, or show concurrent impairments (see Chapter 2, Section 2.3.2.4.). Similarly, 
two patients in the current study showed concurrent impairments on the composites, 
five patients showed isolated impairments on the Executive composite and four patients 
showed isolated impairments on the EMOSOC composites (see Section 5.2.2.3., Table 
5.13.). This profile suggests that for at least four patients, impairments on the measures 
of emotional processing and social cognition might have occurred independently from 
deficits in executive function. Nonetheless, three patients showed dissociations between 
their performances on the composites; the directions of these dissociations indicated 
that all patients were impaired on the Executive composite but unimpaired on the 
EMOSOC composite. No dissociation showed the reverse direction (i.e. impaired on 
EMOSOC but unimpaired on Executive composite). This result indicates that none of 
the isolated impairments on the EMOSOC composite described above were dissociated 
from patients’ performances on the Executive composite. Therefore, it remains possible 
that poor performance on the Executive function composite, while not poor enough to 
qualify for a deficit, might have contributed to the patients’ deficits on the EMOSOC 




Overall, the current study supports the position that deficits in emotional processing and 
social cognition in ALS reflect a primary deficit in executive function. However, the 
patients in the current study did not display significant impairments on several of the 
experimental tasks, such as the ability to recognise basic and social emotion or the 
ability to attribute mental and emotional states to characters in enacted scenarios. 
Instead, patients showed a profile of predominantly executive dysfunction, and the 
social cognition task on which impaired performance was elicited may have loaded 
more on executive resources than the other experimental tasks (see Section 5.4.1.).  
 
5.4.5. Broader theoretical implications 
 
A. Implications for the ALS – FTD cognitive continuum 
The current research adopted a focussed study of executive functioning, emotional 
processing and social cognition in non–demented ALS patients. The neuropsychological 
battery included tests which have demonstrated sensitivity to impairments on these 
domains in patients with ALS–FTD and FTD, referred here collectively as ALS–
FTD/FTD patients. The investigation of executive functioning in the current ALS group 
revealed impairments that are similar in nature to those reported in ALS–FTD/FTD. In 
particular, group level analyses showed that patients displayed difficulties with category 
formation, problem–solving and inhibitory control, while single–case analysis revealed 
that a subset of patients showed impairments on measures of verbal fluency. Similarly, 
significant behavioural differences did not exist between patients and matched controls 
at the current time point. However, increases in apathy, as well as dysexecutive and 
disinhibited behaviour since the onset of ALS were reported by the patients. Common 
cognitive processes and behavioural domains have been implicated in the cognitive 
profile of ALS–FTD/FTD patients (see Chapter 2, Section 2.1). 
 
On the other hand, the investigation of emotional processing and social cognition failed 
to demonstrate impairments in emotion recognition with only partial support for 
impaired ability on a social cognition task. Impairment on the latter task was most likely 
due to a general impairment in executive function, rather than a select ToM deficit per 
se. As in ALS, the relationship between executive function and ToM in FTD is 
controversial. Executive impairment in FTD may mask specific ToM deficits, with 
more severe executive dysfunction associated with greater ToM impairment (Snowden 
et al., 2003). It has also been argued that executive function in FTD may support the 
general ability to process cartoons and stories but is not fundamental to the attribution 
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of mental states to the characters (Lough et al., 2006). A lack of specific ToM 
impairment displayed by patients in the current study is in keeping with Snowden et al’s 
(2003) observations in FTD patients. Nonetheless, dissociation of ToM and executive 
function has been demonstrated in ALS patients elsewhere (see Chapter 2, Section 
2.3.2.4). Furthermore, the errors displayed by the current patients on the social 
cognition task differed from those displayed by a previous FTD group (Snowden et al., 
2003). However, the qualitative differences between the groups may exist due to the 
more impaired cognitive status of the FTD patients. Deficits in the recognition of basic 
and social emotion are pronounced in bvFTD and some SD patients (Eckart et al., 2012; 
Fernandez-Duque & Black, 2005; Keane et al., 2002; Kipps et al., 2009; Omar et al., 
2011; Rosen et al., 2004; Rosen et al., 2002; Snowden et al., 2008); whereas in non-
demented ALS patients the evidence for impairment is inconsistent (see Chapter 2, 
Section 2.3.). One cross–sectional study has suggested that these deficits only emerge 
with the presence of FTD (Savage et al., 2013). Since the study excluded ALS–FTD 
patients it is not known whether the cognitive profile of current sample represents an 
intermediate position between classical ALS and the dementia forms of disease. 
Nonetheless, the primary executive dysfunction present in these patients supports the 
existence of ALS–FTD/FTD cognitive impairment within the non–demented ALS.   
 
Evidence for the progression of FTD–like impairments in ALS patients provides the 
strongest support for a cognitive continuum between ALS, ALS–FTD and FTD. 
Without longitudinal data, it is difficult to determine whether the predominant pattern of 
executive impairment in the current patients will evolve to encompass socio–emotional 
impairments and eventually a full blown FTLD syndrome. The few longitudinal 
investigations of cognition in non–demented ALS have provided mixed evidence for 
progressive cognitive deterioration in such patients (see Chapter 2, Section 2.2.1.7.), 
and none have considered the longitudinal effects of ALS on emotion processing and 
social cognition. This raises an interesting recommendation for future research which 
will be discussed further in Chapter 7.  
 
B. Implications for underling neural substrates in ALS cognitive change 
 
Growing evidence from neuroimaging research has associated the profile of cognitive 
impairment in ALS with underlying cerebral dysfunction (see Tsermentseli et al., 2012 
for review). The majority of studies have focused on the neural underpinnings of 
executive dysfunction, with relatively little exploration of possible correlates of 
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language disruption and changes to emotion and social processing, although 
neuroimaging studies in these latter areas are accumulating (Abrahams et al., 1996; 
Abrahams et al., 2004; Abrahams et al., 2003; Cerami et al., 2013; Goldstein et al., 
2011; Grossman et al., 2008; Lule et al., 2007; Palmieri et al., 2010). In conjunction 
with the emerging cognitive neuroimaging literature in ALS, the current research 
provides possible insight into the neurological substrates of cognitive dysfunction in 
non–demented patients.  
 
While no neuropsychological test is a pure assay of neuronal function, the current 
results indicate a profile of predominantly frontally–mediated executive impairment in 
the ALS group, with relative sparing of cognitive functions associated with emotion and 
social processing. In particular, patients demonstrated impairments on executive tasks 
which have been strongly associated with the functioning of frontal structures in ALS 
patients, such as the DLPFC and AC (Abrahams et al., 1996; Abrahams et al., 1995; 
Abrahams et al., 2004; Abrahams et al., 2003; Kew et al., 1993a). Furthermore, patients 
displayed a predominant pattern of increased apathetic behaviour since ALS onset; this 
pattern has previously been associated with WM reductions in the AC and right frontal 
gyrus (Tsujimoto et al., 2011; Woolley et al., 2011). By contrast, preserved emotion 
recognition, ToM and empathy in the current sample would suggest intact functioning 
of the OFC and/or vmPFC, which are regions strongly implicated in these domains 
(Eslinger, 1998; Gallagher et al., 2000; Heberlein et al., 2008; Hornak et al., 2003; 
Hornak et al., 1996; Shamay-Tsoory et al., 2009; Shamay-Tsoory et al., 2005; Stone et 
al., 1998). However, the contribution of OFC functioning to performance on traditional 
tests of executive function tasks has been suggested (Bertoux et al., 2012; Collette et 
al., 2001; Zald & Andreotti, 2010). As such, the error pattern demonstrated by the 
current patients on the response inhibition task has been associated with OFC 
impairment in lesion and dementia groups (Hornberger et al., 2010; Volle et al., 2012); 
providing partial support for other studies which have implicated this brain region in 
non–demented patients (Meier et al., 2010; Tsujimoto et al., 2011). Early OFC 
involvement is indicated in bvFTD and is suggested to account for the invariable 
breakdown in emotional and social behaviour associated with the disease (Rascovsky et 
al., 2011; Snowden et al., 2001; Wittenberg et al., 2008). The overall pattern of 
performance by the current ALS patients may suggest that while OFC dysfunction was 
sufficient to produce impairments on the response suppression task, it was not severe 
enough to elicit deficits in socio–emotional processing that are attenuated to those of 
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bvFTD patients. This may also explain why reduced empathy, personality change and 
minimal behavioural dysfunction, such as disinhibition, were not present in the current 





































6.1. Introduction and hypotheses 
 
Chapter Three provided an overview of a limited area within ALS research which is 
concerned with the experiences and challenges faced by spouses through caring for their 
ill relative. Early studies focussed on the consequences of patients’ mood and disease 
symptoms on the outcomes of caregivers. In recent years, the growing evidence for 
cognitive–behavioural change in non–demented ALS patients has shifted attention 
towards the impact of such changes on the caregiver. These studies have highlighted the 
importance of patients’ cognitive–behavioural changes, above and beyond their physical 
decline, to caregivers in terms of their mood, perceived strain and burden. The few 
studies which have explored the impact of ALS on the spousal relationship have 
observed associations between caregivers’ perceived marital quality and their 
perceptions of behavioural, communicative and psychosocial changes in their partners. 
These studies have relied on informant–reports of cognitive–behavioural change in 
patients and have not included objective measures of patients’ neuropsychological 
performance. ALS patients have shown impairments on standardised measures of 
executive function and, more recently, changes on measures that examine the 
processing of emotional and social information. No research to date has investigated 
whether patients’ test performance in these cognitive domains contributes to caregivers’ 
experiences of their spouse’s illness. In addition, little research has compared the 
perceptions of caregivers and their spouses on factors outside of the patient’s behaviour, 
Overview  
A primary aim of the work reported in the current chapter is to examine the impact 
of ALS on spousal caregivers of patients with the disease. In particular, this chapter 
will report findings from an investigation of four caregiver outcomes, namely mood, 
perceived burden, strain and marital satisfaction. It will attempt to determine the 
relative contribution of disease symptoms, patient cognition (as quantified by 
objective measures) and caregiver perceptions of cognitive–behavioural function to 
variability in these outcomes. For exploratory purposes, a comparison of caregivers’ 
and patients’ perceptions of patients’ levels of empathy, behaviour and personality 
are also compared. Whether caregiver–patient differences in the perceptions of these 






such as personality and empathy. Furthermore, there has been no exploration of 
caregivers’ perceptions of their spouse’s personality and empathy in the context of 
perceived cognitive–behavioural change and the consequences of these on caregiver 
outcomes.  
 
Hypothesis Four: Predictors of caregiver wellbeing 
 
The current study tests the hypothesis that objective measures of cognitive function and 
caregiver–perceived behavioural impairment in patients with ALS will contribute 
significantly to caregiver wellbeing (in terms of mood, perceived burden and strain), 
above and beyond patients’ disease status and symptoms. This hypothesis will be 
examined in Section 6.2.3.  
 
Hypothesis Five: Predictors of caregiver marital satisfaction  
 
The current study tests the hypothesis that objective measures of cognitive function and 
caregiver–perceived behavioural impairment in patients with ALS will contribute 
significantly to caregivers’ perception of marital satisfaction, above and beyond 
patients’ disease status and symptoms. This Hypothesis will be examined in Section 
6.2.3.  
 
Exploratory Question Two:  Comparisons between patients’ and caregivers’ 
perceptions of patients’ behaviour, empathy and personality 
 
This study explores differences between patients’ and caregivers’ perceptions of 
patients’ behaviour, empathy and personality and whether such differences are 
associated with caregiver outcomes (in terms of caregiver mood, perceived burden, 
strain and marital satisfaction). The study will also explore if caregivers’ perceived 
changes in patients’ personality and behaviour are associated with caregiver outcomes. 









6.2.1. Participant demographics 
 
A. Caregivers 
Table 6.1. summarises the demographic information for the caregiver group (n=35). 
Four caregivers declined to report their date of birth, so average age was calculated 
from 31 participants. The average age of the caregiver group was approximately 58 
years. All patient–caregiver dyads were married and had been so for an average of 32 
years prior to the patient’s illness. The average number of years that caregivers and 
patients had been in a relationship was 33 years. The majority of caregivers in the study 
were female. Only three caregivers had contacted a GP or psychiatrist regarding mental 
health issues (prior to the onset of their partner’s ALS).    
 
B. Demographics and clinical profile of respective patients  
 
The demographic and disease profile of the patients whose spouses participated in the 
study are shown in Table 6.2. Patients had an average disease duration (months since 
symptom onset) of less than three years. The average diagnostic delay (months since 
symptom onset to diagnosis date) was approximately 15 months. Average age at time of 
symptom onset was approximately 61 years. Approximately 77% of patients had limb–
onset disease. The majority of patients were receiving Riluzole, while 9 patients were 
receiving medication with psychoactive properties. 
 
Table 6.1.: Caregiver demographics 
*Mental health=previous contact with a GP or psychiatrist regarding mental health. 
 




Relationship (years) before partner’s illness 
57.7            (10.5) 
14.1            (3.7) 
33.2            (13.0) 
31.6            (13.4) 
    N              (%) 
Gender                                       Women 
                                                    Men                                                   
 
Marital Status                           Married 
 
Mental Health*                             
25               (71.4) 
10               (28.6) 
 
35               (100.0) 
 
3                 (8.6) 
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Table 6.2.: Demographics and clinical profile of disease for ALS patients 
∞ ALSFRS–R:  bulbar= items 1–3; Limb= items 4–9; respiratory=items 10–12; † Disease progression 
rate=(48-ALSFRS–R Total) /months since symptom onset.* MAD/IQR ** Mental health= previous 









 Mean     (SD) 
Age 
Education  
Months since onset 
Months since diagnosis 
Age at symptom onset 
 
ALFSFRS–R total score (max 48)∞ 
ALSFRS–R bulbar severity score
 
ALSFRS–R Limb severity score 
ALSFRS–R Respiratory severity score 
 
Median Disease progression rate† 
Epworth Sleepiness Scale Score 
 
60.9        (8.4) 
14.2        (3.6) 
30.4        (14.3) 
14.8        (12.2) 
58.6        (8.5) 
 
34.1        (8.2) 
9.3          (3.0) 
14           (6.0) 
10.8        (2.0) 
 
0.46        (0.0/0.3)* 
3.3          (2.9) 
 N          (%) 
Region of onset                                         Limb 
                                                                   Bulbar 
 
Currently receiving Riluzole  
 
Currently receiving psychoactive medication 
 
Mental Health**               
               
27         (77.1) 
 
8           (22.9)    
 
28         (80.0)  
 
9           (25.7)   
 
6           (17.1) 
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6.2.2. Caregiver outcomes 
6.2.2.1. Caregiver mood  
 
The mean depression and anxiety levels for caregivers and their partners are 
summarised Table 6.3. The revised HADS scoring scheme (Gibbons et al., 2011)  was 
used for both groups for purposes of comparison
6
. A total score for overall mood, 
HADS Total, was calculated for the purpose of subsequent analyses. Caregivers 
reported significantly higher scores than the patient group for HADS A, HADS D and 
HADS Total scores. However, according to Gibbons et al (2011) criteria, the average 
level of anxiety was within the ‘borderline case level’ for both groups. The average 
level of depression for both groups was within the ‘non–case level’.    
The proportion of participants per group who scored within the ‘case’ range of the 
HADS domains was also examined (see Table 6.4.). Significantly more caregivers than 
patients satisfied criteria for borderline and case–level anxiety. Significantly more 
caregivers than patients satisfied criteria for case–level depression. However, only the 
ratio for borderline case anxiety between groups remained significant following a 
Bonferroni correction (adjusted p<.008).     
 
 
Table 6.3.: HADS D and HADS A scores 
 Mean (SD) t(df)  p d 95% CI 
 Caregivers  
(n=35) 
 ALS  
 (n=35) 
 






 4.3 (3.7) 
 2.5 (2.1) 









HADS Total -4.01 (68) <.001* 0.95 -8.0; -2.7 
p–values from two–tailed t–test. Uncorrected significant results shown in bold–p<.05. Results significant 
following Bonferroni correction are shown in bold*–p<.016. d, Cohen’s d; 95% CI for difference 
between means.  
 
                                                 
 
 
6 Gibbons et al (2011) revised cut–offs: HADS A borderline case (7–8); HADS A case–level (≥9); HADS D 
borderline case (5–7); HADS D case–level (≥8); HADS Total possible case (17–20), HADS Total probable (≥21).  
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Table 6.4.: Proportions of participants by group meeting HADS criteria 
 N (%) X
2






























































































 0.1; 0.4 
 











 p–values from two–tailed Chi–square test except † Fisher–Boschloo test. Uncorrected significant results    
shown in bold–p<.05. Results significant following correction are shown in bold*–p<.008. φc, Cramer’s 




6.2.2.2. Caregiver strain  
 
Morris Strain Scale (MSS) 
Results are reported for 35 caregivers. The mean total score for the strain scale was 26.9 
(SD=5.3, possible range of scores: 6 – 42). An investigation of correlations of the scale 
dimensions found that currently felt strain correlated positively with caregivers’ 
anticipation of strain felt in a year’s time (r=.50, p=.002); how much caregivers 
perceived the patient’s illness was affecting other areas of the caregiver’s life (r=.68, 
p<.001) and how much control caregivers felt they had over their reaction to their 







6.2.2.3. Caregiver burden 
 
One caregiver did not complete the ZBI, therefore results are reported for 34 caregivers. 
The mean score for total burden was 29.4 (SD=14.1; maximum possible score: 88). A 
cut–off score for the ZBI total score of 17 or higher indicates a high level of burden 
(Bedard et al., 2001; Lillo et al., 2012a; Zarit et al., 1980). When this criterion was 
applied in the current study, 28 (82.4%) of the caregivers reported a high level of 
burden (see Figure 6.1.).  
   
 
 
Figure 6.1.: Proportion of caregivers reporting high level of burden 
 
                       







































6.2.2.4. Caregiver marital satisfaction  
 
Three caregivers did not complete the MIS. Therefore, results are reported for 32 
participants. Caregivers rated the quality of their marital relationship with the patient 
currently and two years prior to the onset of the patient’s illness. A total score for both 
premorbid and current marital satisfaction was obtained from summing 24 items of the 
scale (maximum possible score: 96; higher scores indicates higher marital satisfaction). 
Scores for both timeframes are shown in Table 6.5. A paired sample t–test showed a 
significant difference between premorbid and current ratings, with caregivers rating 




Table 6.5.: Caregiver ratings of premorbid and current marital satisfaction 
 Mean (SD) t(df) p d 95% CI 






















N=32. p–values from two–tailed paired sample  t–tests. Significant results shown in bold–p<.05. SD, 














6.2.3. Predictors of caregiver outcomes 
 
 
The current study set out to recruit a minimum of 49 patients and their spouses (see 
power analysis, Chapter 4, Section 4.6.2). However, while 55 patients were recruited, 
only 44 spouses were available for invitation to the study (see Chapter 4, Section 
4.2.2.). Of these caregivers, only 35 consented to take part in the research, with some 
caregivers not completing all of the measures (n=5); leading to a reduction in statistical 
power.  
 
As stated in the hypotheses in Section 6.1., the study’s objective was to determine the 
relative contribution of patients’ cognitive, behavioural and disease factors to caregiver 
outcomes, in terms of mood, perceived strain, burden and marital satisfaction. Since the 
sample size was small, the strategy for selecting predictors to be entered into a 
regression was based on both theory and statistical criteria. This allowed for a reduction 
in the number of predictors entering the final models. Potential predictor variables were 
selected on the basis of past research and the objectives of the study (see Table 6.6. for 
list of these variables). The informant–rated FrSBe (FrSBe–I) and ELQ (ELQ–I) were 
used to measure patients’ behaviour.  Bivariate correlational analyses were conducted to 
determine significant relationships between potential predictors and caregiver outcome 
variables. Variables which showed significant relationships with the outcomes 
(unadjusted p<.05) were entered into a forward selection multiple regression (MR) to 
determine which variables best predicted the relevant outcome. Following these initial 
analyses, the significant predictors were entered into a hierarchical regression.  
 
Selection of predictors 
Caregiver depression: The correlates of caregiver HADS D included ALSFRS–R Tot 
(r=-.38, p=.02, n=35), ALSFRS–R Limb (r=-.44, p=.008, n=35) and informant–rated 
current Apathy (r=.42, p=.02, n=33). The ALSFRS–R Tot and ALSFRS–R Limb 
variables correlated strongly (r=.86, p<.001, n=32); however the assessment of VIF and 
tolerance values indicated multicolinearity was not substantial. A forward selection MR 
indicated that ALSFRS–R Limb was the only variable to enter the model (β=-.22, 
SE=.09, standardised β=-.42, t(31)=-2.6, p=.01, 95% CI [-.4;-.05]), R2=.18, adjusted 
R
2







Table 6.6.: Domains of interest for potential predictors of caregiver outcomes 
Domain Measures 
Disease  ALSFRS–R: Total score, limb severity, bulbar severity, respiratory 
severity subscale scores 
 
Disease duration (months since ALS onset) 
Disease progression rate 
 
 
Cognitive  Executive function composite score 
EMOSOC composite score 







FrSBe–I: Total score; Apathy, Disinhibition, Executive 
Dysfunction subscale scores.  
 
ELQ–I: Total score 
 
 
Relationship years  
Caregiver’s age 
ALSFRS–R, Amyotrophic Lateral Sclerosis Rating Scale – Revised; EMOSOC, Emotional processing     
and social cognition; FrSBe–I, The Frontal Systems Behavioural Scale–informant; ELQ–I, Emotional 
Lability Questionnaire–informant.  
 
 
Caregiver anxiety: The correlates of caregiver HADS A included FrSBe–I Tot current 
(r=.40, p=.02, n=33) and ELQ–I Tot (r=.38, p=.03, n=34). Forward selection MR 
indicated that only the FrSBe–I Tot current entered the model (β=.12, standardised 
β=.40, t(30)=2.4, p=.02, 95% CI [.02; 23]), R2=.16, adjusted R2=.13, F(1,30)=5.65, 
p=.02.  
 
Caregiver strain: The correlates of MSS score included ALSFRS–R Tot (r=-.4, p=.02, 
n=35), ALSFRS–R limb (r=-.45, p=.006, n=35), EMOSOC (r=-.03, p=.04, n=35), 
informant–rated current Apathy score (r=.35, p=.05, n=33), FrSBe–I Tot current (r=.35, 
p=.05, n=33) and ELQ–I Tot (r=.41, p=.02. n=34). A forward selection MR indicated 
ALSFRS–R Limb, ELQ–I Tot and EMOSOC remained in the model, R2=.41, 
adjusted R
2
=.35, F(3,28)=6.61, p=.002. An inspection of regression coefficients showed 






Caregiver burden: The correlates of the ZBI score included ALSFRS–R Tot (r=-.59, 
p=<.001, n=34); ALSFRS–R Limb (r=-.66, p=<.001, n=34), informant–rated current 
Apathy (r=.63, p<.001, n=32), informant–rated current Disinhibition (r=.51, p=.003, 
n=32), informant–rated current Executive Dysfunction (r=.51, p=.003, n=32), FrSBe–I 
Total current (r=.69, p<.001, n=32). Case diagnostics from an initial MR analyses found 
that one participant showed a substantial influence over the model’s predictive capacity 
(Cook’s distance=3.3). After removal of this participant from the analyses, 
multicollinearity statistics indicated that the strong correlation between ALSFRS–R Tot 
and ALSFRS–R Limb (r=.88, p<.001, n=31) was problematic. Since ALSFRS–R Limb 
showed the strongest correlation with the ZBI score, this variable was selected for the 
model. A forward selection MR indicated ALSFRS–R Limb and FrSBe–I Total 




=.84, F(2,28)=80.6, p<.001. An 
inspection of the regression coefficients showed that both variables predicted burden 
significantly (see Table 6.8).   
 
Summary: ALSFRS–R Limb was associated with all the caregiver outcomes, except 
anxiety. The FrSBe–I Total current scores predicted anxiety and burden. Although, 
ALSFRS–R Limb, ELQ–I Tot and EMOSOC were selected for the regression model to 
predict variability in caregiver strain, only ELQ–I Tot and EMOSOC were found to be 


















Table 6.7.: Predictors of perceived strain  





95% CI for B 
1. Constant 







    27.1; 36.6 
 -0.7; -0.1 
2. Constant 
    ALSFRS–R Limb 










    26.0; 34.9 
 -0.6; -0.1 
   0.01; 0.3 
3. Constant 
    ALSFRS–R Limb 
    ELQ–I Tot 











   .43* 
-.37 
     25.5; 33.9 
-0.5; 0.0 
 0.1; 0.3 
-4.2; -0.3 
















Table 6.8.: Predictors of perceived burden 










     10.2 
      0.2 
 
 .78* 
 -58.4; -16.5 
    0.7; 1.4 
 2.  Constant 
FrSBe–I Tot 





      0.1 




  -28.9; 0.7 
    0.7; 1.2 
  -1.5; -0.8 















Measures of caregiver outcome, namely the HADS A, HADS D, MSS and ZBI scores 
demonstrated moderate to high positive intercorrelations. MIS premorbid and MIS 
current did not show strong or significant associations with any of these variables, with 
the exception of the ZBI and MIS current scores (see Appendix IX.). For this reason, 
the investigation of caregiver outcomes was separated into two stages, in keeping with 
the separate hypotheses. The first analysis considers the impact of ALS on caregivers’ 
‘wellbeing’, quantified here by measures of mood, perceived strain and burden. The 
second analysis considers the impact of ALS on caregivers’ perceived marital 
satisfaction.  
 
6.2.3.1. Caregivers’ wellbeing   
 
As the measures of mood, strain and burden showed moderate to high intercorrelations, 
a global outcome measure (Wellbeing) was computed using the following formula from 
Goldstein et al (2006a):  
 
Wellbeing =  
 
 
  * [  
          
               
 +  
   
        
  +  
   
        
 ]  
 
A higher global score indicated less wellbeing. One caregiver did not complete the 
burden measure, so for this participant the strain and mood scores were standardised 
and summed before being multiplied by 0.5 to create a global score. Combining these 
outcome measures offers a conservative approach to examining predictors of caregiver 
experience (Goldstein et al., 2006a).  For the computation of HADS Total see Chapter 
5, Section 5.2.4.  
 
In order to test Hypothesis Four that cognitive and behavioural impairments in patients 
will contribute more to caregivers’ wellbeing than patients’ disease status, a hierarchical 
regression was conducted using the predictors identified in the preceding forward 
selection procedures. The dependent variable was Wellbeing. The independent variables 
were entered in the following blocks:  
 
Block 1: ALSFRS–R Limb 
 
Block 2: FrSBe–I Tot current; ELQ–I Tot and EMOSOC 
 
Results of the regression model are shown in Table 6.9. The total model explained 
45.4% (adjusted R
2
) of the variance in Wellbeing, F(4,27)=7.43, p<.001. The results 
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indicated that as ALSFRS–R Limb increase by 1 SD (6; higher score indicates better 
limb function), the global outcome decreased by 0.37 SD and suggests that ALSFRS–R 
Limb is a significant predictor of Wellbeing [t(27)=-2.54, p=.02]. Independently, as 
FrSBe Tot increased by 1 SD (12.8; higher scores indicate higher behavioural 
dysfunction), the global outcome score increased by 0.35 SD and suggest that the FrSBe 
Total score is also a significant predictor of Wellbeing [t(27)=2.3, p=.03]. The ELQ Tot 
and EMOSOC scores were not significant predictors of global caregiver outcome. This 
fails to support Hypothesis Four that both objective measures of cognition and 
caregiver–rated behavioural indices will contribute to caregiver wellbeing, controlling 
for patients’ disease symptoms. However, it does highlight the individual contribution 






Table 6.9.: Predictors of Wellbeing 





95% CI for B 
1. Constant 






  -.55* 
   1.6; 2.4 
  -0.07; -0.02 
2. Constant 
    ALSFRS–R Limb 
    FrSBe–I Tot 
    ELQ–I Tot 















        -.21 
   0.02; 1.8 
  -0.06; -0.01 
   0.002; 0.03 
 <0.01; 0.02 
 -0.29; 0.05 

















6.2.3.2. Caregivers’ marital satisfaction 
 
In order to test Hypothesis Five that patients’ cognitive and behavioural impairment will 
contribute more to caregivers’ perceptions of current marital satisfaction than disease 
symptoms, the same selection procedure for predictors was used.  
 
Current caregiver marital satisfaction: The correlates of the MIS current scores included 
informant–rated current Apathy (r=-.37, p=.04, n=31), informant–rated current 
Executive Dysfunction (r=-.49, p=.005, n=31), FrSBe–I Tot current (r=-.54, p=.002, 





=.27, F(1,29)=12.12, p=.002, β=-.78, SE=.22, standardised 
β=-.54, t(29)=-3.48, p=.002, 95% CI for β [-1.24; -0.33].  
 
FrSBe–I Tot current scores were entered into a hierarchical MR analysis to predict 
current MIS scores, while controlling for premorbid MIS scores. Case diagnostics from 
an initial MR analysis revealed that one participant showed a substantial influence on 
the predictability of the model (Cook’s Distance=1.6). This case was subsequently 
removed from the analysis.  
 
The final MR analysis results are shown in Table 6.10. The model explained 78.1% 
(adjusted R
2) of the variance in caregivers’ current marital satisfaction, F(2,27)=52.68, 
p<.001. The results indicated that as premorbid MIS scores increase by 1 SD (15.5), 
current MIS increased by 0.68 SD and suggests that premorbid marital satisfaction is a 
significant predictor of current marital satisfaction [t(27)=7.59, p<.001]. Independently, 
as FrSBe Tot–I score increased by 1 SD (9.8), current MIS score decreased by 0.42 SD 
and suggest the FrSBe–I Total current score is also a significant predictor of current 
marital satisfaction [t(27)=-4.65, p<.001]. 
 
This fails to support Hypothesis Five that both objective measures of patient cognition 
and caregiver–rated behaviour will contribute to caregivers’ perceived marital 
satisfaction more than the patients’ disease severity (as measured by ALSFRS–R 
scores). However, as before, it does highlight the individual contribution of caregivers’ 







Table 6.10.: Predictors of current marital satisfaction 




95% CI for B 
1. Constant 








  0.7; 1.2 
2. Constant 
    MIS premorbid 









       -.42* 
  27.4; 88.3 
  0.6; 1.0 
-1.1; -0.4 












6.3. Exploratory study 
6.3.1. Caregivers’ perceptions of patients’ EL  
 
Median scores of patients and caregivers ELQ ratings are shown in Table 6.11. One 
caregiver did not complete this measure. Thus, comparisons of ratings are reported for 
34 couples.  Wilcoxon signed–rank tests revealed no significant differences for ratings 
on the Total ELQ and the domain scores.  
 
Table 6.11.: Comparison of patient and caregiver ELQ ratings 
  Median (MAD/IQR)    Ties z(df) p r 95% CI 
 Caregivers  
 (n=34) 
 ALS  
 (n=34) 
 









 6 (6/20) 
 0 (0/16) 
 0 (0/12) 





















p–values from two–tailed Wilcoxon–signed rank tests., r, Pearson’s correlation coefficient; Hodges–





6.3.2. Caregivers’ perceptions of patients’ empathy 
 
Six caregivers did not complete the informant version of the Interpersonal Reactivity 
Index (IRI–I). Therefore, patients’ and caregivers’ ratings are compared for 29 couples. 
The mean patient– and caregiver–reported data for the four IRI subscales are shown 
graphically in Figure 6.2. Paired–sample t–tests revealed significant differences 
between patient– and caregiver–ratings on levels of Perspective Taking (PT), with the 
inspection of the mean scores suggesting that caregivers rated patients’ level of PT 
lower than patients rated themselves. This difference remained significant following a 
Bonferroni correction (adjusted p<.013). No differences between caregiver– and 




Figure 6.2.: Caregiver and patient IRI ratings 
 
 
Caregivers (n=29); ALS (n=29). Maximum score per subscale=28. PT, Perspective taking; FS, Fantasy 




























A discrepancy score for the PT scale was created by subtracting patients’ PT total 
scores from the caregivers’ PT total scores. Possible relationships between this 
discrepancy score and caregiver outcomes (mood, perceived strain, burden and marital 
satisfaction) were explored. As this investigation was exploratory, the alpha–level was 
not adjusted for multiple correlations. Significant positive relationships between the PT 
discrepancy score (M=-4.0, SD=6.8) and caregiver’s premorbid MIS scores (r=.45, 
p=.02, n=28) and current MIS scores (r=.42, p=.03, n=28) were found.    
 
6.3.3. Caregivers’ perceptions of patients’ behaviour 
 
Two caregivers did not complete the informant version of the Frontal Systems 
Behavioural Scale (FrSBe–I). Caregivers were asked to rate their spouse’s behaviour 
currently and premorbidly (at least two years prior to the onset of ALS). One–way 
repeated measures ANOVAs revealed that caregivers rated patients’ current behaviour 
significantly higher than premorbid levels for the total FrSBe score and the three 
domains of the scale. These differences remained significant following a Bonferroni 
correction (adjusted p<.013) (see Figure 6.3).  
Comparisons of caregivers’ and patients’ ratings of premorbid and current behaviour 
were also examined using split–plot ANOVAs, with Rater (Caregiver; Patient) as the 
between–subjects factor and Time (Premorbid; Current) as the within–subject factors. 
One patient and two caregivers did not complete the FrSBe; results are therefore 
reported for 32 couples. Caregivers did not rate the change in patients’ behaviour since 
their ALS onset as different from the patients themselves [Total FrSBe: F(1,62)=0.10, 
p=.75; ηρ²<.001; Apathy: F(1,62)=2.78, p=.10, ηρ²=.04; Disinhibition: F(1,62)=21.13, 
p=.34, ηρ²=.02; Executive Dysfunction: F(1,62)=0.05, p=.84; ηρ²<.001]. Both patients’ 
and caregivers’ ratings of the patients’ behaviour showed an increase in scores over 
time for all measures [Total FrSBe: F(1,62)=61.65, p<.001, ηρ²=.50; Apathy: 
F(1,62)=119.35, p<.001, ηρ²=.66; Disinhibition: F(1,62)=8.08, p=.006, ηρ²=.12; 
Executive Dysfunction: F(1,62)=24.58, p<.001, ηρ²=.28]. There was a significant effect 
of Rater for the premorbid and current FrSBe total and domain scores, with the 
exception of the Disinhibition subscale score. For the significant group differences, 
caregivers tended to rate patients’ behaviour as higher (more impaired) than the 




The proportions of caregivers’ FrSBe ratings which satisfied criteria for ‘caseness’     
(T–score ≥65) were examined. These proportions were compared to those from patients’ 
ratings of their own behaviour using a McNemar test.  Table 6.13. displays the results of 
these analyses. For the premorbid ratings, caregivers rated proportionally more patients 
as satisfying ‘caseness’ than patients rated themselves, with the exception of the Apathy 
subscale. However, none of the differences in percentages were found to be statistically 
significant. For current behaviour ratings, caregivers again showed proportionally more 
endorsements of ‘caseness’ compared to patients. However, differences between 
percentages were only significant for the Apathy and Executive Dysfunction subscales. 
Only the difference for the Apathy subscale remained significant following a 






Figure 6.3.: Caregiver ratings on FrSBe: premorbid compared to current 
behaviour 
 
N=33.* Significant difference following a Bonferroni correction p<.013. Error bars represent 95% CI     







































Table 6.12.: Comparisons between caregiver and patient ratings of patient   
behaviour 
 
FrSBe T–scores Mean (SD) F(df) p ηρ² 
 Caregivers 
(n=32) 
  ALS 
  (n=32) 
 
   
Total FrSBe (pre.) 








Exec. Dys. (pre.) 












  48.1 (11.6) 
  57.4 (11.5) 
 
  45.3 (12.3) 
  58.2 (14.7) 
 
  53.3 (13.6) 
  54.8 (13.4) 
 
  47.5 (11.3) 


































p–values from split–plot ANOVA. Uncorrected significant results shown in bold–p<.05. Results 
significant following Bonferroni correction are shown as bold*–p<.013. ηρ², partial–eta squared. FrSBe, 




Table 6.13.: Comparisons of caregiver and patient FrSBe ratings satisfying 
‘caseness’ 
 
FrSBe N (%) X
2





   
Tot. FrSBe (pre.) 








Exec. Dys. (pre.)      



































  .18 
  .25 
 
  .65 
<.001* 
 
   .10 
   .74 
 
   .48 











 8.72; 45.9 
p–values from McNemar tests. Uncorrected significant results shown in bold–p<.05. Results significant 
following a Bonferroni correction are shown in bold*–p<.006. 95% CI, Newcombe–Wilson hybrid 
confidence interval for difference between proportions (paired). Disinhib., Disinhibition; Exec.Dys., 
Executive Dysfunction; pre., premorbid; cur., current. 
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The proportion of caregivers’ ratings of patients’ premorbid and current behaviour 
satisfying ‘caseness’ were also compared (n=33). Table 6.14. displays these results. For 
the total score and all domains, caregivers endorsed proportionally more patients as 
meeting ‘caseness’ for the current behaviour period than the premorbid period. The 
relative percentages of ‘cases’ between rating conditions were significantly different for 
all FrSBe domains, with the exception of the Disinhibition subscale. These differences 
remained significant following a Bonferroni correction (adjusted p<.013).   
 
 
Table 6.14.: Comparisons of caregiver premorbid and current FrSBe ratings 
satisfying ‘caseness’ 
 
FrSBe N (%) X
2
(df) p 95% CI 

































   .32 
 









p–values from McNemar tests. Results significant following a Bonferroni correction are shown in bold*–
p<.013. 95% CI, Newcombe–Wilson hybrid confidence interval for difference between proportions 
(paired). Exec.Dys., Executive Dysfunction 
 
 
Discrepancy scores for the FrSBe domains comparing caregiver and patient current 
ratings were created by subtracting patients’ FrSBe T scores from the caregivers’ FrSBe 
T scores. Possible relationships between these discrepancy scores and caregiver 
outcomes (mood, perceived strain, burden and marital satisfaction) were explored (see 
Table 6.15).  As this investigation was exploratory, the alpha–level was not adjusted for 
multiple correlations. The discrepancy score for the current Total FrSBe score 
correlated positively with HADS A, Strain and Burden. There was also a positive 
correlation between the discrepancy score for current Executive Dysfunction              
and caregiver Burden.   









































































































































































Similarly, change scores for FrSBe domains comparing caregivers’ premorbid and 
current ratings were created by subtracting their premorbid ratings from their current 
ratings. Relationships between these change scores and caregiver outcomes were also 
explored, as above. Change scores for the Total FrSBe, Apathy and Executive 
Dysfunction scales were positively associated with measures of mood, strain and 
burden. The Disinhibition change score was positively associated with levels of 
depression, strain, and burden and negatively associated with current marital 
satisfaction. (see Table 6.16).  
 











































































































r values from Pearson’s correlations. Uncorrected significant correlations (p<.05) are shown in bold.  ∞, 
Naperian log transformed data.*back–transformed Mean (CI). Note: sensitivity analyses using 




6.3.4. Caregivers’ perceptions of patients’ personality characteristics 
 
Caregivers were asked to rate patients’ personality characteristics on the NEO–FFI 
currently and premorbidly (at least two years prior to the patient’s ALS onset). Patients 
rated their current personality only. Two–tailed paired samples t–tests found significant 
differences between caregiver– and patient–ratings for current personality. Caregivers’ 
ratings of patients’ current levels of Neuroticism (N) were significantly higher than the 
patients’ ratings of themselves for this domain. Caregivers rated patients as showing 
significantly lower current levels of Extraversion (E) and Conscientiousness (C) than 
patients rated themselves. When a Bonferroni correction was applied (adjusted p<.01), 
only the difference between ratings on the E subscale remained. These results are 
presented in Figure 6.4. One patient and five caregivers did not complete the NEO–FFI 
and thus results are reported for 29 couples. 
For exploratory purposes, caregivers’ mean premorbid ratings were compared with 
patients’ mean current ratings of patient personality. No significant differences were 
found for any of the NEO–FFI domains (see Appendix X), suggesting that the 
discordance found between caregiver and patient ratings of current personality might be 
explained by the caregivers’ perceptions of their spouse’s personality change since the 
onset of ALS. To explore this proposal, two–tailed paired t–tests compared caregiver–
ratings of patients’ premorbid and current personality characteristics (n=30). Caregivers 
rated patients’ as showing significantly higher levels of N currently than premorbidly. 
However, they rated patients as showing significantly lower levels of E and C than prior 
to disease onset. All differences remained significant following a Bonferroni correction 
















Figure 6.4.: Comparison of caregivers’ and patients’ NEO–FFI ratings for 
patients’ current personality 
Caregiver (n=29); ALS (n=29). N, Neuroticism; E, Extraversion, O, Openness, A, Agreeableness, C,  
Conscientiousness. *Significant difference for Bonferroni corrected p<.01. Error bars represent 95%   




Table 6.17.: Comparisons of caregivers’ NEO–FFI ratings for patients’   






Mean (SD) t(df) p d 95% CI 
N=30 Premorbid Current 
 










































  .48 
 
  .09 
 


















 2.3; 8.1  
p–values from two–tailed paired–sample t–tests. Results significant following Bonferroni correction are 
shown as bold*–p<.01.Agreeable., Agreeableness; Conscien., Conscientiousness; d, Cohen’s d for 


























Caregiver ratings which fell into the extreme cut–off categories (Very high; Very low) 
were examined and compared between time points using McNemar tests (see Table 
6.18.). The proportion of patients endorsed as satisfying very high N was significantly 
greater for the current period than the premorbid period. The proportion of cases 
meeting very high levels of E significantly declined across time conditions, while the 
percentage of cases meeting very low levels of E increased significantly. However, 
none of these differences remained significant following a Bonferroni correction.   
According to the NEO–FFI manual, the N domain measures traits of anxiety, hostility, 
depression, self–consciousness, impulsiveness and ability to cope with stress. 
Therefore, caregivers’ endorsements of very high levels of N might reflect their 
appraisals of the patients’ mood. However, none of the patients endorsed by caregivers 
as showing very high levels of current N met criteria for case level HADS A or HAD D. 
Although patients’ mood scores were self–rated rather than proxy–rated, this does 
suggest that the very high N endorsements were not influenced by displays of elevated 
mood in patients.  
 
 







 (df) p 95% CI 
Very high  
(range 66: 75) 
Very low  
(range 25: 34) 
 
Premorbid  Current 
 
   
N – Very high 
N – Very low 
 
E – Very high 
E – Very low 
 
O – Very high 
O – Very low 
 
A – Very high 
A – Very low 
 
C – Very high 















  5 (16.7) 
  5 (16.7) 
 
  1 (3.3) 
  7 (23.3) 
 
  3 (10)  
  4 (13.3) 
 
  5 (16.7) 
  6 (20) 
 
  0 (0) 











































p–values from McNemar tests. Uncorrected significant results shown in bold–p<.05. 95% CI,   
Newcombe–Wilson hybrid confidence interval for difference between proportions (paired). 
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A comparison of caregivers’ and patients’ current personality ratings which were 
endorsed within the extreme cut–off categories (Very high; Very low) was also 
conducted for 29 couples (see Table 6.19.). Compared to patients, caregivers endorsed 
proportionally more patients’ as showing very low levels of E; however, this was not 
significant following a Bonferroni correction. Caregivers and patients did not differ 
significantly with regards to the proportion of cases endorsed as very high or very low 
for any of the other personality domains.   
 
 
Table 6.19.: A comparison of caregivers’ and patients’ current NEO–FFI ratings 






 (df) p 95% CI 
Very high  
(range 66: 75) 
Very low  






   
N – Very high 
N – Very low 
 
E – Very high 
E – Very low 
 
O – Very high 
O – Very low 
 
A – Very high 
A – Very low 
 
C – Very high 







































































p–values from McNemar tests. Uncorrected significant results shown in bold–p<.05. 95% CI, 








Discrepancy scores comparing caregiver and patients’ current ratings for the N, E and C 
current subscales were created by subtracting patients’ current domain total scores from 
the caregivers’ current domain total scores. Possible relationships between these 
discrepancy scores and caregiver outcomes (mood, perceived strain, burden and marital 
satisfaction) were explored. As this investigation was exploratory, the alpha–level was 
not adjusted for multiple correlations. A significant positive correlation was found for 
the E discrepancy score (M=-10.1, SD=12.0) and the current MIS score (r=.50, p=.007, 
n=27). No other significant relationships were found.  
Similarly, change scores comparing caregivers’ premorbid and current ratings of 
patients’ personality characteristics for N, E and C were created by subtracting their 
premorbid ratings from their current ratings. Relationships between these scores and 
caregiver outcome scores were explored as above. Table 6.20. displays the correlations 
and the means and SDs for each change score. The N change score correlated positively 
with every caregiver outcome variable, with the exception of the MIS scores. The E and 
C change scores were negatively associated with the HADS D.   
 
 
Table 6.20.: Correlations between caregiver NEO–FFI change scores and 




















HADS A  (30)  .52 (.003) -.13 (.49) -.15 (.42) 
HADS D   (30)  .70 (.003) -.48 (.008) -.44 (.02) 
Strain   (30)  .43 (.02) -.24 (.2) -.15 (.43) 
Burden  (29)  .52 (.004) -.13 (.5) -.03 (.88) 
MIS premorbid (28)  .18 (.36) -.17 (.39) -.20 (.30) 
MIS current (28) -.10 (.62)  .09 (.65) -.14 (.48) 






6.4. Summary of results 
 
This section summarises the findings from the current chapter. Results that were 
significant following a Bonferroni correction for multiple comparisons will be outlined. 
Uncorrected significant findings (p<.05) will be referred to as trends or tendencies, 
except in the case of exploratory correlational analyses where they will be referred to as 
(significant) associations or correlations.   
 
6.4.1. Participant demographics 
 
Thirty–five caregivers and a subset of 35 respective patients were involved in this 
aspect of the study. All caregiver–patient dyads were married and had been so for an 
average of 32 years before the onset of the patients’ illness. The majority of caregiver 
participants (72%) were female. The majority of patients had the limb–onset form of 
ALS (77%) and an average disease duration of less than three years.  
 
6.4.2. Caregiver perceptions of mood, self–perceived strain, burden and marital 
satisfaction 
 
Caregivers reported significantly higher scores for depression and anxiety than patients. 
The mean anxiety scores were within the ‘borderline case level’ for both groups 
according to revised cut–off criteria (Gibbons et al, 2011); significantly more caregivers 
than patients satisfied this criterion. More caregivers than patients satisfied criteria for 
‘case level anxiety’ and ‘case level depression’, but the differences in proportions 
between groups were not significant following a Bonferroni correction.  
 
The mean score for caregiver strain was 26.9 (SD=5.3). A mean score for burden was 
29.4 (SD=14.1). A large proportion of caregivers (82.4%) satisfied criteria for high 
levels of burden. Caregiver ratings of marital satisfaction were significantly lower 
following the onset of their spouse’s illness than prior to the disease.   
 
6.4.3. Predictors of caregiver outcomes 
 
Forward selection regression analyses identified the following functional relationships:  
 
i) Limb severity (ALSFRS–R Limb) significantly predicted caregiver depression and 
caregiver burden.  
 
ii) Caregivers’ ratings of patients’ current behaviour (FrSBe–I Total current score) 




iii) Emotional lability (ELQ–I tot) and performance on emotional processing and social 
cognition (EMOSOC composite) significantly predicted caregiver strain. 
 
These predictors were entered into the model in order to assess their predictive capacity 
of a global outcome measure of caregiver wellbeing (a summation of standardised 
scores for mood, strain and burden). Only ALSFRS–R Limb scores and the caregiver–
rated FrSBe Total current scores were found to be significant predictors of the global 
outcome scores.  
 
In a separate multiple regression analysis, the FrSBe–I Total current score was found to 
be significant predictor of caregivers’ current marital satisfaction. When the FrSBe–I 
Total was entered into a hierarchical regression controlling for premorbid marital 
satisfaction scores, it remained a significant predictor in the model.  
 
6.4.4. Caregiver perceptions of patients’ EL, empathy, behaviour and personality 
 
The relative perception of patient behaviour was compared between caregivers and their 
spouses. There were no differences between caregivers and patients in ratings of 
patients’ emotional lability on any of the ELQ subscales or total score.  
  
Caregiver ratings of patients’ levels of ‘perspective taking’ (PT) were significantly 
lower than patients’ ratings of themselves. Exploratory correlation analyses found that 
caregiver–patient discrepancy scores (proxy–ratings – self–ratings) for this empathy 
domain correlated positively with caregiver’s perceptions of premorbid and current 
marital satisfaction (i.e. the lower the caregiver’s rating of the patient’s level of  PT 
relative to the patient’s self–rating, the lower the caregiver’s ratings of premorbid and 
current marital satisfaction).        
 
Caregivers rated patients as showing higher levels of behavioural dysfunction following 
the onset of their illness than before their illness for all domains of the FrSBe measure. 
Further analyses which compared caregiver and patient ratings for the two time periods 
were conducted. Caregivers’ and patients’ ratings of the change in patients’ behaviour 
since their disease onset did not differ. Ratings from both groups increased significantly 
over time for all domains. However, caregivers rated patients as showing higher levels 
of premorbid and current behavioural dysfunction than patients rated themselves. This 
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was true for the domains of Apathy, Executive Dysfunction and the Total FrSBe score, 
but not for the Disinhibition domain. 
 
The proportion of patients satisfying ‘caseness’ was compared between the rater groups. 
The proportion of caregivers’ ratings of patients’ ‘caseness’ was significantly different 
from that of patients for the current Apathy domain only, with caregivers endorsing 
more ‘cases’ than patients. Within the caregiver group, the proportion of ratings 
satisfying ‘caseness’ was compared between the premorbid and current rating periods. 
Differences in proportions were significant for the domains of Apathy, Executive 
Dysfunction and the Total FrSBe score; caregivers endorsed more ‘cases’ for the 
current period compared to the premorbid period.  
 
Caregiver–patient discrepancy scores for FrSBe subscales and total score were 
computed. Exploratory correlation analyses revealed that the FrSBe total current 
discrepancy score was positively associated with caregiver anxiety, strain and burden. 
In addition, the Executive Dysfunction discrepancy score correlated positively with 
caregiver burden (i.e. the higher the caregiver’s ratings of the patient’s behavioural 
dysfunction on these domains relative to the patients’ self–ratings, the worse the 
caregiver’s self–ratings of anxiety, strain and burden). Similarly, change scores were 
also calculated for each FrSBe domain (caregivers’ current FrSBe ratings – premorbid 
FrSBe ratings of patients’ behaviour). Exploratory correlational analyses revealed that 
every FrSBe domain change scores correlated positively with caregiver measures of 
depression, strain and burden (i.e. the greater the perceived increase in the patient’s 
behavioural dysfunction on these domains, the worse the caregiver’s self–ratings of 
depression, strain and burden). The Disinhibition change scores correlated negatively 
with current marital satisfaction (i.e. the greater the perceived increase in the patient’s 
level of disinhibition, the lower the caregiver’s ratings of current marital satisfaction). 
The Total FrSBe change scores, the Apathy change scores and the Executive 
Dysfunction change scores correlated positively with caregiver anxiety (i.e. the greater 
the perceived increase in the patient’s behavioural dysfunction on these domains, the 
worse the caregiver’s self–rating of anxiety).  
Caregivers rated patients as showing significantly lower levels of extraversion than 
patients rated themselves. There were trends for caregivers to rate patients as showing 
higher levels of neuroticism and lower levels of conscientiousness than patients rated 
themselves. A comparison of caregivers’ ratings of patient’s premorbid and current 
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behaviour found that caregivers rated patients as showing significantly higher levels of 
neuroticism, but significantly lower levels of extraversion and conscientiousness 
following the onset of ALS.    
 
The proportion of caregivers’ ratings satisfying the extreme cut–off categories (Very 
high; Very low) was compared between premorbid and current time points. Caregivers 
endorsed more ‘very high’ cases of neuroticism in the current period than the premorbid 
period. Caregivers endorsed more ‘very high’ cases of extraversion in the premorbid 
period than the current period. Similarly, cares endorsed more ‘very low’ cases of 
extraversion in the current compared to the premorbid period. However, none of these 
proportions were significantly different following a Bonferroni correction. The 
proportion of caregivers’ and patients’ endorsements for cases meeting the extreme 
NEO–FFI cut–offs were compared. Proportionally more caregivers than patients rated 
patients as showing very low levels of extraversion; this was not significant following a 
Bonferroni correction. No differences in proportions were found between the groups for 
the remaining domains.    
 
Caregiver–patient discrepancy scores for the NEO–FFI domain ratings were calculated. 
Exploratory correlational analyses revealed a positive association between the 
Extraversion (E) discrepancy score and current marital satisfaction (i.e. the lower the 
caregiver’s rating of the patient’s level of  E relative to the patient’s self–rating, the 
lower the caregiver’s current marital satisfaction). Change scores comparing caregivers’ 
premorbid and current ratings of patients’ behaviour were also calculated for the 
personality domains. Exploratory correlational analyses revealed that the Neuroticism 
(N) change score correlated positively with caregiver outcomes of mood, strain and 
burden (i.e. the greater the perceived increase in the patient’s level of N, the worse the 
caregiver’s self–perceived level of strain and burden). The E and Conscientiousness (C) 
change scores correlated negatively with caregiver depression (i.e. the greater the  
perceived reduction in the patient’s level of E and C, the worse the caregiver’s self–






6.5. Discussion of findings 
This chapter reports an investigation of the impact of ALS on a subset of caregivers 
whose ill relative took part in the study. The main hypotheses consider whether 
objective measures of patients’ cognition and caregiver perceptions of patients’ 
behaviour contribute to caregivers’ wellbeing, in terms of their mood, perceived burden, 
strain and marital satisfaction. It also explores relative caregiver–patient perceptions of 
patients’ personality, behaviour and levels of empathy.  This section will indicate the 
position of the study’s findings within the current ALS caregiver literature and discuss 
its theoretical implications. As before, the clinical implications, general limitations and 
recommendations for future research are addressed in the General Discussion (Chapter 
7).  
 
6.5.1. Hypothesis Four: Predictors of caregiver ‘wellbeing’: mood, perceived strain 
and burden 
A relationship between patients’ cognitive–behavioural changes and caregivers’ 
perceived burden has previously been indicated in ALS research (Chio et al., 2010; 
Lillo et al., 2012a). However, these studies have never used objective measures of 
patients’ cognition alongside informants’ ratings of frontally–mediated behaviour in the 
assessment of caregiver outcomes. The current study therefore tested the hypothesis that 
objective measures of patients’ cognition and caregiver ratings of patient behaviour 
would contribute significantly to caregiver outcomes in terms of mood, perceived 
burden and strain, above and beyond patients’ disease status and symptoms. 
 
Objective measures of patients’ cognition did not contribute to the global caregiver 
outcome score while caregiver–rated behavioural dysfunction in patients was a 
significant predictor. A similar pattern of results is usually demonstrated in caregivers 
of patients with MCI (see Dean & Wilcock, 2012 for review, although see Mcade et al, 
2013); whereas objective cognitive measures alone are able to predict stress and burden 
in AD and FTD caregivers (Greve et al., 1994; Miller et al., 2013; Nelis et al., 2011). 
The results indicate that for caregivers of non–demented ALS patients the perceived 
severity of patients’ cognitive impairment might have a greater effect on caregiver 
wellbeing than patients’ actual cognitive impairment. On the other hand, this finding 
might have occurred because the patients for whom spouse data was available possibly 
did not show a great degree of cognitive dysfunction; or at least a degree at which 
patients’ everyday functioning was compromised. For example, perhaps mild to 
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moderate levels of executive impairment found in non–demented patients, which is only 
revealed upon detailed assessment of neuropsychological functioning, does not 
necessarily prevent patients from completing everyday duties that rely on such abilities 
(e.g. the planning of family finances). Therefore, since their spouse remains capable of 
everyday tasks, caregivers might not experience increased distress or burden associated 
with acquiring new duties that were previously shared with or completed exclusively by 
their spouse. In addition, while the FrSBe measures dysexecutive behaviour and 
disinhibition, it also assesses levels of apathy, a measurement that is not directly 
accessible by neuropsychological testing alone. Caregivers’ perceptions of behavioural 
impairment were highest for this domain (see Section 6.3.3.) and of the three FrSBe 
subdomains it correlated strongest with the Wellbeing composite. Thus patients’ 
apathetic behaviour may have been the most salient behavioural feature to the 
caregivers thereby arousing the most distress and burden. Alternatively, the use of 
composite scores as measures of cognition might have prevented the detection of 
possible relationships between patients’ performance on individual tests of 
neuropsychological functioning and the caregiver outcomes. Furthermore, a different 
set of tasks and an extended assessment of the other cognitive domains, such as 
language and memory, may have detected predictive relationships.  
  
Patients’ limb severity was also found to significantly affect caregiver wellbeing: as 
ALSFRS–R scores for the domain decreased (greater functional impairment), the 
Wellbeing composite increased (reduced wellbeing). In fact, patients’ limb severity was 
associated with every caregiver outcome, except anxiety. The relationship between 
caregiver outcomes and patients’ physical symptoms in ALS is unclear. Limb severity 
of ALS patients has previously been correlated with caregiver depression (Chio et al., 
2005; Goldstein et al., 1998), while overall physical impairment has been related to 
caregivers’ anxiety (Pagnini et al., 2010) and burden (Chio et al., 2005; Gauthier et al., 
2007; Hecht et al., 2003; Pagnini et al., 2010). Some studies have found no such 
relationships (Boerner & Mock, 2012; Olsson et al., 2010b; Rabkin et al., 2009), while 
other research has emphasised the importance of behavioural above the physical aspects 
of ALS on caregivers (Chio et al., 2010; Lillo et al., 2012a). In the current study, both 
limb severity and behavioural dysfunction significantly contributed to caregivers’ 
burden, but while anxiety was predicted by perceived behavioural impairment, 
depression was predicted by patients’ limb severity. Anxiety and depression scores were 
also significantly associated with burden scores. These relationships might reveal the 
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specificity with which different ALS symptoms impact on caregivers: while both 
physical and behavioural changes affect the burden felt by caregivers, their reactions to 
the type of impairment might also differ. Patients’ functional impairment may lead to 
increased physical dependence on the caregiver, imposing restrictions upon caregivers’ 
personal time and needs (Chio et al., 2005; Hecht et al., 2003; Krivickas et al., 1997; 
Rabkin et al., 2009), their own physical health (Pagnini et al., 2010; Rabkin et al., 2000; 
Roach et al., 2009) and social relationships (Cobb & Hamera, 1986; Goldstein et al., 
2006a; Ray & Street, 2006), not to mention the psychological burden associated with 
witnessing the restrictions that physical disability poses for their partners’ life 
(Goldstein et al., 1998). It is possible that these aspects of burden are expressed by 
caregivers in terms of increased depressive symptoms, possibly underlying a sense of 
hopelessness with the acknowledgment that their spouses’ condition will deteriorate and 
that their own circumstances will persist or worsen. In addition, behavioural 
dysfunction in patients, such as poor planning and decision–making, a lack of interest in 
completing ordinary tasks and increased impulsivity, may create burden for the 
caregiver as their role encompasses becoming the primary decision–maker (Merrilees et 
al., 2010; Oh & Schepp, 2013). However, these aspects of burden might be expressed 
by caregivers through increased anxiety, reflecting their alarm or confusion at their 
partners’ uncharacteristic demeanour or their anticipated inability to cope with the 
ensuing role–reversal as the disease progresses. It is important to note, however, that the 
current sample size was small and it is possible that other relationships, such as that 
between anxiety and limb severity or depression and behavioural impairment, may have 
been underestimated, thus compromising the suggestion that physical and behavioural 
symptoms pose differential effects on caregiver outcomes. This limitation considered, 
the results indicate that patients’ physical and behavioural symptoms may act in concert 
in their impact on caregivers of non–demented ALS patients.  
 
The EMOSOC score did not predict the global caregiver outcome score, but it was 
found to predict caregiver strain in the initial analyses. However, the direction of the 
relationship between these variables was unexpected: as the EMOSOC scores increased 
by 1 SD, MSS scores decreased by 0.37 SD, indicating that higher impairment on the 
composite scores was associated with lower caregiver strain. This result is contrary to 
the hypothesis and difficult to interpret. It likely represents a spurious relationship due 
to a third variable or an interaction of variables which were not included in the 
regression or not measured at all. Caregiver–rated ELQ was also a significant predictor 
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of strain, in keeping with an earlier study which found that the total score predicted 
overall caregiver outcome (Goldstein et al., 2006a). This corroborates the notion that 
psychosocially salient aspects of ALS, such as EL, are important patient parameters in 
explaining caregiver outcomes.    
 
Some limitations of this aspect of the study deserve consideration. The assessment of 
additional outcomes, such as caregivers’ health status and QoL, might have provided 
greater insight into caregiving experiences in ALS. Although patients identified their 
spouse as the primary informal caregiver, the study did not record the hours spent per 
day caring for their relative (Hecht et al., 2003) or the number of other care dependents 
(Goldstein et al., 2006a), which would have helped to determine the level of care 
involved. Several factors which have been shown to be pertinent to caregiving in ALS 
were not examined. These include, among others: spirituality (Pagnini et al., 2011); 
coping mechanisms (Haley et al., 1987; Murphy et al., 2009); perceived quality of 
social support (Goldstein et al., 2006a); and perceived level of support from health and 
social care services (Peters et al., 2012). Moreover, the measurement of caregivers’ 
attributional styles (Goldstein et al., 2000) might have identified a profile within the 
caregiver participants that showed greater susceptibility to reduced wellbeing. In 
addition, since patients’ mood and wellbeing has shown to be associated with caregiver 
outcomes (Rabkin et al., 2000), the study may have neglected important patient–
parameters that could have further contributed to the caregivers’ experiences. Finally, 
this section of the research considered only the caregiver and therefore cannot 
determine the impact of ALS on patients and their spouses as a dyadic unit.  
 
6.5.2. Hypothesis Five: Predictors of caregiver marital satisfaction  
 
Following the finding that caregivers rated their levels of marital satisfaction as 
significantly reduced since the onset of their spouse’s illness, the current study explored 
predictors of current marital satisfaction, controlling for premorbid satisfaction levels. It 
was hypothesised that objective measures of cognition and caregiver–ratings of 
behavioural dysfunction would predict current marital satisfaction above and beyond 
patient disease factors. The results for caregivers’ marital satisfaction in Section 6.2.3. 
failed to support this hypothesis. While caregivers’ perceptions of total behavioural 
impairment in patients along with premorbid marital satisfaction scores predicted 
current marital satisfaction, neither the Executive function composite nor the EMOSOC 




Previous research identified that caregivers’ ratings of patient cognitive abilities on the 
Dysexecutive Questionnaire (see Wilson et al., 1998) explained 26.5% of the variance 
in marital satisfaction change scores (Goldstein et al., 1998). The current results are 
consistent with these findings, and showed that, together, premorbid marital satisfaction 
and the total scores on the FrSBe explained 78.1% of the variability of caregivers’ 
current marital satisfaction scores. Notably, premorbid marital satisfaction levels had a 
larger positive effect than the negative effect of the total FrSBe scores on current 
satisfaction levels. This indicates that the perceived relationship quality between 
patients and their spouses prior to ALS may protect against perceived loss of marital 
intimacy following the onset of disease, at least from the perspective of the caregiver. 
Current marital satisfaction was in turn negatively correlated with another caregiver 
outcome measure, perceived burden. This finding resonates with that from longitudinal 
data in which a relationship between caregiver–rated MIS scores and burden scores 
emerged at the 12 month study interval. At previous study intervals, MIS scores were 
predicted by caregivers’ perceptions of the patients’ psychosocial function. No measure 
of frontally–mediated behaviour was used (Atkins et al., 2010). In the current study, 
burden itself was predicted by the total behavioural score, indicating that the emergence 
of burden alongside reduced marital satisfaction in Atkins and her colleagues’ study 
may have been influenced by patients’ increased behavioural dysfunction over time. 
The current findings also indicate that while patients’ functional impairment may 
independently impact on caregivers’ perceptions of burden (in addition to depression, 
see Section 6.2.3.), it does not compromise caregivers’ perceptions of the quality of 
their relationship with their spouse. However, the MIS contains only one item of 
physical intimacy. Previous studies in ALS have noted decreased sexual interest and 
activity as well as increased sexual dissatisfaction in both ALS patients and their 
partners (O'Connor et al., 2008; Oh & Schepp, 2013; Wasner et al., 2004). A reduction 
in sexual interest and activity has been related in part to patients’ functional disability 
(Oyebode et al., 2013). Therefore, the inclusion of a measure that indexes sexual 
satisfaction in the current study may have identified a relationship between patients’ 
functional scores and marital satisfaction.  
The current study found no associations between either of the cognitive composites or 
caregiver marital satisfaction; similar reasons to those outlined for the lack of 
relationships between the cognitive measures and caregiver wellbeing might account for 
this null finding (see Section 6.5.1.). The large majority of patients in the current sample 
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showed intact emotion recognition and processing of realistic social exchanges, 
suggesting that they do not experience difficulties with understanding everyday 
interpersonal exchanges. Previous studies of caregivers of dementia patients have 
indicated that emotion recognition difficulties relate to lower caregiver–ratings of 
relationship quality (Greve et al., 1994; Nelis et al., 2011). If, as Savage et al (2013) 
suggest, impaired emotion identification is only a feature of demented ALS patients, the 
inclusion of ALS–FTD patients for comparison with non–demented patients may reveal 
a relationship between reduced marital quality and socio–emotional deficits in 
demented patients only. However, intact emotion recognition and social behaviour does 
not presuppose that patients are insensitive to the needs and emotions of those around 
them. As indicated by the exploratory analyses (see Section 6.3.), caregivers’ ratings of 
patients’ empathy relative to patients’ own ratings of themselves indicated a lower 
ability or tendency to appreciate the perspective of others; the difference between group 
ratings correlated with marital satisfaction.   
 
Perhaps for caregivers of non–demented ALS patients, the perception of the impact of 
the disease on their spouses’ psychosocial functioning (Atkins et al., 2010) rather than 
their actual executive or socio–emotional abilities are important predictors of marital 
satisfaction. The current study did not assess patients’ psychosocial function, precluding 
an examination of its predictive capacity alongside behavioural impairment in the 
regression model. However, the NEO–FFI used in the exploratory analyses (see Section 
6.3.) did find that the caregiver–patient discrepancy score for levels of extraversion 
correlated with marital satisfaction. Similar to psychosocial measures, the E scale 
emphasises opportunities for social interaction, rather than social competence (see 
Sickness Impact Profile, Bergner etal, 1981, as used by Atkins et al., 2010). Reduced 
social interaction may correspond to decreased opportunities for caregivers’ to maintain 
social relationships on account of their caregiving duties. Social support has previously 
predicted caregiver marital satisfaction in cross–sectional (O'Connor et al., 2008) and 
longitudinal research (Atkins et al., 2010); thus the current study might have benefitted 
from examining the number and quality of relationships outside of the caregivers’ 
marriage to estimate their perceived quality of social support. These caveats 
withstanding, the current results highlight and affirm the importance of caregivers’ 
perceptions of patients’ behavioural impairment above the physical impact of ALS on 




6.5.3. Exploratory Question Two:  Comparisons between patients’ and caregivers’ 
perceptions of patients’ behaviour, empathy and personality 
  
The primary aim of the exploratory component of the study was to compare patients’ 
and caregivers’ ratings of patients’ empathy, emotional lability, personality and 
behaviour. As a secondary aim, it explored whether differences in caregiver and patient 
ratings or caregivers’ perception of change in the patient were associated with caregiver 
outcomes. For the convenience of interpretation, in this section caregivers’ ratings will 
be referred to as proxy–ratings while patients’ ratings will be referred to as self–ratings. 
 
No differences were found between self and proxy–ratings on the ELQ, suggesting both 
parties perceived the same level of emotional lability in the patient. However, the 
presence of tied data was high (see Table 6.11.) which may have compromised the 
statistical power of the non–parametric test used.  
 
With respect to the measures of empathy, proxy–ratings were significantly lower than 
self–ratings of ‘Perspective Taking’ (PT), meaning that, relative to patients, caregivers 
perceived patients as being less likely or less able to imagine the cognitive viewpoint of 
another. This corresponds with previous caregiver reports of increased self–
centeredness and reduced concern for others in ALS patients (Gibbons et al., 2008). 
However, Empathic Concern (‘EC’), which assesses the tendency to perceive and 
respond emotionally to the emotional states of others, did not differ between the rater 
groups. This profile of interpersonal behaviour, as reported by the caregivers, might 
imply that patients are able to perceive and experience the emotions and feelings of 
those around them when they encounter overt examples, such as an emotionally–
charged dispute, but show difficulty in anticipating or correctly identifying the more 
subtle or undisclosed intentions and thoughts of others. Caregivers may therefore 
perceive patients as being egocentric or indifferent to others’ feelings or intentions until 
they are made clear. Since neither group were asked to rate empathy retrospectively, it 
is not clear if this discrepancy represents the emergence of reduced cognitive empathy 
after the ALS onset or a pre–existing trait of which the patients are unaware or deny. 
Discrepancy scores between patients and their caregivers for this domain were 
associated with premorbid levels of marital satisfaction, possibly implying a long–
standing trait prior to disease onset. The discrepancy score was also associated with 
current marital satisfaction. This may reflect caregivers’ appraisal that patients prioritise 
their needs above their own, creating resentment which becomes expressed in how they 
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perceive the quality of their relationship with the patient. Alternatively, lower marital 
satisfaction either before or after the disease onset might influence caregivers’ 
perceptions of their spouses’ current empathic behaviour. However, a lack of significant 
differences between group ratings on the remaining empathy subscales argues against a 
consistent reporting bias by caregivers.   
 
Reduced PT as measured by the IRI has been shown in bvFTD patients in previous 
studies, where discrepancies between self– and proxy–ratings extended to the EC 
domain (Hsieh et al., 2013; Rankin et al., 2006). Moreover, reduced overall empathy    
(a summation of caregivers’ PT and EC scores) has also been associated with lower 
relationship quality as perceived by the caregiver (Hsieh et al., 2013). A comparison of 
caregiver data between bvFTD and the current samples might imply that the nature of 
interpersonal change is similar between ALS and bvFTD patients; although 
distinguished on the basis of changes to emotional empathy in the latter patients. These 
distinctions may reflect differences in location and degree of underlying 
neurodegeneration between the patient populations (Rankin et al., 2006) and/or severity 
of impairment to the underlying cognitive processes that are required to interpret 
emotion from others (Shany-Ur et al., 2012).  
 
In the current sample, the overall patient group showed no difficulty relative to controls 
on emotion identification, but did misinterpret the intentions and beliefs of cartoon and 
story characters (see Chapter 5, Section 5.2.2.4.). Although the empathy subdomains 
did not correlate with the composite for socio–emotional functioning, the profile of 
performance demonstrated across the socio–emotional tests by the overall patient group 
does resonate with a profile of reduced cognitive but intact emotional empathy as 
described by the carers of a subgroup of patients.          
 
In terms of personality, caregivers rated patients’ as showing significantly lower levels 
of extraversion than patients rated themselves. There were also tendencies for proxy–
ratings to indicate higher levels of neuroticism and agreeableness than patients’ self–
ratings. When premorbid and current proxy–ratings were compared, significantly higher 
current ratings for Neuroticism (N) and significantly lower current ratings for 
Extraversion (E) and Conscientiousness (C) were indicated from prior to the onset of 
patients’ disease. Patients did not complete the premorbid NEO–FFI, and therefore 
perceived change in personality over the course of disease could not be compared 
between the groups. However, when caregivers’ ratings of patients’ premorbid 
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characteristics were compared with patients’ self–ratings of current characteristics, no 
significant differences were found, indicating that the inconsistencies between the rater 
groups for current behaviour might exist due to the caregivers’ perception of personality 
change in their spouse over time. Apart from a small study which found elevated 
neuroticism in male ALS patients (Peters et al., 1978), the current findings depart from 
those of previous investigations of personality in ALS patients which have noted a 
hard–working autonomous behavioural style (Brown & Mueller, 1970) and high levels 
of extraversion or “cheerfulness” (Veit, 1947). Methodological inconsistencies across 
these studies notwithstanding, the overall pattern of results from the ALS personality 
literature suggests little evidence for distinct personality characteristics in patients per 
se. Rather, the perceived personality change endorsed by caregivers might reflect 
perceptions of broader changes in patients’ cognition, emotional and social behaviour. 
For example, the E domain assesses interest and engagement in social interactions, 
situations from which patients might elect to withdraw because of a lack of interest or 
the anticipated inconvenience of their physical disability. Raised levels of N might 
correspond to caregivers attributing increased depression and anxiety in patients, while 
the C domain, which measures tendencies for proactive deliberation and self–discipline, 
might reflect perceptions of raised apathy and/or impulsiveness in patients. 
 
In the current study, levels of apathy, dysexecutive behaviour and disinhibition, as 
measured by proxy FrSBe ratings, were significantly higher in the period following 
ALS onset than that prior to the patients’ disease. Caregivers and patients did not rate 
the change in behaviour since ALS onset as significantly different from each other; both 
groups were in agreement that behavioural impairment increased over time. However, 
caregivers rated higher levels of behavioural impairment for Apathy and Executive 
Function domains for both the premorbid and current period. In keeping with previous 
reports of caregiver ratings, there was a pattern of predominant apathetic behaviour, 
followed by executive dysfunction and lastly disinhibition (Chio et al., 2010; Grossman 
et al., 2006; Witgert et al., 2010). This pattern may conform to that described as the 
FTD–A behavioural subtype which is characterised by apathy, inertia and loss of 
volition (Snowden et al., 2001). Of the three subtypes, FTD–A is associated with 
predominant frontal lobe atrophy including the DLPFC and relatively less OFC 





Notably, discrepancy scores calculated to reflect discrepancies between self– and 
proxy–ratings for empathy, personality and behaviour were associated with caregivers’ 
outcomes. The lower the caregivers’ ratings of the patients’ tendencies or abilities for 
‘perspective taking’ relative to patients’ self–ratings, the lower caregivers’ rated their 
premorbid and current marital satisfaction. Similarly, the lower the caregiver’s ratings 
of patients’ level of extraversion relative to the patients’ self–ratings, the worse 
caregivers perceived their current relationship with the patient. The discrepancy score 
for patients’ current overall behavioural dysfunction was associated with increased 
caregiver anxiety and worse caregiver strain and burden. Caregiver burden, in turn, was 
associated with discordant ratings between couples regarding patients’ current executive 
dysfunction. The more the caregiver overestimated patient’s behavioural dysfunction on 
these domains relative to the patients’ self–ratings, the worse the caregiver’s rated their 
own anxiety and feelings of strain and burden.   
 
Change scores were also calculated to reflect caregivers’ perceptions of change in 
patients’ personality and behaviour since the onset of their ALS. Caregivers who 
perceived increased levels of neuroticism in patients over the course of their illness 
tended to report greater levels of anxiety, depression, strain and burden. Higher 
depression was also associated with caregivers who perceived greater reductions in 
extraversion and conscientiousness in patients following their disease onset. The 
relationship between caregivers’ outcomes and their perceptions of behavioural change 
in patients since the onset of ALS was also explored. The greater the perceived increase 
in the patient’s overall behavioural dysfunction and levels of apathy, executive 
dysfunction and disinhibition, the worse the caregiver’s self–ratings of depression, 
strain and burden. The greater the perceived increase in the patient’s level of 
disinhibition, the lower the caregiver’s ratings of current marital satisfaction. Finally, 
the greater the perceived increase in the patients’ levels of apathy, executive 
dysfunction and overall behavioural dysfunction, the worse the caregiver’s self–rating 
of anxiety.   
 
Cautious interpretation should be applied regarding these difference and change scores 
which were simply calculated by subtracting responses from one participant group or 
time–point from another. While such scores might show face validity and be intuitively 
appealing, their psychometric properties have not been investigated. Therefore, the 
associations between these scores and the caregiver outcomes should be viewed as 
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purely exploratory. Due to the unadjusted multiple correlations, some of the statistically 
significant results could have occurred by chance. Furthermore, the identification of 
causal relationships is not possible due to the cross–sectional nature of these analyses. 
Nonetheless, these relationships highlight possible additional sources of diminished 
caregiver wellbeing and might argue for the inclusion of caregiver–perceived empathy 
and personality alongside behaviour in future studies of caregiver outcomes in ALS. 
Recommendations for this area of research are discussed in Chapter 7.   
 
Whether the current inconsistencies in patient and caregiver reports are suggestive of 
lack of insight in patients is debatable. Anosognosia for behavioural impairment has 
been suggested to distinguish ALS–FTD patients from non–demented ALS patients. In 
fact, self–ratings of non–demented ALS patients have reported greater behavioural 
dysfunction than proxy–ratings (Abrahams et al., 2005b; Girardi et al., 2011; Woolley 
et al., 2010a). Nonetheless, an earlier study which found endorsements of greater 
behavioural impairment from ALS caregivers relative to patients attributed these 
differences to reduced insight in the patients (Chio et al., 2010). Moreover, there is 
some evidence to suggest that non–demented ALS patients lack insight into their 
cognitive impairment (Stukovnik et al., 2010). In the current study, patients’ 
‘awareness’ was defined as a function of both patient and caregiver perspectives. 
However, it is not certain which ratings provide the most accurate appraisal. This 
question is important because the method chosen for quantifying patient characteristics 
may substantively influence the inferences drawn about the psychological and 
behavioural consequences of ALS. Rather than reduced insight, patients’ responses 
might have been influenced by denial coping mechanisms or social desirability biases. 
Similarly, a large majority (82.4%) of caregivers reported high levels of burden and 
reduced marital satisfaction since the onset of their spouses’ illness. It is possible that 
the caregivers’ perceptions of the patients may have been influenced by their own 
mood, feelings of burden, strain and affection for their partner. In addition, the 
caregivers’ own empathic behaviour and personality characteristics were not examined; 
these traits may have been projected onto their spouse or mediated their responding. 
More generally, these results illustrate the need to examine biases that can occur when 
measuring self– and informant–reported data in ALS. Chapter 7 proposes the means by 




7. General Discussion  
 
The studies reported in this thesis have documented several findings relating to the 
cognitive–behavioural profile of non-demented ALS patients and the impact that 
patients’ cognitive–behavioural change poses for the ALS caregiver. This final chapter 
will provide a summary of the main findings of the research and discuss the 
implications for the management of patients and their caregivers. Subsequently, the 
limitations of the current study are acknowledged and recommendations for future ALS 
research are considered.   
 
7.1. Summary of main findings 
7.1.1. Cognitive impairment in ALS 
 
Chapter Five reported the results of the first study which tested the hypothesis that, 
relative to healthy controls, patients would show impaired performance on tasks 
measuring executive functioning and socio–emotional processing. In support of this 
hypothesis, the results indicated that ALS patients showed higher scores (greater 
impairment) than controls on a canonical variate created by a multivariate procedure. 
Univariate analyses revealed that mean composite scores created to reflect executive 
functioning and socio–emotional processing (EMOSOC) were significantly higher 
(more impaired) in patients than controls. Inspection of the discriminant function 
coefficients indicated that that group membership was maximally differentiated by 
performance on the Executive function composite, which showed greater weighting 
than the EMOSOC composite. This indicates that executive functioning contributed 
more to group differences on the canonical variate than socio–emotional processing.  
 
Single–case analysis revealed that the relative proportion of participants impaired on 
either composite within each group did not differ significantly. Proportionally more 
patients than controls showed concurrent impairments on the Executive and EMOSOC 
composites; proportionally more patients than controls showed isolated impairments on 
the Executive composite and proportionally more patients than controls showed isolated 
impairments on the EMOSOC composite. However, none of the differences in these 
proportions were significantly different. Dissociations of performance between the 
Executive and EMOSOC composites were found for three patients (none were found for 
controls). For all three patients, the directions of these dissociations indicated that 
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patients were impaired on the Executive composite but unimpaired on the EMOSOC 
composite.     
 
Performance on the individual components of the Executive function composite was 
compared between the groups. In addition, groups were compared on the Hayling Test, 
as this was not included in the Executive function composite (see Chapter 5, Section 
5.2.2.1.). Following Bonferroni corrections and relative to control participants, ALS 
patients showed impaired performance on two tests of executive function: the D–KEFS 
card sorting task and the Hayling Test. A trend for impaired performance relative to 
controls on the VFI–S word condition was also found. Single–case analysis revealed 
that significantly more patients than controls were impaired on both conditions of the 
VFI. Trends for proportionally more patients than controls to show impairments on the 
Hayling latency and two error conditions were also found.   
 
An investigation of the differences between participant groups on the EMOSOC 
components was also conducted. Patients performed significantly worse than controls 
on all the subtests of the Happé task; however, no between–group differences were 
observed for the RME and the three subtests of the TASIT. Single–case analysis 
revealed more patients than controls were impaired on the single cartoon abstraction test 
of the Happé task. This pattern of results suggests that the group differences obtained on 
the EMOSOC composite were driven by performances on the subtests of the Happé 
task.  
 
More detailed exploratory analyses were conducted on the subtests of the TASIT and 
Happé tasks to investigate group performances on the conditions within the tests. 
Between–group analyses conducted on the performance of the TASIT subtasks revealed 
no group differences for the emotion recognition test or the two social inference tests 
(minimal or enriched social information subtests). For the Happé cartoon subtasks, 
within–group analyses found that both groups performed better on the mental (ToM) 
cartoon trials than the physical cartoon trials. Conversely, for the Scenario subtask, both 
groups performed better on the physical scenario trials than the mental (ToM) scenario 
trials. Qualitative information from the errors scores on these subtasks indicated that 
patients committed significantly more partial and descriptive errors than controls on the 
single–cartoon inference subtask, whereas they committed significantly more 




Groups were compared on one measure of language (confrontation naming) and 
memory. There were no differences between groups on either test. Overall, the pattern 
of impairments in the ALS sample indicated predominant executive dysfunction, with 
relative sparing of socio–emotional processing and intact language and memory 
functions.  However, the limited number of tasks assessed from the other domains may 
have affected the ability to detect differences.  
 
Because of the potential for psychoactive medication to affect cognitive performance on 
some of the tasks, within–patient group analyses were conducted to compare patients 
receiving psychoactive medication with those not receiving such medication. There was 
a trend for reduced performance in the medicated patient sample relative to the non–
medicated patient sample on the emotion recognition task. Medicated patients also 
showed a trend for superior performance on a delayed cued recall trial compared to 
non–medicated patients.  
 
7.1.2. Behavioural change in ALS 
 
Contrary to Hypothesis Two, patients did not show higher levels of behavioural 
symptomatology than controls for both retrospective and current time periods. 
However, there was a trend for patients to report significantly higher levels of current 
Apathy than controls. Significant interactions between group membership and time 
were found for all domains of the FrSBe. Patients’ overall behaviour scores increased 
over time (i.e. from retrospective to current ratings), while controls’ overall scores 
decreased. This pattern was replicated for the Executive Dysfunction and Disinhibition 
subscales. For the Apathy subscale, both groups reported increased apathy with time, 
but the magnitude of the increase was greater for patients. Within the patient group, the 
proportion of patients that satisfied ‘caseness’ for Apathy and the FrSBe total domains 
increased significantly from the premorbid (retrospective) to current time point. This 
pattern was not demonstrated in the control group. Overall, the results of these analyses 
indicate a change in self–reported behaviour since the onset of ALS, with increases in 
apathy, dysexecutive behaviour and disinhibition relative to controls over the same 









7.1.3. Mood, self–perceived personality and empathy in ALS 
 
Patients and controls did not differ on measures of self–reported anxiety or depression; 
the median scores for either group were not indicative of mood disorder according to 
revised scoring criteria (Gibbons et al., 2011).  
 
There was a trend for patients to report significantly higher current levels of 
conscientiousness than controls on the NEO–FFI scale. However, significantly more 
controls than patients had very low levels of conscientiousness. This suggests that the 
between–group difference in mean ratings for the Conscientiousness domain might have 
been an artefact of the control sample and not an indicator of a disease related change. 
There were no group differences for any of the empathy domains of the self–reported 
IRI measure.   
 
7.1.4. Predictors of emotional processing and social cognition in ALS 
 
In Chapter Five it was hypothesised that ALS patients’ executive (dys)function would 
be the main predictor of their performance on tests of emotional processing and social 
cognition, with smaller contributions from self–reported behaviour, mood, personality 
and empathy. Correlational analyses identified the following predictors which were 
entered into a final hierarchal regression model: Age; years of formal education (control 
variables); the Executive function composite; the FrSBe Total score, HADS T (the 
summation of HADS A and HADS D scores) and the NEO–FFI Openness score. The 
results of the final regression analysis supported the hypothesis. Executive function 
contributed most to the performance of ALS patients on a composite of emotional 
processing and social cognition, with smaller, albeit non–significant, contributions from 
behavioural, personality and mood factors.   
 
7.1.5. Caregivers’ perceptions of mood, strain, burden and marital satisfaction 
 
Caregivers self–reported significantly higher (worse) scores for depression and anxiety 
than patients’ self–reports. The mean anxiety scores were within the ‘borderline case 
level’ for both groups according to revised cut–off criteria (Gibbons et al., 2011); 
significantly more caregivers than patients satisfied this criterion. There was a trend for 
more caregivers than patients to satisfy criteria for ‘case level anxiety’ and ‘case level 
depression’.  
Currently felt strain correlated positively and most strongly with how much caregivers 
felt that their partner’s illness affected other areas of their own life. It also correlated 
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positively with how much strain they anticipated feeling in a year’s time and how much 
control they felt they had over their own reactions to their partner’s illness. A large 
percentage of caregivers (82.4%) satisfied criteria for high levels of burden. Caregiver 
ratings of marital satisfaction were significantly lower following the onset of their 
spouse’s illness than they were reported to have been prior to the disease.  
 
7.1.6. Predictors of caregiver outcomes 
 
Chapter Six tested two hypotheses relating to caregivers’ outcomes; each will be 
described in turn.  The first hypothesis predicted that objective measures of cognitive 
function and carer–perceived behavioural impairment in patients with ALS will 
contribute significantly to carer wellbeing (in terms of mood, perceived burden and 
strain), above and beyond patients’ disease status and symptoms. A series of forward 
selection multiple regressions identified the following functional relationships:  
 
iv) Disease severity, as indicated by the ALSFRS–R Limb severity score, significantly 
predicted caregiver depression and burden, with burden further predicted by 
behavioural symptoms, as measured by the FrSBe total current score. 
 
ii) The overall level of behavioural symptoms, as indicated by the FrSBe total current 
score, significantly predicted caregiver anxiety. 
 
v) Emotional lability and performance on the emotional processing and social 
cognition tasks, which were indicated by the ELQ total and EMOSOC composite 
respectively, significantly predicted caregiver strain. 
 
These predictors were entered into a final hierarchal regression model in order to assess 
their predictive capacity of a global outcome measure of caregiver wellbeing (a 
summation of standardised scores for mood, strain and burden). Only limb severity 
scores (ALSFRS–R Limb) and the caregiver–rated behavioural scores (FrSBe total 
current) were found to be significant predictors of the global outcome scores. These 
results fail to support the hypothesis that both objective measures of cognitive 
performance and caregiver–rated patient behaviour would predict caregiver outcomes. 
Instead, it highlights the combined roles of caregiver perceptions of patients’ behaviour 
and patients’ disease severity in the caregiving experience of ALS.    
 
The second hypothesis predicted that objective measures of cognitive function and 
carer–perceived behavioural impairment in patients with ALS would contribute 
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significantly to caregivers’ perceived marital satisfaction, above and beyond patients’ 
disease status and symptoms. Separate multiple regression analysis found that the 
FrSBe Total current score was a significant predictor of caregivers’ current marital 
satisfaction. When the FrSBe Total was entered into a hierarchical regression 
controlling for premorbid marital satisfaction scores, it remained a significant predictor 
in the model. As before, these results fail to support the hypothesis that both objective 
measures of cognitive performance and caregiver–rated patient behaviour would predict 
caregiver outcomes.  
 
7.1.7. Comparisons between patients’ and caregivers’ perceptions of patients’ 
empathy, behaviour and personality  
 
Caregivers’ ratings of patients’ levels of ‘perspective taking’ (PT) were significantly 
lower than patients’ self–ratings on the IRI. This indicates that, relative to the patients, 
caregivers perceived patients as being less likely or less able to imagine the cognitive 
viewpoint of another person. Exploratory correlation analyses found that caregiver–
patient discrepancy scores for this domain correlated positively with caregivers’ 
perceptions of premorbid and current marital satisfaction (i.e. the lower the caregiver’s 
rating of the patient’s level of PT relative to the patient’s self–rating, the lower the 
caregiver’s ratings of premorbid and current marital satisfaction).   
       
The relative perception of patient behaviour was compared between caregivers and the 
patients themselves. There were no differences between caregivers and patients in 
ratings of patients’ emotional lability for any of the ELQ subscales or the total score. On 
the FrSBe, like the patients themselves, caregivers rated patients as showing higher 
levels of behavioural dysfunction following the onset of their illness than before their 
illness for all domains.  Between–group ratings of the change in patients’ behaviour 
since their disease onset did not differ. Ratings from both groups increased significantly 
over time for all domains. However, caregivers rated patients as showing higher levels 
of premorbid and current behavioural dysfunction than patients rated themselves. This 
was true for the domains of Apathy, Executive Dysfunction and the total FrSBe score, 
but not for the Disinhibition domain. 
 
Caregiver–patient discrepancy scores for FrSBe subscales and total score were 
computed. Exploratory correlation analyses revealed that the current FrSBe Total 
discrepancy score was positively associated with caregiver anxiety, strain and burden. 
 297 
 
In addition, the current Executive Dysfunction discrepancy score correlated positively 
with caregiver burden (i.e. the higher the caregiver’s ratings of the patient’s behavioural 
dysfunction on these domains relative to the patients’ self–ratings, the worse the 
caregiver’s self–ratings of anxiety, strain and burden). 
 
Change scores were also calculated for each FrSBe domain (by subtracting caregivers’ 
ratings of patients’ premorbid behaviour from their current behaviour). Exploratory 
correlational analyses revealed that all the FrSBe domain change scores correlated 
positively with caregiver measures of depression, strain and burden (i.e. the greater the 
perceived increase in the patient’s behavioural dysfunction on these domains, the worse 
the caregiver’s self–ratings of depression, strain and burden). The Disinhibition change 
score correlated negatively with current marital satisfaction (i.e. the greater the 
perceived increase in the patient’s level of disinhibition, the lower the caregiver’s 
ratings of current marital satisfaction). The Total FrSBe change score, the Apathy 
change score and the Executive Dysfunction change score correlated positively with 
caregiver anxiety (i.e. the greater the perceived increase in the patient’s behavioural 
dysfunction on these domains, the worse the caregiver’s self–rating of anxiety).  
  
On the NEO–FFI, caregivers rated patients as showing significantly lower levels of 
Extraversion than patients rated themselves, with trends for higher levels of 
Neuroticism (N) and lower levels of Conscientiousness (C). Caregiver–patient 
discrepancy scores for the NEO–FFI domain ratings were calculated. Exploratory 
correlational analyses revealed a positive association between the Extraversion (E) 
discrepancy score and current marital satisfaction (i.e. the lower the caregiver’s rating 
of the patient’s level of E relative to the patient’s self–rating, the lower the caregiver’s 
current marital satisfaction). Change scores reflecting differences in caregivers’ 
premorbid and current ratings of the patients were also calculated for the personality 
domains. Exploratory correlational analyses revealed that the N change score correlated 
positively with caregiver outcomes of mood, strain and burden (i.e. the greater the 
perceived increase in the patient’s level of N, the worse the caregiver’s self–perceived 
level of strain and burden). The E and C change scores correlated negatively with 
caregiver depression (i.e. the greater the  perceived reduction in the patient’s level of E 




7.2. Clinical implications  
7.2.1. ALS cognitive–behavioural change and the ALS clinic 
 
Despite the noted limitations of the current research (see Section 7.3.), the results of this 
study corroborate the general position that cognitive–behavioural impairment in ALS is 
characterised by executive dysfunction and a range of behavioural change associated 
with frontal subcortical dysfunction. In particular, compared to healthy controls, 
patients showed difficulties on tasks requiring abstract and flexible thinking, problem–
solving and inhibitory control. Whether these deficits manifest in patients’ daily lives 
can be inferred from behavioural data provided by patients or caregivers. Indeed, in 
addition to apathy, both patients and their caregivers in the current sample endorsed 
increased dysexecutive behaviour and disinhibition since the onset of ALS using the 
FrSBe; these endorsements appear to coincide with the profile of performance displayed 
by the patients on the executive function tasks. One might speculate that patients with 
this cognitive and behavioural profile may show problems with, or an indifference 
towards, managing financial affairs, planning for future events or arriving at decisions 
regarding their clinical care. Progressive physical disability may cause patients to 
withdraw from work or increasingly rely on others, thereby relieving patients of their 
usual cognitively–demanding duties. Difficulties with ordinary tasks may therefore go 
un–noticed by clinical teams until patients’ are required to manage and comply with 
palliative aids, such as communicative and respiratory support devices (Abrahams, 
2013). Thus, ALS clinics should screen for cognitive and behavioural impairment in 
newly–diagnosed patients as soon as ethically and practically possible in order to detect 
possible difficulties and direct care strategies.  
 
Along with apathy, ALS patients have been reported by caregivers as showing 
egocentricity and a ‘loss of interest in others’ (Gibbons et al., 2008). In the current 
study, caregivers rated patients as showing a lower ability or tendency to appreciate 
other people’s perspectives than patients rated themselves. This may indicate changes to 
patients’ interpersonal behaviour which patients either deny or of which they are 
unaware. On the other hand, proxy and self–ratings for patients’ level of empathic 
concern were similar. Furthermore, the current overall patient group showed no 
difficulty relative to controls on emotion identification, but did misinterpret the 
intentions and beliefs of cartoon and story characters. Clinicians should be aware that 
while ALS patients may respond appropriately to other people’s emotions, they may not 
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be able to anticipate or be responsive to the thoughts or intentions of those around them. 
This can place strain on the patient’s interpersonal relationships which become more 
important as the patient’s dependency on others increases with their functional decline. 
The implications for and education of the caregiver with regards to possible 
interpersonal changes in the patient should be considered in clinical consultations with 
ALS families (see Section 7.2.2.).  
    
Although not supported in the present study, other cognitive functions such as language, 
memory, emotion processing and ToM have been reported as impaired in patients from 
other ALS studies, with evidence indicating these deficits occur independently or 
alongside executive dysfunction (see Chapter 2, Section 2.3.). This has led to the 
suggestion of a spectrum of cognitive dysfunction within ALS, with some authors 
(Abrahams, 2013; Goldstein & Abrahams, 2013; Taylor et al., 2013) suggesting the 
need for revision of the Strong et al’s (2009) consensus criteria (see Chapter 1, Section 
1.5.3.) to reflect this heterogeneity. The fact that non–executive cognitive functions 
were relatively preserved in the current sample may merely reflect the recruitment of 
patients from a population showing single–domain executive impairment (e.g. Phukan 
et al., 2012) or the choice and number of measures used in the study. An absence of 
executive impairment should not be taken as an indication of intact cognitive function 
in other domains.  
 
Despite over 30 years of documented cognitive impairment in non–demented patients, 
only relatively recently have screening measures specific to ALS been developed. 
Initially screening tools emphasised the detection of executive dysfunction over other 
domains and varied in their use of controls for motor disability (e.g. Flaherty-Craig et 
al., 2006; Woolley et al., 2010b). The Edinburgh Cognitive and Behavioural ALS 
Screen (ECAS; Abrahams et al., 2013) is a brief (~15 – 20 min) multi–domain 
screening measure, assessing executive function, social cognition, language, memory 
and visuospatial functioning. It is designed to minimise the confounds of patients’ 
physical impairment on cognitive performance and is accompanied by a separate 
caregiver interview of the patient’s behaviour, with items also adapted to take into 
account ALS symptoms. Within the cognitive screen social cognition is assessed under 
the domain of executive functioning and comprises a simple ToM task in which 
preference judgments are made on the basis of eye–gaze direction (similar to that which 
was reported to be a sensitive measure by Girardi et al 2011). Whilst preference 
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judgements were not assessed in the current study, patients did show difficulties with 
inferring the thoughts and intentions of cartoon and story characters. Furthermore, their 
performance on ToM tasks appeared to be secondary to their executive dysfunction. 
The current study thus supports the inclusion of social cognition measures in ALS 
cognitive screens. It also provides some justification for their inclusion under the 
assessment of executive function, rather than as a stand–alone domain. Clinics with 
restricted resources will benefit greatly from using the ECAS as it identifies the severity 
and nature of cognitive and behavioural impairment in patients and will allow clinical 
teams to make informed and tailored care arrangements for patients and their families. 
Where severe cognitive deterioration is suspected, detailed neuropsychological testing 
can then corroborate comorbidity of FTD. 
In bvFTD, emotion recognition and social cognitive deficits are pronounced and may be 
independent of executive dysfunction. For this reason, the inclusion of emotion 
recognition and social cognition measures to support a confirmation of a bvFTD 
diagnosis has been proposed (Sarazin et al., 2012; Schroeter, 2012). In the current 
study, ALS patients’ emotion recognition was intact. The current findings would not 
support the use of emotion recognition measures in clinic screening protocols for ALS 
patients. However, as emphasised throughout this thesis, reports of ALS impairments on 
such measures are inconsistent. In particular, it is suggested that the emergence of 
emotional processing deficits in ALS are strongly associated with the presence of FTD 
(Savage et al., 2013). Therefore, in–clinic screening might yet potentially benefit from 
the inclusion of emotional processing paradigms to identify ALS patients with possible 
FTD comorbidity.  
  
7.2.2. ALS caregivers and the ALS clinic 
 
The results of the present caregiver study join a growing body of work which 
underscores the effects of ALS that extend beyond the patient to corresponding family 
members. Perceived lack of support from health and social services has been associated 
with reduced mental health and higher strain in ALS caregivers (Peters et al., 2012); a 
finding which reinforces the duty of the ALS clinical team to address caregiver 
wellbeing.  
 
Caregivers have reported that clinical services place disproportionate focus on the 
practical rather than emotional adjustments to the disease (Brown, 2003; Oyebode et al., 
2013). In the current study, patients’ functional impairment, particularly limb–related 
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impairment, as well as behavioural dysfunction, were the main contributors to reduced 
caregiver wellbeing and marital satisfaction. This suggests that clinical communication 
with ALS families should emphasise the psychological challenges presented by the 
neurobehavioural features, as much as the physical manifestations, of ALS. As a group, 
caregivers’ depression and anxiety levels were significantly higher than in the patients 
themselves. Thus, clinicians should be aware that ALS may bear common but unequal 
outcomes for patients and their caregivers. Moreover, care teams should be aware that 
the symptoms of ALS may pose differential effects upon caregivers. The current results 
revealed that while functional impairment predicted caregiver depression, behavioural 
dysfunction predicted caregiver anxiety; together, these symptoms predicted increased 
burden. Routine monitoring of the patient’s functional, cognitive and behavioural 
functioning may prepare the clinical team to tailor their support for caregivers.   
  
Caregivers perceived patients as showing less cognitive empathy than patients 
perceived in themselves, reported changes in personality since the onset of their 
spouse’s ALS and endorsed higher levels of behavioural impairment in patients than 
patients did themselves. Discrepancies in patients and caregivers perceptions should be 
identified by clinics in order to examine and screen for the possibility of reduced 
awareness or use of coping strategies by patients. ALS caregivers who perceive patients 
as being supportive towards the caregivers’ problems have shown to be more likely to 
report finding positive experiences associated with caring for their ill relative (Boerner 
& Mock, 2012). Therefore, it is important that caregivers are made aware of the 
possible interpersonal or behavioural changes accompanying ALS so that they do not 
misinterpret their partner’s indifference or apathy as resulting from inherent problems 
within their relationship (Abrahams, 2011).  
 
A large majority of caregivers reported a high level of burden and reduced marital 
satisfaction following their partner’s ALS onset. Since some carers may be reluctant to 
discuss such concerns in front of the patient, caregivers should be interviewed 
separately either by clinicians themselves or affiliated psychological services. In clinics 
with limited resources, this could take the form of questionnaire packs for caregivers to 






7.3. General limitations 
 
As alluded to in the previous chapters’ discussions, the current findings should be 
interpreted within the limitations of the study’s design as these may affect the 
generalizability of the results to the wider population of ALS patients and their 
caregivers. Here, the general limitations of the current study are considered.  
7.3.1. Recruitment criteria, sampling bias and participant characteristics 
 
The exclusion criteria adopted by the study in the recruitment of the patients were 
extensive and restrictive. Whilst these criteria were in place to ensure that any cognitive 
or behavioural impairment found in the patients could not be attributed to comorbid 
conditions (e.g. diabetes, psychiatric illness, other neurological phenomena) and ALS–
related factors (e.g. insufficient respiratory function; severe fatigue), the employment of 
these criteria may limit the representativeness of the current patient sample of the ALS 
population as a whole. 
  
Initially it was planned that patients with an FVC of 70% and below were to be 
excluded from the study. In practice, this was difficult to implement as the research sites 
varied in their method and frequency of assessing respiratory functioning in their 
patients. In these instances, the study relied on the clinical judgement of the patient’s 
clinician and a standardised measure of respiratory function completed by the patient 
prior to participation. This might mean that the identification of cognitive dysfunction 
in the current study may have been influenced by the inclusion of patients who 
themselves or their clinician were unaware of subtle decrements in respiratory 
functioning.  
 
At the start of the study, patients were excluded on the basis of receiving psychoactive 
medication. As the study progressed, this was found to be the greatest barrier to 
recruitment and, after much deliberation and consultation with research members, was 
relaxed, allowing patients who were receiving medication for ALS–related symptoms 
(e.g. EL, pain, stiffness) but not mood disorder to be recruited to the study. Analyses 
comparing the patient subgroups indicated that compared to non–medicated patients, 
patients receiving SSRIs and/or benzodiazepines showed a trend for superior 
performance on a delayed cued memory trial. In addition, a trend for worse 
performance by medicated patients on the basic emotion recognition task (TASIT EET) 
was found. These trends, however, were not sufficient to produce overall group 
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differences between patients and controls on the CVLT or EET. While the exclusion of 
psychoactive use is preferable, this is not always practical and may further reduce the 
representativeness of the patient sample to the wider ALS population. Further, the 
pattern of performance by medicated patients found in the current study might inform 
the future study of emotion processing and other cognitive functioning in ALS (see 
Section 7.4.1.).   
 
A strength of the study is the nature of its multicentre recruitment from four tertiary 
care centres and one community–based healthcare hospice. Two–thirds of eligible 
patients approached agreed to take part in the research. However, without detailed 
clinical data for the non–respondents, the influence of participation bias on the current 
study remains speculative. Potentially, patients with significant levels of cognitive–
behavioural dysfunction, physical disability or mood symptoms might have refrained 
from taking part in the research, due to inertia or the expectation that testing would be 
too physically or mentally demanding. Alternatively, patients who do not have a high 
degree of disability and still able to maintain work commitments may have declined due 
to time constraints.  
 
Patients in the current study were ethnically homogeneous (mostly Caucasian), well–
educated (an average of 14.5 years of formal education) and, as a group, were of high 
average intelligence, as measured by the IQ estimates. This might limit the 
generalizability of the current patient results to the ALS population as a whole.  There is 
limited evidence to suggest that lower educational attainment and premorbid IQ is 
positively associated with cognitive dysfunction in ALS (Massman et al., 1996; Phukan 
et al., 2012). Furthermore, Stern’s Cognitive Reserve Hypothesis states that persons 
with higher lifetime intellectual enrichment are better able to sustain neuropathological 
disease before or without succumbing to the clinical manifestation (e.g. dementia) of the 
disease (Stern, 2009). The theory is supported by evidence from cross–sectional and 
longitudinal research suggesting that higher levels of intelligence and educational 
attainment may act as preventive or compensatory factors in the development of age– 
and disease–related cognitive deficits (e.g. Meng & D’Arcy, 2012; Tucker-Drob et al., 
2009). Potentially, the patients in the current study might demonstrate high cognitive 
reserve, and are thus relatively less susceptible to cognitive change; this possibly limits 
the inferences drawn regarding ALS performance on the current set of 




Caregivers were invited to take part in the study on the basis of the patient’s 
participation and their agreement for their spouse to be contacted. The patient’s 
participation was required as the study examined the relationship between objective 
measures of patients’ neuropsychological performance and caregivers’ outcomes. 
Nonetheless, these conditions might have excluded caregivers who were otherwise 
characteristic of the general ALS caregiver population. Of the spouses available for 
invitation, approximately one–fifth declined participation which may further have 
introduced sampling bias into this part of the study. Some caregivers maintained their 
care duties while working part– or full–time, and this might have influenced their 
willingness to take part in the study. Caregivers who were experiencing low mood 
and/or high levels of strain and burden may potentially have been less motivated to take 
part. However, a large majority of caregiver in the study endorsed ZBI scores that met 
cut–off criteria for substantial burden. Conversely, caregivers experiencing high levels 
of strain and burden may have been more motivated to take part to communicate their 
distress. Furthermore, as the study was interested in the impact of ALS on the marital 
relationship, only spouse caregivers were recruited. Thus, the comparability of the 
current findings with those of other studies whereby spousal and filial caregivers are 
analysed together cannot be assumed. 
 
Control participants were matched to patients on demographic and mood variables. This 
was important to ensure that group differences could not be explained by differences on 
background variables; however, it does not eliminate bias associated with self–selection 
recruitment procedures. Certain personality traits, such as increased agreeableness, 
altruism and openness to experience have been positively associated with volunteering 
in research studies (Dollinger & Leong, 1993; Lönnqvist et al., 2007), posing 
implications for the interpretation of group differences on measures of empathy 
personality and behaviour. Higher educational attainment and socioeconomic status are 
also suggested to predict research participation (Rosenthal & Rosnow, 2009); however, 
participants groups were matched on these variables.  
7.3.2. Neuropsychological assessment  
 
A. Patients and controls 
 
Testing of patient participants was conducted in the patient’s home, as opposed to a 
controlled laboratory setting. However, this was necessary to accommodate the patients’ 
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reduced mobility. Stringent testing protocols were followed for both participant groups 
regardless of venue, reducing systematic bias introduced by disparate testing contexts. 
The testing battery was long (approximately 6 hours) raising the risk of fatigue. For this 
reason testing was spaced out over a minimum of two sessions. Where fatigue was 
suspected or expressed, breaks were encouraged or the testing session was terminated. 
Controls were offered the same testing options, although this was rarely required. 
Missing data due to patient disability is a pervasive limitation in neuropsychological 
investigations in ALS. However, the selection of measures ensured that non–
participation due to physical impairment was avoided.   
 
In common with several ALS studies; the selection of cognitive tasks was restricted by 
patients’ motor impairment or what tasks could be modified to accommodate their 
disability. The inclusion of more ecologically–valid tests of executive function (e.g. the 
motor–free Medication Scheduling Task, see Stukovnik et al, 2010) would have 
complemented the current set of measures; however, given the length of the battery and 
the possibility of patient fatigue, this was not practical. Nonetheless, the selected tasks 
possessed good validity and reliability (see Chapter 4) and have provided useful clinical 
information in relation to the patients’ cognitive difficulties. The limitations of the tasks 
used to assess socio–emotional processing were discussed in Chapter Five. As already 
mentioned, a limitation of the neuropsychological battery is that language and memory 
performance was estimated using only one task, potentially under–estimating patients’ 
dysfunctions in these domains.  
 
B. Caregivers 
The excessive time demands involved in caregiving are commonly cited as a barrier to 
research participation (Dura & Kiecolt-Glaser, 1990). For this reason, caregiver 
participants were able to determine the format of their participation: in a one–on–one 
interview with the researcher; answering questionnaires independently and returning 
these to the researcher or a combination of both. While this flexibility might have 
encouraged participation in some caregivers, the mode of participation may have 
influenced responding by participants. Self–administered questionnaire responding 
might have increased participants’ willingness to disclose information regarding 
sensitive items (Tourangeau & Yan, 2007), but they would not have benefitted from the 
presence of the researcher to clarify questions that arose during responding. 
Nonetheless, all caregiver participants received the same informed consent and 
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debriefing procedures which included opportunities to raise their concerns and 
enquiries.   
    
7.3.3. Statistical techniques and sample size  
 
As multiple between–group comparisons were undertaken, the current study conducted 
Bonferroni corrections to reduce the risk of Type I errors. Although this may reduce the 
number of false rejections of the null hypothesis, it might also increase the risk of Type 
II errors. In the current study, findings that were significant following this correction 
were classed as significant findings, while those that were significant only prior to the 
correction were considered as supportive findings or trends. Both were considered in 
discussion of the results. While this may be a prudent approach, no consensus on the 
use of correction methods for multiple testing has been reached (Gelman et al., 2012) 
and thus the interpretation of these findings requires caution.   
Compared to other studies of emotional processing and social cognition in ALS, the 
current patient sample was relatively large (n=55). However, the caregiver sample was 
smaller (n=35) and this may have compromised the study’s ability to detect significant 
effects or relationships. Missing data further reduced the statistical power of certain 
tests. The selection and number of predictors for regression analyses was restricted by 
sample size, in particular for the caregiver study. Thus the parsimonious regression 
models might have excluded patient and/or caregiver factors that could have explained 
additional variance in the criterion variables. Furthermore, and as already mentioned, 
the creation of composite scores to reduce the inflation of Type I error, may have 
masked significant associations in both studies. Moreover, a major methodological 
limitation of the current research is that the data are cross–sectional, and therefore 
precludes identification of causal relationships.  
 
7.4. Directions for future research  
In order to address some of the methodological limitations delineated in Section 7.3. as 
well as those present in the ALS literature, future research is required. In this section, 
recommendations for future studies of ALS are considered.  
7.4.1. Neuropsychological assessment in ALS  
 
The pattern of cognitive performance by the ALS patients in the current study was 
characterised by executive dysfunction, with relative sparing of socio–emotional 
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processing and intact language and memory functions. Deficits in patients were elicited 
on tasks believed to assess DLPFC (e.g. D–KEFS, VFI) and OFC (e.g. Hayling) 
functioning. Historically, measures that load on DLPFC function have predominated in 
ALS cognitive research. Only recently, with the suggestion of bvFTD–like behaviour 
and socio–emotional processing impairments, has OFC assessment gained similar 
attention. There are, of course, limits to the specificity of cognitive tests; nonetheless 
the current study suggests that the design of future ALS neuropsychological 
assessments should test the function of both neural regions. While beyond the scope of 
the current research, future ALS studies could systematically explore overlap and/or 
dissociations in DLPFC and OFC functioning in patients using these and other tasks (as 
per Meier et al, 2010) and examine their relative contribution to emotion recognition 
and/or ToM in patients.   
 
A pervasive limitation of studies which focus on executive functioning or socio–
emotional processing in ALS is the use of a single measure of language and/or memory. 
Phukan et al’s population–based study indicated a heterogeneous profile of cognitive 
impairment in their non–demented ALS cohort, in which several phenotypes were 
differentiated by the presence of predominant or exclusive executive impairment, 
language and/or memory dysfunction (Phukan et al., 2012). Cognitive heterogeneity 
within ALS clinic–based samples is also well documented (see Chapter 2). Detailed 
assessment of each cognitive domain may be unrealistic for most ALS studies. The 
integration of a brief but multi–domain and ALS–specific cognitive battery, such as the 
ECAS (Abrahams et al., 2013), may circumvent time pressures and patients’ fatigue, 
while providing a sensitive screen for impairment on specific domains.   
 
Detailed medical histories and clinical information should be obtained and used to 
screen for factors that might influence cognitive performance. The current results 
reported a trend of worse performance for psychoactive medicated patients compared to 
non–medicated patients on the emotion recognition test. Several cognitive studies do 
not report medication profiles for their patients. At most, some have excluded patients 
receiving SSRIs but not those using benzodiazepines. Further study is required to 
determine the effects of these medications on the cognitive performance and behaviour 
of patients, but in the interest of prudence, up–to–date patient medication profiles 
should be listed and the potential influence of psychoactive medication controlled for 




Different methods were used to analyse the neuropsychological test scores of the 
current sample. Comparisons based on mean and median scores are useful for indicating 
overall differences between groups, but they may mask the potential heterogeneity of 
impairment within ALS samples. Single–case analysis is able to reveal the prevalence 
of impairments within a specific domain and is better positioned to identify subgroups 
within patient samples. For example, while no between–group differences were found 
for the VFI–S score in the current patient sample, single–case analysis revealed that 
significantly more deficits on this index were present in the patient group compared to 
the control group. The current study thus highlights the utility of combining between–
group comparison with single–case analysis in ALS research to fully elucidate cognitive 
performance in patients.  
The current study adopted novel single–case methods developed by Crawford and 
colleagues (2011) to test for (i) deficits on cognitive tasks and (ii) dissociations between 
composites or conditions within tasks, while (iii) controlling for the influence of 
covariates (age, years of education and gender; see Chapter 5, Section 5.2.2.3). 
Different techniques to identify deficits or dissociations in patients’ performance have 
been used in ALS research; possibly contributing to the variable prevalence of 
impairment reported across studies. The current methods show superior control for 
Type I and Type II error rates over other single–case methods, some of which have been 
used in ALS research (e.g. the z–score method) (Crawford & Garthwaite, 2005, 2012). 
While the study did not evaluate different methods of impairment classification, it 
recommends the current methods for use in ALS investigations, particularly when 
control samples are modest or there is a need to partial out the effects of potential 
confounding variables.  
 
The current study also supports the use of quantitative and qualitative (e.g. error scores) 
indices in ALS cognitive assessment, as was used to aid interpretation of patients’ 
performance on the Hayling test and Happé task. As well as characterising performance, 
qualitative information may also reveal impairment patterns that were masked by 
comparing groups on numerical scores alone.      
 
Chapter Two provided a comprehensive overview of the several factors (e.g. onset type, 
presence of EL, etc.) that may influence cognitive status in ALS. However, the study 
itself did not distinguish patients’ performance on the basis of these factors. Future 
research could differentiate between bulbar– and limb–onset patients; those patients 
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with or without bulbar or EL symptomatology or MND phenotypes (PLS, PMA) to 
investigate potential disease markers for the susceptibility of cognitive change in ALS.      
 
Finally, the inclusion of patients with FTLD subtypes would elucidate the boundaries 
between the mild and moderate cognitive–behavioural changes that can occur in ALS 
and the more overt cognitive–behavioural hallmarks of FTD. Studies comparing ALS 
and patients with FTD typically recruit bvFTD patients. Given the heterogeneous 
cognitive involvement demonstrated in non–demented ALS, it is recommended that 
studies also compare ALS patients with ALS–FTD and FTD patients who fulfil SD and 
PNFA criteria. Where it is unrealistic for patients with FTD to complete full test 
batteries, abbreviated versions of tasks could be employed for comparability.     
7.4.2. The assessment of emotional processing and social cognition in ALS  
 
The findings of the current study indicate the value of assessing emotional processing 
and social cognition in ALS patients using both static and realistic measures. Future 
studies using a range of media will help to further characterise the scope of socio–
emotional deficits in ALS. Emotion processing should be assessed using several 
modalities (e.g. speech, faces, words, scenes) to determine if global or select emotion 
processing deficits are apparent in the disease. Social cognition measures should 
differentiate between different components of ToM, such as first–order and second–
order ToM or cognitive and emotional ToM. In addition, several ToM tasks of graded 
difficulty (e.g. both with low and high executive demands) could be used in the same 
battery with the purpose of elucidating the nature of the underlying processes of ToM 
performance in ALS. Importantly, more work is required to determine whether the 
available social cognition tasks reliably measure ToM constructs; this is an issue that is 
acknowledged (Freedman & Stuss, 2011) but not widely debated or researched in the 
general neuropsychological literature.      
 
The developers of the TASIT have shown it to be a valid and reliable assessment of the 
perception of realistic social exchanges (McDonald, 2012). However, as the contextual 
information is presented all at once (e.g. expression, language, tone, gesture), it is not 
possible to determine whether patients may indeed have difficulties interpreting specific 
social cues (e.g. prosodic emotion as opposed to facial emotion), but that these 
impairments are overcome by the presence of auxiliary cues. Administration of this test 
in the current study could have included presenting elements of the exchanges in 
isolation. For example, the emotion recognition test could have been presented without 
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the vocal content (i.e. audio on mute) or sincere and sarcastic conversation could have 
been presented without the visual content (i.e. audio only). ALS patients have 
previously shown difficulties recognising emotionally–toned sentences (Meier et al., 
2010), which might extend to difficulties with linguistic cues used to indicate sarcasm, 
such as intonation and emphasis, in speech. Therefore, future studies could determine 
the specificity of these deficits.  
 
The current study combined scores of emotional processing and ToM tasks under one 
composite of performance (EMOSOC). Future research could investigate the 
relationship between emotion processing and ToM. For example, impaired processing 
of negative emotion in bvFTD patients has been suggested to partially underlie their 
difficulties in discriminating between sincere and sarcastic statements (Kipps et al., 
2009). The current study did not find emotion or sarcasm processing deficits in the 
patient sample, but future work could investigate whether or not differential 
impairments or dissociations on such items exist in ALS.  
 
The advantage of obtaining qualitative information (e.g. error responses) from verbal–
based social cognition measures has already been proposed (see Chapter 5); however, 
the verbal and time demands of such measures may be unsuitable for some ALS 
patients. Future work could shorten existing verbally–based measures, although this 
might jeopardise the sensitivity of the task. Alternatively, non–verbal measures which 
rely on picture–sequencing formats, such as comic strips (e.g. Ciaramidaro et al., 2007; 
Völlm et al., 2006) could be used.          
 
Several studies of socio–emotional processing in ALS have either not assessed 
executive function or included a limited range of tasks to ascertain the construct (e.g. 
Papps et al., 2005; Schmolck et al., 2007; Staios et al., 2013; Zimmerman et al., 2007). 
The results of the present study exhort the inclusion of executive function measures 
alongside socio–emotional tasks to determine the role executive dysfunction plays in 
emotion processing and ToM in patients. Future research is required to determine 
whether the relationship between executive function and social cognition suggested by 
patients’ performance in the current study is reliable, as previous studies have noted 
independence of these constructs in ALS patients (Cerami et al., 2013; Girardi et al., 
2011; Meier et al., 2010). Executive functioning alone was sufficient to predict a 
significant proportion of the variability in socio–emotional processing performance in 
the current patient sample. Nonetheless, a proportion of the variance remained 
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unexplained. Future research is needed to identify additional sources of variance, 
although some error variance will always be present. This might entail using improved 
measures of personality or empathic traits. Similarly, this could be achieved by 
assessing additional cognitive processes which could explain socio–emotional 
processing performance. For example, several studies of neurological patients have 
noted associations between ToM performance and the non–literal semantic–pragmatic 
aspects of language, such as the comprehension of metaphors and irony as well as the 
interpretation of idioms and proverbs (Champagne-Lavau & Joanette, 2009; Martin & 
McDonald, 2003; Monetta et al., 2009; Siegal et al., 1996; Sperber & Wilson, 2002). In 
turn, processing of non–literal speech has been correlated with executive function and 
semantic knowledge in bvFTD patients (Kaiser et al., 2013) and syntactic competence 
in aphasic patients (Papagno & Genoni, 2004). There is increasing recognition of 
language disruption, including semantic processing and syntactic comprehension, in 
non–demented ALS (see Chapter 2, Section 2.2.1.2.); this may co–occur or be 
independent of executive function (Taylor et al., 2013). Future research should 
investigate whether a complex relationship between executive function, language 
processing and social cognition can explain performance on ToM measures in ALS.   
7.4.3. Assessment of personality, empathy and behaviour 
 
Despite the concerns raised regarding the confounds of the several behavioural 
inventories used in ALS research, there remains a great need for validated ALS–specific 
measures. Some recently devised ALS screening batteries include behavioural items 
(e.g. ECAS, Abrahams et al, 2013; ALS-CBS, Woolley et al., 2010b) but these are early 
in the standardisation process. ALS studies of behavioural change should include 
control participants (this is currently not common in practice) and use measures which 
have been validated in the country in which the research is undertaken.   
 
Future study of empathic behaviour in ALS might benefit from more ecologically–valid 
measures of empathy, such as the Multifaceted Empathy Test (MET, Dziobek et al., 
2008) in which respondents rate their emotional response to photographic stimuli 
(emotional empathy) and infer mental states of individuals in scenes (cognitive 
empathy). Alternatively, observational studies of the extent to which patients are able to 
take the perspective of others, as well as their sensitivity and attachment to others in 
naturalistic settings are recommended, although studies of this kind might be difficult to 




Questions remain over whether caregivers’ reports should be accepted as the gold–
standard for behaviour research in ALS. The current study found discordant 
perspectives between patients and their caregivers on the patients’ behaviour, empathy 
and personality traits. Future research should investigate the extent to which these 
perceptions differ and whether they represent psychological responses or biases in ALS 
patients and/or their caregivers or an indication of reduced awareness in patients. This 
might be achieved by incorporating measures of social desirability, denial, coping and 
the assessment of wider cognitive appraisals (e.g. Matuz et al., 2010) alongside self and 
proxy measures of patients’ behaviour and personality. Factors that may influence 
responding, such as mood and burden (or, in the case of patients, of feeling like a 
burden) should also be assessed. This could also potentially expand understanding of 
psychological adjustment in ALS patients and their caregivers. 
  
7.4.4. The assessment of caregivers of people with ALS 
 
The exploratory component of the caregiver study suggests that future studies of 
caregiver outcomes might benefit from measuring their perceptions of patients’ 
empathy and personality alongside behavioural change. Expansion of these findings 
may include measuring the outcomes of caregivers and patients in tandem to explore the 
unique challenges presented by ALS to individual members of the spousal unit, as well 
as the overall ALS dyad. The comparison of spousal and filial caregivers, as well as an 
inspection of gender differences in ALS caregiving was not possible in the current 
research and should be addressed in future work. Furthermore, there is a growing field 
of study that considers the positive aspects of  caregiving (see Boerner et al., 2004; 
Carbonneau et al., 2010). This is a topic yet to be examined by caregiving studies in 
ALS. Future work should address the lack of research in this area in order to fully 
characterise caregiving experiences in ALS and develop better informed psychosocial 
interventions for ALS relatives.   
7.4.5. Longitudinal studies  
 
The majority of longitudinal studies of ALS cognitive change have focussed on the 
assessment of executive function over–time. Findings from these studies have been 
variable, with no consensus regarding the nature of the progression of cognitive 
dysfunction in the disorder (Chapter 2, Section 2.2.1.7.). To date, there have been no 
prospective studies of socio–emotional processing in ALS, with the exception of a 
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neuroimaging study that correlated alterations in patients’ brain response patterns over 
six–months with their evaluations of emotional stimuli at baseline (Lule et al., 2007). 
The current study recommends that future research investigates the progression of 
cognitive–behavioural change in ALS to determine whether or not the observed profiles 
of executive impairment and behavioural change revealed in the current patients would 
evolve to meet diagnostic criteria for FTD. In addition, given the finding of a predictive 
relationship between patients’ executive dysfunction and their performance on a 
composite of socio–emotional tests in the current results, future research should 
investigate the stability of emotional processing and social cognition in ALS patients 
alongside longitudinal assessments of executive function. If executive dysfunction in 
ALS is indeed progressive, as suggested by some studies (e.g. Robinson et al., 2006; 
Schreiber et al., 2005; Strong et al., 1999), it would be of value to investigate whether 
an emergence of deficits in emotion recognition and/or ToM ability occurs at a certain 
degree or stage of executive impairment or is independent of the presence and level of 
executive dysfunction. This design would be in a better position than the current cross–
sectional design to substantiate a causal relationship between executive dysfunction and 
socio–emotional processing in ALS. Longitudinal assessment of other cognitive 
domains is also warranted since population–based research indicates distinct cognitive 
subtypes in ALS with separate clinical trajectories (Elamin et al., 2013). For example, 
the progression of social cognition deficits assessed alongside increasing language 
impairment and executive dysfunction would allow the delineation of complex 
relationships, if any, between these respective cognitive domains.  
 
Longitudinal assessment of ALS patients is challenging due to high attrition associated 
with patients’ deaths and the variable and expeditious nature of disease progression. 
Certain neuropsychological tests become inappropriate as functional ability declines. 
Therefore, such studies should adopt measures that do not require motor function and 
which can be used to assess severely disabled patients. The advancement of brain–
computer interface communication technologies might provide augmentative tools for 
future cognitive assessment in late–stage ALS (Cipresso et al., 2012).     
 
Future research investigating the evolution of caregiver wellbeing and marital 
satisfaction alongside patients’ declining functional status and behavioural change is 
recommended; as these were the patient parameters which best predicted the caregiver 
outcomes in the cross–sectional analyses. Furthermore, although objective measures of 
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patients’ neuropsychological performance were not predictive of caregiver outcomes in 
the current cross–sectional design, there might be merit in investigating whether 
changes in cognitive indices over time (if any) explain variability in caregiving 
outcomes at different stages of disease. Future studies could also investigate whether or 
not the discrepancies between self– and proxy perspectives of patients’ behaviour, 
personality and empathy found in the exploratory component of the study become more 
disparate with time; and if discordant perceptions between the spousal partners 
contribute to caregivers’ experiences over the duration of the patient’s illness.  
 
7.4.6. Multimodal research 
 
Cognitive neuroimaging 
As highlighted throughout Chapter Two, numerous studies have incorporated 
neuroimaging techniques alongside neuropsychological testing to explore the cerebral 
substrates of cognitive and behavioural change in ALS. Emphasis has been placed on 
identifying the neural correlates of executive impairment above other cognitive 
domains. The current study suggests a predominant pattern of executive dysfunction in 
the patient sample. This might seemingly justify the disproportionate focus on executive 
impairment in ALS cognitive neuroimaging research. However, findings of changes in 
socio–emotional processing and memory in non–demented ALS are mixed. In addition, 
language processing deficits have been suggested to be as prevalent, if not more 
prevalent, than executive dysfunction. Both dependence and independence of these 
domains from executive dysfunction has been demonstrated (see Chapter 2). Future 
research should therefore integrate brain imaging with extensive neuropsychological 
batteries encompassing all cognitive domains. This may identify distinct patterns of 
cerebral involvement for different cognitive subtypes (e.g. Phukan et al., 2012). 
Furthermore, the results of the caregiving study from the current research advise the 
assessment of interpersonal (e.g. empathy) and personality traits as an adjunct to 
cognitive and behavioural measures in neuropsychological investigations of ALS. The 
inclusion of these inventories in cognitive neuroimaging studies might reveal 
interactions between patients’ premorbid characteristics, pathological changes and 
cognitive–behavioural impairment (Masellis et al., 2010). 
 
Neuropathology, genotypic variation and ‘cognitive phenotypes’ 
 
Chapter One introduced growing evidence for the influence of genetic factors on 
cognitive profiles in ALS (Byrne et al., 2012; Snowden et al., 2013; Wicks et al., 2009). 
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Although not a focus of the current thesis, the study exhorts the use of genetic and 
neuropathological data in future studies of cognitive–behavioural change in non–
demented patients. Ideally, studies would stratify patients on the basis of genotypic 
information and compare subgroups on a range of neuropsychological indices. 
Alongside in vivo cognitive imaging, neuropathological data could then be collected 
from deceased patients who have donated their brain and spinal tissue. Large–scale 
projects of this kind might be ambitious for single MND centres and would require 
collaboration between numerous research sites. The advent of the MNDA Brain and 
DNA banks, as well as the online ALSOD genetic database (see Chapter 1, Section 
1.3.2.) might enable data sharing between research groups. This necessitates the need 
for a standardised neuropsychological battery to be accessible to all research teams. 
Should distinct cognitive phenotypes continue to be associated with separate ALS 
genotypes this may reconcile discrepant findings between cognitive investigations of 
ALS or explain the heterogeneous profiles of impairment found within these studies. It 
may also delineate the nature of the proposed cognitive continuum between ALS and 
FTLD, as similar genotype–phenotype relationships which have been demonstrated in 
ALS had previously been found for FTD patients (Simon-Sanchez et al., 2012; 




The current thesis has described the literature surrounding cognitive–behavioural 
change in ALS patients and sought to improve upon the methodology of previous 
studies investigating emotional processing and social cognition within the disease. This 
was achieved by using a range of socio–emotional tasks, which varied from static to 
more ecologically–valid measures in a large ALS sample. In addition, the study further 
qualified the relationship between patients’ executive functioning and performance on 
these measures, by using a set of standardised executive function tasks alongside 
assessments of behaviour, personality and empathy. The study suggests a cognitive 
impairment in non–demented ALS patients that is characterised by executive 
dysfunction rather than emotional processing or ToM. Where impaired performance on 
a social cognition task in ALS was reported, this appeared to be secondary to patients’ 
executive dysfunction.  
 
The thesis also sought to expand understanding of caregiving perceptions in ALS. The 
research is the first to include objective measures of patients’ cognitive function, 
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alongside patients’ disease status and behaviour, in examining the impact ALS poses 
upon caregivers in terms of their mood, perceived strain, burden and marital 
satisfaction. Instead of patients’ cognitive status, the results of this study affirmed 
previous reports implicating the role of patients’ functional disability and behavioural 
dysfunction in caregivers’ responses to ALS. These results also suggested a possible 
specificity with which these different symptoms may impact on caregivers. Exploratory 
analyses revealed discordant perspectives between caregivers and patients regarding 
patients’ personality, empathy and behaviour, and highlighted their potential 
implications for caregiver outcomes.   
 
The thesis has outlined several limitations of the current research which restrict the 
interpretation of its results. These caveats, as well as those from the literature, have 
promoted recommendations for the design of future studies of ALS patients and their 
caregivers. It is hoped that this research will contribute to greater awareness and 
acceptance of the multisystem nature of ALS for the future development of 
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3. Information sheets 
     a. ALS participants (and control participants) 
     b. Caregiver participants 
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     a. ALS participants (and control participants) 
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                                      NRES Committee London - Camberwell St Giles 
                                                        (Formerly known as The Joint South London and Maudsley and Institute of Psychiatry 
                                                                                                                                 Research Ethics Committee) 
                                                                                                                Administrative address: Victoria House  
                                                                                                                                                          Capital Park 
                                                                                                                                                               Fulbourn  
                                                                                                                                                            Cambridge 
                                                                                                                                                             CB21 5XB 
 
                                                                                                                                              Tel: 01223 596907 
                                                                                                                                               Fax: 01223 597645 
 
17 May 2012 
 
Ms Tamlyn J Watermeyer 
Department of Psychology, PO78  
Institute of Psychiatry 
De Crespigny Park, London 
SE5 8AF 
 
Dear Ms Watermeyer 
 
Study title: Emotional Processing and Social Cognition in Amyotrophic 
Lateral Sclerosis / Motor Neuron Disease  
REC reference: 11/H0807/1 
Protocol number: CSA/10/042 
Amendment number: Amendment Two 27/04/2012 
Amendment date: 08 May 2012 
Amendment detail: 1.We are modifying one criterion, psychoactive medication use, 
in our exclusion criteria, as we have found that this measure is 
preventing otherwise eligible and suitable participants from 
taking part in the study. Patients are often prescribed 
psychoactive medication for disease symptoms (such as hyper 
salivation, discomfort/pain) and not necessarily mood disorder. 
For that reason, we will not recruit anyone who is experiencing 




mood disturbance (in keeping with our existing exclusion 
criteria) and/or receiving a dose of psychoactive medication that 
would usually be prescribed to treat mood disorder. Therefore, 
patients who are prescribed this medication solely for the 
treatment of disease symptoms will be eligible. 2. We will 
continue to recruit patients through the research centres 
associated with our study as stipulated in the protocol and the 
original REC application. In addition, we would like to allow 
patients whose care falls outside of the NHS Trusts from which 
this study operates but who have contacted us directly to 
volunteer their participation. These patients will be screened 
with the same criteria as the patients recruited from the centres 
and receive the same informed consent procedure. Screening 
will be conducted through liaison with the patient. We will not 
access these patients' medical information unless they consent 
for us to do so and if it is relevant to their participation. We will 
also not invite the patient’s spousal caregiver to the study 
without the patient’s consent. Only with the patient's consent, 
we will inform their GP of their participation in the study or 
report any relevant information (such as depressed mood, 
anxiety, etc.) to their GP or MND Care Team (please see 
attached Consent form: pwMND_Self-Referrers Version1.0 
27/04/2012). These patients will receive the same treatment and 
ethical protection (i.e. informed consent, data protection / 
confidentiality, etc.) as stipulated in the approved ethical 
opinion letter (dated 22/03/2011). 3. We would like to advertise 
this study to the MND community, such as the Motor Neurone 
Disease Association (MNDA), MND conferences or academic 
talks. Please see the advert attached 
(Recruitment_Poster_pwMND_Version1.0_27/04/2012). Patients 
will be able to enquire about the study by contacting the chief 
investigator (telephone number and email provided on the 
advert). After screening for eligibility (through liaison with the 
patient and applying the same criteria as above) and a 
discussion about the research, the patient will be sent a PIS and 
consent form, for them to read. Testing sessions will only be 
arranged once the patient has read the PIS and agrees to take 
part. Again, we will not access these patients' medical 
information unless they consent for us to do so and if it is 
relevant to their participation. We will also not invite the 
patient’s spousal caregiver to the study without the patient’s 
consent. Only with the patient's consent, we will inform their 
GP of their participation in the study or report any relevant 
information (such as depressed mood, anxiety, etc.) to their GP 
or MND Care Team (please see attached Consent form: 
pwMND_Self-Referrers Version1.0 27/04/2012). These patients 
will receive the same treatment and ethical protection (i.e.  
 




informed consent, data protection / confidentiality, etc.) as 
stipulated in the approved ethical opinionletter (dated 
22/03/2011). 
 
The above amendment was reviewed by the Sub-Committee in correspondence at the meeting 




The members of the Committee taking part in the review gave a favourable ethical opinion of 





The documents reviewed and approved at the meeting were: 
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D approval 
of the research. 
 
Statement of compliance 
Document  Version  Date    
Notice of Substantial Amendment (non-CTIMPs)  Amendment Two 
27/04/2012  
    
Covering Letter  from Tamlyn Watermeyer  27 April 2012    
Advertisement  Recruitment poster,pwMND 
v1.0  
27 April 2012    
GP/Consultant Information Sheets  GP Request Letter, v1.0  27 April 2012    
Participant Consent Form: pw_MND self-referrers  1.0  27 April 2012    
Protocol  4.0  27 April 2012    
GP Checklist Self Referral Patients   1.0  27 April 2012    
Confirmation of approval from sponsor  e-mail from Jennifer 
Liebscher, R&D, SLaM/IoP  
09 May 2012    





The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 










Enclosures: List of names and professions of members who took part in the review 
 
Copy to:  Dr Zoe Harris, Kings College Research and Development Office 

























The clinical team at Addenbrookes’ has become aware of a research study in MND that might 
be of interest to you. The study is concerned with thinking patterns and behaviour; it does not 
entail a trial of medication.  
If you are interested in being contacted with more information about this study, please contact 
the researcher Tamlyn Watermeyer: 
 
Ms Tamlyn Watermeyer 
PO78  
Institute of Psychiatry 
De Crespigny Park 
SE5 8AF 
 
Email: tamlyn.watermeyer@kcl.ac.uk  
 
Phone: 020 7848 5715 
 
You are under no obligation to take part in this study. Should you not wish to take part, the care 
you receive at the clinic currently or in future, will not be affected.  
 
Yours sincerely,  
 
Dr Chris Allen 
Consultant Neurologist, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust 
 
Joanna Sasson & Helen Copsey 
 
MND clinic co-ordinators  
 








Research Project Entitled “Emotion in Amyotrophic Lateral Sclerosis /Motor Neuron Disease” 
(REC 11/H0807/1) 
 
Following your clinic appointment at the Motor Nerve Clinic at King’s College Hospital I would like to 
invite you to take part in a research study.  
 
The study is part of a PhD project looking at how thinking patterns, behaviour and responding to 
emotional material might change in some people with motor neuron disease. A PhD student at the 
Institute of Psychiatry, Ms Tamlyn Watermeyer, is carrying out the project, which involves 
questionnaires, interviews, puzzles and tasks that will be done on a laptop computer. The assessment 
would be done in your own home at your convenience. You would not have to travel to King’s unless you 
would prefer to. 
 
I have enclosed information about the project outlining the purpose of the study and what to do if you 
would like to take part. If, after reading the information, you would like to ask any further questions or let 
us know that you would like to take part please contact Tamlyn Watermeyer by email on 
tamlyn.watermeyer@kcl.ac.uk or by phone on 020 7848 5715. Alternatively you can contact the project 
supervisor Professor Laura Goldstein on 020 7848 0218 or laura.goldstein@kcl.ac.uk.  
 
Please contact me if you do not wish to be involved.  If I do not hear from you, Tamlyn will contact you 
by telephone within two weeks to determine if you wish to be involved. If you do not want to take part 
this will not affect your current or future medical care in any way.  
 
Yours sincerely,  
 
 
Ammar Al-Chalabi MB ChB PhD FRCP DipStat,  
 
Professor of Neurology and Complex Disease Genetics 
Director, King’s MND Care and Research Centre  











Participant Information Sheet for People with Amyotrophic Lateral Sclerosis / 




You are invited to take part in a research study on Motor Neuron Disease at the Institute 
of Psychiatry, King’s College London. This study is being conducted as part of a 
student’s PhD research project and is funded by the Medical Research Council. Please 
find below all information relevant to participation in this study. Please ask us if you 
have any questions. Thank you for reading this. 
 
1. Study title:  Emotion in Amyotrophic Lateral Sclerosis/ Motor Neuron Disease 
(ALS/MND) 
 
2. The purpose of the study: The main purpose of this study is to investigate changes 
in emotional, social and everyday behaviour that may occur in some, but not all, people 
with MND and how these relate to thinking, personality and mood. We will compare 
our results to those obtained from people who do not have MND. We also aim to 
investigate the perceptions of such changes from the perspective of the carers of people 
with MND. 
 
3. Why have I been invited?  
We believe that this study may be suitable for you, if you would like to take part. You 
are being invited to take part on the basis of your recent visit to the Motor Nerve Clinic 
at King’s College Hospital. We will be seeing a total of 55 people with MND and we 
will also be seeing a total of 55 healthy volunteers. 
 
4. Do I have to take part? 
No. It is up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive now or at any later date. 
 
5. Description of the study:  
Testing can take place at your home at a time of your convenience or at the King’s 
MND Care & Research Centre if you prefer. If you decide to take part we will start by 
asking you some questions about the duration of your symptoms and how you have 
been feeling in the recent weeks. Then we will move on to a series of tests, similar to 
word games and puzzles, some of which will take place on a laptop computer. Please 
see the enclosed ‘Schedule for Participants’, for a description of each task. 
 




The completion of the tests will take approximately 6 ½ hours. This comprises about 
10-30 mins of gaining your consent to participate; 2 ½ – 3 hrs of interview questions 
and 2 ½ - 3 hrs of the experimental tasks. This is a long time but this can be split into 
two shorter sessions on separate days, if you prefer, and if you need to take a break at 
any time you are free to do so. If you prefer to travel to the King’s MND Care & 
Research Centre to take part in the study, we will reimburse you and your carer for any 
travel expenses incurred.  
  
If you agree to take part, we will arrange the study days to suit you as much as possible. 
You will not have to come off medication or undergo any invasive procedure 
whatsoever, although we would prefer you not to consume any alcohol 24 hours before 
any of the tests. Most of the thinking and behaviour tests are in the form of interviews, 
questionnaires or puzzle-like tests. If you are unable to write we will assist you in filling 
out the questionnaires.  
 
Some of the tests will require you to view videos and other information on a laptop 
computer (such as faces or words) and cartoons. We would, however, like to conduct 
both test sessions fairly close together in time (preferably within two weeks of each 
other).  
 
As part of the study, we would separately like to ask your carer some questions. We are 
interviewing carers to try and get different perspectives about possible changes in 
behaviour that may, or may not, occur in people with MND. This will consist of them 
having an interview that will enquire about any changes that may have occurred since 
the onset of your MND, in areas of your everyday life such as how interested you are in 
things going on around you, how easily you control your emotions and how well you 
are able to organise and plan everyday events. In connection with this they will be asked 
to complete some questionnaires. This will take about 45 minutes – 1 hour, which can 
also be conducted on two separate occasions lasting 25 -30 mins each.  Any responses 
given to us by your carer will remain confidential and we will not reveal them to you.  
We will also not tell your carer how you responded to any of the tests or interviews. 
 
6. Advantages of the study: There are no immediate benefits of this study to you. 
However, we expect that the study will shed new light on the possible emotional, social 
and behavioural consequences of MND, leading to better interventions to assist people 
with MND and their carers. 
 
7. Possible risks and disadvantages of the study:  
Whilst we do not anticipate any health risks from taking part in this study, you and your 
carer may find some of the questions uncomfortable. If you feel upset we will be happy 
to discuss this with you at the time and we will also telephone you the following day to 
see if there are outstanding issues you would like to discuss. All people taking part will 
be given some information about sources of support after the interview is finished. If 
you are upset by any of the issues covered in the interviews we would encourage you to 
contact your GP for advice or we can pass on a request to your MND Care team with 
your permission.  
Due to the length of time it will take to go through and complete the various tests and 
questionnaires you may find testing to be tiring. Therefore we recommend splitting the 




testing into at least two shorter sessions at your convenience, morning or afternoon or 
even on separate days. 
  
8. Confidentiality and publication of data: Your data will be stored under an 
anonymised code available only to the investigators associated with this study. You will 
not be identified in our computers or publications by name, but by ID number, and all 
information will be kept strictly confidential. We expect that the data collected in this 
study will be published in scientific articles, but you will not be personally identifiable 
in any such publications. No personal information will be released to third parties 
without your written approval. The data will be stored without any personal identifying 
information in password-locked computers at the Institute of Psychiatry for 10 years 
after completing the study. If you would like to receive a summary of the research we 
can arrange for this to be sent to you but it will not be until the study has been 
completed. 
  
9. Will my GP know about my participation in the study?  We will only contact 
your GP with your consent. Should you agree, your GP will receive a letter from us 
informing them of your participation and an outline of the study.   
 
10. Discontinuation of the study by the investigators: At any time during the testing, 
the investigators have the right to terminate your participation in the study for any 
reason. If later on in the study it is concluded that you no longer have capacity to 
consent to participating we would like to continue to be able to use any data that we 
have already collected, in an anonymised form.   
   
11. Withdrawal from the study: Your participation in this study is entirely voluntary. 
You have the right to withdraw from the study at any time without penalty of any kind.  
In the event of a future loss in capacity, any data already collected, under your consent, 
may continue to be used, confidentially, in connection with this study. 
 
12. Compensation: You will receive Marks & Spencer vouchers of the value of £30 as 
a token of our gratitude for giving up your time in completing the study investigations. 
We will also reimburse any travel expenses incurred during transport to and from the 
Institute of Psychiatry, should you prefer to travel to King’s MND Care & Research 
Centre for the study.  
  
13. Who is organising and funding the research? 
The study is being undertaken as part of a student’s PhD project and is funded by the 
Medical Research Council. It is being organized in collaboration with Professor Laura 
Goldstein, Professor Richard Brown and Professor Ammar Al-Chalabi. 
 
14.Who has reviewed the study? The study has been reviewed and granted ethics 
approval by South East London Research Ethics Committee 4 (REC 11/H0807/1) 
 
 
15.Contact details for any other inquiries concerning the study: If you have any 
inquiries concerning this study, please refer to the contact details below: 






Ms. Tamlyn Watermeyer 
Department of Psychology, PO78 
Institute of Psychiatry 
King’s College London 
De Crespigny Park 
London SE5 8AF 
Phone: 020 7848 5715         Email: tamlyn.watermeyer@kcl.ac.uk 
 
You can also contact  
Professor Laura Goldstein tel. 020 7848 0218 (laura.goldstein@iop.kcl.ac.uk); 
Professor Richard Brown  tel. 020 7848 0773   (richard.g.brown@iop.kcl.ac.uk) or 
Professor Ammar Al-Chalabi  tel. 020 7848 5187 (ammar.al-chalabi@kcl.ac.uk) if you 
require more information about the study.    
 
 
For independent and general advice on taking part in research please contact:  
 
 Dr. Angela Grainger  
 Assistant Director of Nursing - Nursing Education & Research Lead   


























Following your partner’s/spouse’s agreement to take part in a research study at The Institute of 
Psychiatry, I would like to invite you to also participate in a part of the study. The study is part 
of a student’s PhD project and is funded by the Medical Research Council. The research project 
will examine the nature and extent of emotional, social and behavioural change that sometimes 
occurs in people with MND and the perceptions and impact of these changes, if they occur, 
from the perspective of the carer of the individual with MND. It is hoped that this research may 
increase our understanding of any behavioural and emotional change that may occur in MND as 
well as improve clinical management for people with MND and their carers.  
 
Participation in this part of the study involves asking you a number of questions and asking you 
to fill in some questionnaires, which will be conducted in private; at a time that is convenient 
for you. This is expected to take approximately 45mins – 1 hr, but can be split into two shorter 
sessions of 25 – 30mins, if you prefer. Should you need a break or tend to your spouse/partner, 
you would be free to do so, at any time. Some of the questionnaires can be completed in your 
own time and returned to me at the your spouse’s/partner’s second testing session, if you prefer. 
 
Please refer to the ‘Participant Information Sheet’ and ‘Schedule for participants’, enclosed, for 
details about the types of issues that we would discuss with you. We would like to stress that 
any information you provide us with, will be treated with the strictest confidence and will not be 
relayed to your spouse under any circumstance. 
 
If, after reading the enclosed information, you would like to ask any further questions or inform 
us that you would like to take part please contact me by email on tamlyn.watermeyer@kcl.ac.uk 
or by phone on 020 7848 5715. Alternatively please contact the project supervisor Professor 
Laura Goldstein on 020 7848 0218 or laura.goldstein@kcl.ac.uk.  
 
If you do not wish to participate in the project it would be very helpful if you could let us know. 
If we have not heard from you within two weeks after sending the letter, I will contact you to 
ask if you have any queries about the project.  
 
You are under no obligation to participate and your decision will not affect your 
spouse’s/partner’s current or future medical care in any way.  
 
Yours sincerely,  
Ms. Tamlyn Watermeyer      
PhD Student 
Psychology Dept, , PO 78, Institute of Psychiatry, 
4 Windsor Walk 
De Crespigny Park, 
London SE5 8AF  Tel : 020 7848 5715  Email: tamlyn.watermeyer@kcl.ac.uk 
 






Participant Information Sheet for Spouse/Partners of People with 




You are invited to take part in a research study on Motor Neuron Disease at the Institute of 
Psychiatry, King’s College London. This study is being conducted as part of a student’s PhD 
research project and is funded by the Medical Research Council. Please find below all the 
information relevant to your participation in this study. Please ask us if you have any questions. 
Thank you for reading this. 
 
1. Study title:  Emotion in Amyotrophic Lateral Sclerosis/ Motor Neuron Disease (ALS/MND) 
 
2. The purpose of the study: The main purpose of this study is to investigate changes in   emotional, 
social and everyday behaviour that may occur in some, but not all, people with MND and how these 
relate to thinking, personality and mood. We will compare our results to those obtained from people 
who do not have MND. We also aim to investigate the perceptions of such changes from the 
perspective of the carers of people with MND. 
 
3.   Why have I been invited?  
We believe that this study may be suitable for you if you would like to take part. You are being 
invited to take part because your spouse or partner, who recently visited the Motor Nerve Clinic at 
King’s College Hospital, has agreed for us to contact you. We will be seeing a total of 55 people with 
MND and we will also be seeing a total of 55 healthy volunteers. As part of the study we are hoping, 
wherever possible, to interview the spouse / partner carer of the person with MND. We hope to get 
different perspectives about possible changes in behaviour that may, or may not occur, in people with 
MND, before and after the onset of their disease. We will also be asking carers about their 
experiences of caring for a spouse / partner with MND.  
 
4.   Do I have to take part? 
 No. It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and will be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason.  A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care your spouse / partner 
receives now or at any later date. 
 
5. What does my participation involve?   
 If you decide to take part, the study is in the form of an interview and involves the completion of 
some questionnaires. We will arrange to visit you at your home for this at a time of your 
convenience. Alternatively we can undertake this at the King’s MND Care & Research Centre, if you 
prefer. Should you prefer to travel to the centre, we will reimburse you and, if they come with you, 
your partner/spouse for any travel expenses incurred. If you agree to take part we will arrange the 
study days to suit you and your partner/spouse as much as possible. 
 If you decide to take part we would like to spend approximately 45 minutes – 1 hour with you. In 
addition to spending about 10 - 15 minutes going through the study with you and gaining your 
consent to participate we will ask you to complete some questionnaires. These ask about changes that 
you may have noticed in your spouse since the onset of their illness in terms of their everyday 
behaviour, interest in what is going on around them and their ability to organise and plan things, as 
well as their ability to understand other people’s feelings. We will also ask you some questions about 
their personality, before and after their MND started. We will also ask you some questions about 
your mood and any strain you feel as part of caring for your spouse as well as how you currently 
view the relationship between the two of you. Please see the enclosed ‘Schedule for Participants’, for 
a description of the different questionnaires we will ask you to complete. You do not have to 
complete these all  




 in one go. The interview can be split into two shorter sessions of approximately 25-30 mins on 
separate days if you prefer. If you need to take a break or need to tend to your relative at any time 
during the interview, you are free to do so. Some of the questions can be completed in your own time 
in between your spouse/partner’s testing sessions, if you prefer. Your responses to the interview will 
remain confidential within the research team and we will not reveal them to your partner/spouse, 
under any circumstance.  
  
6. Advantages of the study: There are no immediate benefits of this study to you. However, we expect 
that the study will shed new light on the possible emotional, social and behavioural consequences of 
MND, leading to better interventions to assist people with MND and their carers. 
 
7.  Possible risks and disadvantages of the study:  
While we do not anticipate any health risks from taking part in this study, you may find some of the 
questions uncomfortable. If you feel upset we will be happy to discuss this with you at the time and 
we will also telephone you the following day to see if there are outstanding issues you would like to 
discuss.  All people taking part will be given some information about sources of support after the 
interview is finished. If you are upset by any of the issues covered in the interviews we would 
encourage you to contact your GP for advice or we can pass on a request to the MND Care team with 
your permission.  
 
8.  Confidentiality and publication of data:  
Your data will be stored under an anonymised code available only to the researchers associated with 
this study. You will not be identified in our computers or publications by name, but by number, and 
all information will be kept strictly confidential.We expect that the data collected in this study will be 
published in scientific articles, but you will not be personally identifiable in any such publications. 
No personal information will be released to third parties without your written approval. The data will 
be stored without any personal identifying information in password-locked computers at the Institute 
of Psychiatry for 10 years after completing the study. If you would like to receive a summary of the 
research we can arrange for this to be sent to you but it will not be until the study has been 
completed. 
  
9. Withdrawal from the study: Your participation in this study is entirely voluntary. You 
      have the right to withdraw from the study at any time without penalty of any kind.   
 
10. Who is organising and funding the research? 
 The study is being undertaken as part of a student’s PhD project and is funded by the Medical 
Research Council. It is being organized in collaboration with Professor Laura Goldstein, Professor 
Richard Brown and Professor Ammar Al-Chalabi. 
 
11, Who has reviewed the study? The study has been reviewed and granted 
      ethics approval by South East London Research Committee 4 (REC 11/H0807/1) 
 
12. Contact details for any other inquiries concerning the study: If you have any inquiries 
concerning this study, please refer to below contact details: 
 
Ms. Tamlyn Watermeyer 
Department of Psychology, PO78 
Institute of Psychiatry 
King’s College London 
De Crespigny Park 
London SE5 8AF 
Phone: 020 7848 5715         Email: tamlyn.watermeyer@kcl.ac.uk 
 
You can also contact: 
  
Professor Laura Goldstein tel. 020 7848 0218 (laura.goldstein@iop.kcl.ac.uk); 
Professor Richard Brown  tel. 020 7848 0773   (richard.g.brown@iop.kcl.ac.uk) or 
Professor Ammar Al-Chalabi  tel. 020 7848 5187 (ammar.al-chalabi@kcl.ac.uk) if you require 
more information about the study.    
 
 








Consent Form for People with Amyotrophic Lateral 
Sclerosis / Motor Neuron Disease 
 
Emotion in Amyotrophic Lateral Sclerosis / Motor Neuron Disease (ALS/MND) 
(REC 11/H0807/1) 
 
Please tick each box if you agree to the statement 
 I, __________________________________________, have read the 
 description of the study called “Emotion in Amyotrophic Lateral   
                        Sclerosis/Motor Neuron Disease”. I have had the opportunity to ask   
                         questions and all my queries have been met.  
  Further, I understand that I may ask for more information about each test   
                         either before or after it is given.  
  I understand that I am free to withdraw from the testing at any time if I   
                         desire  without giving a reason; without my medical care or legal rights   
                         being affected.  
  I understand that my personal information will be kept confidential.  
 
  I consent to you contacting my GP to inform them of my participation in  
                       this study. 
 
  I consent to members of the research team for this study, who are either   
                        from King’s College Hospital, London or the Institute of Psychiatry  
                        having access to my medical records, when this is relevant to my taking  
                        part in research.   
 
  I consent to you contacting the MND Research and Care Team, should  
                        you find any new information about me (e.g. depressed mood, anxiety)  
                        that may inform the existing care and support they provide me.   
 
 
  I consent that in the event of a future loss in capacity, any data already  
  collected may  continue to be used, confidentially, in connection with this 
  study. 
 
 
A.I.4.a.: Consent forms: ALS participants (pg. 1 of 2) 
Tamlyn Watermeyer 
PhD Student, Department of Psychology 
PO78, Institute of Psychiatry  
De Crespigny Park  
Denmark Hill 
London SE5 8AF 
Telephone +44 (20) 7848 5715    
tamlyn.watermeyer@kcl.ac.uk 
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            I consent to you asking my spouse/partner to provide some information  
                       about me. I understand that the information he/she provides will be treated                  
           confidentially between my spouse/partner and the research worker. 
.  
  I would like to receive a summary of the results of the study  
 





_____________________________   ________________ 










                     I confirm that I have explained the study to   
 
                   ________________________________________________(name of participant)    
 






_______________________________  ________________ 























Consent Form for Spouse/Partner Carers of 
Patients with Amyotrophic Lateral Sclerosis / Motor Neuron Disease (ALS/MND) 
Emotion in Amyotrophic Lateral Sclerosis / Motor Neuron Disease 
(REC 11/H0807/1) 
 
 Please tick each box if you agree to the statement 
 
  
            I,__________________________________________, have read the description    
of the study called “Emotion in Amyotrophic Lateral Sclerosis / Motor Neuron Disease”. 
I have had the opportunity to ask questions and all my queries have been met.  
 
 Further, I understand that I may ask for more information about each set of questions   
             either before or after it is given. 
 
 I understand that I am free to withdraw from the interview at any time if I desire, without  
giving a reason and without my legal rights and the care of my spouse/partner with 
ALS/MND being affected.   
 
 I understand that the information I provide regarding my spouse/partner will be treated  
 as confidential between myself and the research worker, and that under no    
            circumstance will any information I provide be relayed to my spouse/partner.  
 






PhD Student, Department of Psychology 
PO78, Institute of Psychiatry  
De Crespigny Park  
Denmark Hill 
London SE5 8AF 
Telephone +44 (20) 7848 5715    
tamlyn.watermeyer@kcl.ac.uk 
    
A.I.4.b.: Consent forms: Caregiver participants (pg. 1 of 2) 
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 I would  like to receive a summary  of the results of the study 
 
 





_____________________________   ________________ 









 I confirm that I have explained the study to ________________________________ 




_______________________________  ________________ 
Signature of investigator      Date 
 
_______________________________ 
Name of investigator (in capitals) 
A.I.4.b.: Consent forms: Caregiver participants (pg. 2 of 2) 
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a. Missing data: patients and controls 
 



























 A.II.a.: Missing data: patient and control groups 
 










Reading Mind in the Eyes 
(RME) 
 
Happé Cartoon Task 
 
Happé Scenario Task 
 
D–KEFS Card Sorting Task 
 




Hayling Sentence Completion 
Task 
 


















































































California Verbal Learning Test 
(CVLT) 
 
Weschler Test of Adult Reading 
(WTAR) 
 
Weschler Abbreviated Scale of 
Intelligence (WASI)  
 
































































































N=104. HC, Healthy Controls; TASIT, The Awareness of Social Inference Test; D–KEFS, Delis–
Kaplan Executive Function System; NEO–FFI, NEO Five–Factor Inventory; FrSBe, Frontal Systems 
Behaviour Scale; ALSFRS–R, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.  
 417 
 
 A.II.b.: Missing data: Caregivers 
 
Questionnaire N Missing Count (%) 
 
HADS                                                            35 0 (0) 
 
Morris Strain Scale   (MSS)                                                  





Zarit Burden Interview (ZBI)                             
      
    34 
 
1 (2.9) 
   
Marital Intimacy Scale  (MIS)                                              32    3 (8.6) 
 
NEO–FFI                                                         30 5 (14.3) 
 
Interpersonal Reactivity Scale (IRI)                           
 











    29  
 
    34  
 
    33   
 
    31 
 
    35  
 













  HADS, Hospital Anxiety and Depression Scale; NEO–FFI, NEO Five–Factor Personality Inventory; FrSBe, Frontal   


















c. TASIT Task dialogue and prompt questions 
 
d.  Happe Task examples of cartoon stimuli 
 



























A.III.a.: The TASIT Task: examples of dialogue and question prompts 
 
Social Inference Minimal – sarcastic exchange 
“Date” 
Michael: “Well congratulate me. I’ve got a date with Anne” 
Gary: “With Anne?! You must be joking?!” 
Michael: “Now, don’t be jealous” 
Gary: (rolls eyes and says in sarcastic tone) “Sure, I’m jealous…who wouldn’t be?”  
Michael walks away upset.  
 
Questions:  
a) Is Gary criticising Michael for dating Anne?  
b) Is Gary trying to say it’s a mistake to date Anne? 
c) Does Gary think Anne is a good date?  
d) Is Gary openly impressed that Michael is dating Anne?  
 
Social Inference Enriched – deceptive exchange 
“Boyfriend” 
 Geoff: “What did you think of Annie’s new boyfriend…isn’t he terrible?” 
Jane: (laughing) “He was ghastly! I don’t know what she sees in him. Argh, he was 
such a pain and so boring!” 
Geoff: (laughing) “I know, I thought I’d fallen asleep while he was talking…” 
Jane: “I only listened to him for five minutes, he went on and on about some rubbish...” 
Annie: (interrupts) “Well, what do think of the love of my life? Isn’t he great?” 
Jane: (hiding a laugh) “Hmm, he’s a real catch… I don’t know where you find them!” 
Annie: “I think he’s so interesting” 
Jane: “Yeah…he’s really interesting…I could sit and talk to him all day”   
 
Questions:  
a) Is Jane trying to reassure Annie that she like her new boyfriend? 
b) Is Jane trying to say that she thinks Annie’s boyfriend is great?  
c) Does Annie believe that Jane likes her new boyfriend?  





A.III.b.: The Happé Task: examples of cartoon stimuli 
Cartoon Inference subtask 
‘Physical’ condition                                               ‘Mental’ condition
            
 
Forced–Choice Cartoon Abstraction (Cartoon Pairs) 
‘Physical’ condition                                               ‘Mental’ condition   
                                                      
                                                 




A.III.c.: The Happé Task: examples of written scenarios/stories  
 
‘Physical condition’  
Example 1: Two enemy powers are at war.  Their forces are equally matched.  
However, the Blue army is stronger in foot soldiers, while the Yellow army is stronger 
in air power.  On the day of the deciding battle, there is dense fog over the battlefield.  
The Blue army wins the battle. 
Question prompt: Why did the blue army win?  
 
Example 2: Paul is very rich, and today he is going to buy an expensive new car.  If he 
pays in monthly instalments, the dealer will charge 5% interest on the loan. His bank 
currently gives him 8% interest on the money in his account. Even though he has easily 
enough money to pay the full amount, he decides to pay by monthly instalments. 
Question prompt: Why does Paul pay in instalments?  
 
‘Mental condition’ 
Example 1: A burglar who has just robbed a shop is making his getaway. As he is 
running away, a policeman sees him drop a glove. He wants to tell him he dropped his 
glove.  When the policeman shouts out to the burglar "Hey, you! Stop!”, the burglar 
turns round, sees the policeman and gives himself up. 
Question prompt: Why did the burglar give himself up?  
 
Example 2: During a war, a soldier is taken prisoner by the enemy.  The enemy asks the 
prisoner where his army's tanks are. They think he will lie to them, and they know they 
are either by the sea or in the mountains. The tanks are really in the mountains. When 
the enemy asks him where his tanks are, he says, "They are in the mountains". 










Appendix IV: Effect size and Confidence Intervals (CI) calculations 
 
Cohen’s d:                
     
  





Where M1 = Mean of Group 1; M2 = Mean Group 2; SD1 = Standard Deviation for 
Group 1; SD2 = Standard Deviation for Group 2.  
 




Where z = test statistic; N = total observations 
 
Cramer’s V:    
  
        




 = chi–square statistic; N= total observations; k = the number of rows or 
columns, whichever is smaller in the variable matrix.  
 
Partial–eta squared7:     ηρ² = 
         
                   
 
Where SS effect = Sums of Squares for the effect of interest; the denominator is 
















a. Medication profile: patients and controls 
 



































 A.V.a.: Participant medication profile 
 








Intervention                                                                 Drug  ALS HC 
Disease Management   
Baclofen 4 0 
Fentanyl 1 0 
Diclofen 1 0 
Gabapentin 2 0 
Pregablin 1 0 
Tramadol 1 0 
Naproxen 1 1 
Quinine Sulphate 6 0 
Generic painkillers (e.g. Asprin) (on request) 9 2 
Glycopuronium bromide 1 0 
Diazepam 2 0 
Temazepam (on request) 1 0 
Tizanidine (one patient used only on request) 2 0 
Hyocine (Scopolamine) patches 1 0 
Carbocisteine  3 0 
Amytriptyline 3 0 
Citalopram 4 0 
Total 11 0 
   Riluzole 43 0 
Total 97 3 
Haematology   
Atorvastatin 1 2 
Simvastatin 1 1 
Unknown statin  1 
Atenolol 1 1 
Bendroflumethiaze 1  
Bisoprol 1 1 
Glyceryl Trinitrate 1  
Ramipril  2 2 
Propanadol 1  
Perindopril 1  
Amylodinipine  1 
Linosopril  1 
Daxazosin  1 




Nicorandil 1  
Total 12 15 
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A.V.b.:  Patients receiving psychoactive medication 
 
Patient Participant Medication  Use 
203 Tramadol Pain 
207 Baclofen  Spasticity 
211 Diclofenac Pain 
221 Baclofen Spasticity 
234 Citalopram  EL 
235 Pregablin Pain 
237 Hyocine  Saliva control 







244 Gabapentin Pain 
245 Amytriptyline EL 



























1. Happé subtasks demographics 
      a. Cartoon subtasks  
      b. Scenarios subtask  
 
2. Happé subtasks inter–rater reliabilities 
      a. Inter–rater agreement for response accuracy scores 
 
      b. Inter–rater agreement for error responses 
 























A.VI.1.a.:  Happé cartoon subtests demographics  
 Mean (SD) t(df)  p 
 ALS (n=45)   HC (n=48)   
Age (yrs)            59.4 (9) 
14.76 (3.7) 
  59.8 (9.7) 
  14.56 (2.7) 
0.21 (91) 0.83 
Education (yrs) -0.29 (80.9) 0.78 
 Median (MAD/IQR) U(z) p 
 ALS (n=45)         HC (n=48)   
HADS Depression 2 (4/2)                 1 (4/3) 
4 (2/4)                  3 (2/4) 
890.0 (-1.49) 0.14 
HADS Anxiety 1056.0 (-0.19) 0.85 
 N (%) χ2(df) p 
 ALS  (n=45)   HC (n=48)   
Gender  
 
  Men  
                 Women 
34 (75.5) 
11 (24.4) 
  33 (68.8) 




 Median (MAD/IQR) U(z) p 




112.5 (3.5/9)         114 (4/10) 
 











† WTAR and demographic predicted premorbid FSIQ; * Predicted premorbid FSIQ: ALS (n=44); 














A.VI.1.b:  Happé scenarios subtest demographics  
 Mean (SD) t(df)  p 
 ALS (n=38)   HC (n=45)   
Age (yrs)            58.8 (9.2) 
14.8 (3.5) 
  60.2 (9.5) 
  14. 7 (2.6) 
0.65 (81) 0.52 
Education (yrs) -0.18 (67.1) 0.86 
 Median (MAD/IQR) U(z) p 
 ALS (n=38)          HC (n=45)   
HADS Depression 2.5 (1.5/2)             1 (1/3) 
4 (2/3)                   3 (2/4)        
657.0 (-0.85) 0.07 
HADS Anxiety 848.0 (-0.07) 0.95 
 N (%) χ2(df) p 
 ALS  (n=38)    HC (n=45)   
Gender  
 
  Men  
                 Women 
28 (73.7) 
10 (26.3) 
   30 (66.7) 
   15 (33.3) 
0.48 (1) 0.49 
 Median (MAD/IQR) U(z) p 
 ALS*                    HC (n=45)   
Predicted 
premorbid FSIQ†  
                              
112 (4/8)               114 (4/9)    
 













† WTAR and demographic predicted premorbid FSIQ; * Predicted premorbid FSIQ: ALS (n=38); WASI 












 Not significant following Bonferroni correction (adjusted p<.03); Pearson’s product correlation r=.-2. 
This effect size estimate is small according to Cohen (1988) conventions. 
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 A.VI.2.a.: Inter–rater agreement for response accuracy scores 
 
Item Agreement (%) Kappa p 
Cartoon Inference 
“Gunfight” 91.1 .76 <.001 
“ Children crossing” 94.4 .78 <.001 
“Stage entrance” 95.6 .86 <.001 
“Suit sale” 93.3 .76 <.001 
“Desert island” 92.2 .76 <.001 
“Laboratory” 91.1 .69 <.001 
“Ping–pong” 91.8 .62 <.001 
“Child play” 93.3 .82 <.001 
“Duckshoot” 94.4 .83 <.001 
“Flying Saucers” 94.4 .79 <.001 
“Father & son” 93.3 .83 <.001 
“Photograph” 92.2 .72 <.001 
Cartoon Pairs 












































































































 A.VI.2.b.: Inter–rater agreement for error responses 
 
Item Agreement (%) Kappa p 
Cartoon Inference 
“Gunfight” 76.6 .70 <.001 
“Children crossing” 83.3 .65 <.001 
“Stage entrance” 76.7 .63 <.001 
“Suit sale” 86.7 .72 <.001 
“Desert island” 90.0 .84 <.001 
“Laboratory” 83.3 .68 <.001 
“Ping–pong” 93.3 .73 <.001 
“Child play” 86.7 .77 <.001 
“Duck shoot” 76.7 .66 <.001 
“Flying Saucers” 83.3 .69 <.001 
“Father & son” 83.3 .74 <.001 













































































































A.VI.3.: Happe Cartoon and Scenarios response rimes  
p–values from ANOVAs. ∞ Naperian log transformation applied: original means (SDs) are shown. RT, 



















Mean RT (SD) 
Between–Subjects Effect 




























































a. Demographic and disease characteristics of patient medicine subgroups 
 
b. Patient subgroups MANOVA: medicated versus non–medicated patients 
 
c. Patient subgroups comparisons for Executive function components & Hayling 
Task scores 
 
d. Single–case analysis – Executive function composite components and Hayling 
Task scores: patient medication subgroups 
 
e. Patient subgroups comparisons for EMOSOC components 
 
f. Patient subgroups comparisons for EMOSOC components 
 
g. Patient subgroups comparisons for GNT and CVLT performance 
 
h. Patient subgroups comparisons for IRI ratings 
 
i. Patient subgroups comparisons for FrSBe T–scores 
 
j. Patient subgroups comparisons for ELQ ratings 
 
















A.VII.a.: Demographic and disease characteristics of patient medicine subgroups 
 Mean (SD) t(df)  p   d  
 NM (n=40)   Med (n=15)    
Age (yrs)            59.9 (8.2) 
14.8 (3.6) 
 61.3 (9.3) 
 13.7 (3.4) 
-0.53 (53) .6 -0.16 
Education (yrs) 1.06 (53) .29  0.31 
Months since onset 
Months since diagnosis 
Age at symptom onset 
Epworth Scale  
ALSFRS–R Tot 











 28.47 (11.5) 
 16.8 (11.58) 
 59.2 (9) 
 4.3 (3.3) 
 31.4 (9.2) 
 13.2 (6.9) 
 7.8 (4.1) 

























 Median (MAD/IQR) U(z) p  r 
 NM (n=40)      Med (n=15)              
Disease progression rate 0.5 (0/0.3)     0.6 (0/0.3) 228 (-1.4) .17 -.19 
HADS Anxiety† 4 (0/4)              4 (0/6) 
2 (0/3)              3 (0/4)   
117 (0/14)        111 (0/17) 
113 (0/7)          111 (0/15) 
235 (-1.3) .21 -.18 
HADS Depression† 
WASI FS IQ† 










 N (%) χ2(df) p φc 
 NM  (n=40)  Med (n=15)    
Gender*
 
  Men  
                 Women 
31 (77.5) 
9 (22.5) 
 9 (60) 
 6 (40) 
1.68 (1) .19 .18 
Onset Location* 
                 Limb 






      11 (73.3) 













30 (75)                                                                   
       4 (26.7) 
 










NM, No medication; d, Cohen’s d; r, Pearson’s correlation coefficient; φc, Cramer’s V  p–values from 
two–tailed t–tests except † Mann–Whitney U test; * Pearson’s χ2 test and  **Mental health = previous 







 A.VII.b.: Patient subgroups MANOVA: medicated versus non–medicated patients 
 
Composite NM (n=40)             Med (n=15) 
 
F(df) p ηρ² 






0.45 (1)                    0.46 (1) 
 









  .01 





0.8 (0.73; 0.89)         0.79 (0.65;0.97) 
 










p–values are from ANOVAs. † Untransformed original data. ††Back transformed data. NM, No 





A.VII.c.: Patient subgroups comparisons for Executive function components & 
Hayling Task scores 
 
 Mean (SD) t(df) p d 95% CI 
 NM                 Med     











Hayling Error A 
 





































































































p–values from two–tailed  t–tests; NM, Non–medicated patients; Med, medicated patients; d , Cohen’s 






A.VII.d.: Single–case analysis – Executive function composite components and 
Hayling Task scores: Patient   medication subgroups  
Composite N (%) χ2 (df) p φc 95% CI 
 NM  Med     
D–KEFS sorting  




Hayling Errors A 


































  .16 
  .06 
  .10 
<.01 
  .23 
  .01 
  .11 









p–values from two–tailed  Fisher–Boschloo exact test except † Pearson’s χ2 test. φc, Cramer’s V. 95% 
CI, Newcombe–Wilson hybrid confidence interval for difference between proportions. NM, Non–
medicated patients; M, Medicated patients.  
 
 
A.VII.e.: Patient subgroups comparisons for EMOSOC components  
 
 Mean (SD) t(df) p      d 95% CI 








5.5 (2.5)               
10.7 (6.6)  
12.9 (6.2) 
10.8 (4.6)  
11.8 (5.0)  
11.2 (4.6)  
9.5 (3.9)                
  7.1 (2.4) 
  10.1 (7.2) 
  12.3 (7.7) 
  9.8 (5.6) 
  12.5 (6.2) 
  12.5 (4.7) 
















  0.09 
  0.09 
  0.19 
 -0.12 
 -0.28 








p–values from two–tailed  t–tests; NM, Non–medicated patients; Med, medicated patients;  d , Cohen’s 
d; 95% CI for difference between means. Uncorrected significant results shown in bold–p<.05. Note: 






A.VII.f.: Single–case analysis – EMOSOC composite components: patient  
medication subgroups  
Composite N (%) p φc 95% CI 





























  .04 
 .03 
  .03 
  .01 
<.01 
  .07 








NM, Non–medicated patients; Med, Medicated patients. p–values from two–tailed Fisher–Boschloo 
exact test. φc, Cramer’s V. 95% CI, Newcombe–Wilson hybrid confidence interval for difference 
between proportions. 
 
A.VII.g.: Patient subgroups comparisons for GNT and CVLT performance  
 
 Mean (SD) t(df) p   d 95% CI 
 NM Med     
GNT † 
 





























































































p–values from two–tailed  t–tests; d , Cohen’s d; 95% CI for difference between means. Uncorrected 
significant results shown in bold – p<.05. †Sensitivity analysis using non–parametric tests found same 
non–significant results. Note: higher scores indicate superior performance for CVLT but worse 




A.VII.h.: Patient subgroups comparisons for IRI ratings  
IRI domains Mean (SD) t(df) p d 95% CI 
















































































 p–values from two–tailed paired–sample t–tests. NM, Non–medicated patients; Med, Medicated patients; 
Conscien., Conscientiousness; d, Cohen’s d for paired samples; 95% CI, confidence interval for 
difference between means. 
 
 
A.VII.i.: Patient subgroups comparisons for FrSBe T–scores 
































































Exec. Dys. (pre.)      




















Note. Participants were asked to rate their behaviour at present time and approximately 2 years prior; p–
values are from two–tailed t–tests. NM, Non–medicated patients; Med, Medicated patients; Disinhib., 
Disinhibition; Exec.Dys., Executive Dysfunction; pre., premorbid; cur., currentd, Cohen’s d; 95% CI, 






A.VII.j.: Patient subgroups comparisons for ELQ ratings 
 
 Median (MAD/IQR) U(z) p r 95% CI 































 0.0; 0.0 
-7.0; 0.0 
 0.0; 0.0 
p–values from Mann–Whitney U tests. NM, Non–medicated patients; Med, medicated patients; r, 




A.VII.k.: Patient subgroups comparisons for NEO–FFI T–scores  
NEO–FFI 
T–scores 
Mean (SD) t(df) p d 95% CI 








































































p–values from two–tailed paired–sample t–tests. NM, Non–medicated patients; Med, Medicated patients; 
Conscien., Conscientiousness; d, Cohen’s d for paired samples; 95% CI, confidence interval for 
difference between means. 
 




 When overall mood (HADS T scores) was entered as a covariate in an ANCOVA, the 





a. Comparison of the patients’ self–rated mean FrSBe domain scores with those of 
previous studies 
 



























A.VIII.a.: Comparison of the patients’ self–rated mean FrSBe domain scores with 





Chio et al, 2005 
 
Woolley et al, 
2010 
Girardi et al, 
2011 (Study A) 
Current 
study 











Exec. Dys. (pre.) 


















































FrSBe, Frontal Systems Behavioural Scale; Disinhib., Disinhibition;  Exec.Dys., Executive Dysfunction; 
pre., premorbid; cur., current; — or (–), not provided.  
 
A.VIII.b.:  Proportions of patients satisfying FrSBe ‘caseness’ criteria across 
studies  
FrSBe                          Study N (%) 
T ≥ 65          Witgert et al 2010 
(n=225) 
(proxy–rated) 









































FrSBe, Frontal Systems Behavioural Scale; Exec.Dys., Executive Dysfunction; pre., premorbid; cur., 





  Appendix IX.: Intercorrelations of caregiver outcome measures 
r=Pearson’s correlation coefficient. Significant correlations shown in bold–p<.01. HADS T, Hospital  
Anxiety and Depression Scale scores (n=35); MSS, Morris Strain Scale (n=35); ZBI, Zarit Burden 























































































Appendix X: Comparison of carers’ premorbid and patients’ current ratings of 
patients’ personality  
NEO–FFI–I  
T–scores 
Mean (SD) t(df) p d 95% CI 
    Carer 
Premorbid 
  (n=29) 
 Patient   
 Current 
  (n=29) 


































































p–values from two–tailed paired–sample t–tests. Conscien., Conscientiousness; d, Cohen’s d for paired 





























































“...the sea's only gifts are harsh blows and, occasionally, the chance to feel strong. Now, 
I don't know much about the sea, but I do know that that's the way it is here. And I also 
know how important it is in life not necessarily to be strong but to feel strong, to 
measure yourself at least once, to find yourself at least once in the most ancient of 
human conditions, facing blind, deaf stone alone, with nothing to help you but your own 
hands and your own head...” 
Primo Levi 
Bear Meat 
